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Abstract 
Teladorsagia circumcincta is a common abomasal parasite of sheep in temperate regions 
and is one of the major causes of parasitic gastroenteritis (PGE) in growing lambs. Control 
of infection is achieved using anthelmintic drugs; however, this practice is rapidly 
becoming unsustainable due to widespread anthelmintic resistance within the T. 
circumcincta population. Sheep can acquire protective immunity against this parasite; 
immunity involves local and systemic antibodies and immune cells which can impair worm 
growth and fecundity and lead to expulsion of the parasites from the abomasum. 
Vaccination against this parasite is therefore a feasible option of control. A recent study 
showed that a recombinant vaccine cocktail containing 8 T. circumcincta antigens 
significantly reduced the faecal egg count and worm burdens of immunised sheep, 
compared to an adjuvant-only control group. However, the recombinant antigens induced a 
suboptimal antibody response to the recombinant antigens. This suggests that differencies 
between the native antigens and their recombinant versions may exist, possibly due to 
variations in structure and/or post-translational modifications (PTMs). 
The main aim of this work was to use a novel expression system, the free living nematode 
Caenorhabditis elegans, to generate alternative recombinant versions of two of the T. 
circumcincta antigens used in the 8-antigen vaccine, cathepsin F (Tci-CF-1) and monocyte 
Migration Inhibitory Factor (Tci-MIF-1). This was achieved by micro-injection of C. 
elegans worms with plasmids containing the cDNA sequences of Tci-cf-1 and Tci-mif-1 
followed by purification of recombinant Tci-CF-1 and Tci-MIF-1 from the transformed 
worms. Immune recognition, enzyme activity and biological effects on sheep cells of the 
recombinant antigens were characterised. The results show that immunisation-induced 
antibodies bind to native Tci-CF-1 purified from T. circumcincta L4 ES, whereas 
infection-induced antibodies were unable to bind the recombinant Tci-CF-1 versions. 
Further characterisation of recombinant Tci-CF-1 versions expressed in C. elegans or 
Pichia pastoris showed that in order to be enzymically active, these proteins require 
cleavage of the pro-peptide by an exogenous enzyme and that some differences were 
present in the glycosylation of the recombinant versions and native Tci-CF-1. 
Characterisation of both recombinant Tci-MIF-1 versions showed that although both are 
enzymically active, neither showed a significant inhibitory effect on the migration of sheep 
monocytes or on the activation of sheep macrophages in vitro compared to unstimulated 
controls. It is speculated that Tci-MIF-1 may be involved in T. circumcincta larval 
development rather than host immunosuppression.   
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“… when you have excluded the impossible, whatever remains,  
however improbable, must be the truth.” 
 
Sherlock Holmes  
(by Sir Arthur Conan Doyle, 1859-1930) 
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Chapter 1 – Introduction 
  
1.1 Teladorsagia circumcincta 
Teladorsagia circumcincta (also known as brown stomach worm) is a commonly reported 
parasite of sheep in temperate areas. Previously known as Ostertagia circumcincta, this 
nematode is the principal causative agent of parasitic gastroenteritis (PGE) in growing 
lambs of temperate regions (Bartley et al. 2003, Taylor M. A. et al. 2007). Teladorsagia 
circumcincta is a Strongylid member of the family Trichostrongyloidea and belongs to 
Clade V of the Phylum Nematoda, based on phylogenetic analysis of small subunit RNA 
sequences (Blaxter et al. 1998, Taylor M. A. et al. 2007). As a cause of major production 
losses and clinical PGE, T. circumcincta is a parasite of major importance in the sheep 
industry (Miller et al. 2012, Nieuwhof and Bishop 2005). 
1.1.1 Lifecycle 
T. circumcincta has a direct lifecycle, with eggs produced by adult female worms present 
in the faeces of infected sheep (summarised in Figure 1.1). If conditions are favourable, 
eggs hatch into first-stage larvae (L1) within 24 hours, quickly moulting into the slightly 
larger second larval stage (L2); both these stages remain within the faecal mass. It can take 
from 10 to 14 days on pasture for eggs to develop into the infective stage (L3), which 
retains the external cuticle of the L2 stage and forms the L3 sheath (Keith et al. 1990). At 
the L3 stage larvae move outside the faecal mass and onto the pasture, where they are 
ingested by the sheep host. The L3 larvae reach the abomasum approximately 24-48 hours 
after ingestion, where they ex-sheath, burrow into the gastric glands and undergo further 
moulting into the fourth larval stage (L4). Following development into an immature adult 
stage (L5) within the abomasal mucosa, the adults then emerge into the abomasal lumen 
and complete their sexual maturation. The majority of worms complete their maturation 
and begin releasing eggs approximately 3 weeks after the L3 stages were ingested (Taylor 
M. A. et al. 2007).  
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Figure 1.1 The life cycle of Teladorsagia circumcincta.  
Images of T. circumcincta larvae and eggs courtesy of Dave McBean (Moredun Research 
Institute).  
 
Overwintering on pasture commonly occurs in the case of Trichostrongylid parasites, and 
T. circumcincta is no exception; a study carried out over a period of 3 years showed that 
mild winter conditions significantly increased the number of established worms within 
tracer lambs (Makovcova et al. 2009). Furthermore, T. circumcincta is able to undergo 
hypobiosis, or larval arrest; this may occur when L3 larvae are ingested by sheep in the 
autumn/winter seasons and the arrested early L4 can survive for up to 6 months within the 
host before resuming development. While the processes surrounding larval arrest in 
parasitic nematodes are still not fully understood, it is hypothesised that there is a role for 
both environmentally induced hypobiosis and immune-mediated arrest (Gibbs 1986). 
Furthermore, at lambing time ewes experience a temporary loss of immunity (6-8 weeks 
peri-partum) which results in increased worm burdens and subsequent increased egg 
deposition on pasture. These eggs quickly develop into infective L3 stages in the warmer 
spring temperatures and are abundantly available for recently born, growing lambs to 
ingest (Barger 1993, Gibbs and Barger 1986, Houdijk et al. 2005, Jeffcoate et al. 1992), 
thus optimising spread of infection.   
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1.1.2 Pathology and disease   
Epidemiologically, clinical teladorsagiosis is commonly observed during the summer 
months (Taylor M. A. et al. 2007), although pure teladorsagiosis is less common than PGE 
caused by mixed parasitic infections. The associated clinical signs of PGE range from 
suppressed appetite to diarrhoea, quickly followed by dehydration and sometimes death in 
heavy infections (i.e. a mixed species parasite burden of ~10 000 worms in sheep) 
(Radostits O.M.  et al. 2007); however, the major impact of teladorsagiosis is its effect on 
lamb productivity via a reduction in weight gain (Gibson and Everett 1976). The clinical 
signs and loss of weight gain arise from the physical damage caused by larvae and adult 
worms’ activity on the mucosal surface of the abomasum. It is known that T. circumcincta 
infection suppresses the appetite and induces significant slowing of muscle tissue 
deposition compared to uninfected sheep (Greer et al. 2008). The same study showed that 
by suppressing the host immune response with corticosteroids it was possible to reinstate 
the lost appetite and weight gains, even though the sheep thus treated showed higher FEC 
and worm burdens. This suggests that part of the economic loss due to T. circumcincta 
infection might be due to misdirected immune responses of the hosts which can put a 
check on the growth rates (Greer et al. 2008). 
Parasitic gastrointestinal infection impairs normal abomasal physiology: functional 
changes in the abomasum occur following T. circumcincta infection, which contribute to 
the clinical signs. For example, production of gastrin (a regulator of gastric secretions 
produced by gastric antral G cells in the gastric mucosa) increases through loss of negative 
feedback from gastric acid (Johnson 1987). As T. circumcincta infection can induce 
suppression of gastric acid production, thus increasing the abomasal pH (Simcock et al. 
1999), parasite infection can lead to hypergastrinemia (increases in serum levels of gastrin) 
as a result of parasite-induced damage to parietal cells. Hypergastrinemia was shown to 
occur during nematode infections with T. circumcincta and Haemonchus contortus in 
sheep, and Ostertagia ostertagi in cattle (Anderson et al. 1976, Fox et al. 1993, Scott et al. 
2000, Simpson et al. 1997). However, it has also been shown that in some sheep, plasma 
gastrin levels may return to lower pre-infection levels even though abomasal pH remains 
elevated (Simcock et al. 2006). An increase in the abomasal pH correlated with increased 
numbers of anaerobic bacteria (Simcock et al. 1999). Increased bacterial growth and 
abomasal pH can both impair protein digestion by the sheep host and contribute to cause 
diarrhoea (Radostits O.M.  et al. 2007). Other pathogenic effects of T. circumcincta 
include L3 larvae migrating into the gastric crypts, causing inflammation and immune cell 
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recruitment due to their antigenicity and tissue damage as they grow. The damaged 
abomasal mucosa allows increased permeability; in severe cases the mucosal permeability 
reaches such levels that a protein-losing enteropathy results [reviewed by Stear et al. 
(2003)]. Gross pathological examination shows areas of inflammation of the abomasal 
mucosa and parasitized glands; these reveal altered cell composition and mucous cell 
hyperplasia in histological specimens (Simpson 2000). Furthermore, as a sign of immune 
cell mobilisation following infection, significant increases of eosinophils, CD4
+
 and γδ T 
cells were identified within the abomasal mucosa (Balic et al. 2003). 
1.1.3 Sheep immune response to T. circumcincta 
A protective immune response can be elicited against T. circumcincta following grazing on 
infected pasture (Taylor M. A. et al. 2007), or experimentally by continuous “trickle” 
infection over a period of several weeks (Seaton et al. 1989). Studies have shown that this 
immunity occurs through several mechanisms, against different stages of the parasite, such 
as increased worm loss by exclusion/expulsion of L3 stages, impaired larval development 
at the L4 stage and reduced fecundity in adults (Halliday et al. 2007, Smith et al. 1985, 
Stear et al. 1995, Stear et al. 1999, Strain et al. 2002). Locally produced IgA from the 
gastric environment and lymph nodes (Halliday et al. 2007, Smith et al. 2009) and 
circulating IgE (Huntley et al. 2001, Pettit et al. 2005) were shown to be associated with 
the protective sheep immune response to T. circumcincta. During T. circumcincta 
infection, gastric lymph total IgA and IgA from abomasal mucosae scrapings negatively 
correlated with the length of worms recovered from naturally or deliberately infected sheep 
(Smith et al. 1985, Stear et al. 1995, Stear et al. 1999, Strain and Stear 1999). However, 
the antibody response alone might not be sufficient to elicit a protective immune response 
to T. circumcincta and the recruitment of specialised cells in a T helper 2 (Th2)-biased 
environment, such as DCs, appears pivotal [reviewed by McNeilly et al. (2009)]. Other 
studies have shown the involvement of cellular immune responses by studying the 
expression of genes in the sheep abomasal mucosa and local lymph nodes. In these 
experiments, up-regulation of transcripts related to mucosal and immune cells such as 
integrins, galectins and various cytokines was shown to occur in sheep that have been 
previously infected then challenged with T. circumcincta, compared to sheep naïve to the 
parasite (Knight et al. 2011, Pemberton et al. 2012).  
The local immune responses against gastrointestinal nematodes in sheep involve mucosal 
inflammation, mastocytosis, eosinophilia, hyperplasia of goblet and mucus cells and 
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reduction in parietal cell numbers (Balic et al. 2003, Balic et al. 2000, Craig et al. 2014, 
Scott et al. 1998, Scott et al. 2000, Stevenson et al. 1994). A common host mechanism in 
response to GI inflammation is recruitment of lymphocytes. For example, sheep 
lymphocytes found in the caecum mucosa were activated by artificially induced 
inflammation and were found to migrate preferentially from subcutaneous or intestinal 
locations (Au et al. 2001). This is thought to be due to specific homing receptors in the GI 
tissues, which redirect immune cells to the site where they were first activated (Cahill et al. 
1977, Chin and Hay 1984, Kimpton et al. 1989). For example, in sheep the expression of 
integrin α4β7 on lymphocytes appears to confer their selective homing to the intestinal 
tract; furthermore, chemokines and their receptors have also been shown to be involved in 
sheep lymphocyte homing to the intestinal mucosa [reviewed by McNeilly (2008)]. These 
studies suggest that lymphocytes activated by T. circumcincta infection in the abomasum 
may be able to recirculate via the local gastric lymph nodes, efferent lymphatic ducts and 
blood back into the abomasal mucosa. Relevant to this, Smith and colleagues (1983) have 
shown a significant increase in lymphocytes in gastric lymph of T. circumcincta-naïve 
sheep 8 days after experimental infection with the parasite. In another study, in sheep 
rendered immune to T. circumcincta (by challenge with 50 000 L3 larvae), lymphocytes 
were collected from gastric lymph for up to 8 days after challenge and transferred 
intravenously to another genetically identical worm-free sheep (twins). These lymphocytes 
were able to transfer partial immunity following another T. circumcincta challenge, as 
defined by stunting or loss of worms compared to unchallenged controls (Smith et al. 
1986). The composition of efferent gastric lymph has since been characterised and showed 
increased levels of CD4
+
 and CD8
+
 T cells, B cells and IgA in sheep experimentally 
infected with a T. circumcincta trickle infection and subsequent bolus challenge, compared 
to control sheep that received a primary infection by bolus challenge only in an 
experimental infection setting (Halliday et al. 2009, Halliday et al. 2007).  
With regards to age of the hosts, it appears that immune responses to GI parasites such as 
T. circumcincta take longer to develop in lambs compared to older (> 12 months old) 
sheep. This is demonstrated by the increased morbidity, faecal egg counts and worm 
burdens in younger lambs (4.5 months old) following T. circumcincta infection compared 
to older animals (10 months old; Smith et al. 1985, Stear et al. 1999). These differences 
may be explained by the time taken for development of the adaptive immune system in 
young lambs: for example, γδ T cells which have characteristics of both the innate and 
adaptive immune response, and are not involved in antibody production, constituted 18 % 
of circulating T lymphocytes in sheep foetuses and 60 % of circulating T cell population in 
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4 weeks old lambs’ (Washington et al. 1992). The γδ T cells percentages halved to ~30% 
when reaching 3-4 months old, and reached values of less than 10% in the adult sheep, 
suggesting that a more specific adaptive immune response may develop with older age 
(Hein and Mackay 1991, Watson et al. 1994). Moreover, studies carried out using Merino 
sheep showed that weaner lambs between 4-8 months of age had a lower proportion of 
blood CD4
+
 and CD8
+
 T cells compared to adult sheep (Watson et al. 1994). This suggests 
that the comparatively low numbers of CD4
+
 cells in younger lambs might be insufficient 
to generate an effective Th2-type response and that specific adaptive immune responses 
may be compromised in young lambs. In previous studies, sheep older than 12 months had 
greater numbers of globule leukocytes and mucosal mast cells in the abomasal and small 
intestinal mucosae (Douch and Morum 1993), supporting the hypothesis that age plays an 
important role in the host response against GI parasites. 
1.2 Induction of the immune response 
It is widely accepted that helminth infections elicit a strong Th2 polarised immune 
response (Else 2005, Finkelman et al. 2004, Maizels et al. 2009a). The adaptive immune 
responses are characterised by the recruitment of naïve T helper cells upon recognition of a 
specific antigen by Pattern Recognition Receptors (PRRs) found on antigen presenting 
cells (APCs), such as macrophages and dendritic cells (DCs), though intervention of DCs 
might not always be required to initiate the process. The bias that a naïve Th cell may take 
towards Th1 or Th2 is dependent on the dose, type, presentation of the antigen. A soluble 
antigen (such as those released by helminths) may be sufficient, alone, to initiate a Th2 
response but it may not initiate a Th1 response, which instead requires the presence of 
microbial adjuvants which induce APCs to secrete cytokines such as IFN-γ, IL-2 and IL-12 
(Coico et al. 2003, Jankovic et al. 2001). A number of transcription factors, such as 
STAT6, GATA3 and the NFAT family to name a few, are involved in the initiation of the 
Th2 response by T cells; these factors contribute to the production of effector cytokines 
such as IL-4, IL-5, IL-9, IL-10, IL-13, and IL-21 (Anthony et al. 2007, Grencis 1997, 
Jankovic et al. 2001). The effector cytokines recruit other cell types and promote activation 
and expansion of CD4
+
 Th2 cells, plasma cells secreting IgE, eosinophils, mast cells and 
basophils, in a response that is similar to allergic reactions (Anthony et al. 2007, de Veer et 
al. 2007). Helminth infections can elicit both Th1 and Th2 responses, though Th2 tend to 
be more common. It appears that the protective Th2 responses observed during parasite 
infection can be of two types, either having a direct effect on the parasite (for example, in 
the model parasite, Heligmosomoides polygyrus, the protective Th2 responses mediate 
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worm expulsion), or protecting the host from pathology as it occurs during Schistosoma 
mansoni infection where the protective Th2 response down-regulates an otherwise 
pathological Th1-type response [reviewed in detail by Anthony et al. (2007)]. Studies 
using anti-IL-4 antibodies and IL-4 knock-out mice have shown a critical role for IL-4 in 
driving the host immune response towards a Th2 environment which may confer host 
protection in murine candidiasis, B. malayi and Nippostrongylus brasiliensis infections 
(Kopf et al. 1993, Osborne and Devaney 1998, Romani et al. 1992). Parasitic helminths 
also appear to be able to influence the host responses by inducing a regulatory immune 
response, in order to allow their own survival [reviewed by Maizels et al. (2009a, 2009b, 
2009c)].  
The developing protective immune response against nematode infections is often 
influenced by the presence of glycosylated antigens. The effect of glycosylation on the host 
response can be investigated by periodate treatment of parasite antigens using salts of 
periodic acid such as sodium periodate [NaIO4 (Eberl et al. 2001, Fairlie-Clarke et al. 
2010, Kooyman et al. 2007, Smith et al. 1994, Tawill et al. 2004)]. Sodium periodate salts 
are able to oxidise compounds that contain hydroxyl groups on two or more adjacent 
carbon atoms [vicinal diols, Figure 1.2 (O'Neil 2001)]. If the oxidation process takes place 
in a compound with a ring structure such as saccharide residues, the action of NaIO4 breaks 
bonds between adjacent carbons carrying a hydroxyl group, and generates aldehyde and 
ketone groups by forming double bonds with oxygen atoms in the hydroxyl groups. This 
changes the shape of carbohydrate epitopes (Kristiansen et al. 2010), potentially reducing 
the antibody and cell binding ability.  
 
Figure 1.2 The effect of Na periodate (NaIO4) on vicinal diols to form aldehydes and ketones. 
Adapted from: http://www.masterorganicchemistry.com/2011/10/21/reagent-friday-sodium-
periodate/ 
 
For example, it was shown that lymph node cells from mice immunised with periodate-
treated extracts of Brugia malayi or Caenorhabditis elegans produced significantly less IL-
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4 than mice immunised with the respective mock-treated extracts (Tawill et al. 2004). The 
results suggested that in this model of infection the presence of glycosylated antigens has a 
pivotal role in inducing a Th2-biased immune response.  In cattle, another study showed 
that deglycosylation of Dictyocaulus viviparus antigens using PNGase F resulted in 
reduced antibody reactivities to Excretory/Secretory (ES) antigens in sera of primary 
infected calves, suggesting that the carbohydrate moieties represented immunogenic 
epitopes (Kooyman et al. 2007). In the sheep parasite T. circumcincta, cathepsin F (Tci-
CF-1), a highly immunogenic L4 ES component (Smith et al. 2009), was shown to have 
two putative N-glycosylation sites in the full length Tci-CF-1 sequence (Redmond et al. 
2006). This could suggest that glycosylation of antigens may have an important role in the 
immune response against immunogenic antigens of this parasite. 
However, while glycan epitopes may stimulate immune responses, numerous studies have 
also reported immunosuppressive activities associated with helminth glycans. For example, 
helminths may produce host-like glycosylated antigens to mask their own, or other 
glycosylated molecules that mimic host cytokines. With these types of mechanisms, the 
host immune response may be misdirected towards an immunomodulatory response that is 
non-harmful for the parasite and may allow its survival [reviewed by Maizels and 
Yazdanbakhsh (2003), van Die and Cummings (2010)]. Many parasitic helminths produce 
glycosylated molecules that are putative ligands for lectin receptors on the surface of DCs 
such as Mannose Receptor (MR), CD209 (also known as DC-SIGN) and CD301 (or 
Macrophage Galactose-type C-type Lectin, MGL) (van Die and Cummings 2010). For 
example in mice, one of the main glycan antigens of schistosome eggs (lacto-N-
neotetraose) has been shown to induce in vivo peritoneal macrophages that secrete IL-10 as 
early as 2 hours after injection with the antigen, and that these cells promote in vitro a 
phenotype suppressive of naïve CD4
+
 T cell proliferation (Terrazas et al. 2001). This 
ability of parasites and their glycans to stimulate or modulate/suppress the host immune 
response can represent both an advantage and a disadvantage in the search for novel drug 
targets and vaccine antigens. Both parasitic and free-living helminths have been shown to 
possess a surface coat that is mainly composed of molecules that include lipids and glycans 
(Blaxter et al. 1992). The complexity of this surface coat suggests that they may be too 
complex structures to replicate in vitro. Also this additional layer interposed between the 
worm cuticle and the host immune response can act as decoy mechanism, preventing drugs 
from having an effect on the parasite, preventing initiation of a protective immune 
response and complicating immunoscreening methods to identify vaccine targets (Blaxter 
et al. 1992, Maizels 2009c, Tundup et al. 2012). 
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1.2.1 Alternatively activated macrophages (AAMΦ) 
A major effector cell type of the Th1 immune response is activated macrophages; these 
cells are able to, upon activation, express Tumor Necrosis Factor (TNF)-, inducible Nitric 
Oxide Synthase (iNOS), IL-1, IL-6 and IL-12 following contact with bacterial 
lipopolysaccharide (LPS) or Interferon (IFN)- (Coico et al. 2003). Macrophages of the 
Th1-type response have been named “classically activated” to distinguish them from a 
novel subset of macrophages responsive to IL-4 and IL-13, belonging to the Th2 arm of the 
immune response. These have been identified in recent years and named “alternatively” 
activated macrophages [AAMΦ; Stein et al. (1992) and reviewed by Gordon (2003)]. This 
type of macrophage has been extensively studied in mice; in this species, stimulation of 
peritoneal macrophages with IL-4 and IL-13 resulted in alternative activation, with 
significantly increased products of those genes that are IL-4/IL-13 dependent such as 
Resistin-like molecules (RELM), members of the chitinase family (FIZZ), chemotactic 
factors (Ym-1) and arginase 1 (Arg-1) (Gordon 2003, Loke et al. 2002, Raes et al. 2002). 
Properties of both classically and alternatively activated macrophages are shown in Figure 
1.3. Activation of the alternative macrophage phenotype is commonly observed during 
helminth infections (Flynn et al. 2007, Loke et al. 2000, Loke et al. 2002, Nair et al. 2003, 
Nair et al. 2005). For example, a study that used mice infected with Taenia crassiceps 
showed that acute infection caused Th1-biased activation of peritoneal macrophages, 
whereas chronic infections (> 4 weeks) caused a shift towards a Th2 alternatively activated 
phenotype in these cells (Rodriguez-Sosa et al. 2002). Fizz1 and Ym1 are genes 
characteristically upregulated in the Th2 response to helminth infections in mice. Both 
genes are highly upregulated at the sites of parasite migration and residence during chronic 
infection with the filarial nematode Litomosoides sigmodontis and acute infection with the 
gastrointestinal nematode N. brasiliensis (Nair et al. 2005). Alternative activation was 
demonstrated in vitro by stimulation of the ovine macrophage cell line MOCL7 with adult 
Fasciola hepatica homogenates and ES (Flynn et al. 2007). Furthermore, there is evidence 
that expression of a chitinase 3-like molecule (Chit3-L1, a member of the mammalian 
chitinases family such as Ym1 in mice) is upregulated in the abomasal mucosa and gastric 
lymph nodes of sheep following trickle infection and challenge with T. circumcincta, 
suggesting this parasite may also induce AAMΦ (Knight et al. 2007). 
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Figure 1.3 Schematic diagram showing the principal differences between classically and 
alternatively activated macrophages. 
Panel A: classical activation; panel B: alternative activation. Legend: LPS, 
lipopolysaccharide; IFN-γ, interferon-γ; MHC-II, major histocompatibility complex-II; TNF-α, 
tumour necrosis factor-α; IL, interleukin; MR, mannose receptor; TGF-β, transforming 
growth factor-β. 
 
A defining characteristic of AAMΦ is also the ability to inhibit cellular proliferation; for 
example, IL-4-dependent peritoneal macrophages from mice that received a B. malayi 
infection were able to reversibly inhibit the proliferation of human tumour cell lines (Loke 
et al. 2000). Another study showed that mouse macrophages (peritoneal exudate cells, 
PECs) primed in vivo with S. mansoni glycoconjugates (LNnT-Dex) were able to suppress 
the proliferation of CD4
+
 cells in vitro. However this phenomenon did not involve 
apoptosis, as demonstrated by the significant levels of IL-4 and IL-13 secreted in response 
to anti-CD3/CD28 stimulation following a period of rest of the CD4
+
 cells (Terrazas et al. 
2001). These data indicate that CD4
+
 T cells remained viable in the presence of 
suppressive LNnT-Dex-induced PECs and that they were able to resume cytokine 
production towards a Th2-biased response (Terrazas et al. 2001).  
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IL-10 is a cytokine that has been extensively studied and is produced by a number of cell 
types including T cells, macrophages and B cells. This cytokine is secreted by cell types of 
both the Th1 and Th2 response, and its main activity is in inhibiting cytokine synthesis and 
pro-inflammatory responses in Th1-biased environments (Moore et al. 1993). For example, 
in IL-10 knockout mice, the lack of this cytokine causes chronic enterocolitis and 
dysregulated inflammatory responses (Kuhn et al. 1993, Rennick et al. 1995). The 
inflammatory processes mediated by Th1-driven classically activated macrophages can 
result in immunopathology, if allowed to persist or escalate in the absence of the 
immunoregulatory cytokine IL-10 (Li et al. 1999).  
AAMΦ have been hypothesised to be a Th2 immunoregulatory mechanism that may 
suppress Th1-derived inflammatory responses, and the tissue damage that can occur (Allen 
and Loke 2001); both these effects could occur also through production of IL-10. AAMΦ 
have been shown to play a role during healing processes and able to limit pathology: a 
study using IL-4
-/-
 knock-out mice showed that IL-4 dependent alternative macrophage 
activation was necessary to protect the animals from mortality, liver pathology and sepsis 
due to S. mansoni-induced Th1 response (Herbert et al. 2004). 
1.2.2 Measures of systemic and local antibody responses during 
parasitic helminth infection 
1.2.2.1 Serum samples 
The IgG class of immunoglobulins is the predominant class in blood, lymph, cerebrospinal 
and peritoneal fluid; it is produced in monomers and has the longest half-life of all isotypes 
(Coico et al. 2003), approximately 10 days in the ovine host (Fukumoto and Brandon 
1982). The serum IgG response to any antigen is characterized by a primary peak of 
antibody secretion following the first immunisation with a vaccine or encounter with the 
pathogen, and by a secondary (anamnestic) response following another exposure to the 
same antigens. The secondary response peaks earlier, reaches higher titres, and is 
maintained for longer than the primary IgG response (Coico et al. 2003). These features 
and its long half-life in the serum make IgG the best isotype to measure the systemic 
immune response to a specific pathogen. On the other hand, the IgA class is the major 
immunoglobulin component of external secretions (produced not only systemically but by 
mucosal tissues too) such as saliva, colostrum, milk and mucus. IgA consists of a dimer 
joined by a secretory component which allows its transportation through the lamina 
propria and surface epithelium, from where it is secreted into the lumen. IgA has a half-
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life of 5-6 days (Coico et al. 2003). It has been shown that all or part of the IgA found in 
serum samples may originate from the local tissue/organ of interest (Beh et al. 1974, 
Cripps et al. 1974, Curtain and Anderson 1971), and therefore serum IgA may be used as a 
measure of local immune response. A recently published study investigated the 
correlations between levels of T. circumcincta-specific IgA in serum and abomasal mucus 
of sheep exposed to natural parasite infection and subsequently twice challenged with 50 
000 L3 larvae 12 weeks apart. The results showed that the serum IgA could be correlated 
to the IgA present in abomasal mucus of the same animals; however, the levels of systemic 
IgA were also dependent on the worm burdens of the sheep (De Cisneros et al. 2014). This 
suggests that as the sheep immunity responds locally to parasite infections by secreting 
mucosal IgA, these antibodies bind to the parasite and its ES products and the unbound 
fraction subsequently equilibrates between the mucosal and the systemic compartment via 
the lymphatic system (De Cisneros et al. 2014). Furthermore, an explanation for low 
parasite-specific serum IgA levels in sheep that carry a high worm burden could be due to 
most IgA produced locally binding to nematodes, therefore leaving only a relatively small 
proportion of nematode-specific IgA that can be transferred into serum (De Cisneros et al. 
2014). This suggests that although in most sheep serum IgA is directly correlated to the 
levels of abomasal IgA, in cases of high worm burdens the relationship may be inverted, 
and this could still pose problems in evaluating the local immune response as the worm 
burdens are generally not known until post-mortem examination. 
1.2.2.2 Antibody Secreting Cell (ASC) probes  
When infectious or inflammatory stimuli challenge the immune system, antigens are 
transported via afferent lymph ducts to the local draining lymph nodes by immune cell 
trafficking. Thus, lymph nodes become activated and cell proliferation and differentiation 
takes place (Mirsky et al. 2011). For this reason, culturing of cells derived from lymph 
nodes draining the site of infection can provide a powerful tool to study the local immune 
response to parasitic pathogens (McWilliam et al. 2012). By culturing in vitro cells 
isolated from lymph nodes and collecting the antibody-rich supernatant (ASC probes), it is 
possible to gain a snapshot view of the local challenge-specific antibody response. The 
antibodies generated are not only parasite- and stage-specific, they are also specific for the 
tissue region of the draining lymph nodes collected. This makes them powerful tools for 
immune studies, as each cell clone is specific for one parasite epitope and analysis of ASC 
probe reactivity avoids the polyclonality of serum antibodies (reviewed by McWilliam et 
al. (2012). The use of ASC probes in helminth immunology studies is not new. In 1994, 
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(Meeusen and Brandon 1994a) proved the validity of antigen-specific ASC probes in 
experiments with the cestode Taenia hydatigena in sheep, and in rodent models with the 
liver fluke F. hepatica (Meeusen and Brandon 1994b). Similarly, H. contortus antigens 
were identified, both in the L3 and L4 stages, by using ASC probes generated from the 
abomasal lymph nodes of infected animals (Bowles et al. 1995). One of these antigens, 
named Hc-sL3, was later identified and isolated from the L3 stage (Ashman et al. 1995). 
When injected intradermally with Al-hydrogel as adjuvant, Hc-sL3 was able to confer 
protection in sheep experimentally challenged with 10 000 H. contortus L3, as defined by a 
significant (p value 0.027) decrease in FEC compared to the unchallenged group (Jacobs et 
al. 1999). More recent studies using the ASC probe technique have led to the identification 
of Ascaris suum stage-specific antigens, with antibody binding patterns specific to the 
organ of provenance, of the ASC probes and different from serum antibody responses 
(Jungersen et al. 2001). In sheep infected with T. circumcincta, extensive studies on the 
local immune reactivity of ovine ASC probes have given further insight into the 
relationship between host and parasites (Balic et al. 2003). In this study, 18 months old 
sheep were sourced from pasture and, following levamisole treatment, housed in a worm-
free environment and trickle infected with 3000 T. circumcincta larvae each week for 9 
weeks. Following a rest period of 12 weeks, a group of sheep was challenged with 50 000 
T. circumcincta L3 and another group left unchallenged. The results showed a significant 
(p < 0.05) increase in weight of abomasal lymph nodes in the challenged sheep 5 days post 
challenge (dpc), compared to unchallenged animals. These experiments also showed that 
ASC probes from sheep trickle infected then challenged with T. circumcincta contained 
antibodies specific for L3, L4 and adult stages antigens (Balic et al. 2003). Taken together, 
their results confirm the ability of cells in the local site of infection (in this case, abomasal 
lymph nodes) to develop specificity for parasitic antigens in the course of an active 
infection, and that the antigens recognised are stage-specific; this confirmed the ability of 
the probes to monitor the immune response at the site of infection which is stage-specific 
and dependent on an active infection (Balic et al. 2003). For these reasons, one of the 
approaches used in the study here described was to collect abomasal lymph nodes from 
sheep that had been subjected to a T. circumcincta trickle infection and use the ASC probes 
thus generated as a tool to measure the local immune responses to various T. circumcincta 
native and recombinant antigens (Figure 1.4 shows the location of the abomasal lymph 
nodes in relation to the body of the abomasum). 
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1.2.2.3 Gastric lymph  
Successful implementation of a protocol to collect and re-infuse gastric lymph in sheep 
was first described by Smith et al. (1981). In this study, the authors showed that surgical 
cannulation of the common gastric lymph duct is a viable and efficient way to collect 
lymph samples draining the ovine stomach, which can be used for subsequent experiments 
(Figure 1.4 shows a diagram of the common gastric lymph duct in sheep). The authors 
have shown that T. circumcincta-specific IgA was significantly higher in lymph from 
sheep previously infected compared to the controls and that the mean lymph to serum IgA 
ratio (calculated from the IgA concentrations in paired lymph/blood samples collected on 
the same day) was suggestive of the abomasum being the source of IgA antibodies during 
T. circumcincta infection (Smith et al. 1981). Additionally, the fore-stomachs (rumen, 
reticulum and omasum) are lined with non-glandular epithelium which contrary to 
abomasal mucosa, contains very few IgA-staining plasma cells (Smith et al. 1981), 
suggesting that lymph draining the ruminant stomachs has abomasal provenance. In 
subsequent studies which used the same surgical technique, parasite-specific IgA antibody 
responses were observed after T. circumcincta challenge of animals which had previously 
been infected with T. circumcincta (Smith et al. 1983), showing that T. circumcincta-
specific antibody titres became significantly higher following parasite challenge. 
Teladorsagia circumcincta L4-specific IgA was also detected in gastric lymph of later 
experiments (Halliday et al. 2010, Halliday et al. 2007), confirming that gastric lymph is 
an ideal tool for investigation of local abomasal immunity against the parasite. 
 
Figure 1.4 Schematic representation of the abomasal lymph node chain and the common 
gastric lymph duct location in sheep, in relation to the main body of the abomasum. 
The common gastric lymph duct (indicated by top arrow) drains efferent lymph from the 
abomasal lymph nodes (pink circles), situated on the smaller curvature of the abomasum. 
Adapted from Hein et al. (2004). 
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1.3 Control of parasitic infections 
1.3.1 Anthelmintic treatments 
Teladorsagiosis is a major problem in the sheep industry and control of the parasite relies 
heavily on the use of anthelminthic drugs. Three major classes of chemicals are used: 
benzimidazoles (BZs), levamisole and macrocyclic lactones (MLs, of which the prototype 
is ivermectin). These drugs have different mechanisms of action against the nematodes. 
Benzimidazole-based drugs bind nematode β-tubulin within the parasite’s cells, thus 
preventing microtubule formation and ultimately leading to cell lysis (Prichard 1990). 
Levamisole is another type of anthelmintic drug that acts as a cholinergic agonist at 
neuromuscular junctions (McKellar and Jackson 2004). It is thought that ivermectin and 
other MLs act by competing with gamma amino butyric acid (GABA) and cause paralysis 
of the nematode somatic muscles, through stimulation of glutamate-gated chloride 
channels (Feng et al. 2002). Recently, two new classes of anthelmintics have been 
introduced:  the amino-acetonitrile derivatives (AADs, for example monepantel) which act 
on nematode-specific nicotinic acetylcholine receptors different from those affected by 
levamisole (Kaminsky et al. 2008), and the spiroindoles which are able to block cation 
channels in nematode muscle cell membranes (Little et al. 2011). Despite the number of 
drugs available to treat sheep against GI nematodes, heavy use of all classes and 
underdosing of animals has resulted in widespread anthelmintic resistance. Although 
anthelmintic resistant parasites were already known in the late 1950s (Drudge et al. 1957), 
these had resistance to one class of anthelmintic at any given time and isolates that showed 
resistance to more than one type of drug had been relatively rare. In recent years however, 
single T. circumcincta isolates showing multiple resistance to the three most commonly 
used drug classes have been identified (Bartley et al. 2003, Bartley et al. 2005, Sargison et 
al. 2005, Sargison et al. 2010, Sutherland et al. 2008). These parasite populations pose a 
threat to the sheep industry, and it was reported that some farms were forced to stop all 
sheep operations until clear of the offending parasites (Blake and Coles 2007, Sargison et 
al. 2005). Alternative means of controlling these parasites are urgently needed and an 
increasing effort has recently focused on studying T. circumcincta development and 
survival, in order to identify other potential drug targets. Studies have focused for example 
on the moulting mechanism of the parasite (Stepek et al. 2010a, 2010b). Other studies have 
focused on anthelmintic candidate molecules from plants, such as cysteine proteases from 
papaya latex which have been shown to decrease motility of the mouse parasite 
Heligmosomoides bakeri when co-incubated (Behnke et al. 2008, Stepek et al. 2005).  
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1.3.2 Pasture and flock management  
Although the current dependency on anthelmintic drugs must change in order to stop the 
spread of resistant strains, alternative measures of parasite control such as pasture rotation, 
grazing on tannin-rich plants, manipulation of protein nutrition of the ewes and the use of 
nematophagous fungi are not sustainable practices in the current intensive farming 
industry, for reasons of practicality and costs involved (Sargison et al. 2005).  
Studies have shown that different sheep breeds have different susceptibility to parasitic 
infection and that individuals respond differently to parasite challenge, depending on their 
genotype (Bahirathan et al. 1996, Golding and Small 2009, Good et al. 2006, Miller and 
Horohov 2006). Flock management practices such as breeding of resistant sheep may be an 
option; however, tropical breeds which have shown higher resistance to parasitic infection 
are also less productive under intensive farming techniques than the European-derived 
breeds (Bisset et al. 2001). In addition, although the heritability of genetic traits that appear 
to correlate with parasite resistance (such as low FEC) is similar to other genes of 
productive traits (e.g. meat and wool production), these tend to negatively correlate [i.e. 
sheep resistant to parasitic infection tend to show unfavourable growth rates/fleece weights 
under parasite challenge (Bisset et al. 2001)]. A better option may be to breed parasite 
resilient sheep (less production losses under parasite challenge), than resistant sheep per se 
(lower FEC under the same infection conditions). Introducing resilience in a flock is a less 
straightforward process than introducing resistance, as heritability of the latter trait is 
higher (i.e. a larger proportion of the phenotype observed is due to genetic factors than 
environmental) [reviewed by Bisset et al. (2001)]. The process used to identify the resilient 
sheep (“drench-on-demand”) is similar to the process described as targeted selected 
treatments [TST (Kenyon and Jackson 2012)], albeit with slightly different aims. Both 
result in only some of the animals in the flock being treated with anthelmintic drugs (poor-
doers under parasite challenge), leaving the others (well-doers) to continue the shedding of 
parasite eggs. This allows the establishment of a parasite population called refugia, which 
has not been exposed to anthelmintic drugs and therefore less likely to develop resistance 
(Besier 2012, Kenyon and Jackson 2012). At the same time, sheep that do not require 
drenching but still perform well (regardless of FEC) are the ones that should be retained 
for breeding as representative of the resilient flock. 
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1.3.3 Immunological methods (vaccines) 
An alternative approach to control parasitic helminth infection is the use of vaccines. A 
number of vaccination studies have been carried out with varying results. To date, 
successful immunization against parasitic nematodes has proved largely elusive, with few 
exceptions [reviewed by Geldhof et al. (2007), Newton and Meeusen (2003)]. Successful 
vaccines against helminths may constitute different parasite preparations: live attenuated 
parasite larvae (commercialised against Dictyocaulus viviparus); purified native antigens 
enriched for H11 and the H-gal-GP complex from Haemonchus contortus (Knox and 
Smith 2001) and purified ES-thiol fractions from Ostertagia ostertagi adult worms 
(Meyvis et al. 2007). A summary of those tested and the outcome of vaccination are 
summarised in Table 1.1. 
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 Table 1.1 Examples of immunisation trials against nematodes of livestock using whole 
parasites or native antigens purified from the parasites. 
 
Parasite 
species (host) 
Antigen(s) 
Administration 
route/adjuvant 
Reductions (%) 
References 
FEC 
Worm 
burdens 
D. viviparus 
(cattle) 
Irradiated L3 
larvae 
Oral/no 
adjuvant 
n.c. n.a.^ 
Jarrett et al. 
(1958) 
O. ostertagi 
(cattle) 
ES-thiol 
fractions 
IM/Quil A 62 0 
Meyvis et al. 
(2007) 
Oo-ASP IM/Quil A 74 47 
Meyvis et al. 
(2007) 
Oo-Gal-GP IM/Quil A 22.9 10.9 
Smith et al. 
(2000) 
T. circumcincta 
(sheep) 
L4 ES IM/Freund’s n.c. n.c. 
Rose 1976, 
(1978) 
Irradiated  L3 
larvae 
Oral/n.a. n.c. Stat sig 
Smith et al. 
(1982) 
H. contortus 
(sheep) 
H-Gal-GP IM/Quil A 96 71 
Smith et al. 
(1994, 2000) 
H11 IM/Quil A 99.9 93.6 
Roberts et al. 
(2013) 
HcsL3 SC/AlOH 61 54 
Piedrafita et al. 
(2012) 
Irradiated L3 
larvae 
Oral/n.a. 
Signif. 
delayed 
but not 
reduced 
0 
Smith and 
Angus (1980), 
Urquhart et al. 
(1966) 
Note: This table is not comprehensive. N.c., data not calculated but a reduction was 
apparent; Stat sig, statistically significant but % reduction was not provided; n.a.^, data not 
available as reduction in worm burdens but calculated as statistically significant (p value 
not reported reductions in morbidity and mortality. Adjuvants used: Quil A = Quil A saponin; 
AlOH = aluminium hydroxide. Administration of vaccination: SC = subcutaneous; IM = 
intramuscular. 
 
Helminth vaccine production using live attenuated/killed worms or purified native antigens 
can present difficulties, such as obtaining sufficient quantities of parasite material from 
which to purify protective antigens, and the need to guarantee batch variability, antigen 
stability and biosafety (for the potential presence of adventitious agents) in a large 
industrial production scale (Smith and Zarlenga 2006). For these reasons, parasite vaccine 
research is currently focused on the development of recombinant antigens which should 
overcome the issues outlined above. Recombinant antigen vaccines have been 
demonstrated to be successful against cestodes [reviewed by Lightowlers (2006, 2003)].  
Currently, researchers are increasingly focusing on the production and testing with a focus 
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on antigens identified from parasite Excretory/Secretory (ES) products, gut extracts or 
somatic extracts (Newton and Meeusen 2003, O'Donnell et al. 1989, Redmond et al. 2006, 
Smith et al. 2009). 
The hypothesis behind the use of recombinant antigens is that immunisation of animals 
with a synthetic antigen can achieve a protective immune response, by inducing antibody 
or cellular responses which are able to recognise the native versions of the proteins (Coico 
et al. 2003). This immune response can be similar to that elicited by natural infection 
against parasite antigens which are presented to the host immune system, but also directed 
against “hidden” antigens, such as those present in gut tissues of parasites (Knox 2000). 
There have been a number of helminth recombinant antigens generated with various 
expression systems, achieving very variable and at times inconclusive results when used in 
vaccine and challenge experiments. For example, 3 immunisations of dogs with the 
catalytically active Pichia pastoris-expressed Ac-CP-2 antigen (a cysteine protease) from 
the hookworm Ancylostoma caninum achieved significant reductions in the geometric 
means of faecal egg output [approximately 13 000 eggs/g faeces (epg) and ~ 5000 epg  in 
controls and immunised dogs, respectively] following intradermal challenge with 500 A. 
caninum L3 (Loukas et al. 2004). In contrast, a baculovirus-expressed version of the 
activation-associated secreted protein Oo-ASP-1 did not confer protection against O. 
ostertagi challenge when used to immunise calves (Geldhof et al. 2008), although previous 
immunisation studies showed that native O. ostertagi ASP proteins were protective against 
homologous challenge (Meyvis et al. 2007). 
Vaccine candidates are selected for recombinant expression on the basis of genomic and 
transcriptomic information (cDNA and EST data) (Dalton et al. 2003, Menon et al. 2012, 
Nagaraj et al. 2008), proteomic approaches (Smith et al. 2009) and immune recognition of 
the orthologous/homologous native protein (Nisbet et al. 2009). However, if the 
recombinant version fails to induce a protective immune response it is not known whether 
this is due to inappropriate adjuvant choice (which would affect antigen presentation), 
incorrect form/folding of the recombinant, or whether the original native antigen was not 
an appropriate choice, possibly due to lack of immunological or biological knowledge of 
the native antigen [reviewed by Geldhof et al. (2007), Smith and Zarlenga (2006)].  It has 
been hypothesised that the recombinant versions of nematode antigens produced using 
standard expression systems such as bacteria, yeast and baculovirus, may show high 
degrees of dissimilarity with the native forms. Therefore, antibody or cellular immune 
responses generated against these versions would be less able to recognise the native forms 
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when encountered during a challenge infection (Geldhof et al. 2002, Meyvis et al. 2008, 
Newton and Meeusen 2003). Examples of immunisation trials using recombinant 
nematode vaccine antigens are provided in Table 1.2. 
Differences in conformation and Post Translational Modifications (PTMs) may occur using 
traditional expression systems, especially when dealing with organisms taxonomically very 
distant, leading to the production of enzymes lacking correct folding or with defective 
PTMs and impaired functions [reviewed by (Geldhof et al. 2007). Some nematode proteins 
are highly glycosylated with unique structures such as core α1→3-fucose residues that may 
be nematode-specific (Cipollo et al. 2002, Dell et al. 1999, van Die et al. 1999), and 
appear to be important in stimulating the host immune response. For example, calves 
vaccinated with irradiated D. viviparus larvae show a strong but short-lived serum 
antibody response directed to N-glycans on the nematode surface (Kooyman et al. 2007). It 
is possible that these glycans may be important for vaccination and could have an 
important role establishing a protective immune response.   
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Table 1.2 Examples of immunisation trials using nematode recombinant antigens. 
 
Parasite 
(host) 
Antigen(s) 
Expression 
system 
Administration 
route/adjuvant 
Reduction (%) 
References 
FEC 
Worm 
burden 
O. ostertagi 
(cattle) 
Oo-ASP-1 Baculovirus IM/Quil A 0 0 
Geldhof et al. 
(2008) 
Oo-HSP-18 Baculovirus IM/Quil A -12 -38 
Vercauteren 
et al. (2006) 
A. caninum 
(dog) 
Ac-CP-2 P. pastoris 
IM/AS02, AS03, 
Alum 
Stat 
sig (all 
3 adj) 
Stat sig 
(all 3 
adj) 
Loukas et al. 
(2004) 
T. 
circumcincta, 
H. contortus 
(sheep) 
PP2Ar from 
Angiostrongy
lus 
costaricensis 
E. coli 
Intranasal/ 
Bacterial cell 
walls 
Stat 
sig † 
> 68 † 
Mohamed 
Fawzi et al. 
(2013) 
T. 
circumcincta 
(sheep) 
Tci-CF-1*, 
Tci-APY-1
#
, 
Tci-MEP-1
#
, 
Tci-ES20*, 
Tci-MIF-1
#
, 
Tci-TGH-2
#
, 
Tci-SAA-1
#
, 
Tci-ASP-1
#
 
E. coli (
#
)
 
or 
P. pastoris 
(*) 
IM/Quil A 70-58 55-57 
Nisbet et al. 
(2013) 
H. contortus 
(sheep) 
H11 
C. elegans 
SC/Vax saponin 0 0 
Roberts et al. 
(2013) 
Cathepsin L IM/Quil A 0 0 
Murray et al. 
(2007) 
ES15/ES24 E. coli SC/DDA 0-42 55 
Vervelde et 
al. (2002) 
H-Gal-GP 
E. coli, insect 
cells 
IM/Quil A 2.5 0 
Cachat et al. 
(2010) 
Note: This table is not comprehensive. Stat sig, statistically significant but % reduction was 
not provided; †, reduction was significant (p < 0.05) in immunised and challenged sheep 
compared to control animals which were not immunised (and not injected with adjuvant) 
and received same challenge infection. Adjuvants used: Quil A = Quil A saponin; AS02A = 
monophosphoryl lipid A and QS21 (saponin)-based adjuvant; AS03 = squalene, DL-α 
tocopherol and polysorbate 80-based adjuvant; DDA = dimethyl dioctadecyl ammonium 
bromide. Administration of vaccination: SC = subcutaneous; IM = intramuscular. 
 
1.4 Vaccination trials using T. circumcincta recombinant 
antigens 
Sheep can acquire immunity against T. circumcincta and therefore vaccination is a possible 
alternative to anthelminthic control. While a few promising studies have reported progress 
towards a vaccine using recombinant antigen technology for T. circumcincta (Nisbet et al. 
2013, Redmond et al. 2006, Smith et al. 2009), no commercial vaccine against this parasite 
has been developed. Recent studies carried out at MRI identified a series of potential 
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vaccine candidates for T. circumcincta, which have subsequently been tested in 
immunisation trials (Nisbet et al. 2013). This work focused on a panel of 8 immunogenic 
molecules. These included Tci-CF-1, Tci-MEP-1, Tci-ASP-1 and Tci-ES20, which are 
present in larval Excretory-Secretory (ES) products. These were identified by proteomics 
and immunoscreening of T. circumcincta L4 ES with abomasal IgA probes generated from 
experimentally induced T. circumcincta-immune sheep (Nisbet et al. 2010a, Redmond et 
al. 2006, Smith et al. 2009). Another molecule, Tci-SAA-1, was chosen because of its 
homology with another known surface antigen of hookworm, previously used as a vaccine 
candidate (Nisbet et al. 2009). The final three potential vaccine candidates (Tci-MIF-1 
(Nisbet et al. 2010b), Tci-APY-1 (Nisbet et al. 2011) and Tci-TGH-2 (McSorley et al. 
2010) were investigated on the basis of their putative immunoregulatory functions at the 
host:parasite interface. These antigens were cloned, sequenced and expressed in bacterial 
or yeast expression systems. The cocktail of eight antigens thus developed was used to 
immunise lambs (by means of 3 injections, each including all 8 antigens), which were 
subsequently challenged with a T. circumcincta trickle infection of 4 weeks duration. 
Under these experimental conditions, the recombinant vaccine showed, in two 
immunisation trials, that a significant reduction in egg output (70 % and 58 % reduction in 
faecal egg count in trial 1 and 2, respectively) and adult worm burdens (75 % and 56 % in 
trials 1 and 2, respectively) could be achieved (Nisbet et al. 2013). These very promising 
results have shown that indeed it is possible to vaccinate sheep against T. circumcincta 
with recombinant antigens and achieve protection. However, the purified recombinant 
proteins did not always show optimal expected biological or catalytic activity in in vitro 
assays (e.g. Tci-MIF-1) and it was hypothesised that the recombinant proteins could have 
various degrees of dissimilarity from the native forms, and may therefore induce sub-
optimal immune responses against the native forms of the antigens. It is also still unclear 
whether all the components in this recombinant vaccine had a critical role in inducing the 
protective immune response and further work is required to characterise the recombinant 
vaccine components. 
1.5 Parasitic nematode Excretory/Secretory (ES) 
products  
A number of parasitic nematodes have been shown to excrete and secrete a variety of 
molecules during in vitro culture, and it is thought that this also happens during their 
persistency within the host. These molecules have been named Excretory/Secretory (ES) 
products; ES products were classified as molecules released from specialized secretory-
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excretory organs or as antigens associated with the parasite’s gut or derived from the 
external tegument of the parasite. An extensive description of helminth ES products was 
published more than 20 years ago (Lightowlers and Rickard 1988). This complex mixture 
includes molecules released by the parasite during in vitro culture, which are known or 
presumed to be released in vivo; many of these molecules are released in a stage-specific 
manner (Knox 2000). Studies have focused on the investigation of ES components and 
functions, hypothesising various functions carried out by ES products, including aid during 
host penetration, parasite feeding and evasion of host anti-parasite immune responses, 
including enzymes such as proteases, acetylcholinesterases and superoxide dismutases 
[reviewed by Hewitson et al. (2009), Knox (1994, 2000)]. For example, S. mansoni egg 
antigen (SEA) stimulation induced in vitro suppression of human T cell populations by an 
IL-10-mediated mechanism (King et al. 1996). In another in vitro experiment with the 
filarial parasite B. malayi, PBMC from infected patients stimulated with live L3 or 
microfilariae showed significantly lower cytokine production compared to PBMC from 
uninfected people (Babu et al. 2006). In mice, ES products from the parasite N. brasiliensis 
can inhibit LPS-dependent neutrophil recruitment to the lungs following experimental 
intranasal administration; in addition, H. polygyrus ES and somatic extracts could inhibit T 
cell proliferation and macrophage nitric oxide production in in vitro studies (Marsland et 
al. 2005, Rzepecka et al. 2006).  
In a number of parasite ES products, including T. circumcincta, venom allergen-like 
(VAL) molecules (part of the Activation-associated Secreted Protein (ASP)-like family of 
antigens) have been identified and a role in immunomodulation was suggested (Hewitson 
et al. 2009). Indeed immunosuppressive effects of ES products appear to be conserved in 
the interaction of T. circumcincta with the sheep host. A recent study by Grainger et al. 
(2010) showed the ability of T. circumcincta L4 ES to induce Foxp3 expression (a 
transcription factor associated with T regulatory cell functions) on the surface of murine 
activated CD4
+
 T cells in vitro, suggesting that the parasite may be able to induce this type 
of cell during infection in the definitive host. Furthermore, McNeilly and colleagues (2013) 
were able to confirm that Foxp3
+
 cells were present in the abomasum of infected sheep 
during the early stages of infection, when the L4 stages are predominant. Even more 
interestingly, a major effect of T. circumcincta L4 ES on ovine PBMC was the profound 
suppression of mitogen-induced proliferation; this effect was observed to be heat labile, 
and associated with lack of IL-2Rα up-regulation, suggesting that T. circumcincta ES may 
be able to influence the early activation of T cells.  
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It has been previously shown that ES products from the liver fluke F. hepatica can 
suppress in vitro proliferation of ovine lymphocytes (Jefferies et al. 1996). In particular, 
one F. hepatica ES component, Cathepsin L, was shown to cleave CD4 receptors from 
ovine T cells and that by preventing activation of T helper cells this trematode may be able 
to evade the host immune system (Prowse et al. 2002). In mice, the same F. hepatica 
Cathepsin L protease provoked suppression of Bordetella pertussis-induced IFN-γ 
production, suggesting that this molecule may have an important role in suppressing the 
host Th1 immune response to infection (O'Neill et al. 2001). A cysteine protease, named 
cathepsin F (Tci-CF-1), had been identified as the most abundant L4 ES antigen in T. 
circumcincta (Redmond et al. 2006), and it was hypothesised that this enzyme may be 
responsible or contribute to the suppression of PBMC proliferation observed in sheep. 
Whole T. circumcincta L4 ES was shown to suppress the in vitro proliferation of sheep 
lymphocytes, and the addition of the cysteine protease inhibitor E-64 did not appear to 
affect the inhibitory effect observed (McNeilly 2013). However, direct in vitro experiments 
using purified Tci-CF-1 have not yet been published and at the time of writing it was not 
possible to completely rule out the involvement of Tci-CF-1 in inhibiting sheep cell 
proliferation. 
1.6 Selection of a panel of antigens for this study 
In order to immunise sheep with T. circumcincta antigens in the search for a successful 
vaccine against this parasite, E. coli and P. pastoris expression systems have previously 
been used (Nisbet et al. 2013). However, traditional expression systems such as bacterial 
and yeast cells have potential issues for the generation of vaccine candidates against 
nematodes, in terms of incorrect protein folding, or inappropriate or missing PTMs. In 
addition, not all recombinant vaccine candidates are able to induce a protective antibody 
response able to recognise the native homologues [reviewed by Geldhof et al. (2007), 
Smith and Zarlenga (2006)]. For these reasons, the choice of expression system in this 
study was directed towards a novel type, the nematode C. elegans, which has been shown 
to generate enzymatically active recombinant enzymes and is taxonomically closer to T. 
circumcincta than E. coli or yeast cells (Blaxter et al. 1998, Murray et al. 2007, Roberts et 
al. 2013). The choice for the panel of T. circumcincta antigens selected for expression in 
C. elegans was based on the following criteria i) recombinant versions have already been 
generated and are available for comparative studies, ii) where the in vitro activity of these 
existing recombinants has been characterized it appears that they may not exhibit full 
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functional activity, prompting further studies, and iii) their biological properties are yet to 
be fully characterised. 
1.6.1 Cysteine protease, Tci-CF-1 
The large group of Cysteine (C) Peptidases is subdivided into families (e.g. C1, C2, etc) 
and sub-families (e.g. C1A and C1B); Cathepsin F enzymes belong to the sub-family C1A. 
The C1 family contains enzymes with very diverse enzymatic activity ranges. This 
includes endopeptidases with broad specificity (as in the prototype of this family, papain 
from Carica papaya) and others with narrower endopeptidase specificity (such as glycyl 
endopeptidase), aminopeptidases, and peptidases with both endo- and exopeptidase activity 
(such as Cathepsins B and H) while some family members do not have catalytic activity 
(Rawlings and Barrett 1994). The catalytic residues shared by members of the C1 family 
are cysteine (Cys) and histidine (His). Two other active site residues are found, a glutamic 
acid (Gln) residue preceding the catalytic Cys and an asparagine (Asn) residue following 
the catalytic His. The Gln helps in the formation of the 'oxyanion hole' and the Asn in 
orientating the imidazolium ring of the catalytic His. In those non-peptidase homologues, 
the catalytic residues have been replaced by other residues [see 
http://merops.sanger.ac.uk/index.shtml and (Rawlings et al. 2010)].  Peptidases of the C1 
family are synthesized with a signal peptide to allow their secretion or transportation to the 
lysosome; they also possess a pro-peptide region at the N terminus, which is cleaved for 
activation of the enzyme (Rawlings and Barrett 1994) and they may be modified at N-
glycosylation sites within their amino acidic sequence (Redmond et al. 2006, Santamaria et 
al. 1999). Cathepsin-like cysteine proteases have been identified in many species, both 
prokaryotes and eukaryotes (Berti and Storer 1995, Rawlings and Barrett 1994). In 
helminths, various types of cathepsin enzymes have been identified in the phylum 
Trematoda (O'Neill et al. 2001, Pinlaor et al. 2009, Prowse et al. 2002, Robinson et al. 
2008, Sripa et al. 2010), Cestoda (Li et al. 2006, Sako et al. 2007) and Nematoda (Britton 
and Murray 2002, Murray et al. 2007, Redmond and Knox 2004, Redmond et al. 2006). 
Cathepsin F is one member of the C1A sub-family that has been characterised in many 
species including humans, mice and helminths (Deussing et al. 2000, Pinlaor et al. 2009, 
Santamaria et al. 1999, Wang et al. 1998). Cathepsin F protein was identified by 
immunoblot in T. circumcincta in ES material from L4 larvae (Redmond et al. 2006). The 
protein, Tci-CF-1, has an amino acid sequence of 364 residues (mature enzyme: 214 
residues) and the mature enzyme has an estimated molecular mass of ~24 kDa (Redmond 
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et al. 2006). Two N-glycosylation sites were predicted, one in the pro-region and one in the 
mature enzyme; glycosylation was later confirmed in lectin-binding affinity experiments 
(Redmond et al. 2006). The relationship between Tci-CF-1 and homologous sequences 
from O. ostertagi, H. contortus, C. elegans and Brugia malayi was explored by 
phylogenetic analysis of EST data, which showed the presence of close homologues in 
these other species (Redmond et al. 2006). The transcript is only found in L4 and adult 
stages of T. circumcincta, and not in the pre-parasitic stages, suggesting a particular role in 
the host (Redmond et al. 2006). More recent studies have identified Tci-CF-1 as the 
predominant transcript expressed in the L4-specific nucleotide dataset, and the most 
abundant molecule in L4 ES (Nisbet et al. 2008, Redmond et al. 2006). This enzyme has 
been expressed in recombinant form using the yeast P. pastoris and was included in a 
protective vaccine against T. circumcincta (Nisbet et al. 2013). In sheep immunised with 
this recombinant protein then trickle infected with T. circumcincta L3 there was an 
increase in Tci-CF-1-specific serum IgA and IgG; however in the serum of control sheep 
(trickle infected but not immunised) neither IgA nor IgG binding occurred to the 
recombinant Tci-CF-1 version (Nisbet et al. 2013). These results suggest that Tci-CF-1 
expressed in P. pastoris may not have an optimal structure or correct PTMs in order to 
stimulate the optimal protective immune response required against natural infection. 
1.6.2 Monocyte Migration Inhibitory Factor (MIF), Tci-MIF-1 
A cytokine identified in the mid-1960s and later named Migration Inhibitory Factor (MIF) 
had been shown to play an important role during delayed hypersensitivity reactions in 
guinea pigs (Bloom and Bennett 1966, David 1966). The first type of biological activity 
identified was the inhibition of cell migration. Studies showed that this effect can span 
species differences, when Thor et al. (1968) used human MIF to inhibit guinea pig 
peritoneal macrophage migration. Since then, human and mouse MIF proteins have been 
cloned and characterised (Bernhagen et al. 1994, Weiser et al. 1989), and other functions 
of this cytokine have been described. The first report of the tautomerase activity of MIF 
was provided by Rosengren et al. (1996). Tautomerase activity was defined as the ability 
of an enzyme to catalyse the reaction from dopachrome to 5,6-dihydroxyindole-2-
carboxylic acid [DHICA (Rosengren et al. 1996)]. The same research group showed that 
MIF is also a keto-enol isomerase (Rosengren et al. 1997). Furthermore, mammalian MIF 
has been shown to also possess oxidoreductase activity, dependent on a specific amino acid 
motif (the CALC motif; Kleemann et al. 1998). Biological effects of MIF include a marked 
pro-inflammatory effect, as shown by the increase in lethality of LPS-induced endotoxic 
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shock in mice when recombinant murine MIF was injected (Bernhagen et al. 1993, 
Calandra et al. 1995, Roger et al. 2001).  
MIF protein can be produced not only by activated T cells but also by macrophages 
(Calandra et al. 1995). More recently, a further role in the complex activity of MIF has 
been shown: parasite-derived MIF was associated with the in vivo induction of the 
alternatively activated phenotype (AAMΦ) in peritoneal exudate cells (PEC; a type of 
macrophages) of mice which received intraperitoneal injection of B. malayi L3 stages or 
purified recombinant Bm-MIF-1 (Falcone et al. 2001, Loke et al. 2002). In another study, 
recombinant Bm-MIF-1 was able to induce in vitro the alternatively activated phenotype in 
bone marrow-derived mouse macrophages (Prieto-Lafuente et al. 2009). For example, it is 
thought that the continuous release of Bm-MIF by adult Brugia malayi worms in the host 
may activate an anti-inflammatory pathway in accord with the anti-inflammatory 
phenotype of helminth infection (Kleemann et al. 2000, Maizels and Yazdanbakhsh 2003). 
The debate on the complete roles of MIF is still open, and research on this cytokine 
continues; as described above, the apparent contrasting pro- and anti-inflammatory 
qualities make MIF an interesting subject in the study of the more general biology of the 
immune response to pathogens. A number of MIF homologues have been identified in 
numerous species, including sheep, cattle, ticks, fish and a number of parasitic nematode 
species (Galat et al. 1993, Jaworski et al. 2001, Lopes et al. 2011, Sato et al. 2003, 
Vermeire et al. 2008); such widespread conservation suggests important biological 
functions among organisms [reviewed by Calandra and Roger (2003)]. In studies aimed at 
identification of T. circumcincta vaccine candidates, a MIF-like protein was characterised 
in T. circumcincta L3 stage (Nisbet et al. 2010b). It has been hypothesised that T. 
circumcincta might excrete Tci-MIF-1 from its gut into the host, from where it could 
influence monocyte movement and activation in the abomasum. In that study, preliminary 
data showing Tci-MIF-1 acting as host cytokine mimic was presented; however, its ability 
to inhibit sheep monocyte migration was unconvincing and the presence of Tci-MIF-1 in T. 
circumcincta ES material has not been demonstrated (Nisbet et al. 2010b, Smith et al. 
2009). This suggests that the current existing recombinant version of Tci-MIF-1 may not 
have the correct structure and/or PTMs required to carry out the biological function of 
inhibitor of monocyte migration. However, the potential biological effects and 
immunoregulatory activity on the sheep host make Tci-MIF-1 a promising vaccine 
candidate worth further characterisation in its recombinant forms. 
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1.7 Caenorhabditis elegans as a novel expression 
system 
1.7.1 Model organism 
Caenorhabditis elegans is a free-living nematode which normally resides in soil. It is a 
multicellular organism with a 3.5-day lifecycle and exists in two sexes, hermaphrodite and 
male organisms. The gonad occupies most of the body cavity and is bilobed [see 
http://www.wormbook.org/]. C. elegans belongs to Clade V of the Phylum Nematoda 
(Blaxter et al. 1998) and is therefore related phylogenetically to T. circumcincta and other 
important veterinary trichostrongylid nematodes. 
C. elegans is an ideal model system in which to study nematode biology due to its 
simplicity, short life-cycle, availability of annotated genome sequence and ease of genetic 
manipulation (Brenner 1974, C. elegans Sequencing Consortium 1998). In this study, both 
Tci-CF-1 and Tci-MIF-1 will be expressed in recombinant form using C. elegans as an 
alternative expression system. Expressing proteins using C. elegans involves the cloning of 
the desired gene into an appropriate plasmid vector, which is then micro-injected into the 
gonad of young adult C. elegans hermaphrodites. The selected gene is injected together 
with another plasmid encoding a marker gene which generates an identifiable marker 
phenotype (Mello et al. 1991). The resulting progeny are screened for expression of the 
marker phenotype as an indication of successful transformation (summarised In Figure 
1.5). Individual worms are picked, separated and maintained in culture to assess their 
ability to generate a stable clone expressing the injected genes. After at least two 
generations, the line can be considered stable and the worms screened by PCR for 
inclusion of the gene of interest, or directly for protein expression (Murray et al. 2007, 
Roberts et al. 2013). Previous studies have shown that C. elegans can be used as an 
alternative to the traditional bacterial and yeast systems to express nematode proteins and 
to study conservation of function across species (Britton and Murray 2002, Murray et al. 
2007, Pillai et al. 2005, Redmond et al. 2001). Indeed C. elegans has been the expression 
system of choice in characterisation of the activity and immunogenicity of H. contortus 
cathepsin L cysteine protease (Murray et al. 2007) and more recently for the 
aminopeptidase H11 (Roberts et al. 2013). Both were shown to be active and glycosylated 
in C. elegans with similar glycans to those of the native parasite proteins. 
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Figure 1.5 Diagram showing the theory of the C. elegans transformation protocol by 
microinjection.  
Plasmids encoding the gene of interest and a marker gene are microinjected into the gonad 
of each C. elegans hermaphrodite (in pink). The progeny of each injected worm is screened 
for the presence/absence of marker phenotype; transformation is considered successful if 
worms maintain the transformed phenotype for subsequent generations, which can be 
isolated as a stable line. 
 
1.8 Aims of this study 
The overall aim of this work was to contribute to the further development of the prototype 
recombinant subunit T. circumcincta vaccine (Nisbet et al. 2013), by understanding the 
differential host immune response to native and recombinant versions of putative 
protective antigens and engineering the recombinant subunits to overcome such 
differences. Existing recombinant versions of T. circumcincta vaccine candidates may be 
inducing a sub-optimal immune response, most likely due to differing structure and/or 
PTMs compared to the native versions. In this respect, the overall aim of this work is to 
evaluate a nematode-based expression system, in an attempt to improve the existing 
recombinant versions in regards of their immune recognition and biological functions. 
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The specific aims of this work were: 
i) To investigate the sheep antibody response against native preparations of native Tci-CF-
1 (purified from T. circumcincta L4 ES) and compare these with immunisation-induced 
antibody responses to recombinant P. pastoris-expressed Tci-CF-1. This will be achieved 
using a combination of ELISA and Western blotting techniques with ovine biological 
samples of different provenance (serum, lymph node cell supernatants and gastric lymph), 
to highlight the differences between systemic and local immune responses to naive and 
recombinant Tci-CF-1. 
ii) To generate C. elegans-expressed recombinant T. circumcincta vaccine candidates. 
iii) To investigate the properties of recombinant versions of Tci-CF-1 and Tci-MIF-1; this 
will be achieved by characterisation of the specific enzyme activity, immunogenicity 
and/or effects on cell migration, cytokine release and gene expression as appropriate for 
each molecule. 
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Chapter 2 - Characterisation of Ovine Antibody 
Binding to Native and Recombinant Teladorsagia 
circumcincta cathepsin F (Tci-CF-1) 
  
2.1 Introduction 
Both cellular and humoral responses are involved in the acquired immunity to T. 
circumcincta parasites in sheep (Halliday et al. 2009, Halliday et al. 2007, Smith et al. 
1986, Smith et al. 1983). In this context, IgA antibodies have been associated with 
reductions in adult worm length by inhibiting worm growth and delaying worm 
development (Halliday et al. 2007, Stear et al. 1995, Stear et al. 1999, Strain et al. 2002), 
whereas IgE responses were correlated with reduced faecal egg counts (Huntley et al. 
2001, Pettit et al. 2005). Significantly higher levels of IgE against a “High Molecular 
Weight Allergen”, an L3 stage-specific T. circumcincta antigen, were observed in 6 month 
old lambs termed “responders” (with low cumulative FEC scores; mean values not 
available) when compared to sheep termed “non-responders” (those with high FECs; mean 
values not available; Huntley et al. 2001). Previous studies have shown that, in sheep that 
received a T. circumcincta L3 trickle infection followed by an anthelmintic treatment and a 
50 000 L3 bolus challenge seven days later, gastric lymph IgA reactivity to L4 
Excretory/Secretory (ES) products increased significantly from pre-challenge levels, 
between 6-10 days post challenge (dpc) (Halliday et al. 2007). During the course of a 
similar experiment, a negative correlation was found between worm burdens and L4 ES-
specific lymph IgA levels at 10 dpc (Routledge 2008). Teladorsagia circumcincta L4 ES-
specific serum IgG levels were shown to be significantly higher between 2 and 10 dpc in 
sheep that received an L3 trickle infection followed by a 50 000 L3 bolus  challenge 
(previously infected) compared to the control group (primary infected T. circumcincta 
naïve sheep which only received a bolus challenge; Routledge 2008). Although there is 
strong evidence to suggest that immunity against this parasite depends on the production of 
specific antibodies, the involvement of cellular immune responses cannot be excluded. 
Indeed, as discussed in a review by McNeilly et al. (2009), the recruitment of immune cells 
in a Th2-biased environment, such as DCs, mast cells, eosinophils and lymphocytes, 
appears pivotal in building a complete immune response to gastric parasites such as T. 
circumcincta (Balic et al. 2003, Balic et al. 2000, Craig et al. 2014, Scott et al. 1998, Scott 
et al. 2000, Stevenson et al. 1994). 
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Although serum IgA levels to T. circumcincta L4 somatic extracts were shown to be 
positively correlated with mucus IgA against the same antigens (Stear et al. 1995), serum 
IgA binding to these antigens showed heterogeneous antigen recognition patterns in 
individual sheep (Strain and Stear 1999). Variability in the individual sheep serum IgA 
response to L4 ES antigens was also documented (Routledge 2008). In an experiment 
carried out by Stear et al. (1995), 6-month old lambs exposed to natural mixed parasite 
infection were included in an experimental model where, after housing in a helminth-free 
environment for three months, they received two T. circumcincta bolus challenges (50 000 
L3, 12 weeks apart). In this study it was shown that as the worm burdens in the sheep hosts 
increased, there was a decrease in the proportion of T. circumcincta L4 somatic extract-
specific IgA transferred from mucosa to serum (Stear et al. 1995). These results were 
further confirmed by De Cisneros and colleagues (2014). Taken together, these examples 
suggest that, although easily accessible for sampling, serum might not represent the 
optimal sample type to measure local immune responses and the immunogenicity of T. 
circumcincta antigens in the sheep host. The possibility of surgically accessing the efferent 
lymph ducts draining the cranial digestive tract (including the abomasum) allows the 
collection of lymph draining the site of T. circumcincta infection (Smith et al. 1981). This 
technique has proved useful in understanding the kinetics of the local mucosal responses to 
T. circumcincta, providing an alternative to post-mortem derived abomasal mucus 
(Halliday et al. 2010, Halliday et al. 2009, Halliday et al. 2007, Smith et al. 1983, 1983). 
Additionally, Antibody Secreting Cell (ASC) probes, generated from lymph nodes 
anatomically close to the site of infection, have been shown to be a useful tool to 
investigate the parasite antigen-specific immune responses, providing a stage- and tissue-
specific snapshot of the antibody reactivity elicited by the parasites T. circumcincta, 
Ascaris suum, Haemonchus contortus, Ostertagia ostertagi, Taenia hydatigena and 
Fasciola hepatica  (Balic et al. 2003, Bowles et al. 1995, De Maere et al. 2002, Jungersen 
et al. 2001, Meeusen and Brandon 1994b, Meeusen and Brandon 1994a). 
ES products of helminths can provide antigenic stimulus to the host immune system, 
providing a valuable source of antigens and making ES products promising vaccine 
candidates against ruminant parasites (Knox 2000, Lightowlers and Rickard 1988, Nisbet 
et al. 2013, O'Donnell et al. 1989, Schallig et al. 1997, Vercauteren et al. 2004). For 
example, immunising calves with O. ostertagi thiol-enriched ES products resulted in a 
protective immune response against the parasite, with a significant reduction of 56–62 % in 
cumulative faecal egg counts (FECs) and a significant reduction in worm length following 
25 days (1000 L3/day, 5 days/week) of trickle infection (Geldhof et al. 2002, Geldhof et 
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al. 2004, Meyvis et al. 2007). The choice of adjuvant was also found to influence the 
outcome of the protection trials: calves vaccinated with O. ostertagi ES-thiol fractions and 
Quil A as adjuvant showed a 56 % reduction in FEC and significantly less eggs/female 
worms compared to animals vaccinated with O. ostertagi ES-thiol/aluminium hydroxide 
and an adjuvant control group (Geldhof et al. 2004). Ostertagia ostertagi thiol-bound ES 
was fractionated using a Q-Sepharose anion exchange column to separate components in 
activation-associated secreted proteins (ASPs), cysteine proteases and a further remaining 
fraction. Each was used to immunise calves and a significant reduction in FEC (70-80 %) 
and worm length was induced by each fraction compared to the control group (Meyvis et 
al. 2007). In another study, preliminary data on the immunisation of lambs using 
concentrated ES products from mixed stage T. circumcincta in Freund’s complete adjuvant 
resulted in lower worm burdens, worm lengths and FECs compared to the control lambs 
(Rose 1976, 1978). In these studies, although no statistical analysis was carried out, the 
data collected showed protective potential of the concentrated mixed-stage ES products 
used. Based on success of O. ostertagia ES-fractionation studies, further immunisation 
trials were carried out using a detergent-soluble, ConA-binding fraction of T. circumcincta 
L4 whole worms (Halliday and Smith 2011). This preparation however, contrary to the 
encouraging results shown by Geldhof et al. (2002, 2004) and Meyvis et al. (2007), 
showed that no protection could be achieved against T. circumcincta L3 bolus or trickle 
infection challenge with the L4 fraction (Halliday and Smith 2011). 
It has been shown that native ES products exhibit stage-specificity and are low in protein 
levels when produced in vitro; for example, Trichostrongylus colubriformis produced ~1 
mg ES protein per 25 000 adult worms per day (Emery 1996). Teladorsagia circumcincta 
L4 harvested from five donor sheep seven days after challenge with 150 000 L3 each 
produced ~2 mg protein over two days of in vitro culture (David Frew, personal 
communication). These factors would make native antigen production from ES an 
expensive way to manufacture vaccines, with the added problems of batch variability and 
difficulties in performing quality controls (Emery et al. 1993, Smith and Zarlenga 2006). 
The low protein yield has led to further analysis of the composition of parasite ES, for 
identification and expression of protective antigens as recombinant proteins (Schallig et al. 
1997, Smith et al. 2009). The advantages in a vaccine development approach would be that 
recombinant antigens can be engineered and manipulated to be as closely structured as 
possible to the desired native protein if this was not available or easily accessible, or to 
specifically add different features [e.g. modifying signal sequences to improve purification 
steps, targeting a specific promoter to induce expression, modifying glycosylation sites or 
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engineering fusion proteins and viral vectors by adding epitopes from other antigens 
(chimeras); Hansson et al. 1994, Keyt et al. 1994, Koths 1995, Liljeqvist and Stahl 1999, 
Makrides et al. 1996, Suarez et al. 1997, Walmsley and Arntzen 2000, Yusibov et al. 
1997)]. In addition, recombinant proteins can be produced on larger scales, with less cost 
and reductions in the use of donor animals compared to using native ES preparations, 
although the knowledge on the native antigens on which they are based on must be sound 
(Geldhof et al. 2007).  
Parasite ES products contain, among other proteins, a wide range of proteases [(Yatsuda et 
al. 2003), reviewed by Knox (1994)]; for example, the activity of four classes of proteases 
has been shown in Trichinella spiralis L1 ES (Lun et al. 2003). Teladorsagia circumcincta 
ES products are also a complex mix of molecules (Craig et al. 2006). Proteomic data were 
obtained from T. circumcincta L3- and L4-derived ES from larvae cultured in vitro 
following collection at 1, 3 and 5 days post infection (Smith et al. 2009). BLAST analysis 
of the data against T. circumcincta EST databases revealed 15 significant matches, ten of 
which were found to be L4-specific [an aspartyl protease, several ASP-like proteins, an 
apyrase, an astacin-like metalloprotease, a cysteine protease and several proteins of 
unknown function (Smith et al. 2009)]. One of the matches, a cysteine protease named Tci-
CF-1, had been previously identified as the most abundant protein in T. circumcincta L4 
ES (Redmond et al. 2006), and as the predominant transcript present in the L4-specific 
nucleotide dataset (Nisbet et al. 2008). Tci-CF-1 has an estimated molecular mass of 24 
kDa and it was shown to have close homologues in other helminth species such as O. 
ostertagi, H. contortus, Caenorhabditis elegans and Brugia malayi. Two N-glycosylation 
sites were predicted and subsequently confirmed in lectin-binding affinity experiments 
(Redmond et al. 2006). Tci-CF-1 was shown to be an immunogenic component of L4 ES 
in immunoblot experiments in which lymph IgA derived from sheep previously infected by 
trickle infection with T. circumcincta L3 (2000 L3 three times a week for 9 weeks) and 
mucus IgA from sheep grazed on naturally infected pasture, then trickle infected with T. 
circumcincta L3 (2000 L3 three times a week for 10 weeks), bound to this and other 
antigens in T. circumcincta L4 ES (Redmond et al. 2006, Smith et al. 2009). Serum IgG 
and IgA from sheep immunised with a recombinant version of Tci-CF-1 and trickle 
infected with T. circumcincta also showed reactivity to native Tci-CF-1 in immunoblots of 
L4 ES. These characteristics were pivotal in choosing Tci-CF-1 as a vaccine candidate 
(Nisbet et al. 2013). 
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Recombinant Tci-CF-1 expression was first carried out in E. coli but the protein was 
expressed in an insoluble form. During an experimental infection regime, serum and 
gastric lymph antibody binding (IgA, IgG1 and IgG2) to E. coli-expressed Tci-CF-1 
showed no significant difference between sheep which received a primary infection and 
those previously infected with T. circumcincta (in the form of a trickle infection followed 
by a 50 000 L3 bolus challenge; Routledge 2008). This showed that the recombinant E. 
coli-expressed protein was not recognised by infection-induced antibodies. These results 
also suggests that E. coli-expressed Tci-CF-1 may not have undergone the correct post-
translational modifications required for solubility and/or antibody binding observed 
previously in gastric lymph of trickle infected and challenged animals against the native 
form of Cathepsin F (nTci-CF-1) (Redmond et al. 2006). E. coli expression systems do not 
always complete the post-translational modifications required to generate a recombinant 
protein similar to the native form. Notable is the lack of glycosylation and the difficulty in 
expressing proteins containing disulphide bonds, due to the reducing environment of the 
prokaryotic cytoplasm (Macauley-Patrick et al. 2005). To overcome these limitations, an 
alternative approach, using yeast Pichia pastoris as an expression system has several 
advantages, among which are very high levels of secretion into an almost protein-free 
medium, ease of fermentation, high cell density and the possibility to maintain genetic 
stability and scale-up expression without loss of yield (Darby et al. 2012, De Schutter et al. 
2009, Romanos 1995). Importantly, P. pastoris is also capable of performing post-
translational modifications such as folding and glycosylation that cannot be performed in 
prokaryotic systems (Bretthauer and Castellino 1999, Macauley-Patrick et al. 2005). This 
may be an advantage when expressing a glycosylated protein such as nTci-CF-1 (Redmond 
et al. 2006).  
A recent study (Nisbet et al. 2013) showed the protective effect of a T. circumcincta 
vaccine containing 8 different recombinant antigens; one of the antigens included in the 
panel was a Tci-CF-1 version expressed in the yeast Pichia pastoris. In these experiments, 
the development of serum IgG and IgA responses which recognised the recombinant Tci-
CF-1 versions was shown, following immunisation with the recombinant protein cocktail. 
These antibodies in a serum pool from immunised sheep were shown to bind to native Tci-
CF-1 in immunoblots of T. circumcincta L4 ES. In the control group animals (which only 
received trickle infection following immunisation with adjuvant only), the IgG and IgA 
binding to native Tci-CF-1 in immunoblots of T. circumcincta L4 ES was markedly less 
compared to the immunised animals. However, in the control trickle-infected only sheep 
there was also lack of either IgG or IgA reactivity against the recombinant P. pastoris-
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expressed Tci-CF-1, suggesting that infection-induced antibodies were able to a certain 
extent to bind native Tci-CF-1 but unable to recognise the recombinant version. Moreover, 
the T. circumcincta trickle infection did not induce a serum antibody booster in the 
immunised animals (anamnestic response), also suggesting that vaccination-induced B 
cells and antibodies were not able to respond to the native antigens (Nisbet et al. 2013). 
Therefore, this study proposed to generate a recombinant version of Tci-CF-1 expressed in 
P. pastoris and to compare its immune recognition with that of the native form (nTci-CF-
1) purified from T. circumcincta L4 ES. 
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The overall aims of this chapter are: 
i) to purify native Tci-CF-1 from L4 ES material; 
ii) to generate a full length nucleotide sequence of Tci-CF-1, to be used for downstream 
cloning and recombinant protein expression in the yeast Pichia pastoris; 
iii) to assess the differential immune recognition of nTci-CF-1 and P. pastoris-expressed 
Tci-CF-1 (PiTci-CF-1) using serum, antibody secreting cell (ASC) probes and gastric 
lymph samples from a number of animals with different infection status in order to 
investigate the recognition of these antigens by the local and systemic antibody response to 
T. circumcincta.  
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2.2 Materials and methods 
2.2.1 Purification of native Tci-CF-1 (nTci-CF-1)  
2.2.1.1 Purification of nTci-CF-1 from L4 ES samples 
Teladorsagia circumcincta L4 ES was fractionated by Stuart Smith, George Newlands and 
Neil Inglis at MRI. The ES samples were obtained by a stock previously generated at MRI 
and following application to a Superose 12 HR 10/30 size exclusion column (GE 
Healthcare, Little Chalfont, UK) using an Äkta Protein Purifier HPLC system (GE 
Heathcare), were eluted in PBS. Fractions thus obtained by gel filtration were collected 
and stored at -80°C until use. SDS-PAGE analysis was carried out as described in 
Appendix B to determine which fractions contained nTci-CF-1.  
2.2.1.2 Enrichment of nTci-CF-1 using a thiol-sepharose column 
A protocol adapted from (Geldhof et al. 2002) was used to further purify nTci-CF-1 from 
one of the L4 ES fractions previously obtained. An empty column (GE Healthcare) was 
pre-packed with 1 g of thiol-sepharose matrix (Activated Thiol-Sepharose® 4B, GE 
Healthcare) that had been re-hydrated overnight in 10ml of PBS to give a  ~5 ml gel bed 
column volume. The packed column was equilibrated in PBS using a chromatography 
pump (Pharmacia Biotech, GE Healthcare) at 4°C for 2.5 h, at a flow rate of 10 ml/h. 
Native Tci-CF-1 samples were incubated with 2.5 mM Dithiothreitol (DTT, Sigma 
Aldrich, Gillingham, UK) at 37°C for 30 min, then washed in PBS using Amicon Ultra-15 
centrifugal filter with a 10 kDa MWCO (Merck-Millipore, Billerica, MA, USA), to reduce 
the concentration of DTT to < 0.02 mM. The samples were applied to the column and re-
circulated (1 ml/h) overnight at 4°C. The unbound fraction was collected until the UV 
absorbance levelled to base line; the column was washed with 5 column volumes of PBS. 
The bound fraction was eluted in 10 ml of PBS/50 mM DTT. The eluted fraction was 
buffer exchanged and concentrated in PBS using an Amicon Ultra-15 centrifugal filter with 
a 10 kDa MWCO (Merck-Millipore). Concentration of thiol-enriched nTci-CF-1 was 
estimated by band densitometry on a Coomassie-stained gel using the ImageQuant 4000 
(GE Healthcare) instrument and accompanying software. The protein purity before and 
after thiol-enrichment was estimated using the software ImageJ by densitometry analysis 
of the mean grey value for each entire lane and bands within, after background subtraction; 
the purity was calculated as % purity = [value(band)/value(lane)] × 100. The concentrated 
fractions were aliquoted and stored at -80°C until use. The identity of the major band 
39 
 
present in pre- and post-thiol enrichment fraction was confirmed by Liquid 
chromatography – Electron spray ionisation - Tandem mass spectrometry (LC-ESI-
MS/MS) performed at MRI by the Proteomics Department. 
2.2.2 Generation of full length cDNA Tci-cf-1 sequence 
2.2.2.1 PCR amplification of Tci-cf-1 from L4 cDNA 
Fourth stage larval (L4) T. circumcincta cDNA and primers for PCR amplification of Tci-
cf-1 full length sequence were provided by Dr Alasdair Nisbet (MRI) (see primers set no.1, 
Table 7.1, Appendix A). Each reaction was made up with of 5 μl 10x Advantage® 2 PCR 
Buffer (Clontech, Saint-Germain-en-Laye, France), 1 μl each of 5’ and 3’ primers set 1 (10 
pmol working solution), 1 μl 50x dNTP Mix (Clontech, Saint-Germain-en-Laye, France), 2 
μl of L4 cDNA, 1 μl of 50 X Advantage® 2 Polymerase Mix (Clontech), made up to 50 μl 
with dH2O. Cycling conditions were: 1 min at 95°C, 30 cycles of (15 sec at 95°C, 3 min at 
55°C, 3 min at 68°C). Negative controls included dH2O instead of cDNA template.  
2.2.2.2 Cloning procedures 
The full length Tci-cf-1 PCR products were column purified (QIAquick PCR Purification 
Kit, Qiagen, Manchester, UK), cloned into pGEM-T Easy and transformed into 50 μl of 
JM109 competent cells by heat shock according to the manufacturer’s instructions 
(Promega, Southampton, UK). The transformed cells were incubated in 950 μl SOC 
medium (Appendix D) at 37°C for 2.5 h, with shaking. Luria-Bertani (LB) agar plates were 
prepared as described in Appendix D; to 50 ml of molten LB agar, 200 μl of 25 mg/ml 
ampicillin stock (final concentration 100 μg/ml) were added. Once set, 20 μl of 50 mg/ml 
X-Gal stock (Promega) and 10 μl of 1M IPTG were spread over each plate. One hundred 
microliters of transformed cells in SOC medium were spread over each plate. The plates 
were left overnight at 37°C, white colonies picked the following day with a sterile 
toothpick and placed in 40 μl of dH2O. Colony PCR was carried out as follows: 2.5 μl 10 
X PCR reaction buffer with MgCl2 (Roche, Welwyn Garden City, UK), 0.5 μl each of 5’ 
and 3’ primer set 1 (10 pmol working solution, Table 7.1), 1 μl dNTPs (Roche), 2.5 μl of a 
dH2O solution in which individual colony stabs have been suspended, 1.25 U of Taq DNA 
Polymerase (Roche), made up to 25 μl with dH2O. Cycling conditions were: 5 min at 94°C, 
30 cycles of (30 sec at 94°C, 30 sec at 55°C, 1 min 30 sec at 72°C) and a final extension 
period of 7 min at 72°C. Colonies that resulted positive for PCR product ligation into 
plasmid were amplified overnight in 10 ml LB broth (Appendix D) with the addition of 
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100 μg/ml ampicillin. Plasmid DNA was purified from overnight cultures using the 
Wizard® Plus SV Minipreps DNA Purification System (Promega) following the 
manufacturer’s instructions. 
2.2.2.3 Sequencing and sequence analysis 
Plasmid insert DNA was sequenced by Eurofins MWG Operon (Germany) using the 
commercially available primers SP6 and T7. Further sequencing primers were used as 
indicated in each relevant section of this chapter. The sequence data were analysed with 
the software packages DNASTAR Lasergene 8 (DNASTAR Inc., Madison, WI, USA) and 
the freeware Chromas Lite (Technelysium Pty Ltd) to visualise chromatograms. The free 
online alignment tool ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/) was used for 
sequence alignment studies. 
2.2.3 Generation of recombinant Tci-CF-1 in the yeast Pichia 
pastoris 
The full length Tci-cf-1 generated in Section 2.2.2 was modified by PCR to omit the signal 
sequence and insert restriction sites as follows: primer set no. 2 (Table 7.1) was used in 
reactions containing 5 μl of 10 X PCR Buffer for KOD Hot Start DNA Polymerase 
(Toyobo Novagen, supplied by Merck4Biosciences UK), 2 μl of MgSO4 (final 
concentration 1 mM), 5 μl of dNTPs (final concentration 0.2 mM), 1.5 μl (15 pmol) each 
of the 5’ and 3’ primers, 0.5 μg of a plasmid template from one of the clones containing 
full length Tci-cf-1, 1 unit of KOD Hot Start DNA Polymerase (Toyobo Novagen) made 
up with dH2O to a final volume of 50 μl. Cycling conditions were: 2 min at 94°C, 30 
cycles of (15 sec at 94°C, 30 sec at 58°C, 1 min 30 sec at 72°C) and a final extension 
period of 5 min at 72°C. The Tci-cf-1 product (with restriction sites and without signal 
sequence) was double digested with XbaI and PmlI (New England Biolabs, Hitchin, UK). 
The plasmid pPICZα C (Invitrogen, Paisley, UK) was linearised using XbaI and PmlI 
(New England Biolabs), gel-purified and then used to ligate the Tci-cf-1 sequence as 
follows: 5 μl of 2 X Ligation Buffer (Promega), 1 μl (210 ng) digested Tci-cf-1, 3 μl (11 
ng) of gel-purified, linearised pPICZα C and 1 μl of T4 Ligase enzyme (Promega). The 
ligation reaction was used to transform E. coli JM109 competent cells (Promega) by heat 
shock method and cultured on Low Salt Luria-Bertani (LB) agar plates (Appendix D) with 
25 μg/ml of Zeocin®. Colony PCR was carried out using primers sets no. 2 or the α-factor 
(F) and 3’AOX (R) oligonucleotide primers (all in Table 7.1, Appendix A) in separate 
reactions. Colony PCR was carried out using primer pair 5’AOX (F) and 3’AOX (R) and 
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set no. 3 [Tci-cf-1 internal primers, ForIN (F) and RevIN (R); Table 7.1]. Reactions were 
made up of 12.5 μl of SapphireAmp® Fast PCR Master Mix (TaKaRa BioInc, Shiga, 
Japan), 0.5 μl of each forward and reverse primer (working solution 10 pmol) and 9.5 μl of 
dH2O. The following cycling conditions were used: 5 min at 94°C, 30 cycles of (30 sec at 
94°C, 30 sec at X°C, 1 min 30 sec at 72°C) and a final extension period of 5 min at 72°C, 
where X was Tm - 2°C. 
Sequences of isolated plasmids were analysed as described in section 2.2.2.3. A clone of 
the pPICZα C plasmid containing Tci-cf-1 was purified then linearised using PmeI (New 
England Biolabs). The transformation of Pichia pastoris cells (strain X33 Mut
+
) was 
carried out following the manufacturer’s instructions (EasySelect™ Pichia Expression Kit, 
Invitrogen, Paisley, UK). Pichia pastoris cells were made competent and transformed by 
electroporation using the following conditions: 1.5 kV, 25 μF and 200  using a Gene 
Pulser® II (Bio-Rad, Hemel Hempstead, UK) apparatus. The transformed cells were plated 
on Yeast Peptone Dextrose Sorbitol (YPDS) agar plates (Appendix D) with 100 μg/ml 
Zeocin®, and incubated at 29°C for 2 days until colonies developed. Colony PCR was 
carried out as described above using a primer combination consisting of forward: factor 
(primer set 4), reverse: RevIN (primer set 3) (see Table 7.1). Colonies were grown in 
BMGY (Appendix D) and subsequently maintained in BMMY (Appendix D) for 96 h, 
when the expression of Tci-CF-1 was induced with 0.5 % methanol following the 
manufacturer’s instructions. SDS-PAGE analysis was used to identify a colony expressing 
Tci-CF-1.  
2.2.4 Recombinant protein purification using Ni2+ columns 
The cell culture supernatants of P. pastoris cultures were applied to a Ni
2+
 column 
(HisTrap™ HP Column, GE Healthcare) to purify the expressed, histidine-tagged proteins. 
Briefly, the column was attached to a bench-top chromatography pump system (Pharmacia 
Biotech) and washed with dH2O for 5 min at a flow rate of 1 ml/min. The column was then 
equilibrated with 5 column volumes of Binding Buffer A (Appendix D). The P. pastoris 
supernatant was applied neat to the column and left to re-circulate through the column for 
1-2 h at a flow rate of 1 ml/min. The column was then washed with 5 column volumes of 
Binding Buffer A before applying Elution Buffers 1-4 (Appendix D) containing an 
imidazole step gradient ranging between 165-500 mM. The purified recombinant Tci-CF-1 
was dialysed against 0.1 M Sodium Phosphate Buffer, 0.5 M NaCl pH 7.4 using a Mini 
Dialysis Kit (GE Healthcare) with a molecular weight cut-off (MWCO) of 8 kDa. Protein 
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expression and identity as Tci-CF-1 was confirmed by SDS-PAGE analysis and by Matrix 
Assisted Laser Desorption/Ionisation - Time of Flight (MALDI-ToF) spectrometric 
analysis carried out at MRI Proteomics Unit.   
2.2.5 Experimental animals  
2.2.5.1 Serum and lymph nodes provenance 
As described previously by Nisbet et al. (2013), fourteen Texel crossbred lambs, 204-206 
days old at the start of a prototype recombinant vaccine experiment, were reared under 
conditions to exclude helminth infection and separated in groups of 7 (Group A: 
immunised, B: control). Subsequently, twenty-eight Texel crossbred lambs, 172-178 days 
old at the start of the experiment, were also separated in groups of 7 animals each (Groups 
C: immunised, killed at d 84 post immunisation (p.i.), D: control, killed at d 84 p.i., E: 
immunised, killed at d 112 p.i., F: control, killed at d 112 p.i.). Each animal in groups A, C 
and E received three immunising doses 3 weeks apart, each containing 50 μg of each of 8 
recombinant antigens, one of which was PiTci-CF-1. The injections contained also 
PBS/urea and Quil A as adjuvant (immunised groups). Each animal in groups B, D and F 
only received PBS/urea/Quil A injections (control groups). The injections were 
administered for each animal subcutaneously, in the cervical area, following this pattern: 
left side of the neck for the first injection, right for the second injection, and left side for 
the last injection. Following the final antigen immunisation or mock immunisation, every 
animal in each group received a trickle infection of 3 000 T. circumcincta L3, three times a 
week for 4 weeks. Blood samples were taken weekly and at post mortem, which took place 
84 days (groups A-D) or 112 days (groups E-F) after the start of the experiment. All 
animals from groups A and B and two randomly chosen animals from each group C and D 
were used in the work described herein for the collection of serum and lymph node 
samples. The experimental plan for groups A-D is outlined in Fig. 2.1. 
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Figure 2.1 Diagram outlining the experimental protocol for animals in groups A-D. 
Serum samples were collected weekly, but only the dates on which samples relevant to this 
project were collected are shown by annotation with red arrows. “Imm” represents dates on 
which sheep were immunised; “Trickle” represents the trickle infection (3 times weekly 
between day 42 and 70). At post mortem, the last serum and lymph node samples were 
collected. 
 
Antibody Secreting Cell (ASC) probe samples were collected, as described below, from 18 
animals included in the study outlined in Fig. 2.1, listed in Table 2.1. To reflect the local 
immune responses to T. circumcincta following trickle infection, two to four lymph nodes 
from the abomasal lymph node chain were collected from each of the 14 animals (7 
immunised, 7 non-immunised controls) in groups A and B, and from 4 randomly chosen 
animals in groups C (2 immunised) and D (2 non-immunised controls). From the same 
animals both left and right pre-scapular lymph nodes were also collected, as the 
immunisation protocol was administered on rotation between the left and right side of the 
neck, as described above. The collection method is described in Section 2.2.5.4. Within the 
same animal, cells from the same lymph node location (i.e. abomasal chain or left/right 
pre-scapular) were pooled prior to in vitro culture. This yielded two supernatant samples 
from each animal, one pool of abomasal lymph node cells secreted antibodies (Abo), and 
one pool of pre-scapular cells secreted antibodies (PreSc). Table 2.1 (below) summarizes 
the animals used for serum and lymph node collection. 
2.2.5.1.1 Additional serum samples 
Two serum samples, representing pre- and post-immunisation with a previously generated 
PiTci-CF-1 version, were made available by Dr Alasdair Nisbet and Dr Tom McNeilly 
(MRI). These samples originated from a pilot immunisation trial of sheep immunised with 
50 μg each of three T. circumcincta recombinant proteins, one of which was PiTci-CF-1, 
for each immunisation (2 in total, administered intramuscularly at day 0 and 28 of the 
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experiment). Quil A was used as adjuvant. Serum samples were collected weekly for 6 
weeks throughout the experiment, though for the purposes of this study only the pre-
immunisation (day 0) and the final (day 42, at post-mortem examination) samples were 
used. The sheep did not receive T. circumcincta trickle infections (see Table 2.1). 
Table 2.1 List of all the experimental animals from which serum and lymph node samples 
were collected for this project. 
 
Animal 
number 
Code 
given 
Breed/Age 
at start of 
experiment 
Infection/Immunisation 
status 
Time points 
used in this 
project 
Reference 
6450H Imm.1 
Texel X, 
204-206d 
 
Immunised, trickle 
infected for 4 weeks 
From start of 
trial: 
 
Serum: 0, 21, 
42, 63, 84 d 
 
ASC: 84 d 
(PM) 
Nisbet et al. 
(2013) 
6451H Imm.2 
6455H Imm.3 
6474H Imm.4 
6496H Imm.5 
6507H Imm.6 
6508H Imm.7 
679J Imm.8 Texel X, 
172-178d 683J Imm.9 
6453H Ctrl.1 
Texel X, 
204-206d 
 
Adjuvant-only, trickle 
infected for 4 weeks 
6462H Ctrl.2 
6468H Ctrl.3 
6482H Ctrl.4 
6484H Ctrl.5 
6492H Ctrl.6 
6494H Ctrl.7 
639J Ctrl.8 Texel X, 
172-178d 661J Ctrl.9 
Sheep 1 
Unknown 
Immunised,  
not trickle infected 
Serum: 0, 42 
d (PM) 
Tom 
McNeilly and 
Alasdair 
Nisbet, 
unpublished 
data 
Sheep 2 
Sheep 3 
 
2.2.5.2 Gastric lymph provenance 
A number of gastric lymph samples had been collected during previous experiments in 
collaboration between MRI and R(D)SVS, described by Halliday et al. (2007, 2010). 
Animals had been treated as follows: sheep were trickle infected with 2 000 T. 
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circumcincta L3, three times a week, for 8 weeks, then 2 days later cleared of infection 
with an anthelminthic treatment (benzimidazole class, at the dose of 5 mg/kg) and 7 days 
later challenged with a bolus of 50 000 T. circumcincta L3 larvae (termed “previously 
infected” sheep from here onwards). Lymph samples from 6 of those animals between +4 
and +10 days post-challenge infection (dpc) (representing the anamnestic response to T. 
circumcincta)  were retrieved from the collection stored at MRI. Multiple lymph samples 
from each individual animal at different time points between +4 and +10 dpc were pooled 
to give a representative anamnestic lymph sample for each animal. Controls were animals 
which only received a primary infection as a bolus of 50 000 L3 T. circumcincta at the 
same time as the previously infected animals (termed “primary infection” sheep from here 
onwards). The samples were collected between -2 and +2 dpc from 6 animals, before a 
primary immune response to T. circumcincta antigens was developed [as shown by 
Halliday et al. (2007), the peak lymph IgA following T. circumcincta infection occurs after 
+6 dpc, before decreasing around +10 dpc]. Multiple lymph samples from each individual 
animal at different time points between -2 and +2 dpc were pooled to give a representative 
anamnestic lymph sample for each animal.  
In addition, a smaller set of 3 gastric lymph samples was obtained courtesy of Dr John 
Huntley and Dr David Smith (Moredun Research Institute). The animals in this group had 
been part of a previous experiment (David Smith, 1987 unpublished data). Included in this 
group were gastric lymph samples from 3 animals which received an 8-week T. 
circumcincta trickle infection and subsequently treated with fenbendazole, then received a 
50 000 infective T. circumcincta L3. From one of the animals, lymph was collected -5dpc 
to represent the antibody levels after trickle infection, but before the bolus challenge. From 
the remaining 2 animals, the lymph was collected +5 dpc to reflect the anamnestic 
response to T. circumcincta following bolus challenge. 
In certain experiments indicated in the results section of this chapter, lymph samples from 
each animal in the previously infected or primary infection group were pooled and named 
+ve lymph pool and -ve lymph pool respectively. Table 2.2 (below) summarizes the 
animals used for serum and lymph node collection. 
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Table 2.2 List of all the experimental animals from which lymph samples were retrieved for 
this project. 
 
Animal 
number 
Breed/Age 
at start of 
experiment 
Infection/Immunisation 
status 
Time points 
used in this 
study 
Reference 
B067 Dorset x 
Suffolk, 
12 months “Primary Infection” 
Single challenge with L3 
bolus 
2 dpc 
Halliday et al. 
(2009) 
B072 -1, 0 dpc 
B103 2 dpc 
1820 Dorset x 
Suffolk, 
5 months 
0 dpc 
n/a 1858 -2, -1 dpc 
1872 -3 dpc 
A295 
Blackface x 
BF Leicester, 
11 months 
“Previously-infected” 
Trickle infected for 8 
weeks, cleared then 
challenged with L3 bolus 
8, 10 dpc 
Halliday et al. 
(2007) 
A611 4, 8, 9 dpc 
A1008 6 dpc 
No Tag 7, 8 dpc 
1831 Dorset x 
Suffolk, 
5 months 
8, 9 dpc 
n/a 
1880 5, 6, 7, 8 dpc 
614, 
17/2/87 
Suffolk X, 
9 months 
“Previously infected” 
Trickle infected for 8 
weeks, cleared then 
challenged with L3 bolus 
-5 dpc 
Courtesy of Dr D. 
Smith and Dr J. 
Huntley (MRI) 
614, 
27/2/87 
5 dpc 
1138K, 
27/2/87 
L3 bolus = 50 000 T. circumcincta infective stage larvae (L3); dpc = Days post L3 bolus 
challenge. 
 
2.2.5.3 Collection of serum samples 
Blood samples were collected by jugular venepuncture using plain Vacutainers (BD 
Biosciences, Oxford, UK). Samples were left at room temperature overnight to facilitate 
clot formation and retraction. The following morning, sera was collected from each tube, 
centrifuged at 1200 x g for 10 min, then aliquoted and stored at -20°C until use. 
2.2.5.4 Collection of lymph nodes for the generation of Antibody Secreting 
Cell probes (ASC) 
Lymph nodes were collected aseptically at post-mortem using sterile scalpel blades and 
autoclaved surgical scissors and forceps, sprayed thoroughly in 70 % ethanol between 
samples. Each lymph node was placed in 35 ml of ice cold Sheep Wash Medium (SWM, 
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Appendix D) and kept on ice until processed. In sterility in a tissue culture hood the lymph 
nodes were placed in a Petri dish and residual adipose tissue was removed, five ml of 
SWM were added and then using a sterile scalpel/scissors/forceps kit the tissue was cut 
into ~1-2 mm
3
 pieces. The tissue was placed in sterile Stomacher
®
 80 bags and stomicated 
for 1 min using a Colworth Stomacher
®
 80 paddle blender (Seward Ltd. Worthing, UK), 
after which the cell suspension was filtered through sterile microscope lens cleaning tissue 
which had been folded three times. The filtered cells were washed twice in 25 ml SWM at 
100 x g for 10 min then re-suspended in 10 ml of ASC culture medium (ASC-CM, 
Appendix D). Cells were counted by Trypan Blue exclusion in a haemocytometer and 
incubated for 5 days at 37°C, 5 % CO2 in 24- or 48-well plates at a concentration of 5 x 10
6 
viable cells/ml in ASC-CM. After 5 days the cell cultures were harvested, centrifuged at 
100 x g for 10min and the supernatant containing antibodies (ASC probes) aliquoted and 
stored at -20°C. 
2.2.5.5 Collection of gastric lymph 
This process was described in detail by Smith et al. (1981) and was followed with minor 
changes in the studies from which the samples used in this project were retrieved (Halliday 
et al. 2010, Halliday et al. 2007). Briefly, the common gastric lymph duct, which contains 
efferent lymph draining all four stomachs, was cannulated during abdominal surgery of 
selected sheep. An intravenous indwelling catheter was also placed, to allow re-infusion of 
lymph. Cannulated sheep were housed in individual pens and lymph was collected into 
sterile, heparinized drainage bags supported by a harness. Every day the lymph flow rate 
was estimated, aliquots collected into heparinised tubes and the remaining lymph re-
infused under gravity. 
2.2.6 Indirect ELISA for detection of T. circumcincta antigen-
specific antibody responses 
Unless otherwise indicated, all ELISA experiments were conducted as follows: flat bottom 
high binding plates (Bio-one, Greiner, Stonehouse, UK) were coated with 50 μl 
antigen/well (Table 2.3) in carbonate coating buffer pH 9 (Appendix D) and incubated at 
4
o
C overnight. The following day the plates were washed 4 times in wash buffer (PBST, 
Appendix D) and 100 µl/well of blocking buffer (TBST/5 % soya, Appendix D) were 
added. Plates were incubated for 1 h at room temperature (RT), then washed 4 times in 
PBST. Samples were distributed at 50 µl/well final volume of the appropriate 
serum/lymph/ASC probe dilution in TBST (Table 2.4) and incubated for 1 hr at RT. After 
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another 4 washes, the plates received 50 µl/well of secondary antibody (as detailed in 
Table 2.4), diluted in TBST. Following 4 further washes in PBST, the plates were 
incubated for 1 hr at RT with 50 µl/well of a tertiary antibody (HRP-conjugated, as 
detailed in Table 2.4) diluted in TBST. Plates were washed 4 times in PBST then 
developed with o-Phenylenediamine dihydrochloride substrate (Sigmafast OPD, Sigma-
Aldrich, Gillingham, UK), 50 µl/well, at RT for 5-15 min. The reactions were stopped by 
the addition of 30 µl/well of 2.5 M H2SO4 then read at 490 nm using a Sunrise™ plate 
reader (Tecan, Männedorf, Switzerland). Table 2.4 reports the antibody combinations used.  
Table 2.3 Concentration of antigens used in ELISA assays. 
 
Antigen g/ml 
L4 ES* 5 
nTci-CF-1^ 1 
PiTci-CF-1† 1 
Description of antigens: * T. circumcincta L4 ES products; ^ native Tci-CF-1 purified from T. 
circumcincta L4 ES; † recombinant Tci-CF-1 purified from P. pastoris cell culture 
supernatant. 
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Table 2.4 Concentration of antibody used in ELISA assays. 
 
Indirect IgG detection 
Sample (primary antibody) Secondary antibody Tertiary antibody 
Type Dilution Type Dilution Type Dilution 
Serum 1:1000 
Anti-
goat/sheep 
IgG:HRP 
(clone GT-34, 
A9452, Sigma-
Aldrich) 
1:1000 n/a 
ASC probes neat As above As above 
Lymph 1:10 As above As above 
Indirect IgA detection 
Sample (primary antibody) Secondary antibody Tertiary antibody 
Type Dilution Type Dilution Type Dilution 
Serum 1:10 
Mouse anti 
bovine-ovine 
IgA (clone K84 
2F9, MCA628, 
Serotec) 
1:250 
Rabbit anti 
mouse 
IgG:HRP 
(clone n/a, 
P0260, Dako) 
1:1000 
ASC probes neat As above As above 
Lymph 1:10 As above As above 
 
All data were normalized for plate-plate variations, allowing comparison using the 
following method: all ODs were blank-corrected and a normalization coefficient was 
calculated for each plate using the formula below: 
NC [plate A] =   Average OD of positive sample [plate A] 
    Average [positive sample OD of all plates] 
Subsequently, all ODs in each plate were divided by the correspondent normalization 
coefficient for the same plate. 
2.2.7 Immunoassay for sodium periodate sensitive/insensitive 
epitopes 
For these ELISA experiments, standard steps as detailed in Section 2.2.6 were used and 
antigen periodate treatment was carried using a protocol adapted from Fairlie-Clarke et al. 
(2010): plates were coated overnight with native or recombinant T. circumcincta antigens, 
then blocked for 1h with TBST/5 % soy milk (Appendix D) and washed. After the wash 
steps, wells were incubated with 50 μl/well of 20 mM NaIO4 solution (Appendix D) for 1 h 
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at 37°C, in the dark. Wells were washed with 50 mM Sodium Acetate Buffer (Appendix 
D) for three times and subsequently incubated with 50 μl/well of 50 mM NaBH4/TNTT for 
30 min at 37°C. Control wells were incubated in 50 mM Sodium Acetate Buffer, instead of 
20 mM NaIO4 solution. Wells were then washed with PBST for 4 times, resuming the 
standard ELISA protocol as described above.  
2.2.8 SDS PAGE and Western blotting 
The techniques used in this Chapter to carry out protein electrophoresis using 
polyacrylamide gels (SDS-PAGE) are described in detail in Appendix B (Section 8.1). 
Unless otherwise stated, 130 ng of protein preparation was added to 5 μl of NuPAGE® 4 X 
LDS Sample Loading Buffer with the addition of 2 μl of NuPAGE® Reducing agent (all 
from Invitrogen), for a total volume of 20 μl. These samples were heated at 70°C for 10 
min and loaded into individual wells of the gel. Gel and electrophoresis chambers 
assembly were carried out following the manufacturer’s instructions. Running conditions 
were 200 Volts for 35 min. Gels were routinely stained with Coomassie-based dye 
(SimplyBlue™ SafeStain, Invitrogen) or silver staining (SilverQuest™ Silver Staining Kit, 
Invitrogen). If gels were used for Western blotting, the transfer onto nitrocellulose 
membrane was carried out using iBlot System (Invitrogen). The membranes were stained 
with Ponceau S (Sigma-Aldrich) to identify bands and cut into strips. Blocking was 
routinely carried out overnight using 20 ml TNTT (Appendix D). The protein preparations 
and the serum or lymph samples used to probe each strip are detailed in the relevant 
Results sections. Secondary and tertiary antibodies and their working dilutions are detailed 
in Table 2.5. Detection of bound antibodies was carried out using Amersham ECL Prime 
Western Blotting Detection Reagent (GE Healthcare) following the manufacturer’s 
instructions. 
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Table 2.5 Working dilutions of the antibodies used in Western blot experiments. 
 
Sample (primary antibody) Secondary antibody Tertiary antibody 
Type Dilution Type Dilution Type Dilution 
Serum 
1:1000 
(IgG) 
Anti-goat/sheep 
IgG:HRP (clone 
GT-34, A9452, 
Sigma) 
1:1000 n/a n/a 
1:100 (IgA) 
Mouse anti 
bovine-ovine 
IgA (clone K84 
2F9, MCA628, 
Serotec) 
1:500 
Rabbit anti mouse 
IgG:HRP (clone 
n/a, P0260, Dako) 
1:1000 
Gastric lymph 1:100 
Anti-goat/sheep 
IgG:HRP (clone 
GT-34, A9452, 
Sigma) 
1:1000 n/a n/a 
Mouse anti 
bovine-ovine 
IgA (clone K84 
2F9, MCA628, 
Serotec) 
1:500 
Rabbit anti mouse 
IgG:HRP (clone 
n/a, P0260, Dako) 
1:1000 
 
2.2.9 Statistical analysis 
Statistical analysis was carried out using GraphPad Prism version 5.01 and GenStat 12
th
 
Edition. Arithmetic means with standard errors and replicate number (n) are shown 
throughout this chapter. Data were checked for normal distribution by analysing the 
histogram of frequencies and residual plots. If data were not normally distributed, a Box-
Cox transformation (Box 1964, Peltier et al. 1998) was used to choose the appropriate 
transformation method; the details of each transformation are provided for the data sets in 
each figure throughout this chapter. For data normally distributed (with or without 
transformation), a one-way Analysis of Variance (ANOVA) test was used, followed by the 
Tukey post hoc test for pair wise comparison of means; when only one pair of means was 
compared, an unpaired two-tailed t-test was used. The Area Under the Curve (AUC) data 
were calculated for each group of animals and each antibody isotype over the 84 days of 
the experiment and used to compare statistically the antibody responses between groups 
using an unpaired, two-tailed t-test. This test was also used to determine whether there was 
statistical significance in the increase of antigen-specific antibody levels detected within 
each sample group between day 0 of the experiment and day 84. If data were not normally 
distributed and Box-Cox analysis failed to suggest an appropriate transformation method, 
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the non-parametric Mann-Whitney test and Kruskal-Wallis test were used (details are 
provided for the data sets in each figure). P values of < 0.05 were considered significant.   
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2.3 Results 
2.3.1 Purification of native Tci-CF-1 (nTci-CF-1)  
A typical profile of T. circumcincta L4 ES fractionation by gel filtration chromatography, 
monitoring absorbance at 280 nm, is shown in Figure 2.2. The presence and relative 
abundance of nTci-CF-1 was confirmed by SDS PAGE analysis of ES fractions; by using 
silver staining, it was possible to identify the eluted fractions containing enriched nTci-CF-
1 (Figure 2.2). The identity of the prominent band observed in lanes C5 to D12 of Figure 
2.2 was confirmed as Tci-CF-1 by LC-ESI-MS/MS analysis carried out by the Proteomics 
Facility at MRI.   
 
Figure 2.2 Size Exclusion Chromatographic Fractionation of Teladorsagia circumcincta L4 
ES Products.  
Panel (A): an equal amount (13 µl) of each eluted fraction was loaded per lane under 
reducing conditions. Protein bands were visualized with silver staining. Red box highlights 
the presence of nTci-CF-1 bands. M: molecular weight marker (kDa); ES: L4 ES prior to 
fractionation. Panel (B): representative chromatograph showing typical absorbance of 
elution fractions of T. circumcincta L4 ES during size exclusion chromatography using a 
Superose 12 HR 10/30 size exclusion column. X axis: progressive number of eluted 
fractions; y axis: UV absorbance in mAU.  
Only one of the 250-500 μl fractions eluted contained what visually appeared to be the 
most abundant and pure nTci-CF-1 (lane C9). The fractions preceding and following C9 
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also contained nTci-CF-1 but, in these fractions, it was still mixed with other parasite 
products of similar, but not identical, mass. These more complex fractions were treated 
with a protocol adapted from Geldhof et al. (2002). By pooling and treating the fractions 
containing nTci-CF-1 with DTT and loading the sample onto a thiol-sepharose pre-packed 
column, it was possible to further purify nTci-CF-1 from the more complex fractions. 
Silver stained SDS PAGE gels showed that a large amount of nTci-CF-1 did not bind to 
the thiol column and was therefore lost in the unbound fraction (Figure 2.3). The relative 
purity of nTci-CF-1 was estimated by band densitometry to be 85.13 % before thiol 
enrichment, and 84.9 % afterwards. The concentration of nTci-CF-1 was also estimated by 
band densitometry against a BSA standard curve to be ~10 μg/ml before thiol enrichment, 
and ~5 μg/ml after. The low yield of thiol-purified nTci-CF-1 (1-2 μg from each 200 μg L4 
ES aliquot) was not sufficient for downstream applications. Taking into account the 
relative purity of the nTci-CF-1 fractions before and after thiol enrichment (equivalent to 
C9 in Figure 2.3), the nTci-CF-1 fraction as eluted from the size exclusion chromatography 
was considered of acceptable quality to be used for ELISA assays without further 
purification steps.  
 
Figure 2.3 SDS-PAGE analysis of thiol-eluted nTci-CF-1. 
Silver stained gel. Lane 1: gel filtration fraction enriched with nTci-CF-1 (collected from a 
subsequent enrichment and equivalent to C9 in Figure 2.2); lane 2: flow-through (unbound) 
from thiol column; lane 3: thiol-eluted nTci-CF-1; M: molecular weight marker (kDa). 
 
2.3.2 Generation of P. pastoris-expressed Tci-CF-1 (PiTci-CF-1) 
Full length Tci-CF-1 was amplified omitting the signal peptide from T. circumcincta L4 
cDNA by PCR, subcloned into pPICZα C and transformed into yeast cells. Colony PCR 
and DNA gel electrophoresis, from randomly selected yeast colonies, confirmed successful 
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transformation. Protein expression was induced and recombinant Tci-CF-1 (PiTci-CF-1) 
was purified. Protein identity was confirmed by SDS-PAGE analysis (Figure 2.4 A, lane 
2), MALDI-ToF and finally by Western blot using a PiTci-CF-1 anti-serum previously 
raised in sheep at MRI (Figure 2.4, B). Mean purified protein yield was calculated as 
109.56 μg/ml of packed cells volume (n = 2). SDS-PAGE analysis revealed that purified 
PiTci-CF-1 migrates as two bands at around 48 kDa and 34.7 kDa, suggesting a degree of 
post-translational processing occurring within the yeast cultures. The identity of both bands 
had been confirmed as PiTci-CF-1 by MALDI-ToF. The process of cloning and generating 
another recombinant version of PiTci-CF-1, instead of using the previously purified form 
(Nisbet et al. 2013), was necessary in view of the subsequent generation of Tci-CF-1 in C. 
elegans. Thus, the two recombinant versions would have identical amino acid sequences 
and therefore also allow later comparisons of antibody recognition and enzyme activity 
between the two. 
 
Figure 2.4 SDS-PAGE analysis of enriched nTci-CF-1 and purified PiTci-CF-1 and 
immunoblot of PiTci-CF-1.  
(A) Lane M: molecular weight marker (kDa); lane 1, red box: nTci-CF-1; lane 2: PiTci-CF-1, 
both solid and dotted red arrow (as determined by MALDI-ToF). (B) Western blot of PiTci-
CF-1 probed with, lane 1: sheep anti-PiTci-CF-1 serum, lane 2: control serum (pre-
immunisation). Bound antibody was detected by chemiluminescence using ECL substrate. 
 
2.3.3 Differential recognition of nTci-CF-1 and PiTci-CF-1 by 
antibodies from serum  
To investigate the systemic and local immune responses against native T. circumcincta 
antigens and PiTci-CF-1 in the serum of sheep which had been immunised with PiTci-CF-
1 [as part of an 8-recombinant antigen cocktail in adjuvant (Nisbet et al. 2013)] or 
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adjuvant-only, and subsequently trickle challenged with T. circumcincta, an indirect 
ELISA was carried out. This evaluated the serum IgA and IgG reactivity to L4 ES products 
[(of which native Tci-CF-1 is the most abundant antigen (Redmond et al. 2006)] and 
purified PiTci-CF-1.  
Serum IgG and IgA reactivity against L4 ES in the control group, which received a T. 
circumcincta trickle infection and mock immunisation with adjuvant only, were detectable 
after day 42, when the trickle infection started (Figure 2.5), showing the effect of exposure 
to the parasite. Although serum IgA levels in the group immunised with the cocktail 
vaccine replicated the same pattern as the control group and no difference was observed 
(AUC p = 0.2685; Figure 2.5, Panel A), the serum IgG response against L4 ES antigens in 
the immunised group was significantly higher (AUC p < 0.0001) than the control animals. 
IgG levels in immunised sheep started rising at an earlier time point than in the control 
sheep during the experiment (day 21), after two immunisations and three weeks before the 
initiation of the trickle infection [Nisbet et al. (2013) and Figure 2.5, Panel B]. However, 
this antibody response started to decline from day 63 onwards.  
In sheep immunised with the cocktail vaccine, containing a version of PiTci-CF-1, a 
significantly higher serum IgA and IgG response was observed to this recombinant protein 
in the immunised group compared to the controls, starting after the first immunisation 
(AUC p = 0.0001 and p < 0.0001 for IgA and IgG respectively; Figure 2.5, panels C and 
D). However it is shown that the IgG response started to decline at day 63 [Figure 2.5, 
Panel D and Nisbet et al. (2013)]. The lack of IgA and IgG reactivity against PiTci-CF-1 in 
the control animals (Figure 2.5, panels C and D) suggested that the antibodies elicited by T. 
circumcincta trickle infection, which bound to L4 ES (Figure 2.5, panels A-B), did not 
cross-react with the recombinant yeast-expressed PiTci-CF-1. 
An unpaired, two-tailed t-test showed that in each group considered (i.e. immunised or 
control sheep) the antibody levels at day 84 of the experiment (both IgA and IgG) were 
significantly higher (p < 0.005) than at day 0 of the experiment, with the exception of 
PiTci-CF-1-specific IgA in the control group, where the increase was not significant. 
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Figure 2.5 The serum IgA and IgG responses in immunised and control sheep to T. circumcincta L4 ES antigens and recombinant PiTci-CF-1.  
Panels A-B: serum IgA and IgG responses to L4 ES during an experimental infection regime. Panels C-D: serum IgA and IgG responses to PiTci-CF-1 
during an experimental infection regime. Red circles: control animals; black squares, immunised animals. Data represent mean±SEM, n=9 per group. Plots 
on the right of each graph show the statistical analysis of the calculated AUC for each group, with respective p values shown on the top right corner. 
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The serum IgG response in immunised animals against PiTci-CF-1 was further 
investigated in ELISA experiments to examine the specificity for glycan residues that may 
have been present in PiTci-CF-1. This was achieved by treating the coating antigen (PiTci-
CF-1) with a solution of sodium periodate (NaIO4). “Untreated” wells were incubated with 
the same buffers as described in the materials and methods section 2.2.7 with the exception 
of periodate solution. The serum samples used were from day 63 of the experiment when 
IgG levels had peaked against PiTci-CF-1 (see Figure 2.5), and were significantly higher in 
the immunised animals compared to the controls (Figure 2.6, panel A). Following 
periodate treatment, a statistically significant loss of PiTci-CF-1-specific IgG binding was 
observed in the immunised animals, whereas no appreciable change was seen in the control 
animals. Serum IgG binding to PiTci-CF-1 in immunised animals was still significantly 
higher following periodate treatment, relative to reactivity of control animals (Figure 2.6, 
panel A). 
 
Figure 2.6 The effect of sodium periodate treatment of PiTci-CF-1 on binding of serum IgG 
from PiTci-CF-1 immunised sheep. 
(A): green striped bars: periodate untreated (Per-) samples; black dotted bars: periodate 
treated (Per+) samples. Data represent mean ±SEM, n=9 per group with all samples 
analysed in duplicate. Overall one-way ANOVA p value displayed below the graph. Post-
ANOVA analysis: Tukey’s multiple comparison test. *** = p <0.001. Panel (B): percentage of 
IgG binding loss in serum from immunised animals following periodate treatment of PiTci-
CF-1. Mean OD loss 48.72 %, range 27.72-72.57 %. Green bars: NaIO4 untreated (Per-) 
samples. Purple bars: periodate treated (Per+) samples. Error bars represent SEM. 
 
The loss of IgG binding to PiTci-CF-1 was observed in each of the individual serum 
samples of immunised animals, and it was shown to have a wide range of variability 
between animals (mean OD loss 48.72 %, range 27.72-72.57 %, Figure 2.6, panel B). 
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2.3.4 Differential recognition of nTci-CF-1 and PiTci-CF-1 by 
antibodies from Antibody Secreting Cell (ASC) probes 
A snapshot of the local immune response against a specific stage/antigen of a parasite can 
be obtained by investigating the antibody responses of ASC probes generated from local 
lymph node cells (McWilliam et al. 2012). Abomasal and pre-scapular lymph nodes were 
collected from 7 animals in groups A and B, and from 2 randomly chosen animals in 
groups C and D (see Section 2.2.5.1 for a summary of experimental plan), to match the 
serum samples for which antibody reactivity was investigated in Section 2.3.3. Abomasal 
lymph nodes were collected to reflect the local antibody response to T. circumcincta 
infection.  The pre-scapular lymph nodes were chosen as they drained the site of 
immunisation, and therefore immune responses at this lymphatic site would reflect 
immunisation-induced immune responses. From these lymph nodes, ASC probes were 
generated and used in ELISA experiments to test the IgA and IgG binding to L4 ES 
antigens, enriched nTci-CF-1 fractions and purified recombinant PiTci-CF-1. Figure 2.7 
summarizes the findings. 
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Figure 2.7 The ASC probes IgA and IgG responses from lymph nodes of immunised and 
control sheep to T. circumcincta L4 ES antigens, nTci-CF-1 and recombinant PiTci-CF-1, 
during an experimental infection regime. 
Sheep were immunised with a T. circumcincta recombinant antigen cocktail containing 
PiTci-CF-1. All animals received a trickle infection (3 000 L3, 3 times a week for 4 weeks) and 
ASC probes generated at 6 weeks post-infection. Rows share the antigen used to coat the 
plates, columns share the antibody isotype (IgA or IgG). Abo: abomasal ASC probes; PreSc: 
pre-scapular ASC lymph node probes. Data represent mean ±SEM, n=9 per group with all 
samples analysed in duplicate. Overall one-way ANOVA p value displayed below each 
graph. Post-ANOVA analysis: Tukey’s multiple comparison test. *** = p <0.001; ** = p < 0.01; 
* p <0.05. Statistical analysis was carried out on untransformed (panels C, D and F) or 
transformed (panels A, C and E) data. Untransformed data represented in all panels. Data in 
panels A, B and E was transformed prior to statistical analysis using the following: OD
0.5
, 
1/OD
0.25
 and OD
0.25
 respectively. 
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IgA from Abomasal lymph node ASC probes showed significantly higher binding to L4 
ES and nTci-CF-1, but not to PiTci-CF-1, compared to the correspondent pre-scapular 
probes in both groups of animals (immunised and controls; Figure 2.7, panels A, C and E). 
In control animals, IgA from pre-scapular ASC probes were not able to bind any of the 
three antigen preparations tested. IgA binding to PiTci-CF-1 was significantly higher in 
pre-scapular ASC probes from immunised animals compared to both the abomasal probes 
from the same (immunised) animals, and pre-scapular probes from the control animals 
(Figure 2.7, panel E). These results show that trickle infection-induced abomasal IgA was 
able to bind native parasite antigens such as nTci-CF-1 and those found in L4 ES; 
however, these did not bind to recombinant PiTci-CF-1.  
ASC abomasal and pre-scapular IgG reactivity was also investigated. In immunised sheep, 
IgG binding from pre-scapular ASC probes to nTci-CF-1, L4 ES and PiTci-CF-1 was 
significantly higher than in the control group (Figure 2.7, panels B, D and F). Pre-scapular 
ASC probe IgG from immunised animals showed significantly higher binding to PiTci-CF-
1 than either L4 ES (p < 0.001) and nTci-CF-1 (0.001 < p < 0.01). In the control sheep, 
IgG from pre-scapular ASC probes did not bind to any antigen tested, and IgG from the 
abomasal probes did not bind either nTci-CF-1 or PiTci-CF-1.  
IgG reactivity to periodate treated PiTci-CF-1in the pre-scapular ASC probes from the 
immunised animals was evaluated. The immune response elicited by the vaccine antigen 
PiTci-CF-1 was periodate sensitive (Figure 2.8, panel A) and individual serum samples 
showed a wide range of OD loss following periodate treatment (mean OD loss 56.39 %, 
range 86.82-36.17 %; Figure 2.8, panel B). 
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Figure 2.8 The effect of sodium periodate treatment of PiTci-CF-1 on binding of pre-scapular 
ASC IgG from PiTci-CF-1 immunised sheep. 
(A): blue bar: periodate untreated (Per-) samples; yellow bar: periodate treated (Per+) 
samples. Two-tailed, unpaired t-test p = 0.0002; Data represent mean ±SEM, n=9 per group 
with all samples analysed in duplicate. Panel (B): percentage of IgG binding loss in 
immunised animals to purified PiTci-CF-1 following periodate treatment. Mean OD loss 56.39 
%, range 86.82-36.17 %. Blue bars: periodate untreated (Per-) samples. Yellow bars: 
periodate treated (Per+) samples. Data represent mean ±SEM. 
 
2.3.5 Differential recognition of nTci-CF-1 and PiTci-CF-1 by 
antibodies from gastric lymph 
IgA antibodies in the gastric lymph of sheep previously infected with a T. circumcincta 
trickle infection then bolus challenged showed significantly higher binding to L4 ES and 
nTci-CF-1 than those in the lymph of T. circumcincta-primary infection animals (collected 
from helminth-free animals, at time points between -2 and +2 days of primary bolus 
challenge). There was no significant difference between previously infected and primary 
infection animals for lymph IgA binding to PiTci-CF-1. Lymph samples from sheep that 
had been previously infected showed significantly higher binding to L4 ES and nTci-CF-1 
than to PiTci-CF-1 (Figure 2.9).   
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Figure 2.9 The gastric lymph IgA responses from previously infected and primary infection 
sheep to T. circumcincta L4 ES antigens, nTci-CF-1 and recombinant PiTci-CF-1, during an 
experimental infection regime. 
Data represent mean ±SEM, n=5 (primary infection) and 8 (previously infected); all samples 
analysed in duplicate. Overall one-way ANOVA p <0.0001. Post-ANOVA analysis: Tukey’s 
multiple comparison test. *** = p <0.001; ns = p not significant. 
 
Periodate treatment of nTci-CF-1 showed loss of IgA reactivity in gastric lymph (Figure 
2.10, panel A), with a wide range of variability between animals (mean OD loss 60.05 %, 
range 40.86-81.62 %; Figure 2.10, panel B). When PiTci-CF-1 was treated with sodium 
periodate (Figure 2.11), the binding of lymph IgA to the periodate-untreated antigen was 
not significantly different between the previously infected and the primary infection groups 
(as seen in Figure 2.9). However, samples from previously infected animals showed 
significantly higher binding to periodate treated PiTci-CF-1 compared to lymph from 
primary infection animals.  
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Figure 2.10 The effect of sodium periodate treatment of nTci-CF-1 on binding of gastric 
lymph IgA from previously infected and primary infection sheep during an experimental 
infection regime. 
Data represent mean ±SEM, n=3 (primary infection) and 5 (previously infected); all samples 
analysed in duplicate. Panel (A): pink bars: periodate untreated (Per-) samples; green 
striped bars: periodate treated (Per+) samples. Overall one-way ANOVA p value displayed 
below the graph. Post-ANOVA analysis: Tukey’s multiple comparison test. *** = p <0.001; ** 
=  p < 0.01; ns = not significant. Panel (B): the percentage of IgA binding loss to nTci-CF-1 
following periodate treatment in previously infected animals. Mean OD loss 60.05 %, range 
40.86-81.62 %. Red bars: periodate untreated (Per-) samples. Yellow bars: periodate treated 
(Per+) samples. Data represent mean ±SEM. 
 
Figure 2.11 The effect of sodium periodate treatment of PiTci-CF-1 on binding of gastric 
lymph IgA from previously infected and primary infection sheep during an experimental 
infection regime. 
Data represent mean ±SEM, n=3 (primary infection) and 5 (previously infected); all samples 
analysed in duplicate. Pink bars: periodate untreated (Per-) samples. Green striped bars: 
periodate treated (Per+) samples. Overall one-way ANOVA p value displayed below the 
graph. Post-ANOVA analysis: Tukey’s multiple comparison test. * =  p < 0.05.  
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Lymph IgG also experienced loss of reactivity to nTci-CF-1 following periodate treatment 
of the antigen (Figure 2.12). In this experiment primary infection animals showed pre-
periodate treatment IgG reactivity comparable to previously infected animals; this may 
have been due to non specific cross-reactivity of the sheep gastric lymph IgG to nTci-CF-
1. Both decreases in OD observed following periodate treatment were statistically 
significant.  
Tables 2.6 to 2.8 summarise the findings of this chapter in regards to IgG and IgA 
reactivity. 
 
Figure 2.12 The effect of sodium periodate treatment of nTci-CF-1 on binding of gastric 
lymph IgG from previously infected and primary infection sheep during an experimental 
infection regime. 
Data represent mean ±SEM, n=3 (primary infection) and 7 (previously infected); all samples 
analysed in duplicate. Pink bars: periodate untreated (Per-) nTci-CF-1. Green striped bars: 
periodate treated (Per+) nTci-CF-1. Overall one-way ANOVA p value displayed below the 
graph. Post-ANOVA analysis: Tukey’s multiple comparison test. ** =  0.001 < p < 0.01; * =  
0.01 < p < 0.05; ns = p > 0.05.  
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Table 2.6 Tables summarising the IgA and IgG reactivity of serum to different T. 
circumcincta antigens in immunised (then trickle infected) and in control (trickle infected 
only) sheep. 
 
Antigen 
Serum IgA 
Immunised Adjuvant-only controls 
L4 ES - (^) - (^) 
nTci-CF-1 n/d n/d 
PiTci-CF-1 +  -  
 
Antigen 
Serum IgG 
Immunised Adjuvant-only controls 
L4 ES + -  
nTci-CF-1 n/d n/d 
PiTci-CF-1 +  -  
Legend: + signs: antibody detection significantly higher than the other sample group 
considered in the same experiment; - signs: antibody detection not significantly different 
from the other sample group; n/d: not determined; (^): antibody binding was detected in 
both groups but there was no significant difference. Immunised: sheep were immunised 
with a PiTci-CF-1 preparation and trickle infected with T. circumcincta L3 for 4 weeks; 
adjuvant-only controls: sheep received a mock immunisation and were trickle infected for 4 
weeks.  
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Table 2.7 Tables summarising the IgA and IgG reactivity of serum to different T. 
circumcincta antigens in immunised (then trickle infected) and in control (trickle infected 
only) sheep. 
 
Antigen 
ASC probes (IgA) 
Immunised Adjuvant-only controls 
Abo Pre-Scap Abo Pre-Scap 
L4 ES + - + - 
nTci-CF-1 + - + - 
PiTci-CF-1 - + - - 
 
Antigen 
ASC probes (IgG) 
Immunised Adjuvant-only controls 
Abo Pre-Scap Abo Pre-Scap 
L4 ES - + - - 
nTci-CF-1 - + - - 
PiTci-CF-1 - + - - 
Legend: + signs: antibody detection significantly higher than the other sample group 
considered in the same experiment; - signs: antibody detection not significantly different 
from the other sample group. Immunised: sheep were immunised with a PiTci-CF-1 
preparation and trickle infected with T. circumcincta L3 for 4 weeks; adjuvant-only controls: 
sheep received a mock immunisation and were trickle infected for 4 weeks. Abo: abomasal 
ASC probe; Pre-Scap: pre-scapular ASC probe. 
 
Table 2.8 Table summarising the IgA reactivity of gastric lymph to different T. circumcincta 
antigens in previously infected (trickle + bolus challenge) and primary infection (bolus 
challenge only) sheep. 
 
Antigen 
Gastric Lymph 
Previously infected Primary infection 
L4 ES n/d - 
nTci-CF-1 + - 
PiTci-CF-1 - - 
Legend: + signs: antigen-specific IgA detection significantly higher than the other sample 
group considered in the same experiment; - signs: antibody detection not significantly 
different from the other sample group. Prev. Inf.: lymph collected 6-10 days T. circumcincta 
50 000 L3 bolus challenge from animals that received previous trickle infection (8 weeks); 
Primary infection: lymph collected -2 to +2 days post T. circumcincta 50 000 L3 bolus 
challenge. 
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2.4 Discussion 
In this chapter it was demonstrated that native Tci-CF-1 (nTci-CF-1), a major component 
of T. circumcincta L4 ES, can be purified from the complex ES mix by size exclusion 
chromatography. However, treatment with DTT and application of the ES-purified nTci-
CF-1 fraction to a thiol-sepharose column did not yield further purification of this antigen, 
and protein loss occurred in the process. Thiol columns have been previously used to 
enrich cysteine proteases in Ostertagia ostertagi ES material (Geldhof et al. 2002, Geldhof 
et al. 2004). In these studies, DTT was used prior to application of the ES material and in 
the elution buffer, and the process was replicated for this project using T. circumcincta ES. 
DTT is a protective agent for disulphide groups (Cleland 1964, O'Neil 2001) and it is 
capable of maintaining them in the reduced state of thiols. This ability is favourable in the 
context of cysteine protease purification, as they possess a cysteine residue in the active 
site, and cysteine, containing a sulphide group (-SH), is able to form disulphide bonds with 
other –SH residues in the amino acid chain in order to achieve correct folding. Therefore 
DTT may help during the purification process, as the disulphide bonds in the amino acid 
chain are reduced to thiols that are then able to bind to the thiol-sepharose matrix of the 
HPLC column. However, this process may lead to protein unfolding (due to reduction of 
disulphide bonds to -SH between amino acid residues) and precipitation, potential 
disruption of the active site and unexpected interactions between amino acid and 
carbohydrate residues (Alliegro 2000, Cho et al. 2008, Cleland 1964); these could lead to 
loss of antibody binding and enzymatic activity. For the above reasons, it was decided not 
to pursue further purification of native Tci-CF-1 by using thiol columns, as it is shown here 
that this process would not lead to a purer fraction, with in addition loss of protein quantity 
and potential loss of activity and correct folding.  
In this chapter, differential antibody recognition of L4 ES antigens, purified nTci-CF-1 and 
recombinant PiTci-CF-1 was observed in three different experiment types, using a range of 
ovine biological samples to reflect the differences in local and systemic immune response. 
Antibody responses appear to have an important role in the control of parasitic infections 
in ruminants, and it has been shown that excretory-secretory (ES) products and purified 
native antigens were the target of antibodies found in systemic and local environment in 
several ruminant host-parasite systems (Britton et al. 1993, De Maere et al. 2002, Geldhof 
et al. 2002, Halliday et al. 2007, Smith et al. 1986, Smith et al. 1994, Stear et al. 1995, 
Stear et al. 1999 b). For example, in previous studies on the ovine immune response to H. 
contortus experimental infection, significantly higher (p < 0.05) serum and abomasal 
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mucus IgG and IgA responses against ES products of adult worms were observed in 
previously infected sheep compared to uninfected animals (Lacroux et al. 2006). In cattle 
infected with the lungworm Dictyocaulus viviparus it was shown that in both groups of 
previously infected (by trickle infection with 100 L3/day for 5 days, then challenged with 
1500 L3) and control animals (only challenged), all serum immunoglobulin isotypes tested 
(IgA, IgG1 and IgG2) were reactive with adult ES antigens (Kooyman et al. 2007). In T. 
circumcincta trickle infection and challenge experiments, L4 ES-specific gastric lymph 
IgA levels were significantly higher in previously infected sheep compared to sheep 
subjected to primary challenge (Halliday et al. 2007). In an immunisation experiment of 
cattle with native purified Oo-ASP proteins (obtained by ES fractionation) plus Quil A 
adjuvant, followed by trickle infection with O. ostertagi, native ASP-specific IgG1 and 
IgG2 levels were significantly higher in both the serum and the abomasal mucus of the 
immunised animals than in the adjuvant only control group animals (Van Meulder et al. 
2013). In this experiment, the Oo-ASP/QuilA immunised cattle also showed significantly 
lower FEC compared to the adjuvant only animals; although correlations between ASP-
specific serum antibodies and FEC were not investigated (Van Meulder et al. 2013), the 
findings discussed here have underpinned the use of ES proteins as prototype vaccines. 
In the work presented in this chapter, serum IgA and IgG responses to T. circumcincta L4 
ES, native Tci-CF-1 and P. pastoris-expressed Tci-CF-1 were analysed during the course 
of a T. circumcincta experimental immunisation trial in sheep: groups of animals were 
immunised with 8 recombinant antigens or received a mock immunisation of adjuvant 
only, three times each; immunisations were three weeks apart (d 0, d 21 and d 42). All the 
animals received a T. circumcincta L3 trickle infection for 4 weeks, starting on the day of 
the last immunisation (d 42), and were euthanized 84 days after the start of the experiment 
(experimental plan Fig. 2.1). Teladorsagia circumcincta L4 ES-specific IgA and IgG were 
detected in all groups except one (serum IgG in immunised sheep) from day 42 onwards.  
In immunised sheep, the serum IgG response against L4 ES was evident three weeks 
before the start of the trickle infection, from day 21 [Figure 2.5 and Nisbet et al. (2013)].  
This suggests that the IgG response induced by immunisation and directed against the 8 
components of the recombinant was to a certain degree reactive to the native ES antigens 
used to coat the plates.  
In addition, the serum IgG response to L4 ES in immunised animals was significantly 
higher than in control animals, demonstrating that immunisation-induced IgG antibodies 
were able to bind native antigens present in the L4 ES preparation used in ELISA 
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experiments. In this chapter, serum IgA was only detectable after the start of the trickle 
infection at day 42 in each group of animals, suggesting a mucosal origin for parasite-
specific serum IgA, probably triggered by the trickle infection.  
In the immunised animals, serum IgA and IgG responses against recombinant PiTci-CF-1 
started to increase shortly after the start of the immunisation protocol (between day 0 and 
21), as these animals had received parenteral administration of PiTci-CF-1. However IgA 
and IgG levels peaked shortly afterwards, and both were shown to decline by the end of the 
trickle infection at day 70 (see experimental plan in Figure 2.1 and Figure 2.5), suggesting 
that, although T. circumcincta infection induced parasite-specific antibodies, these did not 
recognise recombinant PiTci-CF-1 and did not contribute to boost the PiTci-CF-1-specific 
antibody responses. This is an interesting finding in the light of the differential IgG and 
IgA binding observed in the control animals against PiTci-CF-1. In this case, none of the 
animals showed any serum antibody reactivity against the recombinant antigen, supporting 
the hypothesis that parasite-induced responses may not optimally recognise recombinant 
antigens and that the recombinant PiTci-CF-1 version may have differed subtly from the 
native nTci-CF-1 form. Indeed previous work using a T. circumcincta recombinant antigen 
showed no significant difference between primary infection or previously infected animals 
in regards to serum IgA or IgG binding to recombinant Tci-CF-1 expressed in E. coli, 
which was not recognised by either antibody isotype (Routledge 2008).  
Culturing of cells derived from lymph nodes draining the site of infection can provide a 
powerful tool to study the local immune response to parasitic pathogens [reviewed by 
McWilliam et al. (2012)]. Antigen-specific ASC probes have been validated to study the 
local immune response to parasitic antigens in various experiments with different 
helminths: cestodes such as Taenia hydatigena in the sheep host (Meeusen and Brandon 
1994a), in rodent models with the liver fluke, Fasciola hepatica (Meeusen and Brandon 
1994b) and nematodes such as Haemonchus contortus (Bowles et al. 1995). In ovine 
experimental T. circumcincta infection models, ASC probes have been successfully used in 
previous experiments, where probes from sheep challenged with T. circumcincta showed 
differential antibody binding to antigens from L3, L4 and adult stages (Balic et al. 2003) 
when harvested at different time points post-infection.  
The results of this chapter show that in abomasal ASC probes generated from sheep trickle 
infected with T. circumcincta, the IgA binding to native antigens such as L4 ES and nTci-
CF-1 was significantly higher than the control probes from pre-scapular lymph nodes in 
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the same animals. This suggests that an immune response against T. circumcincta was 
present locally in the abomasal lymph nodes and was significantly higher than at the pre-
scapular site which is anatomically distant. This showed how the physical distance and 
absence of lymph mixing from the abomasal infection site maintains a relatively naïve 
state of the pre-scapular lymph node cell populations to T. circumcincta antigens, making 
these a suitable negative control.  
In this chapter, cross-recognition of immunisation-induced antibodies to nTci-CF-1 was 
shown. The binding of pre-scapular probe IgG to this antigen in the immunised sheep was 
statistically higher than in the abomasal probes from the same animals. In contrast, those 
sheep that only received a mock immunisation and trickle infection did not show any 
difference between abomasal and pre-scapular probe IgG binding to L4 ES and nTci-CF-1. 
A very similar picture was observed when comparing the antibody responses to 
recombinant PiTci-CF-1: the control, trickle infected only sheep did not show reactivity to 
this antigen, whereas the immunised sheep showed a significantly higher IgA and IgG 
response in the pre-scapular probes compared to the abomasal probes. This phenomenon 
reflected the close proximity of the pre-scapular lymph nodes with the injection sites in the 
neck; because these lymph nodes drain the injection site, the recombinant antigens present 
in the vaccine appeared to stimulate a B cell response in the local lymph nodes, observed 
as IgA and IgG binding to PiTci-CF-1 which was a component of the vaccine. However, 
there was no binding to PiTci-CF-1 by any of the abomasal probes, in any of the groups, 
suggesting that the trickle infection-induced antibody response observed against the native 
antigens in L4 ES and purified nTci-CF-1 was not cross-reactive with the recombinant, 
yeast-expressed Tci-CF-1.  
A technical limitation of ASC probes is that collection of the lymph nodes of interest can 
only be carried out at post mortem, or subjecting the experimental animals to numerous 
surgical operations, which could be considered unpractical and unethical. With these 
considerations in mind, the availability of efferent lymph from the common gastric duct 
still gives the opportunity to study the local immune response when investigating gastro-
intestinal parasites such as T. circumcincta, without having to kill the experimental 
animals. The antibodies secreted in the ASC probes supernatant could be considered a 
purer representative of the efferent lymph from a few very specific lymph nodes of the 
abomasal chain. However, the antibodies in lymph found in the common gastric lymph 
duct would ultimately have been produced in the same lymph nodes, by the same 
infection-induced local B cell populations. To these antibodies, in gastric lymph there is 
 72 
 
also the addition of antibodies from other plasma cells in the abomasal lamina propria. 
This effectively enhances the potential parasite-induced specific reactivity of the lymph 
sample compared to the ASC probes. Furthermore, the samples retrieved for the work 
described in this chapter had been generated (for the previously infected animals) by 
trickle infecting sheep for 8 weeks, followed by a subsequent 50 000 T. circumcincta L3 
bolus challenge. Because of the prolonged exposure to the parasite, this protocol was 
considered appropriate to have generated lymph samples with higher levels of specific 
anti-T. circumcincta IgA and IgG than those found in the ASC probes used in previous 
ELISA experiments. The description of gastric lymph collection from sheep infected with 
T. circumcincta was first published in 1981 by Smith et al., and it has proven to be an 
useful tool in investigating the local immune response against this parasite (Halliday et al. 
2010, Halliday et al. 2009, Halliday et al. 2007, Smith et al. 1981, Smith et al. 1983, 
1983). In this chapter it is shown that T. circumcincta trickle infection-induced serum and 
ASC probe antibodies were not able to bind to PiTci-CF-1, whereas recombinant antigen 
immunisation-induced systemic antibodies and antibodies generated by pre-scapular ASC 
probes were able to bind native antigens in L4 ES and nTci-CF-1. These results were 
further confirmed by gastric lymph ELISA experiments: here it is reported that the binding 
of lymph IgA from T. circumcincta previously infected animals (which received a trickle 
infection and a bolus L3 challenge) to L4 ES was significantly higher than in control 
primary infection animals (effectively naïve to T. circumcincta, as samples were collected 
before the insurgence of a primary immune response), as observed previously (Halliday et 
al. 2007). Moreover, binding of lymph IgA from the previously infected animals to 
purified nTci-CF-1 also was significantly higher compared to that of primary infection 
animals. Neither group of sheep lymph samples showed significant IgA binding to the 
recombinant PiTci-CF-1, except in one case. In periodate-treated PiTci-CF-1 wells, lymph 
IgA from previously infected sheep showed significantly higher binding than lymph from 
primary infection sheep (Figure 2.11). There was not a significant difference in the 
periodate-untreated wells, as previously shown (Figure 2.9). This suggests that the use of 
periodate on the yeast-expressed recombinant Tci-CF-1 might have uncovered epitopes 
previously hidden by carbohydrate structures, for example within the peptide backbone, 
and that the Tci-CF-1-specific IgA present in lymph from previously infected sheep could 
then bind.  
Taken together, the results of this chapter showed lack of binding by T. circumcincta 
infection-induced antibodies to the recombinant protein PiTci-CF-1, compared to native L4 
ES antigens and native Tci-CF-1. However, a certain degree of cross-reactivity was 
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observed by immunisation-induced antibodies with the native L4 ES and purified nTci-CF-
1. This suggests that the immunisation-induced immune response may be able to recognise 
epitopes shared between the native and yeast-expressed Tci-CF-1, but also that other 
factors are involved for optimal immune recognition. 
Salts of periodic acid such as the sodium periodate used in this work oxidise hydroxyl 
groups of carbohydrate residues on two or more adjacent carbon atoms (vicinal diols) to 
aldehyde and ketone groups (O'Neil 2001), changing the shape of such epitopes 
(Kristiansen et al. 2010). Periodate-induced disruption of the shape of the epitopes in these 
carbohydrate residues (forming part of the N-linked glycan residues) has the potential of 
reducing the antibody binding ability (Fairlie-Clarke et al. 2010). Previous work conducted 
in a mouse system of malaria-nematode co-infection showed that periodate treatment of a 
P. pastoris-expressed merozoite antigen of the malarial parasite Plasmodium chabaudi 
chabaudi (MSP-119) was able to significantly reduce serum IgG3 binding in mice infected 
with P. chabaudi. Also significantly reduced was serum IgG1 and IgG2a binding to 
periodate-treated Nippostrongylus braziliensis somatic extract (NbA) in mice co-infected 
with P. chabaudi and the nematode N. braziliensis (Fairlie-Clarke et al. 2010). In another 
study on the lungworm parasite D. viviparus, results showed that several adult ES antigens 
carry N-linked glycans, and that de-glycosylation by PNGase F resulted in reduction of 
serum IgA, IgG1 and IgG2 binding from cattle that received a primary infection (Kooyman 
et al. 2007).  
In this chapter, a marked loss of antibody binding in each of the sample types investigated 
was observed following periodate treatment of T. circumcincta native and recombinant 
PiTci-CF-1. This finding supports the hypothesis that periodate-sensitive epitopes may be a 
prominent feature of Tci-CF-1 proteins and potently affect the ability of serum, ASC 
probes and lymph antibodies to bind to their target antigens. However, in the D. viviparus 
study discussed above, serum IgG1 of previously infected animals binding to de-
glycosylated ES antigens was increased compared to the glycosylated native version, 
suggesting that the primary immune response was directed against glycan antigens and that 
subsequent parasite challenge elicited an IgG1 response against the protein backbone 
(Kooyman et al. 2007). Fairlie-Clarke et al. (2010) also observed that periodate treatment 
of Pichia pastoris-expressed recombinant MSP-119 (not glycosylated in the native form) 
significantly increased serum IgG2a binding compared to the untreated MSP-119 in mice 
co-infected with P. chabaudi and N. braziliensis. In this case it was suggested that the 
periodate treatment exposed protein epitopes previously masked by the inappropriate 
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glycosylation by P. pastoris. Although work carried out in this chapter showed that both 
native and recombinant Tci-CF-1 contained periodate-sensitive epitopes and gave 
indications on the presence of glycan structures, the serum and ASC probes IgG 
recognition to PiTci-CF-1 in control animals was not enhanced by periodate treatment of 
the antigen. This suggests that the differences in antibody recognition observed between 
the two Tci-CF-1 versions may not only be due to differing glycan structures. Here it is 
also demonstrated that gastric lymph IgA binding from previously infected animals to 
periodate-treated PiTci-CF-1 was significantly higher than in lymph from T. circumcincta 
primary infection animals. A significantly higher serum IgG binding to periodate-treated 
PiTci-CF-1 was also observed in immunised animals compared to controls. This result 
indicates a degree of antibody recognition in protein epitopes of periodate-treated PiTci-
CF-1. 
Following the periodate treatment experiments, the conclusions that can be drawn are i) 
antibody responses elicited during T. circumcincta trickle infection were not able to cross-
react with recombinant PiTci-CF-1, suggesting that there were conformational or post-
translational differences between native and recombinant forms of the protein; ii) vicinal 
diol epitopes, which are periodate-sensitive and commonly found on glycan structures, are 
a prominent feature of each Tci-CF-1 version and variably but constantly affect the ability 
of serum, ASC probes and lymph antibodies to bind to nTci-CF-1. Taken together, these 
results suggest that although PiTci-CF-1 was not recognised by serum, ASC probe, or 
lymph antibodies from T. circumcincta infected sheep, a few shared protein epitopes 
conferred by the shared amino acid chain may become available if the recombinant version 
was disrupted by means of chemicals. For this reason, in a following chapter the antibody 
reactivity to nTci-CF-1 and PiTci-CF-1 was investigated following the denaturing effects 
of protein blotting. 
The findings discussed above have shown once again that engineering a recombinant 
vaccine candidate against nematode infections can be more complex than anticipated 
(Geldhof et al. 2007). To begin with, different types of native antigens have been used as 
vaccine candidates against helminth parasites.  These include a commercialized live 
attenuated parasite vaccine (Bovilis™ Huskvac against Dictyocaulus viviparus), purified 
native antigen vaccines such as H11 and H-gal-GP complex in Haemonchus contortus 
(Knox and Smith 2001) and Ostertagia ostertagi ES fractions (Meyvis et al. 2007). The 
major issue with vaccines using live attenuated/killed worms or purified native antigens is 
the difficulty in obtaining sufficient quantities of worms to produce the vaccine, with the 
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added problems of production on a larger scale, such as batch variability and antigen 
stability, being the most difficult to overcome (Smith and Zarlenga 2006). Currently, 
research is increasingly focused on the production of recombinant antigens, following the 
identification of candidates in the parasites’ ES products or somatic extracts (Meyvis et al. 
2007, O'Donnell et al. 1989, Smith et al. 2009). There have been a number of helminth 
recombinant antigens generated with various expression systems, achieving variable and 
mostly inconclusive results [reviewed by Geldhof et al. (2007), Lightowlers et al. (2003), 
Smith and Zarlenga (2006)]. For example, vaccination with the yeast-expressed Ac-CP-2 
antigen (a cysteine protease) from the hookworm Ancylostoma caninum achieved a 
significant reduction in the egg output and stunted worm growth compared to the controls 
(Loukas et al. 2004). However a C. elegans-expressed cysteine proteinase from H. 
contortus, Hc-CPL-1, did not elicit protection against homologous challenge (Murray et al. 
2007), although protection afforded by native Hc-CPL-1 is not known due to its low 
abundance.  In many cases, if the recombinant version fails to induce a protective immune 
response it is not known whether the original native antigen was an inappropriate choice, 
possibly due to lack of knowledge about the native antigen, or whether the unsuccessful 
efficacy was due to incorrect formation of the recombinant [reviewed by Geldhof et al. 
(2007), Smith and Zarlenga (2006)]. Differences in conformation and Post Translational 
Modifications (PTMs) can occur using traditional expression systems, especially when 
dealing with organisms taxonomically very distant, leading to the production of enzymes 
lacking correct folding or with defective PTMs and impaired functions (Geldhof et al. 
2007). Nematode proteins are highly glycosylated with unique structures, such as core 
α1→3-fucose residues that may be nematode-specific (Cipollo et al. 2002, Dell et al. 1999, 
van Die et al. 1999), and appear to be important in the host immune response. Sera from 
animals vaccinated with irradiated D. viviparus larvae have shown that there is a strong but 
short-lived immune response directed against N-glycans on the surface of antigens 
(Kooyman et al. 2007) and that glycans of nematodes are able to induce a strong Th2 
immune response (Tawill et al. 2004, Thomas and Harn 2004). Therefore, correct 
glycosylation may be important for effective vaccination.   
The hypothesis emerging from the results discussed in this chapter is that a likely cause of 
the differential antibody binding observed was due to altered folding and/or post-
translational modifications (PTMs), such as glycosylation of the recombinant PiTci-CF-1 
compared to the native version. For this reason, we aimed to express the same antigen in a 
different, novel expression system, the free-living nematode Caenorhabditis elegans, to 
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further investigate the enzymatic activity as an indication of correct folding, and 
glycosylation characteristics of each Tci-CF-1 version.  
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Chapter 3 - Generation of Teladorsagia 
circumcincta Proteins Using Caenorhabditis 
elegans  
  
3.1 Introduction 
Local and systemic antibodies elicited by Teladorsagia circumcincta trickle infections of 
sheep bind native, but not Pichia pastoris-expressed Tci-CF-1 (see Chapter 2). The 
discrepancy observed may be attributed to differences between the recombinant and native 
protein in regards to protein folding and post-translational modifications (PTMs), as these 
can differ depending on the expression system chosen (Darby et al. 2012, Ferrer-Miralles 
et al. 2009, Macauley-Patrick et al. 2005). A system which expresses parasitic nematode 
proteins in a form resembling the native protein, including correct folding and appropriate 
PTMs, would therefore be advantageous to vaccine development. For this reason, it was 
proposed to use an alternative expression system, the free-living nematode Caenorhabditis 
elegans to generate a recombinant version of Tci-CF-1 more similar to the native version. 
This model organism belongs to Clade V of the phylum Nematoda (Blaxter et al. 1998). Its 
phylogenetic relationship to Clade V parasitic nematodes, such as Haemonchus contortus 
and Trichostrongylus colubriformis, and its amenability to genetic manipulation suggested 
C. elegans may be an appropriate system for the study and expression of parasite genes 
(Grant 1992, Murray et al. 2007). For example, the insertion of a β-tubulin gene, tub-1, 
from benzimidazole susceptible H. contortus isolates conferred thiabendazole (TBZ) 
sensitivity when expressed in a C. elegans TBZ-resistant mutant (Kwa et al. 1995). Others 
reported that C. elegans was able to express a cystatin gene from the filarial nematode 
parasite Acanthocheilonema viteae, as observed in immunoblots of the recombinant protein 
probed with a monoclonal anti-his tag antibody or cystatin-specific antibodies (Pillai et al. 
2005). Another study into the functions of nematode proteases showed, in RNAi 
experiments, that a C. elegans cathepsin L protease (Ce-cpl-1) was pivotal in controlling 
embryogenesis of this worm (Hashmi et al. 2002). As this gene was found to be highly 
conserved among nematodes, it was hypothesised that cathepsin L may be essential for 
parasitic nematode development (Britton and Murray 2002). To prove this hypothesis, a C. 
elegans genetic mutant of cpl-1 (strain ok360) was rescued by micro-injection with the 
orthologous cathepsin L gene from H. contortus (Hc-cpl-1), resulting in almost complete 
rescue of the embryonic lethal phenotype: 4-5 % arrested embryos compared to the 
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untransformed ok360 worms (100 % embryo mortality; Britton and Murray 2002). More 
recently, it was shown that H. contortus Hc-CPL-1 could be successfully expressed and 
purified in active form using C. elegans as an expression system (Murray et al. 2007).  
An effective way to genetically modify C. elegans is to micro-inject a DNA construct 
encoding the desired protein into the gonad of hermaphrodite worms; this may be 
incorporated into germline cells in the gonad and form an extrachromosomal array in the 
following generations. Selection of transformed progeny can be achieved by co-injecting a 
marker gene (Han and Sternberg 1990, Mello et al. 1991). The use of dominant marker 
genes such as dpy-7:gfp or rol-6 is a useful tool to identify transformed worms when 
generating C. elegans transgenic lines (Britton and Murray 2002, Murray et al. 2007). In 
C. elegans, rol-6 encodes a collagen protein (Kramer et al. 1990), and mutations of the rol-
6 gene generate worms with a specific locomotion defect – a right-handed twisted 
phenotype when moving (Cox et al. 1980). Worms expressing a gene of interest together 
with rol-6 can therefore be identified and selected based on their roller phenotype. An 
alternative approach is to use a wild-type gene as a marker to rescue a specific mutant 
phenotype.  Gene rescue (or functional complementation) can be used to distinguish 
untransfomed/mutant from transformed/wild type organisms. The technique was originally 
devised in the fruit fly Drosophila melanogaster (Lewis 1945) and the original aim of the 
technique was to ascertain whether a wild-type gene can restore the function of a defective 
mutant, to demonstrate that the mutation is occurring in the same gene as the wild-type. 
This can be achieved in C. elegans by using genes from the same species (Gomez et al. 
2012), but also from different species, to identify the functions of orthologous genes [for 
example, rescue using human and rat NLGN1 genes (Calahorro and Ruiz-Rubio 2012), 
human GRB2 and Drosophila drk genes (Stern et al. 1993) or T. circumcincta cat-4 gene 
(Baker et al. 2012)]. In this chapter, two approaches for transforming C. elegans with two 
different T. circumcincta protein expression constructs were used; first, the micro-injection 
of rol-6 as dominant phenotypic marker gene in wild type C. elegans, alongside a plasmid 
encoding Tci-cf-1. Second, the rescue of the C. elegans mutant strain DR96 (unc-76 
defective) was carried out by micro-injecting Ce-unc-76 gene to rescue the wild type 
phenotype, along with a plasmid encoding T. circumcincta monocyte Migration Inhibitory 
Factor (Tci-mif-1) to distinguish successfully transformed worms from untransformed 
mutants. 
Macrophage Migration Inhibitory Factor (MIF) was first identified during studies of 
delayed-type hypersensitivity reaction in guinea pigs (Bloom and Bennett 1966), however 
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its functions had been unclear until the cloning of human MIF cDNA (Bernhagen et al. 
1994). In more recent years, it was demonstrated that MIF molecules have pivotal 
functions as regulators of innate immunity in infection and inflammation models [reviewed 
by Calandra and Roger (2003)]. A MIF-like molecule (Tci-MIF-1) has been identified in T. 
circumcincta extracts and Tci-MIF-1 mRNA was shown to be more abundantly present in 
eggs, L3, and adult stages and, in lower levels, in L4 larval stages. Tci-MIF-1 protein 
abundance was higher in L3 somatic extract than extracts from L4 and adult worms, and 
immunohistochemical staining of T. circumcincta of L3, L4 and adult worms showed 
localization of the protein in the worm gut (Nisbet et al. 2010b). By virtue of its postulated 
immunoregulatory functions (Bernhagen et al. 1993, Calandra et al. 1995, Calandra and 
Roger 2003, Falcone et al. 2001), and its abundance in the infective L3 stages, a 
recombinant version of Tci-MIF-1 was expressed in E. coli (EcTci-MIF-1) and used in 
immunisation trials of sheep which were then challenged with a T. circumcincta trickle 
infection (Nisbet et al. 2010b, Nisbet et al. 2013). The recombinant Tci-MIF-1 showed the 
conserved dopachrome tautomerase enzyme activity associated with MIF; however 
monocyte migration inhibition, which is a known function of MIF proteins from other 
nematodes (Pastrana et al. 1998, Tan et al. 2001), was not demonstrated (Nisbet et al. 
2010b). This may have been due to partial failure of the expression system to deliver 
correct Post-Translational Modifications (PTMs), affecting the cell recognition of the 
recombinant protein expressed in E. coli. Therefore it was proposed to express Tci-MIF-1 
in C. elegans to try to deliver a vaccine candidate with structure and PTMs more similar to 
the native protein found in T. circumcincta L3 larvae. 
The proposed method of purification for the C. elegans-expressed recombinant proteins 
involved the insertion of a poly-histidine tag at the protein C-terminus and the use of metal 
ion affinity chromatography. This was based on the fact that histidine is the main amino 
acid in proteins that interacts with immobilized metal ions [reviewed by Kuo and Chase 
(2011)]. Metal ions have been used to purify proteins for decades, thanks to the affinity of 
histidine-rich proteins for heavy metals such as copper (Cu), zinc (Zn), nickel (Ni) and 
cobalt (Co) (Porath et al. 1975). The metal ions can be immobilized in an agarose or silica 
gel matrix and then used to bind amino acid residues in chromatographic systems 
[Immobilized Metal Affinity chromatography (IMAC)]. Nickel ions are highly specific for 
binding peptides and proteins containing neighbouring histidine residues and the use of 
poly-histidine fusion tags ranging between 2-10 residues fused with recombinant proteins 
has become the most widely used type of affinity fusion tag since its first application 
(Hochuli et al. 1987, Hochuli et al. 1988, Terpe 2003). As this method was used in 
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previous studies to purify recombinant T. circumcincta recombinant antigens such as 
Pichia pastoris-expressed Tci-CF-1 (PiTci-CF-1) and E. coli-expressed Tci-MIF-1 (EcTci-
MIF-1; Nisbet et al. 2010b, Nisbet et al. 2013), the same system was considered 
appropriate for purification of C. elegans-expressed proteins in this project.  
The overall aims of this chapter are therefore: 
i) to express a recombinant version of Tci-CF-1 (that shares the same amino acid sequence 
as PiTci-CF-1) in the free-living nematode C. elegans; 
ii) to express a recombinant version of Tci-MIF-1 (that shares the same amino acid 
sequence as EcTci-MIF-1) in the free-living nematode C. elegans; 
iii) to efficiently purify both proteins. 
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3.2 Materials and methods 
3.2.1 Generation of vector encoding Tci-cf-1 for C. elegans 
microinjection 
A PCR product containing the full length Tci-cf-1 gene sequence generated in Chapter 2 
was used at a 1:100 dilution as template for PCR reactions aimed at introducing restriction 
enzyme digestion sites and a C-terminal poly-histidine (10x) tag by two subsequent PCR 
rounds. The primer sets used for PCR amplifications, colony PCR and sequencing are 
listed in Table 7.2 (Appendix A). Standard PCR, cloning into pGEM-T (Promega) and 
sequencing (Eurofins MWG Operon, Germany) conditions are detailed elsewhere [Chapter 
2, Sections 2.2.2 (cloning and sequencing) and 2.2.3 (PCR methods)]. Plasmid insert DNA 
from one colony containing the correct Tci-cf-1 sequence in frame with a 10x histidine tag 
and with NotI and SalI restriction sites inserted was PCR amplified and purified as 
described in Chapter 2. This product was used in downstream cloning into a C. elegans-
expression plasmid vector. This vector was originally generated by Dr Brett Roberts 
(University of Glasgow), and its structure is similar to that of the plasmid vector described 
by Britton and Murray (2002); the areas flanking the restriction sites upstream included 1.7 
kb of C. elegans cathepsin L gene promoter (Ce-cpl-1) and 500 bp of Ce-cpl-1 3’ 
untranslated region (3’ UTR) downstream (Figure 3.1). The plasmid was named ABR-09, 
and this name is maintained throughout this work. The vector ABR-09 was engineered to 
contain a XhoI restriction sequence, which creates an overhang (TCGA) identical and 
therefore compatible with the one generated by SalI, which was used for the cloning of the 
Tci-cf-1 insert. 
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Figure 3.1 Map of the vector ABR-09 used for cloning and expression of Tci-cf-1 and Tci-mif-
1 genes in C. elegans. 
The map shows the restriction sites relevant to this study (NotI and XhoI), Ce-cpl-1 promoter 
(blue arrow) and C. elegans cpl-1 3’ UTR (green bar). The free software SnapGene Viewer 
was used to generate this map.    
 
Restriction enzyme digests were carried out to release the Tci-cf-1 sequence from pGEM-T 
and to linearize ABR-09. The restriction digests included 5 μl Reaction Buffer D 
(Promega, Southampton, UK), 10 μg BSA, 7 μl of Tci-cf-1 plasmid and 10 U of enzyme, 
made up to 50 μl with dH2O. The Tci-cf-1 insert was released from pGEM-T using 10 U 
SalI in a first reaction incubated at 37°C for 1 h, after which 10 U NotI (all from Promega) 
was added and the reaction incubated for another 2 h. The released Tci-cf-1 insert was gel 
purified (QIAquick Gel Extraction Kit, Qiagen, Manchester, UK) following the 
manufacturer’s instructions. In addition, after the last wash with the buffer provided, one 
extra isopropanol wash was carried out before eluting the DNA with pre-warmed (50°C) 
dH2O. The ABR-09 vector was linearized following a similar procedure with the 
restriction enzymes XhoI and NotI (all from Promega) to create compatible ends. The 
ligation reaction between linearized ABR-09 and released Tci-cf-1 was: 7 μl of gel-purified 
Tci-cf-1, 1 μl of double digested ABR-09, 1 μl 10 X T4 Ligase buffer and 1 μl of T4 
Ligase enzyme (Promega). Cloning into JM109 cells and colony PCR were carried out as 
previously detailed in Chapter 2.2.2 using primer sets 2, 3 and 4 as listed in Appendix A, 
Table 7.2.  Colonies containing Tci-cf-1 were amplified and plasmid DNA column purified 
using a Plasmid Mini Kit (Qiagen). A final restriction analysis was carried out in single 
reactions using AsuII and BamHI (Roche) and EcoRI and HindIII (Promega) to confirm the 
insertion of Tci-cf-1 sequence into ABR-09 in the correct position. The final construct 
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encoding Tci-CF-1 (Figure 3.2) was sent to Dr Collette Britton at the University of 
Glasgow for micro-injection into C. elegans wild type, strain Bristol N2. 
 
 
Figure 3.2 Diagram of the Tci gene constructs inserted into plasmid ABR-09 for micro-
injection into C. elegans. 
 
3.2.2 Generation of vector encoding Tci-mif-1 for C. elegans 
microinjection 
A plasmid containing Tci-mif-1 insert in pET-22b(+) (Novagen, Darmstadt, Germany) was 
provided by Dr Alasdair Nisbet at MRI as a scraping of cell culture glycerol stock. The 
scraping was suspended in 40 μl of dH2O and used as template for PCR reactions aimed at 
introducing NotI and XhoI restriction sites and a C-terminal poly-histidine tag at the 3’ end 
of the amplicon by two PCR rounds, using primer set number 5 listed in Table 7.2 
(Appendix A). Standard cloning into pGEM-T (Promega) and sequencing (Eurofins MWG 
Operon, Germany) conditions are detailed elsewhere (Chapter 2, Sections 2.2.2.2 and 
2.2.2.3). One colony containing the correct Tci-mif-1 sequence in frame with 10x poly-
histidine tag, NotI and XhoI restriction sites was digested to release the Tci-mif-1 insert 
from pGEM-T following the procedure detailed in Section 3.2.1; ABR-09 was also 
linearized. The digested Tci-mif-1 insert DNA was column purified (QIAquick PCR 
Purification Kit, Qiagen) and ligated into linearized ABR-09 (Figure 3.1). The ligation 
reaction was as detailed above in Section 3.2.1. The transformation of ligated products, 
colony PCR (using primer sets 4 and 5, Table 7.2), and sequencing methods (using primer 
sets 3 and 6, Table 7.2) have been detailed in Chapter 2. One colony including the correct 
Tci-mif-1 sequence in frame with 10x poly-histidine tag was amplified overnight in LB 
broth and column purified (Plasmid Mini Kit, Qiagen), before being sent to Dr Collette 
Britton at the University of Glasgow for micro-injection into C. elegans unc-76 mutant 
strain DR96. 
3.2.3 Routine maintenance of C. elegans  
Unless otherwise stated, all protocols and media recipes were adapted from the publicly 
available Wormbook (http://www.wormbook.org/). Briefly, C. elegans worms of mixed 
stages were routinely maintained on Nematode Growth Media (NGM, Appendix D) poured 
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in 90mm Petri dishes and left to solidify. After 1-2 days of plates resting upside down to let 
all condensation evaporate, a thin lawn of E. coli OP50 strain was seeded onto each plate, 
making sure not to reach the edge of the agar. Within 2 days the plates were ready to use 
for worm growth. Fresh plates were left at 4°C until use. Individual worms showing the 
transformed phenotype were picked from plates in which they had been left to proliferate 
for at least 3 days, using a worm pick made of a 0.2 mm platinum wire fused to the end of 
a glass Pasteur pipette. The worms were deposited gently onto the agar of a new NGM 
plate, not in contact with the E. coli lawn, and allowed to crawl off the pick. The plates 
were maintained in incubators at a constant temperature of 20°C (± 1°C).  
If worm stocks became contaminated with yeast or bacteria other than E. coli OP50, the 
plates were treated as follows to remove the contamination (adapted from Wormbook, 
http://www.wormbook.org/chapters/www_strainmaintain/strainmaintain.pdf). Briefly, 
plates containing contaminated worms were selected for presence of gravid hermaphrodites 
and washed with sterile H2O to free the worms. A 1:1 solution of 1 N NaOH and 
household bleach (5 % NaClO) was prepared and two 20 μl drops were positioned at 
diagonal edges of a clean NGM plate. Five gravid hermaphrodite C. elegans were put in 
each drop and left to die. The solution killed the contaminant and worms leaving viable 
eggs. The following day, hatched larvae had crawled free from contaminant. If the 
contaminants were not eliminated but only reduced, the procedure was repeated. 
3.2.3.1 Storage of worms 
For short term storage of worms, 10-15 worms were moved onto a fresh NGM plate in 
which 25-30 ml of liquid NGM had been allowed to set and an E. coli OP50 lawn allowed 
to grow. The plates were wrapped in Parafilm and left in the incubator at 15°C for up to 
three weeks. Worms were then picked individually or chunks of agar (carrying worms) 
from the old plate transferred onto a fresh NGM plate to allow feeding and recovery. 
For long term storage of worms, two methods were used: i) starved L1-L2 worms were 
collected from NGM plates by washing the plates with ~1 ml of S Buffer (Appendix D) for 
each vial and worms collected in sterile Eppendorfs.  An equal volume of S Buffer/ 30 % 
glycerol was added and mixed. One millilitre of worm suspension was aliquoted into 
several labelled 1.8 ml vials for long term freezer storage (Nunc® CryoTubes®); the vials 
were packed in a Styrofoam box appositely prepared with slots to hold cryovials. The box 
was kept at -80°C until further use. To recover worms it was sufficient to thaw one vial 
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and pour the contents onto a fresh NGM plate. Thawed vials could not be re-frozen. 
Freezing method ii) the Soft Agar Freezing Solution was melted in a microwave and left to 
settle in a water bath at 55°C for 15-20 min. Worms were collected at the L1-L2 stage 
from starved plates using ~1 ml S Buffer for each vial to freeze and put on ice in an 
Eppendorf.  The same volume of Soft Agar Freezing Solution was added and mixed well. 
One millilitre of this suspension was aliquoted into several 1.8 ml cryovials (Nunc) and put 
at -80°C using the Styrofoam box. To recover worms, a small scoop of frozen suspension 
was collected and deposited to thaw onto a fresh NGM plate. The thawing recovery 
procedure was repeated if an insufficient number of worms colonized the plate. 
3.2.4 C. elegans microinjection  
This procedure was carried out by Dr Collette Britton and Dr Brett Roberts at the 
University of Glasgow. To allow positioning for microinjections, young adult C. elegans 
were picked and placed in a drop of mineral oil on a glass cover slide onto which a drop of 
molten 1 % agarose had been previously poured and left to cool to create a “sticky” pad for 
the worms to adhere to. The cover slide was transferred to the micro-injecting microscope 
and a glass needle used to inject DNA into the gonads of the worms. The injected C. 
elegans hermaphrodites were recovered from the agar pad with a drop of M9 Buffer 
(Appendix D) and deposited in a fresh NGM plate to recover. The plates were kept at 20°C 
and screened every day for progeny expressing the marker phenotype. Each generation was 
maintained in a separate plate. Generated C. elegans transgenic lines were also screened by 
Western blot using anti-His antibody for the presence of the desired protein [C. elegans 
expressed Tci-CF-1 (CeTci-CF-1) or C. elegans expressed Tci-MIF-1 (CeTci-MIF-1)] in 
the separate lines.  
3.2.5 Generation of C. elegans biomass 
Stable worm lines showing recombinant protein expression by Western blot, were 
harvested from NGM plates with 2 ml M9 buffer and 100 μl of the worm suspension were 
transferred onto Peptone Rich agar plates (Appendix D), pre-seeded with a lawn of E. coli 
BL22 strain. The plates were incubated at 20°C for 3.5-5 days depending on the growth 
rate of the worms and subsequently harvested before the plates reached complete depletion 
of the E. coli lawn. The worms were harvested by washing the plates with ice cold 0.1 M 
NaCl, washing at least twice with the ice cold solution. The worm suspension was placed 
in centrifuge tubes and centrifuged at 7000 x g for 5 min. The pellet was resuspended in 20 
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ml 0.1 M NaCl, then the same volume of 60 % sucrose was added before centrifugation at 
3500 x g for 5 min. Sucrose is toxic to C. elegans at such concentrations, therefore the 
worms were quickly harvested with a broken glass Pasteur pipette and transferred to a 
fresh centrifuge tube pre-filled with ice cold 0.1 M NaCl. The worm solution was washed 3 
times in 0.1 M NaCl at 7000 x g for 5 min. After the final wash, the pellet was resuspended 
in the same volume of Binding Buffer B (Appendix D) before freezing at -80°C for at least 
30 min or until ready to process. The worm suspension was thawed on ice before 
sonication (10 cycles of 10 sec on/20 sec off) on ice. One millilitre aliquots of the 
sonicated suspension were applied to a glass homogeniser and worms disrupted manually 
into a homogenate. To complete protein release from the worm lysate, Triton X-100 to a 
final concentration of 0.1 % was added to the worm homogenate and left on a rocking 
device for 30 min at 4°C. Subsequently the homogenate was aliquoted in 1.5 ml 
Eppendorfs and centrifuged at 13 000 x g for 5 min. The cleared lysate (CL) was collected 
and centrifuged again at 13 000 x g for 3 min, the supernatant collected and the pellet 
resuspended in 2-3 ml Binding Buffer B before repeating the process from the sonication 
onwards. The pool of cleared lysate was filtered using a 20 ml sterile syringe (BD 
Bioscience) and single-use Minisart filters (Sartorius, Goettingen, Germany); first the 
lysate was applied to a 0.45 μm filter followed by a 0.2 μm filter to remove all residual 
debris. The samples thus obtained were immediately used for protein purification. 
3.2.6 Protein purification using metal ion columns (IMAC) 
3.2.6.1 Cobalt (Co2+) ion columns 
The cleared lysate generated from C. elegans transformed worms in section 3.2.5 was 
applied to the Co
2+
 Immobilized Metal ion Affinity Chromatography [IMAC; HiTrap 
Talon® crude, GE Healthcare UK Ltd (Little Chalfont, UK)] purification system, 
following a protocol adapted from (Murray et al. 2007). Briefly, the column was attached 
to a bench-top chromatography pump system (Pharmacia Biotech, now part of GE 
Healthcare) previously washed with dH2O for at least 5 min at a flow rate of 1 ml/min; the 
column was washed with 5 column volumes of dH2O and equilibrated with 5 column 
volumes of Binding Buffer B (Appendix D).  
The C. elegans cleared lysates containing Tci-CF-1 or Tci-MIF-1 were applied in their 
entirety (~20-40 ml) to the column and left to re-circulate through the column for 1-2 h at a 
flow rate of 1 ml/min. This allowed the whole sample volume to circulate at least three 
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times through the column, which was then washed with 5 column volumes of Wash Buffer 
(Appendix D) before applying Elution Buffers 1-5 (all in Appendix D) containing an 
imidazole step gradient ranging between 165-500 mM imidazole. The recombinant 
proteins were dialysed against Dialysis Buffer 2 (Appendix D); Mini Dialysis Kit (GE 
Healthcare) with a molecular weight cut-off (MWCO) of 8 kDa (Tci-CF-1) or 1 kDa (Tci-
MIF-1) were used to dialyse the purified proteins in two washes of 500 ml buffer, 
overnight and 3 hours in length respectively. On one occasion explained in the relevant 
results section, Slyde-a-lyzer dialysis cassettes, with a MWCO of 20 kDa (Pierce), were 
used for dialysis in Dialysis Buffer 2 for recombinant Tci-CF-1. 
Protein identity was confirmed for both Tci-CF-1 and Tci-MIF-1 by Matrix Assisted Laser 
Desorption/Ionisation - Time of Flight (MALDI-ToF) spectrometric analysis performed at 
MRI Proteomics Unit. 
3.2.6.2 Nickel (Ni2+) 
Purification of C. elegans-expressed Tci-CF-1 protein was carried out using IMAC 
systems with Ni
2+
 ions as described previously in Section 2.2.4 of this thesis. 
3.2.7 Whole worm SDS-PAGE and Western blot protocols 
Western blot analyses of C. elegans transformed adult worms were carried out adapting the 
general Western blot procedure described in Appendix B. Equal numbers (between 100-
200) of C. elegans rol-6 phenotype (rollers), rescued DR96 or N2 (Bristol strain, wild 
type) worms were picked into 65 μl of ice cold PBS, to which 25 μl of NuPAGE® sample 
loading buffer and 10 μl of NuPAGE® reducing agent were added (Invitrogen, Paisley, 
UK), for a total volume of 100 μl. The samples were heated at 70°C for 10 min and 13 μl 
were loaded into wells of NuPAGE® Bis-Tris 4–12 % gels; electrophoresis and standard 
Western blotting were carried out as described in Appendix B. Wash buffer was PBST 
(Appendix D) and blocking and diluting buffer was PBST-Milk (Appendix D). The 
primary antibody was a mouse Anti-His (C-term) antibody (clone #3D5, 1:1500 dilution, 
Invitrogen) and secondary antibody was a rabbit anti-mouse IgG:HRP diluted 1:1000 
(clone n/a, P0161, Dako) in PBST-Milk. Blots containing rol-6/Tci-cf-1 transformed worm 
extract were probed with a 1:1000 dilution of anti-PiTci-CF-1 sheep serum [previously 
generated at MRI by Dr Tom McNeilly and Dr Alasdair Nisbet, unpublished data)] and an 
anti-goat/sheep IgG:HRP (clone GT-34, A9452, Sigma-Aldrich) diluted 1:1000 in TNTT 
as secondary antibody.  Pre-immune serum from the same sheep was used as a control. 
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Western blots of DR96 unc-76 rescued/Tci-mif-1 worms were routinely blocked and 
washed in TNTT, probed with a 1:50 dilution of anti-EcTci-MIF-1 rabbit serum (Nisbet et 
al. 2010b) and goat anti-rabbit IgG:HRP conjugate (clone n/a, P0488, Dako) diluted 
1:1000 in TNTT as secondary antibody. All blots were developed with ECL or DAB as 
previously detailed in Appendix B. Western blots of IMAC-purified protein were carried 
out as described in Appendix B, with the antibodies detailed above. 
3.2.8 Statistical analysis 
Statistical analysis was carried out using GraphPad Prism version 5.01 and GenStat 12
th
 
Edition. Arithmetic means with standard errors and replicate number (n) are shown. Data 
were checked for normal distribution by analysing the histogram of frequencies and 
residual plots. For comparison of one pair of means, an unpaired two-tailed t-test was used. 
P values of < 0.05 were considered significant.   
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3.3 Results 
3.3.1 Generation and purification of C. elegans- expressed Tci-CF-
1 (CeTci-CF-1)  
The transgenic C. elegans injected with Tci-cf-1 and Ce-rol-6 expressed the roller 
phenotype. A high proportion of the worms had incorporated the marker plasmid (at least 
50 % of the worms displayed the transformed phenotype). A protein of the predicted size 
of Tci-CF-1 (~45 kDa including 10x His tag) was detected in whole roller worm Western 
blots using an anti-His tag antibody. However, a band of similar size was also detected in 
blots of wild type worms (Figure 3.3). The lane containing the transformed roller worm 
extract showed a more intense band compared to the lane containing N2 worms extract. 
Considering that the same number of N2 and roller worms had been loaded onto the gel, 
this suggested that His-tagged recombinant Tci-CF-1 and other C. elegans histidine rich 
protein(s), each similar in size, could be detected by the anti-his tag monoclonal antibody. 
 
Figure 3.3 Immunoblot of C. elegans N2 and Tci-cf-1/rol-6 roller worms, showing the 
expression of CeTci-CF-1 in the transformed worms. 
Lane 1: 100 whole N2 worms; lane 2: 100 whole roller worms. One hundred worms were 
incubated in SDS loading buffer and reducing agent at 70°C for 10 min. The proteins were 
transferred onto nitrocellulose membrane. Immunoblot was probed with anti-His tag:HRP 
antibody (1:1500, Invitrogen) and developed using the ECL system. 
To address this, another immunoblot was probed with an anti-PiTci-CF-1 ovine serum 
previously generated at MRI. A band of the expected size (between 38 and 49 kDa 
markers) was present only in the lane loaded with extract of roller worms, when probed 
with anti-PiTci-CF-1 anti-serum, but not with pre-immune serum from the same animal 
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(Figure 3.4). This indicated that C. elegans transformed with rol-6/Tci-cf-1 expressed a 
recombinant version of Tci-CF-1. Additional bands are observed due to cross-reactivity of 
the antiserum with C. elegans extract proteins. This may have been due to epitope 
similarities between C. elegans antigens and other immunogenic antigens commonly 
encountered by sheep immune system, resulting in a complex polyclonal serum antibody 
population. The serum used for Fig. 3.4 was collected from sheep that had not been, to the 
writer’s knowledge, previously infected with T. circumcincta.  
 
Figure 3.4 Immunoblot of C. elegans roller and N2 worms, showing the expression of CeTci-
CF-1 (red box). 
Lanes 1 and 3: 100 whole roller worms; lanes 2 and 4: 100 whole N2 worms. Worms were 
incubated in SDS loading buffer and reducing agent at 70°C for 10 min. The proteins were 
transferred onto nitrocellulose membrane. Immunoblot A probed with sheep serum before 
immunisation with PiTci-CF-1. Blot B was probed with serum post immunisation. The blots 
were developed with ECL.  
 
A protein of the expected size of Tci-CF-1 was purified from the cleared lysate of roller 
worms using a Ni
2+
 chelating column. However, the eluted fractions contained many 
contaminating proteins (Figure 3.5).  
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Figure 3.5 SDS-PAGE analysis of C. elegans fractions from roller worms expressing CeTci-
CF-1, eluted from a Ni
2+
 IMAC system. 
Coomassie stained gel. Lane M: molecular weight marker (kDa); lanes 1-2: flow-through 
(unbound fractions); lane 3: fraction eluted with 50 mM imidazole; lane 4: 200 mM imidazole; 
lane 5: 350 mM imidazole; lanes 6-8: 500 mM imidazole (putative CeTci-CF-1, solid line box). 
Lane P: control of PiTci-CF-1 (dotted line box). 
A more sensitive method was developed using a Co
2+
 chelating column, in an attempt to 
purify CeTci-CF-1 alone. The result was partially successful, as all contaminating proteins 
except one were eliminated from the eluted fraction containing CeTci-CF-1 (eluted using 
165 mM imidazole; Figure 3.6). The identity of CeTci-CF-1 was confirmed by the MRI 
Proteomics Facility by MALDI-ToF analysis.  
 
Figure 3.6 SDS-PAGE analysis of T. circumcincta L4 ES-purified native Tci-CF-1 (nTci-CF-1), 
purified recombinant PiTci-CF-1 and CeTci-CF-1.  
Coomassie stained gel. Lane 1: molecular weight marker; Lane 2: nTci-CF-1; lane 3: PiTci-
CF-1; lane 4: CeTci-CF-1 (solid arrow) and contaminant C. elegans protein (dotted arrow). 
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3.3.2 Identification of a C. elegans galectin in the CeTci-CF-1 
eluted fractions 
Upon investigation and analysis by mass spectrometry (Lc-ESI MS/MS), the contaminant 
protein in each CeTci-CF-1 eluted fraction was identified as Ce-LEC-8, a galectin (NCBI 
Protein accession number NP509649, estimated molecular weight: 20.4 kDa). This protein 
possesses a high number of histidine residues (25 of 180 total residues, 13.8 %, Table 3.1), 
giving it potential affinity for the chelating ions in the columns used for purification. 
Protein structure was predicted using the free software Jalview v2.6.1, integrating Jmol 
(Cole C. 2008, Waterhouse 2009) and the position of histidine residues highlighted to 
show the presence of surface clusters of this amino acid (Figure 3.7). 
Table 3.1 The amino acid composition of Ce-LEC-8, highlighting histidine as the most 
abundant residue. 
 
Amino Acid Frequency 
His 25 
Val 14 
Gly 14 
Ala 13 
Ser 13 
Phe 12 
Glu 12 
Ile 11 
Asn 10 
Leu 8 
Asp 8 
Thr 7 
Tyr 7 
Pro 7 
Arg 6 
Lys 4 
Gln 4 
Met 2 
Trp 2 
Cys 1 
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Figure 3.7 Predicted tertiary structure of Ce-LEC-8, viewed from different angles to show the 
histidine clusters.  
Histidine residues highlighted in green. The predicted 3D structure was generated importing 
the Ce-LEC-8 amino acid sequence into Jalview software v2.6.1; settings were Style: 
perspective depth, and Scheme: CPK spacefill. 
 
The contaminant protein could be purified from N2 wild type C. elegans worms following 
the same protocols used for CeTci-CF-1 and its identity was confirmed by SDS-PAGE 
analysis and Lc-ESI MS/MS as Ce-LEC-8 (Figure 3.8).  
 
Figure 3.8 SDS-PAGE analysis of C. elegans fractions from N2 worms showing Ce-LEC-8, 
eluted from a Co
2+
 IMAC system. 
Coomassie stained gel. Lane M: molecular weight marker (kDa); lane 1: flow-through 
(unbound fractions); lane 2: wash fraction (40mM imidazole); lanes 3-4: 165 mM imidazole; 
lane 5: 350 mM imidazole. Ce-LEC-8 bands are shown in the solid line box. 
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3.3.3 Generation and purification of C. elegans-expressed Tci-
MIF-1 (CeTci-MIF-1) 
The C. elegans unc mutant strain DR96 transformed with unc-76 wild type gene and Tci-
mif-1 showed a wild type phenotype, in contrast to the un-transformed worms that still 
displayed the unc-76 deficient DR96 phenotype. A very high proportion of the worms had 
incorporated the marker plasmid (at least 75 % of the worms displayed the transformed 
phenotype). A protein of the predicted size of Tci-MIF-1 was detected in Western blots of 
transformed worms displaying the wild-type phenotype, using an anti-His tag antibody 
(data not shown). No other protein except CeTci-MIF-1 was bound by the anti-His tag 
antibody in the extract from DR96 worms, though another unidentified C. elegans protein 
previously observed in N2 worm extracts (~49 kDa, Fig. 3.4 lane 1) was again bound by 
the anti-His tag antibody in control strips of N2 worms extracts. Following Co
2+
 chelation 
chromatography and elution using 500 mM imidazole, a protein of the expected size of 
recombinant Tci-MIF-1 (~13.7 kDa including 10x His tag) was purified from the cleared 
lysate of rescued DR96 worms (Figure 3.9). The identity of CeTci-MIF-1 was confirmed 
by Western blot using anti-Tci-MIF-1 rabbit serum [previously generated by immunising 
rabbits with a recombinant E. coli version of Tci-MIF-1 (Nisbet et al. 2010b)]; further 
analysis was carried out by the MRI Proteomics Facility by MALDI-ToF and the identity 
of CeTci-MIF-1 was confirmed. 
 
Figure 3.9 SDS-PAGE analysis of CeTci-MIF-1 purified from DR96 C. elegans worms rescued 
with unc-76 and Tci-mif-1 genes.  
Coomassie stained gel. The fractions shown were eluted from a Co
2+
 IMAC system. Lane 1: 
molecular weight marker; Lane 2: CeTci-MIF-1 (pre dialysis); lane 3: CeTci-MIF-1 (pooled 
fractions post dialysis). 
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A protein of the same estimated molecular weight as Ce-LEC-8 was also eluted at the same 
imidazole concentration as before (~165 mM) from the cleared lysate of rescued C. 
elegans DR96 worms (Figure 3.10). The protein identity was not further investigated as 
Tci-MIF-1 eluted at higher imidazole concentration (> 350 mM) and therefore, in contrast 
to CeTci-CF-1, no further purification of CeTci-MIF-1 was required. 
 
Figure 3.10 SDS-PAGE analysis of CeTci-MIF-1 and hypothesised Ce-LEC-8 purified from 
DR96 C. elegans worms rescued with unc-76 and Tci-mif-1 genes.  
Coomassie stained gel. The fractions shown were eluted from a Co
2+
 IMAC system. Lane M: 
molecular weight marker; Lane 1: Flow through; lane 2: wash buffer (40mM imidazole); 
lanes 3-5: elution buffer (imidazole 165 mM), hypothesised Ce-LEC-8 inside box; lane 6: 
eluted fraction (imidazole 200 mM); lane 7: eluted fraction (imidazole 350 mM); lane 8: eluted 
fraction containing CeTci-MIF-1 indicated by the arrow (imidazole > 350 mM). 
 
3.3.4 Characteristics of C. elegans transformed strains 
Transgenic C. elegans populations appeared to differ in regards to the efficiency of 
transformation in the stable transformed progeny, the time needed to reach a similar 
number of worms per NGM agar plate following transfer onto fresh substrate, their 
movement abilities, and the total yield of purified recombinant protein. Following micro-
injections and screening of subsequent generations, each transformed C. elegans 
population showed a mixed phenotype, with a high proportion of worms displaying the 
marker phenotype in any one generation. From previous experience and PCR experiments 
using transformed C. elegans worms, it was shown that worm lines carrying the marker 
plasmid also carried the protein expression plasmid (Dr Collette Britton, personal 
communication). Therefore, the presence of transformed phenotype in the rol-6/Tci-cf-1 
injected C. elegans population suggested that not only the marker gene had been 
incorporated as extrachromosomal arrays, but also the plasmids encoding T. circumcincta 
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proteins. However, roller populations constantly displayed a lower transformation 
efficiency (50-60 % transformed worms/plate) compared to rescued DR96 strain (75-90 
%). The discrepancy was maintained when equal numbers of transformed worms were 
transferred onto fresh NGM agar plates. 
Following transfer of ~15-20 roller worms, rescued DR96 or N2 worms onto fresh NGM, 
daily microscopic observations showed that roller worms completed consumption of all 
bacterial lawn (reaching near starvation point) on average 2-2.5 days later than either N2 or 
rescued DR96 worms. This phenomenon was maintained during the process of generating 
biomass for protein purification, as roller worms required between 4 and 5.5 days to reach 
the levels of worm biomass considered appropriate for protein purification, whereas either 
rescued DR96 and N2 generally required 3-4 days (see Table 3.2).  
Table 3.2 Observations on some transformed C. elegans strain characteristics. 
 
Worm 
phenotype 
Estimate transformation 
efficiency (% of 
transformed worms/plate) 
Approximate number 
of days needed to 
reach near starvation 
(on NGM) 
Movement ability 
Roller 60 % 5-6 
Limited to circular 
areas; sinusoidal 
movements at 
times 
Rescued DR96 75-90 % 3.5-4 Sinusoidal 
N2 n/a 3.5-4 Sinusoidal 
 
Roller worms have limited freedom of movement compared to rescued DR96 or N2, with 
their movements only limited to circular areas as defined by their rotation axis, with rare 
linear movements. This might have had limiting effects on their ability to forage on fresh 
bacterial lawn, and move away from exhausted areas. On the contrary, N2 and rescued 
DR96 worms displayed the wild type movement phenotype, mostly in linear direction.  
Data on the total yield of recombinant protein per harvest was collected following protein 
purification. A harvest was defined as ~35 peptone-rich agar plates onto which C. elegans 
biomass was generated. Following extraction of the protein-rich cleared lysates and their 
application to Co
2+
 columns, multiple eluted fractions of CeTci-CF-1 and CeTci-MIF-1 
were collected (at least two eluted fractions/harvest); the protein concentration in each 
eluted fraction was estimated either by band densitometry or BCA assay, and the total μg 
protein/ml of packed worms volume data extrapolated. The mean recombinant protein 
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yield/ml of packed worm volume was 5.18 μg (CeTci-CF-1; SD = 3.76 and n = 4) and 
11.17 μg (CeTci-MIF-1; SD = 7.64 and n = 4); the range of yields was broad: 2.83-10.78 
μg/ml of packed worms for CeTci-CF-1 and 4.13-20.67 μg/ml of packed worms for CeTci-
MIF-1. The difference observed between C. elegans-expressed recombinant proteins total 
yields was not significant (p = 0.1926, n = 4), as shown in Figure 3.11. However, care must 
be taken interpreting the results comparing the yield of two recombinant C. elegans 
populations, as further data on the effect that different T. circumcincta genes might have on 
C. elegans is currently not available. 
 
 
Figure 3.11 The average recombinant protein yield (CeTci-CF-1 and CeTci-MIF-1)/ml of 
packed worms (C. elegans rollers and rescued DR96 worms, respectively). 
The ranges of protein yields/ml of packed worms was broad: 2.83-10.78 μg/ml of packed 
worms for CeTci-CF-1 and 4.13-20.67 μg/ml of packed worms for CeTci-MIF-1; data shown 
were the mean±SEM of yield from 4 different experiments. Unpaired, two-tailed t-test p = 
0.1926, not significant. 
 
3.3.5 Attempts to further purify CeTci-CF-1  
Denaturing SDS-PAGE analysis consistently showed that CeTci-CF-1 was co-eluted in 
tandem with another protein identified as Ce-LEC-8 (Figure 3.6). The contaminating 
protein was estimated to be twice as abundant as CeTci-CF-1 in the eluted fractions (~2:1 
ratio). Attempts to separate CeTci-CF-1 from Ce-LEC-8 were made as follows: 
1) size exclusion chromatography (using the same conditions described in Chapter 2 to 
fractionate T. circumcincta L4 ES), as the two proteins differed substantially in size (~43 
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kDa and ~20 kDa, see Fig. 3.6); however this approach was not successful as the recovery 
of CeTci-CF-1 in the 250 μl eluted fraction was negligible and estimated below 2 μg/ml.  
2) Slyde-a-lyzer dialysis cassettes, molecular weight cut-off (MWCO) 20 kDa (Pierce), as 
opposed to the Mini Dialysis Kit (GE Healthcare) described in Chapter 2, were also 
unsuccessful in separating the two proteins as some of the contaminant and most of CeTci-
CF-1 were undetectable post-dialysis (Figure 3.12).  
 
Figure 3.12 SDS-PAGE analysis of Co
2+
 eluted CeTci-CF-1 before and following dialysis with 
a Slide-A-Lyzer device. 
Coomassie stained gel. Lane M: molecular weight marker (kDa); lanes 1-3: representative of 
each 1 ml aliquots of CeTci-CF-1 fraction following dialysis; lane 4: CeTci-CF-1 before 
dialysis (solid arrow), and contaminant protein (dotted arrow). 
 
3) Shallower imidazole gradient in the Co
2+
 column elution buffers, as opposed to one 
single step from 40 mM imidazole wash to 165 mM imidazole elution buffer, to try and 
separate the two proteins. This approach was also unsuccessful, as the contaminant protein 
and CeTci-CF-1 shared overlapping elution conditions (Figure 3.13); in addition, this 
process contributed to further diluting CeTci-CF-1.  
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Figure 3.13 SDS-PAGE analysis of CeTci-CF-1 elution from roller C. elegans worms lysate 
over a shallow imidazole gradient.  
Silver stained gels. Two gels were needed to analyse all fractions. At the bottom of each 
lane the imidazole concentration (mM) used to elute each fraction is indicated. From the first 
lane on the far left: molecular weight marker (kDa); second lane: roller worms cleared lysate 
before application to the Co
2+
 column; all other lanes: the fractions eluted from the Co
2+
 
column. CeTci-CF-1 eluted at a narrower imidazole gradient (100-200 mM, solid line box) 
than the contaminant C. elegans proteins (40-500 mM, dotted line box). 
   
4) As the contaminant protein was identified as C. elegans galectin Ce-LEC-8, and it was 
hypothesised that it may bind to galactose residues, a further attempt was made to separate 
the two proteins using D-Galactose agarose beads to bind Ce-LEC-8 leaving CeTci-CF-1 
in solution. The method was partially successful, as the beads were able to remove most of 
the Ce-LEC-8; however, at the same time, much of the CeTci-CF-1 was also lost (Figure 
3.14).  
With these results in mind, it was decided not to pursue further purification of CeTci-CF-1, 
and all its subsequent uses were adjusted for the presence of C. elegans LEC-8. 
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Figure 3.14 SDS-PAGE analysis of proteins purified from C. elegans N2 and roller worms 
following D-galactose agarose chromatography. 
Coomassie stained gel. Lanes 1 and 6: molecular weight markers (kDa); lane 2: Ce-LEC-8 as 
purified from N2 (wild type) worms, before galactose agarose beads chromatography. Lane 
3: the same Ce-LEC-8 from N2 worms, after galactose chromatography. Lane 4: CeTci-CF-1 
(solid line box), containing similar amounts of Ce-LEC-8 (lower band). Lane 5: the same 
CeTci-CF-1 fraction (dotted line box) and Ce-LEC-8 (lower band), after galactose agarose 
chromatography. 
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3.4 Discussion  
The work described in this chapter represents the first successful attempt, to date, of 
generating and expressing T. circumcincta vaccine candidates using C. elegans. This 
chapter reports the generation and purification using C. elegans of two distinct T. 
circumcincta vaccine candidates, Tci-CF-1 and Tci-MIF-1, previously generated in other 
expression systems (Nisbet et al. 2010b, Nisbet et al. 2013). It was demonstrated that both 
micro-injection approaches taken (transformation of wild type N2 C. elegans worms with 
rol-6/Tci-cf-1 genes and rescue of wild type phenotype of DR96 using unc-76/Tci-mif-1 
genes) are viable methods for the expression of T. circumcincta genes using C. elegans. 
Both proteins were purified in amounts sufficient for their subsequent characterisation. The 
experiments carried out have shown that C. elegans-expressed recombinant proteins were 
better purified using IMAC systems based on Co
2+
 ions, rather than Ni
2+
.  
Initial immunoblots of transformed roller worms using an anti-His tag antibody showed the 
presence of a histidine-rich protein of similar mass (~45 kDa) to CeTci-CF-1. However, 
the anti-His tag antibody also bound to this protein in extracts of N2 worms, indicating that 
it was a C. elegans contaminating protein and not related to Tci-CF-1. As variable 
reliability in the binding of anti-his tag antibodies to poly-histidine tags situated at the C-
terminus of recombinant proteins was previously demonstrated by Debeljak et al. (2006), 
further experiments were carried out to identify the presence of CeTci-CF-1. To confirm 
that CeTci-CF-1 was expressed in the roller worms, extracts were probed on western blot 
with an anti-PiTci-CF-1 sheep serum which contains PiTci-CF-1-specific IgG. As the two 
proteins shared the same amino acid sequences, serum raised against the Pichia pastoris-
expressed version of Tci-CF-1 was likely to contain antibodies that recognised epitopes of 
another recombinant version expressed in C. elegans.  This identified a protein of the 
correct size only in transformed roller worms and allowed identification of CeTci-CF-1. In 
addition, as previously shown in Chapter 2 of this thesis, antibodies elicited by 
immunisation with PiTci-CF-1 were able to bind native Tci-CF-1, therefore it was very 
likely that these antibodies would be cross-reactive with a C. elegans-expressed Tci-CF-1 
version.  
Numerous recombinant nematode proteins have been generated in bacterial, yeast, 
baculovirus and more recently, in C. elegans expression systems [reviewed by Geldhof et 
al. (2007)]. Recombinant protein purification by using matrix-immobilized Ni
2+
 ions has 
been commonplace since its first application (Hochuli et al. 1988), and applied 
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successfully to previous purifications of T. circumcincta recombinant proteins [Tci-ASP-1; 
Tci-MIF-1; Tci-TGH-2; Tci-APY-1; Tci-SAA-1; Tci-CF-1; Tci-ES20; Tci-MEP-1 (Nisbet 
et al. 2010b, Nisbet et al. 2013, Nisbet et al. 2011)]. In this chapter, it is demonstrated that 
Ni
2+
 ions were insufficiently specific in their affinity for recombinant CeTci-CF-1, with 
multiple C. elegans proteins eluting from the chromatography column in each fraction. A 
similar problem has been noted before in the E. coli expression system, where most of the 
contaminants were found to be proteins that tightly bind to metal ions through surface 
clusters of histidine residues or other metal-binding residues  [reviewed by Bolanos-Garcia 
and Davies (2006)]. For example, the peptidyl-prolyl cis–trans isomerase SlyD (also 
known as WHP) is a major host cell contaminant protein in E. coli which binds nickel ions 
and often co-puriﬁes with heterologous recombinant histidine tagged proteins when using 
nickel-based IMAC (Hottenrott et al. 1997, Wülfing et al. 1994). SlyD (WHP) was, 
however, found to have reduced afﬁnity for Co2+ than Ni2+ ions, showing an alternative 
solution to the problem of co-puriﬁcation (Wülfing et al. 1994). In this chapter it was 
shown that most C. elegans contaminant proteins that co-eluted with CeTci-CF-1 also had 
lower affinity for cobalt IMAC system and that, with the exception of one contaminant, no 
other C. elegans protein bound to the Co
2+
 columns used, thus yielding an almost pure 
CeTci-CF-1. Indeed in the last remaining contaminant C. elegans protein, identified as the 
C. elegans galectin LEC-8, histidine was found to be the most abundant residue in its 
amino acid sequence (13.8 % histidine residues), as also described by (Nemoto-Sasaki et 
al. 2008). In addition, the histidine residues appeared to form surface clusters in the 
predicted tertiary protein structure, suggesting that they could have mimicked the presence 
of a his-tag and therefore increasing Ce-LEC-8 affinity for the Co
2+
 ions used for 
purification, as shown by [Hayama (2000), meeting abstract available at 
http://www.wormbase.org/resources/paper/WBPaper00011877#0--10]. A protein of the 
same estimated molecular weight as Ce-LEC-8 could also be identified in fractions eluted 
at low imidazole concentration (165 mM) from DR96 rescued C. elegans lysate. However, 
in this case further identification and purification steps were not required, as CeTci-MIF-1 
eluted at higher imidazole concentrations (> 350 mM) without other contaminant proteins 
being identified, at least by Coomassie staining.  
In this chapter, rol-6 was incorporated as a marker gene for transformation in extra 
chromosomal arrays of wild type N2 C. elegans. The marker gene rol-6 has been used in 
micro-injections of C. elegans worms since the early 1990s (Han and Sternberg 1990, 
Mello et al. 1991). Worms carrying this semi-dominant roller allele are characterised by a 
right-hand twisted helix in the muscle and cuticle layers of the body. Normal motion 
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observed in wild type C. elegans propels the worms forward or backward in a sinusoidal 
manner, whereas rol-6 instead causes the worms to roll along its longitudinal axis and to 
move in circles (Higgins and Hirsh 1977, Mello et al. 1991). Variability of the 
transformation efficiency of worms transformed with rol-6 has been shown (Link 1995, 
Mello et al. 1991). Following gonadal injection in C. elegans, transgenes form large 
extrachromosomal arrays which, once established, are transmitted to between 10 and 90 % 
of the progeny. Therefore, some offspring of transgenic animals will lose the transgenes 
and will not show the marker phenotype (Mello et al. 1991). For example, in C. elegans 
worms transformed to express human β-amyloid peptide, inheritance of the rol-6 marker 
gene and β-amyloid injected gene was variable between lines, ranging between 20-70 % 
(Link 1995). This was supported by the findings of this chapter, where roller worm 
populations constantly displayed lower estimated transformation efficiency (50-60 % 
transformed worms/plate) compared to unc-76 rescued DR96 worms (75-90 %). The most 
likely explanation for this is that greater expression of rol-6 is required to distinguish this 
phenotype from untransformed worms, compared to the unc-76 rescued phenotype; this 
could mean that worms expressing low levels of rol-6 could be missed during screening. 
In an RNAi study using feeding of bacterial clones, the rol-6 RNAi worms were associated 
with a dumpy and egg laying variant phenotype [defined as abnormal oviposition by 
WormBase vWS238; 
http://www.wormbase.org/species/all/phenotype/WBPhenotype:0000640#0--10] (Kamath 
et al. 2003). Inefficient egg laying of roller worms may explain the upward trend observed 
in this chapter in the number of days required for roller worms to completely consume all 
the bacterial lawn, compared to either rescued DR96 or N2 worms.  
Using the gene rescue transformation approach, the marker gene unc-76 was used in this 
chapter to rescue the mutated strain DR96, restoring the wild type phenotype. Both the 
techniques here described have been previously used to express H. contortus vaccine 
candidate genes: roller worms were used to express Hc-CPL-1 and DR96 worms rescued 
with unc-76 expressed H. contortus pepsinogen (Murray et al. 2007, Redmond et al. 2001). 
Worms from the DR96 strain have a slower growing rate than wild type and co-injection of 
the rescue plasmid containing unc-76 resulted in phenotypic rescue to the wt phenotype, 
which grows more quickly than the DR96 strain (Redmond et al. 2001).   
Recombinant protein expression in bacterial and yeast systems can yield considerable 
amounts of protein [up to 25 g/L for recombinant nitrilase from the Pasteurella ﬂuorescens 
system (Chen 2012)]. In addition, each recombinant protein-expressing cell population 
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would consist of a very large number of cells and would have descended from a single 
clone. In the case of C. elegans, micro-injection in the gonad results in the construct 
encoding the desired protein being incorporated into extrachromosomal arrays. As these 
are not stably inherited, not all individuals in the population derived from the injected 
worms will express the recombinant protein (Evans, 2006). Using C. elegans as an 
expression system, recombinant protein yield has been shown to be comparatively low for 
some proteins: for example, recombinant H. contortus pepsinogen was occasionally 
detected in immunoblots as a weak band in extracts of some batches of transgenic worms, 
indicating that expression levels were low (Redmond et al. 2001). However, sufficient 
amounts of other proteins, such as Hc-CPL-1 and Hc-H11, have been expressed for use in 
immunisation studies (Murray et al. 2007, Roberts et al. 2013). Integration of 
extrachromosomal arrays into the genome to allow stable inheritance in all progeny has 
been tried but did not increase protein yield, possibly due to the lower copy number of 
plasmid following integration compared to extrachromosomal maintenance (Dr Collette 
Britton, personal communication).  
In this chapter, a wide range of recombinant protein yield/harvest was shown between 
CeTci-CF-1 (mean recombinant protein/harvest 5.18 μg/ml packed worms volume, SD = 
3.76 and n = 4) and CeTci-MIF-1 mean recombinant protein/harvest 11.17 μg/ml packed 
worms volume, SD = 7.64 and n = 4), but never reached the amounts of protein purified 
from either P. pastoris (PiTci-CF-1; mean recombinant protein/harvest 109.56 μg/ml 
packed cells volume, n = 2) or E. coli (EcTci-MIF-1; mean recombinant protein/harvest 
155.50 μg/ml packed cells volume, SD = 145.74 and n = 3). The data above only refers to 
an estimate of the packed worm or cell volume as appeared immediately before sonication 
[also described by Roberts et al. (2013)]; a calculation of the % of recombinant protein as 
fraction of the total protein content was not possible in this study as total protein was not 
always determined prior to recombinant protein purification. 
During these experiments, the number of purification attempts differed throughout and 
therefore comparisons between yields must be interpreted carefully. Indeed if the density 
of two worm populations (rollers and rescued DR96) appeared roughly equal between 
plates at the time of harvest, and a roughly equal volume of packed worms was collected, 
the higher efficiency of transformation observed in DR96 rescued C. elegans most likely 
explains the higher yield, with greater numbers of worms expressing the recombinant Tci-
MIF-1, compared to rollers expressing Tci-CF-1. However, the aim of this study was to 
generate and purify T. circumcincta vaccine candidates using C. elegans transformed 
 105 
 
worms, which was successfully achieved. The variable yields may be attributable to a 
dilution factor of the T. circumcincta proteins on preparation of worm protein extracts. It is 
also possible that expression of recombinant proteins, especially of active enzymes such as 
Tci-CF-1 and Tci-MIF-1, might be harmful to C. elegans, and therefore the worm 
organism would regulate its expression. However, there was no evidence of any toxicity in 
the transgenic worms generated in this study. Comparison between the two methods used 
in this chapter to generate T. circumcincta recombinant proteins should be carefully 
interpreted and would require further studies. At the time of writing, no information was 
available regarding the possible effect that the two different genes (Tci-cf-1 and Tci-mif-1) 
might have had on the C. elegans transformed populations or indeed on the efficiency of 
transformation. 
The C. elegans specific promoter used (Ce-cpl-1 promoter) allows constitutive protein 
expression only in those cell populations where the promoter is activated [gut and 
hypodermic cells (Hashmi et al. 2002)]. Tissue/cell-specific promoters might be used to 
direct transgene expression in certain parts of the worm’s body, however gene regulation is 
a complex matter even in a small organism like C. elegans (Okkema and Krause, 2005). If 
gene activation and protein expression only happened in certain cell types, as might be the 
case for the C. elegans modified strains used in this project, this would lead to a reduced 
protein production compared to bacterial or yeast populations of millions of unicellular 
organisms where each cell is over-expressing the desired product. Previous studies using a 
heat shock promoter for inducible expression of H. contortus genes in C. elegans did not 
enhance expression (Dr Collette Britton, personal communication) and this approach is 
limited by the short time that worms can tolerate heat shock treatment. Other approaches 
using the Q repressible binary system [by inducing expression of the transcriptional 
activator QF (Wei et al. 2012)] and ligand binding to engineered protein destabilising 
domains [small domains that bind to a protein of interest and will degrade the complex in 
absence of a specific ligand (Cho et al. 2013)] can result in inducible gene and protein 
expression in C. elegans, but these have not been widely tested for high-throughput protein 
purification purposes in mind. 
Two different approaches have been used in this thesis to transform C. elegans worms, 
employing two marker genes to screen the progeny for successful transformation; both 
approaches were validated for this purpose. However, improvements may be necessary to 
increase the efficiency of transformation and protein expression, especially when using rol-
6: for example, micro-injecting the plasmid encoding for Tci-cf-1 into DR69 worms 
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together with unc-76 (restoring the wild type phenotype) might be an alternative to try and 
increase the amount of recombinant protein purified. Another possibility could be to 
engineer a different vector for C. elegans micro-injection that included a less specific 
promoter than the one used (Ce-cpl-1 promoter), so that most C. elegans tissues would be 
expressing the recombinant protein. 
During the purification process of CeTci-CF-1, a contaminant protein was consistently co-
purified. This was later identified as a C. elegans protein rich in histidine residues, Ce-
LEC-8, as also shown by Nemoto-Sasaki et al. (2008). Various methods were used to try 
and isolate CeTci-CF-1 from the contaminant protein; however, all attempts failed to 
deliver a purer CeTci-CF-1 fraction, and the recovery rate of CeTci-CF-1 was very poor. 
Therefore, subsequent experiments involving CeTci-CF-1 took into account the presence 
of Ce-LEC-8. Co-purification of host proteins in recombinant expression systems has been 
described previously (Bolanos-Garcia and Davies 2006, Wülfing et al. 1994). To try and 
resolve this problem, further experiments of CeTci-CF-1 expression could be carried out 
using a C. elegans lec-8 mutant strain (available from the National BioResource Project, 
Japan) in an attempt to obtain a purer preparation. 
Overall, the results of this chapter showed that C. elegans was a viable method to express 
recombinant T. circumcincta vaccine candidates; however, further work is required to 
improve the yield of recombinant proteins from the transformed C. elegans populations. 
This could be achieved by investigating larger scale C. elegans biomass production, for 
example by culturing transformed C. elegans in liquid medium as previously shown 
(Murray et al. 2007); or by engineering the worms so that they could be induced to over-
express the recombinant protein, as it is the standard procedure in E. coli and yeast cell 
systems.  
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Chapter 4 – Characterisation of Antibody 
Reactivity, Enzyme Activity and Glycosylation of 
Native and Recombinant Tci-CF-1 from 
Teladorsagia circumcincta  
  
4.1 Introduction 
A highly immunogenic cysteine protease enzyme, termed cathepsin F (Tci-CF-1), has been 
shown to be the most abundant protein in T. circumcincta L4 Excretory/Secretory (ES) 
products. This molecule is bound by IgA antibodies from the gastric lymph and mucus of 
sheep rendered immune to T. circumcincta by experimental infection (Redmond et al. 
2006, Smith et al. 2009). By virtue of its immunogenicity and abundance in L4 ES, a 
recombinant Tci-CF-1 version expressed in the yeast Pichia pastoris was included in a 
panel of 8 vaccine candidates in recent immunisation studies (Nisbet et al. 2013). Findings 
of Chapter 2 of this thesis have shown that Tci-CF-1 purified from T. circumcincta L4 ES 
(nTci-CF-1) was recognized by IgA and IgG antibodies from serum and by IgA from 
gastric lymph of sheep which had been rendered immune by trickle infection with T. 
circumcincta. However, these antibodies were not cross-reactive with a Pichia pastoris-
expressed version of Tci-CF-1 (PiTci-CF-1). In contrast, IgG generated from pre-scapular 
antibody secretory cell (ASC) probes of sheep immunised subcutaneously (in the neck) 
with PiTci-CF-1 was able to bind PiTci-CF-1 and, to a lesser degree, nTci-CF-1. The 
differences observed may be caused by differences in the protein folding or Post-
Translational Modifications (PTMs) between the two Tci-CF-1 versions. In this respect, 
Western blotting techniques may allow investigation of the immune response to an antigen 
(or antigen mix) without the influence of tertiary protein structures, as the standard protein 
electrophoresis techniques involve denaturing and reducing conditions which facilitate 
linearization of peptides (Collins et al. 2004, Geldhof et al. 2003, Harper et al. 1990, 
Jungersen et al. 2001, Kurien and Scofield 2006, Vercauteren et al. 2004, Wedrychowicz 
et al. 1994).  
PTMs occur at distinct amino acid side chains or peptide termini; common PTMs are 
polypeptide cleavage (e.g. cleavage of pro-peptides from pro-enzymes or “zymogens” in 
enzyme maturation), acetylation, phosphorylation and glycosylation of amino acid 
residues. PTMs which result in the addition of extra moieties are covalent chemical 
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modifications of proteins mediated by enzymes (Farley and Link 2009). One post-
translational modification that may be carried out by lysosomal enzymes is cleavage of the 
pro-peptide, also known as maturation of the enzyme [reviewed by Turk et al. (2012)]. The 
secondary and tertiary structure of enzymes is such that, once correctly folded and 
maturation is completed, the enzyme is able to carry out its catalytic functions by using the 
active site thus formed (Rawlings and Barrett 1994, Santucci et al. 2008). Proteolytic 
enzymes such as cysteine proteases undergo maturation by cleaving of the pro-peptide (and 
signal peptide if initially present); this can occur by self-activation, in which a small 
subfraction of the enzyme becomes catalytically active by a change in environment (e.g. 
drop in pH, within lysosomal granules or in vitro), which in turn is able to activate the 
remaining enzyme molecules (McQueney et al. 1997, Rozanov and Strongin 2003). 
Enzyme maturation can also occur by trans-activation, in which a simple environment 
change is not sufficient to induce initial pro-peptide cleavage and the involvement of 
another, different, protease is necessary to activate the cysteine protease pro-enzyme 
(Menard et al. 1998, Sajid et al. 2003).  
 Members of the C1 family of cysteine proteases, such as Tci-CF-1, are characterised by a 
“catalytic diad” of cysteine (Cys) and histidine (His). The crystal structure of this type of 
cysteine protease shows an amino acid chain folded to form two domains, with a cleft (the 
active site) lying between them. The active site residues cysteine and histidine are situated 
across from each other on either side of the cleft, to aid in the positioning of the substrate 
[reviewed by Rawlings and Barrett (1994) and Storer and Menard (1994)]. The correct 
folding of the peptide chain is therefore strongly associated with the protease’s ability to 
degrade its substrate: if the folding is incorrect it is likely to affect not only the overall 
tertiary structure, but more specifically the active site. If the active site is missing or 
misshapen due to inappropriate on incomplete folding, the protease would not be able to 
degrade the substrate and therefore is considered enzymically inactive (Hosfield et al. 
1999, Santucci et al. 2008). Recombinant protein expression systems may generate 
correctly folded zymogens which do not require activation; or they may require further 
steps to induce their maturation, such as lower buffer pH; or they may generate insoluble, 
incorrectly folded proteins (often in inclusion bodies) that may not be activated because of 
defects of their conformation before or after the processes used to purify them. For 
example, a recombinant version of the H. contortus antigens H11 and Hc-CPL-1 were 
generated using the free-living nematode Caenorhabditis elegans and both showed 
conserved aminopeptidase or cathepsin L activity (Murray et al. 2007, Roberts et al. 2013). 
The cysteine protease Cathepsin L1 of the trematode parasite Fasciola hepatica was 
 109 
 
expressed in the yeast P. pastoris and the recombinant protein could auto-activate at low 
pH, although the cleavage site of the pro-enzyme was different to that observed in the 
presence of exogenous activating enzymes (Collins et al. 2004). In another study, the 
Haemonchus contortus cysteine proteases hmcp-1, -4, and -6 were expressed as insoluble 
proteins in Escherichia coli and, although their enzyme activity was not reported, the 
authors implied an associated lack of catalytic activity by suggesting a need to express the 
enzymes in a eukaryotic system for catalytically active hmcp-1, -4 and -6 (Redmond and 
Knox 2004). More recently, a P. pastoris-expressed Tci-CF-1 generated at MRI (Nisbet et 
al. 2013) had been demonstrated to be enzymically inactive (Dr Tom McNeilly and Dr 
Alasdair Nisbet, personal communication). Another P. pastoris-expressed Tci-CF-1 
version generated during this study (PiTci-CF-1, see Chapter 2), sharing 96 % amino acid 
sequence identity with the previously generated P. pastoris recombinant version, showed 
lack of reactivity with antibodies from serum and gastric lymph of sheep which had been 
rendered immune by trickle infection with T. circumcincta. These combined results using 
P. pastoris-expressed Tci-CF-1 versions suggested that the recombinant system might have 
produced incorrectly folded enzyme, resulting in an enzymically inactive protein which 
was not optimally bound by antibodies raised against the native version.  
Cysteine proteases of the C1 family are synthesized as zymogens (or pro-enzymes) with a 
pro-peptide region at the N terminus, which must be cleaved for activation of the enzyme 
(Rawlings and Barrett 1994). The PiTci-CF-1 version considered here had been generated 
as a zymogen and, although two bands of the protein were visualized in some 
polyacrylamide gels of the recombinant protein, suggesting a degree of cleavage may 
occur during expression in P. pastoris, there had been no prior evidence that this cleavage 
enzymically activated PiTci-CF-1 by removing all or part of the pro-peptide. Thus, the 
presence of the pro-peptide (or part of it) in the PiTci-CF-1 version used to immunise 
sheep might have influenced the differences in antibody recognition shown in Chapter 2 of 
this work, where the immunised animals mounted an immune response to the recombinant 
and the native Tci-CF-1 versions, but the antibodies from T. circumcincta trickle infected 
animals were not able to bind PiTci-CF-1 perhaps because of “epitope masking” by the 
pro-peptide on the recombinant version. 
Another post-translational modification that can affect the antibody recognition of an 
antigen is glycosylation: The presence of glycans, their number, size and structure confers 
a specific 3-dimensional shape to the glycosylated protein, determining epitope structure 
and availability for cell and antibody binding in the immune response, along with potential 
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immunomodulatory effects (Kooyman et al. 2007, Paschinger et al. 2012, van Die et al. 
1999). Glycosylation, or lack of it, can also affect enzyme activity, as shown by Fan et al. 
(1997); in this study mutagenesis of naturally occurring glycan groups (i.e. deletions of one 
of 5 glycans) of rat dipeptidyl peptidase IV (DPPIV, CD26) was carried out. The results 
showed that upon expression of the mutated DPPIV versions in Chinese Hamster Ovary 
(CHO) cells, the proteolytic activity of one of the mutants was reduced by 90 % compared 
to the wild type enzyme (Fan et al. 1997). In the trematode parasite Schistosoma mansoni, 
studies have identified immunogenic glycoproteins (such as the schistosome soluble egg 
antigen, SEA) which provoke peritoneal B cell expansion and cytokine production, and 
that this activity is lost upon deglycosylation [reviewed by Thomas and Harn (2004)]. 
Nematode glycans and glycoproteins have also been shown to be highly immunogenic, 
with bias towards a Th2 immune response [reviewed by Dell et al. (1999) and Harn et al. 
(2009)]. This was shown by experiments using BALB/c mice immunised with PBS-soluble 
extracts of mixed adult Brugia malayi antigen (BmA) or mixed-stage C. elegans antigen 
(CeA; Tawill et al. 2004). The results showed that lymph node cells collected from mice in 
either immunisation protocol, stimulated with sodium periodate-treated soluble extracts of 
both nematodes (therefore with disrupted glycan structures) induced significantly less IL-4 
production than the respective untreated extracts (Tawill et al. 2004). Many of the potential 
vaccine candidates identified from parasitic nematodes of sheep such as Haemonchus 
contortus [H11 and the H-gal-GP complex (Knox and Smith 2001, Smith et al. 1997)] and 
T. circumcincta (Tci-CF-1; Redmond et al. 2006) are glycosylated proteins or protein 
complexes. In cattle, a study showed that there is a strong but short-lived antibody 
response (IgG1) directed against N-glycans on the surface of Dictyocaulus viviparus L3 
larvae, as shown by serum from calves vaccinated with irradiated L3 larvae (Kooyman et 
al. 2007). Studies have shown that vaccination of lambs with adult H. contortus ES 
antigens resulted in multiple anti-glycan antibodies, the specificity of which varied 
depending on the adjuvant used (van Stijn et al. 2010). In these animals, IgG antibodies 
from serum that had in a previous study correlated with protection against H. contortus 
challenge [by FEC and worm burden reductions, (Vervelde et al. 2003)] showed binding to 
the glycan moiety Galα1–3GalNAc, suggesting its contribution to protection against 
parasite infection (van Stijn et al. 2010). 
Five distinct types of carbohydrate-peptide bonds have been identified, and the linkage of 
N-acetyl-D-glucosamine (GlcNAc) to asparagine (“Asn” or “N”) residues (N-linked 
glycosylation) represents the most widely distributed peptide-carbohydrate bond. This is 
the site of attachment of a large variety of complex and polymannose oligosaccharides 
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[reviewed by Spiro (2002)]. Cathepsin F enzymes from both mammals and helminths 
possess predicted N-glycosylation sites within their amino acid sequences (Deussing et al. 
2000, Pinlaor et al. 2009, Redmond et al. 2006, Santamaria et al. 1999). Analysis of the 
inferred amino acid sequence from the mRNA representing T. circumcincta Tci-CF-1 
demonstrated the presence of two potential N-linked glycosylation sites, one on the pro-
peptide region and another on the mature enzyme. Previous lectin binding experiments 
confirmed the presence of glycans on Tci-CF-1 (Redmond et al. 2006); however no more 
detail about the glycosylation pattern of native Tci-CF-1 has been published. 
From the examples described above, it appears that PTMs may be playing a role in 
influencing the enzyme activity and the specific antibody binding of recombinant P. 
pastoris-expressed Tci-CF-1 (PiTci-CF-1). In particular, the presence of the pro-peptide 
and/or inappropriate glycosylation by yeast cells may be a hindrance to substrate 
interactions and antibody binding to this antigen. To examine this further, another 
recombinant version of Tci-CF-1 expressed using the nematode C. elegans was generated 
(see Chapter 3), in an attempt to deliver a vaccine candidate with structure and PTMs more 
similar to native Tci-CF-1 than to PiTci-CF-1. 
The overall aims of this chapter therefore are: 
i) To investigate the hypothesised differences in PTMs between Tci-CF-1 versions by 
inferred amino acid sequence alignment and annotations, to reveal the overall amino acid 
residue identity and whether active site and glycosylation-linked amino acid residues were 
conserved between Tci-CF-1 versions. 
ii) To further investigate the ovine gastric lymph antibody recognition of native and 
recombinant P. pastoris-expressed (generated in Chapter 2) and C. elegans-expressed Tci-
CF-1 (generated in Chapter 3) versions by (a) ELISA and (b) Western blotting of 
denatured proteins to expose shared epitopes.  
iii) To investigate the cysteine protease activity of each Tci-CF-1 version by using 
substrates specific for papain-like enzymes such as cathepsin F (Fonovic et al. 2004, 
Pinlaor et al. 2009, Wang et al. 1998) and a cysteine protease-specific inhibitor and to 
investigate the activation of both recombinant PiTci-CF-1 (generated in Chapter 2) and 
CeTci-CF-1 (generated in Chapter 3) by inducing cleavage of the pro-peptide. 
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iv) To investigate the glycosylation of each purified Tci-CF-1 version using glycan-
specific stains, enzymatic deglycosylation and lectin binding experiments. 
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4.2 Materials and methods 
4.2.1 Sequence alignment, annotations and BLAST analysis 
4.2.1.1 Tci-CF-1 amino acid sequence alignment and annotations 
Alignment of PiTci-CF-1 and CeTci-CF-1 amino acid sequences with the inferred protein 
sequence from the published mRNA sequence for Tci-CF-1 [NCBI accession number 
ABA01328 (Redmond et al. 2006) was carried out using the free online software ClustalW 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). Annotation of predicted signal peptide 
cleavage site and N-glycosylation sites was carried out by comparison with the previously 
published sequence (Redmond et al. 2006). 
4.2.1.2 Ce-LEC-8 nucleotide and amino acid sequence BLAST analysis 
The Ce-LEC-8 amino acid sequence (NCBI protein accession number NP509649) 
identified by LC-ESI MS/MS (see Chapter 3, section 3.3.2) was used in BLAST analyses 
to search for T. circumcincta homologues. The databases used were: i) NCBI EST database 
(nBLAST), in which a T. circumcincta adult cDNA library clone was identified; ii) 
Nembase sequence database (tBLASTn); iii) in-house (data collected by Dr Alasdair 
Nisbet) T. circumcincta fourth larval stage (L4) 454 sequence database (tBLASTx). The 
software ClustalW was used for amino acid and nucleotide sequence analysis. 
4.2.2 Purification of native Tci-CF-1 
Native Tci-CF-1 (nTci-CF-1) was purified from T. circumcincta fourth larval stages (L4) 
Excretory/Secretory (ES) products as described in Chapter 2 of this thesis. 
4.2.3 Generation and purification of recombinant Tci-CF-1 
versions 
4.2.3.1 Pichia pastoris-expressed Tci-CF-1 
PiTci-CF-1 was expressed using the yeast P. pastoris and purified as described in Chapter 
2 of this thesis. 
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4.2.3.2 Caenorhabditis elegans-expressed Tci-CF-1 
CeTci-CF-1 was expressed using the free living nematode C. elegans and purified as 
described in Chapter 3 of this thesis. 
4.2.4 Provenance of sheep gastric lymph and serum samples 
4.2.4.1 Gastric lymph 
The provenance and collection of sheep gastric lymph samples used in ELISA experiments 
and Western blots are described in Chapter 2 of this thesis (Sections 2.2.5.2 and 2.2.5.5). 
4.2.4.2 Anti-Pichia pastoris-expressed Tci-CF-1 serum 
Ovine serum samples containing anti-PiTci-CF-1 specific IgG were provided by Dr 
Alasdair Nisbet and Dr Tom McNeilly (MRI). Details of the animals and the immunisation 
protocol are detailed in Chapter 2 (Section 2.2.5.1.1) of this thesis.  
4.2.5 Purification of Ce-LEC-8 from N2 C. elegans worms 
This procedure was carried out as described in Chapter 3 of this thesis. Biomass of N2 C. 
elegans worms was generated using Peptone-rich agar plates (Appendix D) and the 
harvested worms used to extract a cleared lysate as previously described (Chapter 3). The 
cleared lysate was applied to a Co
2+
 IMAC system and the identity of the eluted protein 
confirmed by SDS-PAGE analysis and MS/MS-LC/ESI carried out at MRI Proteomics 
Facility. 
4.2.6 Indirect ELISA for detection of T. circumcincta antigen-
specific antibody responses 
These experiments were carried out using purified CeTci-CF-1 at a dilution of 1 μg/ml as 
coating antigen (Ce-LEC-8 was also present in these preparations at approximately twice 
the concentration of Tci-CF-1, resulting in ~ 2 μg/ml after dilution). Control wells were 
coated with Ce-LEC-8 purified from N2 C. elegans worms, as described below (section 
4.2.6.1), at 2 μg/ml. The protocol used and the antibody combinations were as previously 
detailed in Section 2.2.6 of this thesis. 
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4.2.6.1 Immunoassay for sodium periodate sensitive/insensitive epitopes 
The immunoassay experiments using sodium periodate were carried out without further 
modifications from the protocol detailed in Section 2.2.7 of this thesis. Briefly, antigens at 
the concentrations detailed above were used to coat high binding microtitre plates at 4°C 
overnight. The following day, the plates were washed 4 times in PBST (Appendix D) and 
blocking of the wells occurred for 1h with TBST/5 % soy milk (Appendix D). After further 
4 washes, wells were incubated with 50 μl/well of 20 mM NaIO4 solution in 50 mM 
Sodium Acetate Buffer (Appendix D) for 1 h at 37°C, in the dark. Wells were washed 
three times with 50 mM Sodium Acetate Buffer (Appendix D) and subsequently incubated 
with 50 μl/well of 50 mM NaBH4/TNTT for 30 min at 37°C. Control wells were incubated 
in 50 mM Sodium Acetate Buffer, instead of 20 mM NaIO4 solution. Wells were then 
washed four times with PBST, resuming the standard ELISA protocol as described in 
Section 2.2.6 of this thesis. 
4.2.7 SDS-PAGE and Western blots 
Native and recombinant proteins were electrophoresed in denaturing conditions in 
polyacrylamide gels (NuPAGE® Bis-Tris 4–12 %, Invitrogen, Paisley, UK) as detailed in 
Appendix B. Transfer of proteins onto nitrocellulose membrane and general 
immunoblotting techniques are also detailed in Appendix B. Following overnight blocking 
of membranes in TNTT, strips were incubated with sheep serum (1:1000 for detection of 
IgG or 1:100 for detection of IgA) or gastric lymph (1:100) samples. Following three 20 
min washes in TNTT, some blots were treated with periodate to disrupt glycan structures 
as follows: blots were washed twice in 50 mM sodium acetate buffer (Appendix D) for 20 
min. Subsequently, periodate-treated blots were incubated for 1 h at RT in sodium 
periodate buffer (Appendix D), whereas untreated strips were incubated in acetate buffer. 
All blots were washed twice in 50 mM sodium acetate buffer (Appendix D) for 10 min, 
then washed twice in TNTT for 10 min. All blots were incubated in freshly prepared 50 
mM sodium borohydride solution (Appendix D) for 30 min, then washed three times in 
TNTT for 10 min.   
Periodate-treated and untreated blots developed for IgA-binding were incubated for 1 h at 
RT with a monoclonal mouse anti-bovine/sheep IgA antibody (clone K84 2F9, MCA628, 
Serotec) at 1:500 dilution. Blots were washed three times for 20 min in TNTT then 
incubated for 1 h at RT with a rabbit anti-mouse IgG:HRP antibody (clone n/a, P0260, 
Dako) or a rat anti-mouse IgG1 heavy chain:HRP antibody (clone LO-MG1-2, MCA336P, 
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Serotec), both at a dilution of 1:1000. Subsequent washes were carried out twice for 20 
min then overnight in TNTT. Strips developed for IgG detection were incubated for 1 h at 
RT with a monoclonal mouse anti-goat/sheep IgG:HRP antibody (clone GT-34, A9452, 
Sigma-Aldrich, Gillingham, UK) at 1:1000 dilution, washed twice for 20 min in TNTT 
then one last wash overnight. Bound antibodies were revealed with the chemiluminescent 
substrate ECL Prime Western Blotting Detection Reagent (GE Healthcare, Little Chalfont, 
UK) following the manufacturer’s instructions. Some strips were also developed with 3,3′-
Diaminobenzidine (DAB, SIGMAFAST™ DAB with Metal Enhancer, Sigma Aldrich). 
4.2.8 Cysteine protease activity assays 
4.2.8.1 Microplate methods for self- and trans-activation assays of Tci-CF-1 
The procedure used in these assays was adapted from methods described by Nisbet and 
Billingsley (2000) and Pinlaor et al. (2009). Each “working buffer” was prepared fresh at 
RT by adding 100 X cysteine and 100 X DTT solutions to the stock buffers (Appendix D) 
to give final concentrations of 5 mM cysteine and 8 mM DTT. An aliquot of each buffer 
thus prepared was set aside for the addition of the inhibitor E-64 (stock prepared as 100 X, 
Appendix D) to a final concentration of 10 µM. Ten stock solutions of the reaction product 
7-Amino-4-methylcoumarin (AMC, Sigma Aldrich) were prepared in DMSO. These were 
used as individual components of a 10-point standard curve in each assay, in which 6 µl of 
each stock was added to the reaction buffer. The range of the final concentration of 
substrate for the AMC standard curve was 476.19-0.05 μM. A serial dilution of the 
substrate Z-Phe-Arg-AMC (Z-FR-AMC, Enzo Life Sciences, Exeter, UK) was also 
prepared in DMSO; seven dilutions were made in 100 % DMSO and the range of the final 
concentrations used was 476.19-0.48 μM. A black flat bottom 96-well plate was used for 
this assay; reaction buffers were distributed at 115 μl/well (120 μl/well for the standard 
curves), then 5 μl of PBS were added (for the “substrate control” wells). To investigate the 
trans-activation of Tci-CF-1 versions, 5 µl (13.7 ng) of liver-purified human Cathepsin L 
(hCath L; diluted from stock solution 0.274 mg/ml in buffer pH 5.5; Enzo Life Sciences) 
were added to the positive control wells. In the test wells, 50 ng of each recombinant Tci-
CF-1 version (diluted from stock solution in buffer pH 4.5) were added to 13.7 ng of hCath 
L in a final volume of 5µl. When T. circumcincta L4 ES was used, 100 ng were added to 
the reaction buffer in a final volume of 5 µl. Buffer + PBS only wells were used as blank. 
The plate was incubated at 37°C for 20 min to allow enzyme activation in the wells 
containing recombinant Tci-CF-1 and hCath L, then 6 μl/well of a serial dilution of 
substrate Z-FR-AMC were added. The reactions were incubated at 37°C for the whole 
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duration of the assay (120 min) and the fluorescence emitted was measured with a 
Synergy™ HT fluorescence plate reader and Gen5 Data Analysis Software (both from 
BioTek, Winooski, USA) every 60 sec, using an excitation wavelength of 370 nm and 
measuring emission at 450 nm. Each assay was carried out in triplicate and repeated three 
times. A plot of time vs fluorescence was generated and the velocity of each reaction in the 
linear phase (during the first 20 min) was calculated from the raw data (Relative 
Fluorescence Units, RFU) using the following method:  
i) Blank-adjusted RFU value was obtained with this equation: 
[RFU21 min-Blank RFU21 min]- [RFU1 min-Blank RFU1 min] 
ii) The blank-adjusted RFU value obtained was then used to calculate the relative 
concentration of product [P] based on the AMC standard curve generated for each 
experiment.  
iii) The [P] value thus obtained was the amount of product generated by the enzyme during 
a 20 min period.  
iv) To calculate the reaction rate per minute (the amount of product /min or initial velocity, 
vi), each value obtained in iii) was divided by 20; this value was the reaction rate in each 
reaction, which contained between 13.7-63.7 ng of enzyme.  
v) The values obtained in iv) were adjusted for each mg of enzyme present in the reactions; 
adjusted reaction rates were plotted for each enzyme on histograms representing vi/min/mg 
during the linear phase of the reactions. 
For the initial pilot experiments and the investigation of self-activation of Tci-CF-1 
versions at different pH, the chromogenic substrate Z-FR-pNA (Enzo Life Sciences) was 
used instead of the fluorogenic substrate. In these experiments a 10 mM stock solution of 
the chromogenic substrate Z-Phe-Arg-pNA (Z-FR-pNA) was prepared in DMSO. The 
assays were carried out without modifications from the method described above, except 
that no pNA standard curve was prepared and the reactions were incubated at RT and 
absorbance readings (OD405 nm) were taken every 60 sec for 120 min.  
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4.2.8.2 Investigation of the activation of recombinant PiTci-CF-1 using SDS-
PAGE analysis, Western blot and ELISA 
For the self-activation of PiTci-CF-1, working buffer was prepared fresh by adding 100 X 
cysteine and 100 X DTT solutions to 100 µl of stock buffer pH 4.5 (Appendix D) to give 
final concentrations of 5 mM cysteine and 8 mM DTT. Five microliters of PiTci-CF-1 
(1.15 µg) were added and mixed by pipetting. An identical reaction was prepared 
alongside, with the addition of 100 X E-64 to a final concentration of 10 µM. A 13 µl 
aliquot (0 min) was collected from each reaction and prepared for gel electrophoresis by 
mixing with 5 µl of NuPAGE® 4 X LDS Sample Loading Buffer with the addition of 2 μl 
of NuPAGE® Reducing agent (all from Invitrogen) then heated at 70°C for 10 min. The 
reactions were incubated at 37°C and further aliquots were collected at 30, 60, 90 and 120 
min and prepared as above for gel electrophoresis and Coomassie staining, which were 
carried out under the same conditions described in Appendix B. 
For the trans-activation of PiTci-CF-1, reactions were prepared as follows: to 1 ml of stock 
buffer pH 3.5 (Appendix D) were added 100 X cysteine and 100 X DTT solutions to give 
final concentrations of 5 mM cysteine and 8 mM DTT. To 345 µl of this buffer, E-64 was 
added to give a final concentration of 10 µM. To 115 µl aliquots of each working buffer 
thus prepared (with or without E-64), one of the following were added: i) 5 µl (1.15 µg) of 
PiTci-CF-1; ii) 5 µl (13.7 ng) of hCath L diluted in buffer pH 5.5; iii) 1.15 µg of PiTci-CF-
1 were added to 13.7 ng of hCath L (stock concentration 0.274 mg/ml) in a final volume of 
5 µl. One 115 µl aliquot did not receive enzyme to serve as negative control. A 13 µl 
aliquot (0 min) was collected from each reaction and prepared for gel electrophoresis as 
described above. The reactions were incubated at 37°C for 20 min and further aliquots 
were collected and prepared as above for gel electrophoresis. To each reaction, 6 µl of Z-
FR-AMC (final concentration 476 µM) was added and all were incubated at 37°C. At 80 
and 140 min further aliquots were collected and prepared for gel electrophoresis and silver 
staining, which were carried out under the same conditions described in Appendix B. 
Aliquots of each reaction were also collected at 80 min to use in Western blot analysis. The 
samples were loaded in a polyacrylamide gel and blotted as described in Appendix B. 
Immunoblotting was carried out as described previously in Section 4.2.7. 
For the ELISA assay of the recognition of trans-activated PiTci-CF-1, reactions were 
prepared as follows: to 100 µl of stock buffer pH 4.5 (Appendix C) were added 100 X 
cysteine and 100 X DTT solutions to give final concentrations of 5 mM cysteine and 8 mM 
DTT. To each reaction 4.35 µl of PiTci-CF-1 (final concentration 10 µg/ml) were added. 
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In the reactions where hCath L was added, this was diluted 1:100 in the final reaction 
volume (i.e. 1 µl of stock 0.274 mg/ml hCath L). Some reactions were prepared and 
immediately diluted 1:10 in carbonate buffer (Appendix D; PiTci-CF-1 final concentration 
1 µg/ml) to coat wells of a high binding microtitre plates. The remaining reactions were 
incubated at 37°C for 20 min, before being also diluted 1:10 in carbonate buffer to coat 
wells of a high binding microtitre plates. Three reactions received the addition of E-64 to 
give a final concentration of 10 µM. The following reactions were prepared: i) PiTci-CF-1 
alone, immediately diluted; ii) PiTci-CF-1 alone, incubated at 37°C for 20 min; iii) hCath 
L alone, incubated at 37°C for 20 min; iv) PiTci-CF-1 and hCath L, immediately diluted; 
v) PiTci-CF-1 and hCath L, incubated at 37°C for 20 min; vi) PiTci-CF-1, hCath L and E-
64, incubated at 37°C for 20 min; vii) hCath L and E-64, incubated at 37°C for 30 min, 
then PiTci-CF-1 added, then further 20 min incubation; and viii) hCath L and E-64, 
incubated at 37°C for 20 min. The plates thus coated were incubated overnight at 4°C, 
subsequently blocked and ELISA protocol carried out with gastric lymph samples as 
described in Section 2.2.6 of this thesis. 
4.2.9 Staining of protein-linked glycans 
Protein-linked glycans were visualized by staining SDS-PAGE gels of native and 
recombinant Tci-CF-1 with a glycan-specific stain supplied with the Pro-Q® Emerald 300 
Gel and Blot Stain Kit (Invitrogen), following the manufacturer’s instructions. Briefly, 
standard protein electrophoresis was carried out as described in Section 2.9.1; all washes 
and incubations were on a rotary shaker. The gel was fixed in Fix solution (50 % methanol 
and 5 % acetic acid in dH2O) for 45 min. This was followed by two further washes in 
Wash solution (3 % glacial acetic acid in dH2O) of 20 min each; the gel was then incubated 
in 25 ml of Oxidizing Solution (acetic acid/periodic acid) with gentle agitation for 30 min. 
After three further washes in Wash solution, the gel was stained using 25 ml of freshly 
prepared Staining Solution (Pro-Q® Emerald 300 stock solution 1:50 into Pro-Q® 
Emerald 300 staining buffer; both provided with the kit), incubated in the dark with gentle 
agitation for 120 min. The gel was then washed twice in Wash solution and visualized 
using a UV transilluminator. 
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4.2.10 PNGase-F and O-glycosidase removal of glycans 
4.2.10.1 PNGase-F 
The reactions were carried out as follows using PNGase-F enzyme and buffers supplied by 
New England Biolabs (Hitchin, UK): 225 ng (22.5 µl) of recombinant proteins in 
Phosphate Buffer (Appendix D) were mixed with 2.5 μl of 10 X Glycoprotein Denaturing 
Buffer. The proteins were denatured by heating at 100°C for 10 min; the reactions were 
allowed to cool then the following were added: 5 μl 10 X G7 Reaction Buffer, 5 μl 10% 
NP40, 5 μl PNGase F (1000 U), 10 μl dH2O to a total volume of 50 μl. The reaction was 
incubated at 37°C for 1 h. To these, LDS Sample Buffer (Invitrogen) and reducing agent 
were then added for electrophoresis as described in Appendix B. The polyacrylamide gel 
was stained with Coomassie blue. 
4.2.10.2 O-glycosidase 
The reactions were carried out as follows using O-glycosidase and Neuraminidase 
enzymes and buffers supplied by New England Biolabs: 225 ng (22.5 µl) of recombinant 
proteins in Phosphate Buffer (Appendix D) were mixed with 2.5 μl of 10 X Glycoprotein 
Denaturing buffer. The proteins were denatured by heating at 100°C for 10 min in a heat 
block, then the following were added: 5 μl 10 X G7 Reaction Buffer, 5 μl 10% NP40, 5 μl 
Neuraminidase, 2.5 μl of a 1:40 dilution of O-glycosidase (1000 U) and 7.5 μl dH2O to a 
total volume of 50 μl. The reactions were incubated at 37°C for 2.5 h. To these, LDS 
Sample Buffer (Invitrogen) and reducing agent were added for electrophoresis as described 
in Appendix B. The polyacrylamide gel was stained with Coomassie blue. 
4.2.11 Lectin probes 
Lectin binding experiments on native and recombinant versions of Tci-CF-1 were carried 
out as follows: proteins were electrophoresed and transferred onto nitrocellulose membrane 
as described in Appendix B. The membrane was then cut into strips using a clean scalpel 
blade and each strip was incubated with a different biotinylated lectin (Table 4.1, all 
supplied by Vector Laboratories Inc., Burlingame, CA, USA) diluted 1:400 in TNTT for 1 
h at RT (final concentrations were 12.5 µg/ml for all lectins except Ulex europaea 
agglutinin, UEA, which was 5 µg/ml). Following three 20 min washes in TNTT on a 
rocker, each strip was incubated for 1 h at RT with Streptavidin-Peroxidase Polymer, 
Ultrasensitive (Sigma) diluted 1:1000 in TNTT. After three further 20 min washes in 
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TNTT, all the strips were developed with 3,3′-Diaminobenzidine (DAB, 
SIGMAFAST™ DAB with Metal Enhancer, Sigma), following the manufacturer’s 
instructions. 
Table 4.1 The panel of lectins used in this study. 
 
Lectin name Abbreviation Plant of origin Residue specificity 
Lentil lectin LCH Lens culinaris 
Fucosylated core 
regions of bi- and tri-
antennary complex N-
glycans; α-D-mannose; 
α-D-gluocose 
Concanavalin A ConA 
Canavalia 
ensiformis 
Branched α-mannosidic 
structures; high 
mannose type, hybrid 
type and biantennary 
type N-glycans 
Agglutinin DBA Dolichos biflorus 
GalNAcα1-3GalNAc; 
GalNAcα1-3Gal 
Agglutinin UEA Ulex europaea Fucα1-2Gal-R 
Soybean agglutinin SBA Glycine max 
terminal α,β GalNAc; 
α,β Gal 
Peanut agglutinin PNA Arachis hypogea 
Galβ1-3GalNAcα1-S/T 
(T antigen) 
Wheat germ 
agglutinin 
WGA Triticum vulgaris Sialic acid 
Agglutinin I RCA I Ricinus communis βGal 
Legend: GalNAc = D-N-Acetylgalactosamine; Gal = D-Galactose; Fuc = D-Fucose. 
 
4.2.12 Statistical analysis 
Statistical analysis was carried out using GraphPad Prism version 5.01 and GenStat 12
th
 
Edition. Arithmetic means with standard errors and replicate number (n) are shown 
throughout this chapter. Data were checked for normal distribution by analysing the 
histogram of frequencies and residual plots. Data normally distributed were analysis using 
a one-way Analysis of Variance (ANOVA) test was used, followed by the Tukey post hoc 
test for pair wise comparison of means; when only one pair of means was compared, an 
unpaired two-tailed t-test was used. P values of < 0.05 were considered significant.   
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4.3 Results 
4.3.1 Comparison of Tci-CF-1 versions by inferred amino acid 
sequence alignment 
Differing post-translational modifications (PTMs) between native and P. pastoris-
expressed Tci-CF-1 (PiTci-CF-1) were hypothesised to be the cause of differences 
previously observed (Chapter 2 of this thesis) in antibody reactivity of sheep samples 
(serum, ASC probes and gastric lymph) to the two antigens. It was hypothesised that 
differences in the linear amino acid sequences may have been present between Tci-CF-1 
versions, such as mutations or deletions in certain amino acid residues that might have 
modified the folding and/conformation of the active site. This was first investigated by 
sequence alignment and annotation; the newly generated C. elegans-expressed Tci-CF-1 
(CeTci-CF-1, see Chapter 3) was included in the analysis. The amino acid sequence of Tci-
CF-1 inferred from the published mRNA sequence [NCBI accession number ABA01328; 
(Redmond et al. 2006)] was compared to the amino acid sequences inferred from the 
cDNA of the two recombinant versions generated in this project (PiTci-CF-1 and CeTci-
CF-1). The comparison was carried out by ClustalW sequence alignment. The results 
showed that amino acid sequence identity between Tci-CF-1 versions was > 98 %. The 
putative site of signal peptide cleavage had been previously identified during in silico 
analysis of the inferred amino acid sequence of Tci-CF-1 cDNA generated from T. 
circumcincta L4 worms RNA (Redmond et al. 2006). Although the sequence encoding the 
signal peptide had been omitted from the Tci-CF-1 construct expressed in P. pastoris, the 
signal peptide had been maintained for expression in C. elegans and it showed 100% 
identity with signal peptide from the inferred amino acid residues in the published 
sequence (Figure 4.1, closed circle). Comparison between the published sequence of Tci-
CF-1 and both recombinant versions generated for this study showed that putative N-
glycosylation sites were maintained (Figure 4.1, open triangles), as were the catalytic 
residues Cys27 and His161 (Figure 4.1, boxes). The differences in six amino acid residues 
shown between the publicly available Tci-CF-1 sequence (pavTci-CF-1, inferred from T. 
circumcincta L4 RNA) and the sequences of the two recombinant versions (PiTci-CF-1 
and CeTci-CF-1) are likely to be due to polymorphisms within the T. circumcincta 
population. 
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Figure 4.1 The alignment of inferred amino acid sequence of recombinant Tci-CF-1 versions 
generated in this project compared to the publicly available Tci-CF-1 amino acid sequence 
PiTci-CF-1: inferred (from L4 cDNA) P. pastoris-expressed Tci-CF-1 amino acid sequence; 
CeTci-CF-1: inferred (from L4 cDNA) C. elegans-expressed Tci-CF-1 amino acid sequence; 
pavTci-CF-1: publicly available nucleotide sequence (published with NCBI accession 
number ABA01328), inferred from T. circumcincta L4 cDNA, generated from RNA material. 
Identical amino acid residues are marked by asterisks, highly similar residues by a colon, 
less similar residues by a full stop and highly different residues by a space. The predicted 
signal peptide cleavage site is indicated by a closed circle; the pro-peptide sequence is in 
italics and the site of its cleavage from the mature enzyme is marked by an arrow; open 
triangles indicate the predicted N-glycosylation sites; the active site residues cysteine and 
histidine are boxed.  
 
4.3.2 IgA Immune reactivity of gastric lymph to Tci-CF-1 versions 
Following successful expression and purification of CeTci-CF-1, ELISA experiments were 
carried out to investigate its immune reactivity compared to PiTci-CF-1 and native Tci-CF-
1 (see Chapter 2 of this thesis). Gastric lymph samples were collected during experiments 
detailed in Halliday et al. (2009, 2007) from: i) sheep that were previously trickle infected 
with T. circumcincta (2000 L3, three times a week for 8 weeks), then received a bolus 
challenge of 50 000 L3; and ii) sheep that were housed in helminth-free conditions, which 
did not receive a trickle infection, but only the bolus challenge (primary infection sheep). 
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Gastric lymph was collected from previously trickle infected sheep between +6 and +10 
days post challenge (dpc); from primary infection sheep lymph was collected between -2 
and +2 dpc. 
IgA antibodies in the gastric lymph of sheep previously infected with T. circumcincta did 
not show significantly higher binding to CeTci-CF-1 (co-purified with Ce-LEC-8) than 
lymph from T. circumcincta primary infection animals (Figure 4.2, panel A). 
 
Figure 4.2 Ovine gastric lymph IgA binding to CeTci-CF-1 (co-purified with Ce-LEC-8) and to 
purified Ce-LEC-8. 
Data represent mean ±SEM, n=5 (from primary infection sheep, grey bars) and 8 (previously 
infected sheep, dotted bars); all samples analysed in duplicate. Unpaired two-tailed t-test p 
value shown next to each graph. Panel (A): microplates were coated with 1 μg/ml CeTci-CF-
1 (~2 μg/ml Ce-LEC-8). Panel (B): microplates were coated with 2 μg/ml purified Ce-LEC-8. 
 
To characterise the effect of the presence of the co-purifying contaminant Ce-LEC-8 on the 
IgA binding in these experiments, Ce-LEC-8 was purified from C. elegans worms, strain 
N2 and used to coat microplates at the same concentration that would have been present in 
the CeTci-CF-1 preparations. The results showed that gastric lymph IgA binding to Ce-
LEC-8 alone was approximately equal to that observed for CeTci-CF-1/Ce-LEC-8 (Figure 
4.2, panel B), indicating no, or very little specific binding of IgA to CeTci-CF-1.  
Both CeTci-CF-1 and Ce-LEC-8 purified from N2 worms were treated with periodate in 
further ELISA experiments, to investigate whether the antibody binding observed (Figure 
4.2) was periodate sensitive. The results showed that following periodate treatment, ovine 
gastric lymph IgA reactivity decreased for both CeTci-CF-1 and Ce-LEC-8 (Figure 4.3), 
however the reductions in OD were not statistically significant.  
 125 
 
 
Figure 4.3 Ovine gastric lymph IgA binding to CeTci-CF-1 (co-purified with Ce-LEC-8) and 
purified Ce-LEC-8, before and after periodate treatment of the antigens by ELISA. 
Data represent mean ±SEM, n=3 (from primary infection sheep) and 7 (previously infected 
sheep); all samples analysed in duplicate. Overall ANOVA p value shown below each graph. 
Panel (A): microplates were coated with 1 μg/ml CeTci-CF-1 (~2 μg/ml Ce-LEC-8), then 
treated with periodate (grey bars) or left untreated (striped bars). Panel (B): microplates 
were coated with 2 μg/ml purified Ce-LEC-8, then treated with periodate (gray bars) or left 
untreated (striped bars). 
 
Immunoblots were used to visually determine the binding of lymph IgA to Tci-CF-1 
versions. Gastric lymph of individual sheep was used to probe each Tci-CF-1 version; 
lymph samples were divided in two sub-groups; those from previously infected animals 
and those from sheep that received a T. circumcincta primary infection. The results showed 
that gastric lymph IgA of previously infected animals was able to bind nTci-CF-1, whereas 
IgA in lymph collected from sheep exposed to the T. circumcincta challenge (i.e. still 
helminth-naive animals) only bound nTci-CF-1 weakly (Figure 4.4, panel A). A similar 
result was observed for each of the recombinant Tci-CF-1 versions; lymph IgA from 
previously infected animals showed stronger binding to both PiTci-CF-1 and CeTci-CF-1 
than lymph IgA from naïve sheep (Figure 4.4, panels B-C).  
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Figure 4.4 Immunoblots showing the gastric lymph IgA binding to Tci-CF-1 versions. 
Molecular weight markers (kDa) positioned to the left of each panel. Equal amount of 
proteins were loaded in each lane; (A) native Tci-CF-1; (B) P. pastoris-expressed Tci-CF-1; 
(C) C. elegans-expressed Tci-CF-1. Each strip was probed with gastric lymph from 
individual sheep (numbers at the bottom of each strip, same numbers across represent the 
same sheep), then IgA binding was detected with a secondary anti-sheep IgA antibody and 
developed by chemiluminescence. Lymph samples 1-3 were collected from “previously 
infected” animals between +6 and +10 days post bolus challenge (dpc): These “previously-
infected” sheep had received a T. circumcincta trickle infection for 8 weeks (3000 L3, three 
times a week), then 7 days later, received a bolus challenge of 50 000 L3. Lymph samples 4-
5 were collected between -2 and 0 dpc from helminth-naïve sheep prior to a primary bolus 
challenge. 
  
Periodate-sensitive epitopes were identified in nTci-CF-1 in ELISA experiments, as 
defined by the IgA response induced in gastric lymph by T. circumcincta trickle infection 
(see Figure 2.10 in section 2.3.5 of this thesis). Furthermore, periodate-sensitive epitopes 
were also identified in PiTci-CF-1 during ELISA experiments, as defined by the IgG 
response from serum and pre-scapular ASC (see Figures 2.6 and 2.8, sections 2.3.3 and 
2.3.4 of this thesis). In the current chapter, immunoblots were also treated with periodate to 
investigate whether the lymph IgA reactivity shown to each Tci-CF-1 version still retained 
characteristics of periodate-sensitivity following the denaturing conditions occurring 
during electrophoresis and blotting. In addition, as CeTci-CF-1 was co-purified with Ce-
LEC-8, immunoblots allowed visualisation of the relative antibody binding to each of the 
two proteins. The results showed that following periodate treatment of immunoblots, 
lymph IgA binding to each Tci-CF-1 version from previously infected sheep was 
maintained, albeit to a lesser degree, as shown in periodate untreated immunoblots (Figure 
4.5).  
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Figure 4.5 Immunoblots showing the gastric lymph IgA binding to purified Tci-CF-1 versions 
before and after periodate treatment of the antigens. 
Molecular weight markers (kDa) positioned to the left of each panel. Equal amounts of 
proteins were loaded in each lane. Strips marked with § were probed with gastric lymph 
pooled from 4 sheep previously infected with a trickle infection and a T. circumcincta bolus 
challenge; strips marked with † were probed with lymph pooled from 3 sheep undergoing T. 
circumcincta primary infection, before bolus challenge. All strips were washed and 
incubated using the same antibodies and buffers, except those marked with Per-, strips that 
did not receive periodate treatment; Per+, strips that received periodate treatment. Panel 
(A): nTci-CF-1; panel (B): PiTci-CF-1; panel (C): CeTci-CF-1. 
 
4.3.3 Cysteine protease activity of native and recombinant Tci-CF-
1  
Cysteine protease activity in Tci-CF-1 versions was investigated using the cysteine 
protease-specific substrates Z-FR-pNA and Z-FR-AMC. The positive control used 
throughout was a purified cathepsin L from human liver (hCath L). Specific cysteine 
protease activity was shown by failure of any of the enzymes to release chromogenic pNA 
and fluorescent AMC groups when the cysteine protease-specific inhibitor E-64 was added 
to the reactions. 
Initial experiments were performed to determine whether T. circumcincta L4 ES and/or 
purified nTci-CF-1 were able to degrade the chromogenic substrate Z-FR-pNA across a 
range of pH values. The reaction rates expressed in μOD/min were calculated in the linear 
phase of the reactions. Enzyme activity was demonstrated for L4 ES and nTci-CF-1 at each 
pH evaluated, and a small degree of apparent activity only at pH 5.5 for both recombinant 
Tci-CF-1 versions (Figure 4.6). Neither of the two recombinant Tci-CF-1 versions was 
able to replicate the small amount of enzyme activity observed in Figure 4.6 and therefore 
they were subsequently considered not active. 
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Figure 4.6 Rate of the linear phase of protease activity reactions using Z-FR-pNA for Tci-CF-
1 native and recombinant versions. 
An equal amount of protein (50 ng) was added in each reaction except L4 ES (100 ng) and 
CeTci-CF-1, where Ce-LEC-8 was also present. A blank OD reading (from wells without 
enzyme) was subtracted from each sample absorbance data. The rate of each reaction is 
shown as μOD/min during the linear phase. A range of pH was tested for the optimal 
reaction conditions. Two duplicate wells for each reaction. All enzyme activity was inhibited 
by the addition of E-64. 
 
These results were very close to the sensitivity limits of the assay and therefore could not 
be reliably repeated.  For this reason, a more sensitive fluorescent substrate (Z-FR-AMC) 
was used to determine the cysteine protease enzyme activity of native and recombinant 
Tci-CF-1 and L4 ES. 
The results confirmed that T. circumcincta L4 ES and purified nTci-CF-1 were 
enzymically active over a range of pH values, with peaks of activity at pH 4.5 and 5.5 
(Figure 4.7). Neither recombinant Tci-CF-1 version was able to degrade the substrate used 
at pH 3.5 and 4.5. Although a small amount of enzyme activity could be recorded at pH 5.5 
and 7 (CeTci-CF-1), these results were thought to derive from the presence of Ce-LEC-8 in 
the purified protein preparation used, as control reactions containing purified Ce-LEC-8 
showed a higher fluorescence background.  
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Figure 4.7 Rate of the linear phase of protease activity reactions using Z-FR-AMC for Tci-CF-
1 native and recombinant versions. 
An equal amount of protein (50 ng) was added in each reaction except L4 ES (100 ng) and 
CeTci-CF-1, where Ce-LEC-8 was also present. The fluorescence data was blank corrected. 
Two duplicate wells for each reaction. The rate of each reaction is shown as RFU/min during 
the linear phase. A range of pH was tested for the optimal reaction conditions.  
 
Maximum protease activity in L4 ES and purified nTci-CF-1 preparations was observed at 
pH 4.5 and 5.5; all subsequent experiments were therefore conducted at pH 4.5. 
Both initial experiments with Z-FR-pNa and Z-FR-AMC had shown that over a two hour 
incubation, neither recombinant Tci-CF-1 was able to degrade the substrates at low pH. 
Therefore, attempts were made to activate both PiTci-CF-1 and CeTCI-CF-1 recombinant 
versions by inducing cleavage of the pro-peptide by two methods. First, self-activation was 
attempted by incubating each recombinant Tci-CF-1 version in buffer at pH 4.5 
(representing a drop in pH from the neutral conditions at which it was purified) in the 
presence of DTT and cysteine. Electrophoresis and Coomassie staining of PiTci-CF-1 
incubated in buffer pH 4.5 with the addition of DTT and cysteine in the presence or 
absence of E-64 over a two hour period showed that self-activation was not a mechanism 
by which this enzyme could be activated. PiTci-CF-1 bands did not show a size shift 
(suggesting cleavage) at any of the time points analysed, and the presence of E-64 did not 
show differences compared to the reactions where it was absent (Figure 4.8). For CeTCi-
CF-1, no protein bands were visible in gels with any treatment, even after silver staining, 
making it impossible to assess activation by this method. 
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Figure 4.8 SDS-PAGE analysis of PiTci-CF-1 incubated at pH 4.5. 
Equal amounts of protein were incubated at 37°C, pH 4.5 in the presence of DTT and 
absence (left side of the dotted line) or presence (right side) of E-64 for a maximum of 120 
min; equal aliquots were collected every 30 min, heat inactivated and loaded on gel. The gel 
was stained with Coomassie blue. The time (min) at which each aliquot was collected is 
shown at the bottom of each lane. M: molecular weight marker (kDa). 
 
As it appeared that PiTci-CF-1 could not be self-activated by a drop in pH and/or 
incubation with DTT and cysteine, an attempt at trans-activation was made by adding an 
exogenous enzyme (hCath L) to the reactions containing PiTci-CF-1. The results showed 
that, at pH 3.5, the pH at which hCath L was shown to be most active in preliminary 
experiments, a proportion of PiTci-CF-1 was cleaved by hCath L over a period of 140 min 
and a band of slightly smaller size (~38 kDa) appeared between the two PiTci-CF-1 bands 
(~48 and ~34 kDa) in silver stained polyacrylamide gels in the absence of E-64 after 20min 
of co-incubation (Figure 4.9, panel A). This additional band was not present in the 
reactions incubated in the presence of E-64 (Figure 4.9, panel B). Again, no bands were 
visible following either treatment of CeTci-CF-1. 
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Figure 4.9 SDS-PAGE analysis of PiTci-CF-1 incubated over a period of time at pH 3.5 in the 
presence of human Cathepsin L. 
Equal amounts of protein were incubated at 37°C, pH 3.5 for in the presence of h Cath L 
enzyme, in the absence (A) or presence (B) of E-64 for a maximum of 140 min; equal 
aliquots were collected at 20, 80 and 140 min, heat inactivated and loaded on gel. The gel 
was silver stained. The bands shown are: PiTci-CF-1 as expressed by the yeast cells (black 
solid and dotted arrows), hCath L (solid red arrow) and PiTci-CF-1 as cleaved in this 
experiment (solid green arrow). The time (min) at which each aliquot was collected is shown 
at the bottom of each lane. M: molecular weight marker (kDa). 
 
It was not clear from SDS-PAGE analysis whether the addition of hCath L was effective in 
trans-activating PiTci-CF-1 by cleaving the pro-peptide or whether the band observed in 
Figure 4.9A (green arrow) was a degraded, but inactive version of PiTci-CF-1. For this 
reason, cysteine protease-specific assays were carried out using Z-FR-AMC, co-incubating 
PiTci-CF-1 or CeTci-CF-1 alone or in the presence of hCath L. By analysing the enzyme 
activity over 60 min periods at a range of substrate dilutions, it was shown that, at the 
highest substrate concentration used (476 μM), the reaction rates were significantly higher 
for both PiTci-CF-1 and CeTci-CF-1 co-incubated (for the whole assay duration, 20 + 120 
min) with hCath L, compared to hCath L alone or the pre-trans-activated recombinant 
proteins alone (Figure 4.10).  
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Figure 4.10 Graph showing the fluorescence emitted over 60min by enzyme digestion of Z-
FR-AMC by PiTci-CF-1 and CeTci-CF-1 with or without hCath L and the rate of the enzyme 
reactions during the linear phase. 
Relative fluorescence units (RFU) were plotted vs time (min). The final concentration of the 
substrate was 476 μM. (A): black closed circles, hCath L only wells (13.7 ng/well); red closed 
squares, purified PiTci-CF-1 (50 ng/well) co-incubated with hCath L (13.7 ng/well); green 
closed triangles, purified PiTci-CF-1 (50 ng/well); data represent mean±SEM, n=4 (except 
PiTci-CF-1 where n=1) (B): black closed circles, hCath L only wells (13.7 ng/well); purple 
closed squares, purified CeTci-CF-1 (50 ng/well) co-incubated with hCath L (13.7 ng/well); 
green closed triangles, purified CeTci-CF-1 (50 ng/well); data represent mean±SEM, n=4 
(except CeTci-CF-1 where n=1). (C): The reaction rates expressed in μM AMC produced/min 
were calculated in the linear phase of the reactions (20 min). Data represent mean±SEM, 
n=3. Overall ANOVA p = 0.0042; post-ANOVA analysis: Tukey’s multiple comparison test. ** 
= 0.001< p <0.01; * = 0.01< p <0.05.  
 
When lower substrate concentrations were used (47.6-28.3 µM), the reactions containing 
the two recombinant Tci-CF-1 enzymes showed different rates, depending on whether 
PiTci-CF-1 or CeTci-CF-1 was present. The reaction rates for PiTci-CF-1 co-incubated 
with hCath L appeared lower than hCath L alone, but this difference was not significant 
(Figure 4.11, panel A). The reaction rates for CeTci-CF-1 co-incubated with hCath L 
appeared to coincide with hCath L alone at these lower substrate concentrations (Figure 
4.11, panel B). 
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Figure 4.11 Graph showing the fluorescence emitted over 60 min by enzyme digestion of Z-
FR-AMC by PiTci-CF-1 and CeTci-CF-1 with the addition of hCath L. 
Relative fluorescence units (RFU) were plotted vs time (min). The final concentration of the 
substrate is shown above each graph. Data represent mean±SEM, n=4. (A): reaction rates of 
hCath L alone (black closed circles) or PiTci-CF-1 co-incubated with hCath L (red closed 
squares) at concentrations of Z-FR-AMC of 47.6 and 23.8 µM as shown. (B): reaction rates of 
hCath L alone (black closed circles) or CeTci-CF-1 co-incubated with hCath L (purple closed 
squares) at concentrations of Z-FR-AMC of 47.6 and 23.8 µM as shown. 
 
By removing the pro-enzyme, epitopes of the mature enzyme may be more readily 
available for antibody binding. To investigate the hypothesis that enzyme activation by 
exogenous cleavage of the pro-peptide might enhance antibody binding to PiTci-CF-1, an 
ELISA experiment was carried out. PiTci-CF-1 alone or co-incubated with hCath L at 
different times (0 and 20 min) were used to coat microtitre plates to characterise the gastric 
lymph IgA reactivity to cleaved PiTci-CF-1. The gastric lymph used was a pool of samples 
from 5 previously infected sheep that received a T. circumcincta trickle infection and a 
bolus challenge (samples were collected between +6 and +10 days post-challenge, dpc). 
The results in Figure 4.12 showed that there was no significant increase in lymph IgA 
binding to hCath L-treated PiTci-CF-1, either at the moment of mixing (no incubation) or 
after a period of co-incubation at 37°C (20 min). 
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Figure 4.12 Ovine gastric lymph IgA binding to PiTci-CF-1 co-incubated at 37°C with or 
without addition of hCath L, in the presence or absence of E-64. 
Equal amounts of PiTci-CF-1 (1 µg/ml) were used to coat a microtitre plate as follows: yellow 
bar, PiTci-CF-1 alone without incubation; blue bar, PiTci-CF-1 alone incubated at 37°C for 
20min; grey bar, PiTci-CF-1 and hCath L were mixed but not incubated; pink bar, hCath L 
alone; green bar, PiTci-CF-1 and hCath L, mixed and incubated at 37°C for 20 min; black bar, 
as the green bar with the addition of E-64. Gastric lymph used was a pool of samples from 5 
sheep that received a T. circumcincta trickle infection and challenge protocol; samples were 
collected between +6 and +10 dpc.  
 
An immunoblot experiment was carried out to visually investigate the cleavage of PiTci-
CF-1. This experiment was also used to compare the binding of lymph antibodies from T. 
circumcincta previously infected sheep with the binding of antibodies from PiTci-CF-1-
immunised sheep, against hCath L-cleaved PiTci-CF-1. In this experiment, PiTci-CF-1 
was incubated with hCath L for 80 min, with or without E-64, to induce cleavage of the 
pro-peptide and subsequently loaded in a polyacrylamide gel. The proteins were 
transferred onto a nitrocellulose membrane and were probed with two different pools of 
gastric lymph (from T. circumcincta previously infected or primary infection sheep), or a 
sheep anti-PiTci-CF-1 serum sample (samples provenance described in Section 4.2.4). The 
results showed that post-immunisation serum IgG from sheep immunised with PiTci-CF-1 
was able to bind PiTci-CF-1, and that binding to PiTci-CF-1 was not observed for IgG 
from pre-immunisation serum (Figure 4.13, Ai-ii). To a lesser extent, sheep gastric lymph 
IgA from previously infected animals bound to PiTci-CF-1, however in this case the 
difference in intensity of the binding detected compared to primary infection sheep lymph 
was minimal (Figure 4.13, A1-2). Human CathL-mediated cleavage of PiTci-CF-1 pro-
peptide did not greatly enhance binding to gastric lymph IgA from previously infected 
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sheep compared to primary infection sheep lymph, although a weak band corresponding to 
cleaved PiTci-CF-1 could be detected (Figure 4.13, B1-2). However, it was shown that 
post-immunisation serum IgG was able to bind an additional two bands (Figure 4.13, Bi), 
in the trans-activated PiTci-CF-1 compared to the unactivated PiTci-CF-1 lane alone (Ai), 
showing that hCath L was able to cleave the PiTci-CF-1 zymogen. This also showed that 
cleaved PiTci-CF-1 forms may still be bound by recombinant PiTci-CF-1-specific 
antibodies. The last panel of this experiment (Figure 4.13, C) showed that the addition of 
E-64 completely inhibited cleavage of PiTci-CF-1 by hCath L, and that the additional 
bands described were a product of the 80 min co-incubation of Pi Tci-CF-1 with hCath L, 
and not a previous autolysis of PiTci-CF-1. The same identical experiment was carried out 
using CeTci-CF-1 in the presence or absence of hCath L and E-64 in immunoblots probed 
with gastric lymph or serum; however no information could be gained as no protein was 
detected in either of the blots (Figure 4.14). 
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Figure 4.13 Immunoblots showing the antibody binding of gastric lymph IgA or serum IgG to 
PiTci-CF-1 cleaved with hCath L. 
Molecular weight markers (kDa) on the left of each panel. An equal amount of PiTci-CF-1 
incubated or not with hCath L (1:100 dilution), with or without E-64 was loaded in each lane. 
For all panels: lane 1, pool of gastric lymph from T. circumcincta previously infected sheep 
(collected between +6 and +10 days post bolus challenge); lane 2, pool of gastric lymph 
from T. circumcincta primary infection sheep (collected between -2 and +2 days post bolus 
challenge); lane 3, negative control incubated without primary antibody (lymph). In all 
panels, lane i) incubated with sheep anti P. pastoris-expressed Tci-CF-1 serum (post-
immunisation); lane ii) incubated with sheep anti P. pastoris-expressed Tci-CF-1 serum (pre-
immunisation); lane iii) negative control incubated without primary antibody (serum). Panel 
(A): PiTci-CF-1 alone was loaded in each lane; panel (B): PiTci-CF-1 was co-incubated with 
hCath L for 80 min before loading onto the gel; panel (C): PiTci-CF-1 was co-incubated with 
hCath L and E-64 for 80 min before loading onto the gel. In all lanes numbered 1-3, lymph 
IgA binding was shown with a secondary mouse anti-sheep IgA antibody, a tertiary rat anti-
mouse IgG:HRP antibody. In all lanes numbered i-iii, serum IgG binding was shown with a 
secondary rabbit anti-sheep IgG:HRP antibody. Antibody binding in all blots was revealed 
with chemiluminescent substrate for HRP. 
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Figure 4.14 Immunoblots showing the antibody binding of gastric lymph IgA or serum IgG to 
CeTci-CF-1 cleaved with hCath L. 
Molecular weight markers (kDa) on the left of each panel. An equal amount of CeTci-CF-1 
incubated or not with hCath L (1:100 dilution), with or without E-64 was loaded in each lane. 
For all panels: lane 1, pool of gastric lymph from T. circumcincta previously infected sheep 
(collected between +6 and +10 days post bolus challenge); lane 2, pool of gastric lymph 
from T. circumcincta primary infection sheep (collected between -2 and +2 days post bolus 
challenge); lane 3, negative control incubated without primary antibody (lymph). In all 
panels, lane i) incubated with sheep anti P. pastoris-expressed Tci-CF-1 serum (post-
immunisation); lane ii) incubated with sheep anti P. pastoris-expressed Tci-CF-1 serum (pre-
immunisation); lane iii) negative control incubated without primary antibody (serum). Panel 
(A): CeTci-CF-1 alone was loaded in each lane; panel (B): CeTci-CF-1 was co-incubated with 
hCath L for 80 min before loading onto the gel; panel (C): CeTci-CF-1 was co-incubated with 
hCath L and E-64 for 80 min before loading onto the gel. In all lanes numbered 1-3, lymph 
IgA binding was shown with a secondary mouse anti-sheep IgA antibody, a tertiary rat anti-
mouse IgG:HRP antibody. In all lanes numbered i-iii, serum IgG binding was shown with a 
secondary rabbit anti-sheep IgG:HRP antibody. Antibody binding in all blots was revealed 
with chemiluminescent substrate for HRP.  
 
4.3.4 Glycosylation analysis of nTci-CF-1, PiTci-CF-1 and CeTci-
CF-1 
Each version of Tci-CF-1 generated and/or purified in this study was first confirmed to be 
glycosylated using a glycan-specific gel stain kit. By using the glycan-specific stain, nTci-
CF-1 (mature enzyme) and CeTci-CF-1 (zymogen) showed fluorescent signals of similar 
intensity, whereas PiTci-CF-1 (zymogen) showed higher fluorescence (Figure 4.15). 
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Figure 4.15 SDS-PAGE and glycan stain analysis of Tci-CF-1 versions. 
PM: protein molecular marker (kDa); GM: glycan molecular marker (CandyCane, Invitrogen); 
lane 1: L4 ES; lane 2: purified nTci-CF-1 (solid line box); lane 3: purified PiTci-CF-1 (both 
bands within the dashed line box); lane 4: purified CeTci-CF-1 (dotted line box) and Ce-LEC-
8 (solid line red box). Equal amounts of protein were loaded in each lane; the gel was 
stained using a glycan-specific stain (Invitrogen). 
 
Subsequently, electroblots of each protein were probed with a panel of 8 different lectins, 
each with different glycan residue specificity (Figure 4.16). 
 
Figure 4.16 Electroblots showing lectin binding to Tci-CF-1 versions. 
Molecular weight marker (kDa) positioned to the left of each panel. Panel (A): nTci-CF-1; 
panel (B): PiTci-CF-1; panel (C): CeTci-CF-1. Numbers at the bottom of each correspond to 
the lectins used: 1, LCH (Lentil lectin from Lens culinaris); 2, ConA (Concanavalin A from 
Canavalia ensiformis); 3, DBA (Dolichos biflorus agglutinin); 4, UEA (Ulex europaea 
agglutinin); 5, SBA (Soybean agglutinin from Glycine max); 6, PNA (Peanut agglutinin from 
Arachis hypogea); 7, WGA (Wheat germ agglutinin from Triticum vulgaris); 8, RCA I (Ricinus 
communis agglutinin I); -ve, electroblot of each protein incubated in buffer. 
 
The lectin panel used to investigate the reactivity of glycans in each version of Tci-CF-1 
highlighted similarities in the glycosylation of nTci-CF-1 and recombinant versions, 
although one notable difference was in the binding of Peanut agglutinin (PNA, Figure 4.16, 
 139 
 
lane 6) to nTci-CF-1 and, to a lesser extent, to PiTci-CF-1 but not to CeTci-CF-1. It was  
apparent that most other lectins bound to PiTci-CF-1 in a similar pattern to nTci-CF-1, but 
to a much stronger degree. It was also shown that ConA and to a lesser extent LCH, bound 
to both PiTci-CF-1 bands (high and low molecular weight), however other lectins only 
bound to the higher molecular weight isoform. The results are summarized in Table 4.2. 
Table 4.2 Panel of lectins used to probe the glycan composition of the structures present in 
each Tci-CF-1 versions purified for this thesis.  
 
Lectin 
PiTci-CF-1 
(only higher molecular 
weight band if not specified) 
nTci-CF-1 
(mature enzyme) 
CeTci-CF-1 
(zymogen) 
1. LCH ++++ (both bands) ++ ++ 
2. ConA ++++ (both bands) ++ ++ 
3. DBA +++ + + 
4. UEA ++ + +/- 
5. SBA ++ +/- + 
6. PNA +/- ++ - 
7. WGA +/- - - 
8. RCA I +/- - +/- 
Lectins used were: LCH: Lentil lectin from Lens culinaris, ConA: Concanavalin A from 
Canavalia ensiformis, DBA: Dolichos biflorus agglutinin, UEA: Ulex europaea agglutinin, 
SBA: Soybean agglutinin from Glycine max, PNA: Peanut agglutinin from Arachis hypogea, 
WGA: Wheat germ agglutinin from Triticum vulgaris, RCA I: Ricinus communis agglutinin I. 
 
Further characterisation of the glycan structures of Tci-CF-1 versions was carried out  
using PNGase F and O-glycosidase enzymes. The aim of this experiment was to 
investigate whether a shift in size could be induced by treatment of each Tci-CF-1 version 
with enzymes capable of removing glycan structures. Untreated Tci-CF-1 proteins 
(approximately 130 ng) were loaded in the gel (Figure 4.17, lanes 1-4-7), to ensure 
visualisation upon staining, and to act as positive control for the staining process (as this 
was the standard visualised amount used in SDS-PAGE gels throughout this thesis). 
However, due to an unavoidable dilution process during the enzymatic PNGase F and O-
glycosidase reactions, only ~60 ng/well enzyme-treated Tci-CF-1 proteins could be loaded 
in the gel. For this reason, the untreated wells could not be directly compared to the treated 
ones. The results of this experiment showed that PiTci-CF-1 possessed PNGase F-sensitive 
glycans, as shown by the size shift, but not O-glycosidase-sensitive glycans (Figure 4.17, 
lane 5). The size of native Tci-CF-1 appeared unchanged following either enzymatic 
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treatment, as did CeTci-CF-1. This experiment suggests that PNGase F treatment was only 
successful in removing N-linked glycans from PiTci-CF-1. The presence of Ce-LEC-8 is 
shown in Figure 4.17 but no size shift was observed following treatment of the CeTci-CF-
1/Ce-LEC-8 protein preparation. 
 
 
Figure 4.17 SDS-PAGE analysis of the size shift of Tci-CF-1 versions following PNGase F 
and O-glycosidase treatment. 
Coomassie blue stain was used. M: molecular weight marker (kDa). Asterisks indicate 
PNGase F bands; open circles indicate O-glycosidase. The solid line box encloses nTci-CF-
1, untreated (lane 1), PNGase F-treated (lane 2) and O-glycosidase-treated (lane 3). The 
dotted line box encloses PiTci-CF-1, untreated (lane 4), PNGase F-treated (lane 5) and O-
glycosidase-treated (lane 6). The dashed line box encloses CeTci-CF-1, untreated (lane 7), 
PNGase F-treated (lane 8) and O-glycosidase-treated (lane 9). The presence of Ce-LEC-8 is 
shown.  
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4.4 Discussion 
The results from this chapter showed that it was possible to identify conserved catalytic 
amino acid residues and N-linked glycosylation sites in amino acid sequence alignments of 
each Tci-CF-1 version; each clone had been generated by PCR on cDNA from L4 stage 
RNA material. The ability of each Tci-CF-1 version to degrade a substrate specific for 
papain-like enzymes (Z-FR-AMC) was demonstrated, suggesting that both PiTci-CF-1 and 
CeTci-CF-1 were correctly folded to the extent that they could form a functional active 
site. Additionally, evidence of the presence of glycosylation was provided for each of the 
Tci-CF-1 versions investigated, and immunoblots showed that antibody binding to 
recombinant Tci-CF-1 versions may be enhanced by denaturing conditions. Finally, a C. 
elegans galectin (Ce-LEC-8) consistently co-eluted with CeTci-CF-1 and showed a degree 
of non-specific binding with sheep IgA. 
This chapter showed that, upon denaturing T. circumcincta recombinant Tci-CF-1 versions 
in immunoblots, gastric lymph IgA from sheep that received an immunising T. 
circumcincta trickle infection was able to bind these antigens. These results were in 
contrast to those described in Chapter 2 of this work, where it was shown by ELISA that 
Pichia pastoris-expressed Tci-CF-1 was not recognised by antibodies from T. circumcincta 
immune sheep.  The differences observed had been attributed to failure of the yeast 
expression system to deliver correct protein folding and/or post-translational modifications 
(PTMs). The work shown in this chapter set out to answer these questions. First, antibody 
reactivity to each purified Tci-CF-1 version was investigated using immunoblots in 
addition to ELISA assays. Western blotting techniques allow investigation of the immune 
response to an antigen (or antigen mix) without the interference of tertiary structures, as 
standard protein electrophoresis techniques generally involve denaturing and reducing 
conditions which facilitate linearisation of amino acid sequences. For samples containing 
more than one protein, Western blotting gives the ability to visually determine which 
protein the antibodies bind to [reviewed by Harper et al. (1990) and Kurien and Scofield 
(2006)]. Western blotting experiments have been previously used to show the antibody 
immune response to complex preparations such as parasite somatic extracts, excretory-
secretory products, but also to purified native and recombinant proteins (Collins et al. 
2004, Geldhof et al. 2003, Jungersen et al. 2001, Vercauteren et al. 2004, Wedrychowicz 
et al. 1994). Here, immunoblots showed that denaturing conditions could reveal shared 
epitopes in native and recombinant Tci-CF-1 and confirmed that the previous differences 
in antibody binding shown in ELISA experiments between the native and recombinant Tci-
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CF-1 were likely to be caused by differences in protein folding or PTMs. However it must 
be noted that non-specific antibody binding occurred in blots probed with lymph from 
previously infected sheep, resulting in more intense background staining (Figure 4.4). This 
might reflect a simple quantitative increase in non-specific IgA binding in lymph from 
previously infected sheep compared to lymph from primary infection sheep; for this reason 
it was not attempted to quantify the intensity of the Tci-CF-1-specific antibody binding in 
the immunoblots. 
In periodate-treated immunoblots of each Tci-CF-1 version, a degree of lymph IgA binding 
was lost compared to untreated blots, suggesting the presence of periodate-sensitive 
epitopes, most probably glycans. These results, along with those from periodate-treated 
ELISAs (Chapter 2) in which it was shown that a significant (p ≤ 0.0002) degree of 
antibody reactivity to native Tci-CF-1 is directed towards glycan epitopes, support the 
hypothesis that Tci-CF-1 glycans may not have been correctly replicated in the 
recombinant versions considered in this work. Hyperglycosylation of recombinant proteins 
has been reported previously in experiments with a Pichia pastoris-expressed ENV 
glycoprotein from human immunodeficiency virus (HIV; Scorer et al. 1993); in addition, 
yeast glycan structures might have differed from those of nematode glycans which present 
core fucose structures not identified elsewhere (Haslam et al. 2000, Haslam et al. 1998, 
Khoo et al. 1997, Poltl et al. 2007, van Die et al. 1999). The inappropriate glycosylation 
that is likely to have occurred using the yeast expression system could have negatively 
affected the ability of sheep antibodies to bind to Tci-CF-1 protein epitopes (see Chapter 2 
discussion for more details).  
It has been shown that protein conformation is essential to enzyme activity, as denatured 
proteins only retain partial activity compared to the native state (Anfinsen 1973). 
Recombinant expression systems have been variably successful in generating active 
proteases, as often the recombinant protein of interest is found in a denatured state within 
inclusion bodies and requires extraction techniques that may allow refolding [reviewed by 
Marston (1986) and Georgiou and Valax (1996)]. However, recombinant expression of 
active proteases can be achieved, particularly when baculovirus/insect cell expression 
systems are employed e.g. with the H. contortus protease H11 (Smith et al. 1997), a 
cathepsin D (Ac-APR-1) from the dog hookworm Ancylostoma caninum which was also 
expressed in active form using baculovirus (Williamson et al. 2002). Indeed C. elegans has 
also been shown to generate enzymically active proteases, such as another recombinant 
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version of H. contortus H11 and a cysteine protease (Hc-CPL-1) from the same parasite 
(Murray et al. 2007, Roberts et al. 2013).  
In the generation of recombinant proteins and especially enzymes and/or proteins that will 
constitute vaccine antigens the importance of disulphide bonds should be noted. Disulphide 
bonds can occur between two cysteine residues in any amino acid chain, and can occur 
spontaneously or be dependent on the activity of another enzyme within the endoplasmic 
reticulum (ER) of cells (Anfinsen 1973, Frand et al. 2000). During this and a previous 
study (Redmond et al. 2006) of Tci-CF-1 versions it has been noted that the amino acid 
chain of this protein contains 6 cysteine residues which could contribute to the folding of 
the mature protein. It has been shown in Chapter 2 of this thesis that a fraction of native 
Tci-CF-1 can be purified using a thiol column; this suggests that a degree of disulphide 
bond activity can take place between cysteine residues in this protein and the –SH residues 
within the column. These results open the possibility that the native mature version of Tci-
CF-1 (nTci-CF-1) may be folded by means of disulphide bonds and that could influence 
the antibody recognition of conformational epitopes. This could explain the differences 
observed between antibody binding to nTci-CF-1 and the two recombinant versions 
generated in this study. Reducing conditions used in SDS-PAGE and Western blotting 
would not allow studies of the potential disulphide bonds present in this protein. An 
alternative could be to use non-reducing conditions and, if further funding became 
available, a crystallography study of the native and recombinant versions of Tci-CF-1 
would provide some useful information regarding the shape of this enzyme. 
In this chapter it was shown that T. circumcincta L4 ES contains active cysteine proteases, 
as it was able to degrade the cysteine protease-specific substrates used and activity was 
inhibited by addition of the cysteine protease-specific inhibitor E-64 (Figures 4.6 and 4.7). 
Of the L4 ES proteases, the most abundant is Tci-CF-1 (Redmond et al. 2006); in purified 
form this protein was also able to degrade the substrates, albeit with weaker activity than 
L4 ES. This was initially thought to be caused by a dilution factor, as L4 ES was used in 
the assays at a concentration 20-fold higher than nTci-CF-1. However, the complete 
composition of T. circumcincta L4 ES is currently unknown; therefore it is possible that 
other less abundant cysteine proteases with higher affinity for the substrate could have 
been responsible for the activity observed. Another possibility is that nTci-CF-1 may have 
been partially degraded during purification from ES, therefore losing some enzyme 
activity. When each purified recombinant Tci-CF-1 version was examined for cysteine 
protease activity, neither showed the ability to degrade the substrates used. However, this 
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result could be explained as both recombinant proteins were expressed as zymogens and 
therefore the pro-peptide had not been cleaved to release the mature enzymes. Enzymatic 
activity of cathepsins B and L is inhibited by the pro-peptide lying in the substrate binding 
cleft, and it is thought that this mechanism may be a feature of all papain-like cysteine 
proteases (Coulombe et al. 1996). As only mature native Tci-CF-1 can be found in T. 
circumcincta L4 ES (suggested by the molecular size and the cysteine protease activity), it 
is likely that in the parasite, a cleaving process takes place before the enzyme is excreted or 
secreted.  
Experiments to investigate the enzyme activity of Tci-CF-1 recombinant versions were 
carried out at pH 4.5, which represents a drop from the neutral pH at which the proteins 
were stored. The lack of activity observed in the unmodified recombinant proteins in 
experiments at pH 3.5, 4.5, 5.5 and 7 using the substrate Z-FR-AMC suggested that these 
enzymes were not able to self-activate. This was later confirmed by SDS-PAGE analysis, 
showing that prolonged incubation of the recombinant proteins (120 min) at pH 4.5 in the 
presence of DTT was not sufficient to induce protein activation by cleavage of the pro-
peptide. These results were in contrast with the findings shown by different cysteine 
proteases, FhCL1 and FhCL3 from Fasciola hepatica, which were expressed in the yeast 
Hansenula polymorpha and only required a short incubation at 37°C to self-activate 
(Corvo et al. 2013). Another enzyme (BCP), the acid cysteine protease from the silk moth 
Bombyx mori, is able to self-activate when incubated in vitro at pH 4 in the presence of 
DTT (Takahashi et al. 1997).  
However, this is not the only activation pathway for cysteine proteases. A recombinant P. 
pastoris-expressed cathepsin F, from the liver fluke Opistorchis viverrini (Ov-CF-1), could 
be trans-activated by addition of an exogenous cathepsin L [from the trematode F. 
hepatica, FhCL1 (Pinlaor et al. 2009)]. Another papain-like cysteine protease, 
recombinantly expressed in P. pastoris, is Schistosoma mansoni cathepsin B1 
(SmCB1pm); this was activated by the presence of recombinant activated S. mansoni 
asparaginyl endopeptidase (SmAE), also expressed in P. pastoris (Sajid et al. 2003). 
Further investigations in this chapter showed that both recombinant Tci-CF-1 versions 
could be activated by trans-activation carried out by an exogenous protease (human 
Cathepsin L, hCath L). The trans-activation of both recombinant Tci-CF-1 versions by 
adding hCath L resulted in the enhanced ability of both PiTci-CF-1 and CeTci-CF-1 to 
degrade the fluorescent substrate Z-FR-AMC. Furthermore, PiTci-CF-1 secreted by Pichia 
pastoris cells has been shown to migrate as two bands during gel electrophoresis (see 
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Figure 2.4) indicating that the yeast may be able to generate a cleaved form of recombinant 
Tci-CF-1. However, recombinant PiTci-CF-1 is enzymatically inactive, suggesting that the 
cleaved version (of lower molecular weight) is not the active enzyme. This was supported 
by the finding in this chapter that when PiTci-CF-1 was activated by hCath L a 38 kDa 
band, presumably the active enzyme, was released; this cleaved form appeared of higher 
molecular mass than the cleavage product seen in the original inactive PiTci-CF-1. 
Moreover, the majority of PiTci-CF-1 was secreted as a zymogen (of higher molecular 
mass ~49 kDa) and therefore requiring activation. The differences in estimated molecular 
mass between the PiTci-CF-1 zymogen, the P. pastoris-cleaved smaller Tci-CF-1 and the 
hCath L-cleaved intermediate size PiTci-CF-1 may indicate that the exogenous enzyme 
hCath L cleaves the enzyme at a more appropriate site in the amino acid chain, leaving 
extra amino acids that might be vital to the correct activity of PiTci-CF-1. Further work 
may be carried out to investigate the site of cleavage in both P. pastoris-cleaved smaller 
Tci-CF-1 and the hCath L-cleaved intermediate size Tci-CF-1, and compared if possible to 
Tci-CF-1 purified from T. circumcincta L4 ES. This would shed more light on the 
mechanisms that lead to the activation of Tci-CF-1.  
Pro-peptide cleavage experiments were also attempted with CeTci-CF-1. However, no 
protein bands were stained by either coomassie blue or silver staining in polyacrylamide 
gels, and immunoblotting also did not reveal protein bands corresponding to CeTci-CF-1. 
It was hypothesised that in these experiments the initial concentration of the protein (~10 
µg/ml) and the subsequent dilutions necessary to carry out the experiments exceeded the 
sensitivity of the detection methods. As the amount of purified CeTci-CF-1 protein was 
limited, further attempts to detect the pro-peptide cleavage were abandoned. However, in 
future experiments a modification to the immunoblotting technique could be introduced. 
Experiments have previously reported that heating nitrocellulose membranes (by boiling in 
water at 100°C, autoclave at 120°C, or baking at > 80°C) following dot blots and protein 
transfer can increase the sensitivity of detection for certain antibody-protein pairs 
(Swerdlow et al. 1986). 
At the highest Z-FR-AMC substrate concentration used (476 μM) the reaction rates were 
significantly higher for both PiTci-CF-1 and CeTci-CF-1 incubated with hCath L, 
compared to hCath L or the recombinant enzymes alone. This suggests that the co-
incubation of hCath L with both recombinant Tci-CF-1 versions could activate the latter 
two. When the experiments were repeated at lower substrate concentrations (47.6-23.8 
μM) the reaction rates for co-incubated hCath L and recombinant Tci-CF-1 were lower 
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than or similar to hCath L alone (Figure 4.11). This suggests competition for the substrates 
within this system, where both recombinant Tci-CF-1 and Z-FR-AMC were substrates for 
hCath L initially, followed by competition between activated recombinant Tci-CF-1 and 
hCath L for Z-FR-AMC substrate.  
Native Tci-CF-1 is present in T. circumcincta L4 ES as a mature enzyme (as deduced from 
the estimated molecular weight in polyacrylamide gels). The mature Tci-CF-1, without the 
pro-peptide, would therefore have been an antigenic stimulus for those sheep that had been 
trickle infected with T. circumcincta L3; this means that antibodies specific for the pro-
peptide were unlikely to be present in the serum, ASC probes or gastric lymph samples. 
For this thesis, samples from the T. circumcincta trickle infected sheep were used to 
investigate antibody binding to PiTci-CF-1 and CeTci-CF-1 and neither achieved 
statistically significant antibody binding. It is suggested here that the presence of the pro-
peptide of PiTci-CF-1 and CeTci-CF-1 might have negatively affected binding of 
antibodies specific for the mature domain of Tci-CF-1. This might have occurred as the 
pro-peptide was positioned across the active site and could have masked epitopes present 
in the cleft. Another hypothesis is that the glycan group present on the pro-peptide of 
recombinant Tci-CF-1 could also have negatively affected antibody binding by masking 
protein epitopes. However, the real cause of the lack of antibody reactivity against PiTci-
CF-1 remains unclear, as immunoblots and ELISA experiments of PiTci-CF-1 cleaved 
with hCath L showed that it was not possible to significantly enhance antibody binding by 
removing the pro-peptide. This could imply that infection-induced antibodies do not 
recognise the structure of recombinant CF-1 even after pro-peptide removal. Another 
hypothesis is that glycosylation on PiTci-CF-1 was too different from that on the native 
Tci-CF-1 from T. circumcincta, and antibodies were unable to recognise epitopes. 
Alternatively, hyperglycosylation of PiTci-CF-1 may have masked protein epitopes similar 
to nTci-CF-1that would otherwise have been bound by antibodies. 
To further investigate the presence and relevance of PTMs in Tci-CF-1 versions, 
experiments were carried out first to confirm the presence of glycosylation and 
subsequently to try and characterise it. Glycosylation of native and recombinant Tci-CF-1 
versions was confirmed by the use of a glycan-specific stain in polyacrylamide gels. As 
equal amounts of protein were loaded in each lane, the much higher fluorescence achieved 
by PiTci-CF-1 compared to nTci-CF-1 suggested that the former may have been 
hyperglycosylated by the yeast expression system. Yeast expression systems have been 
shown to hyperglycosylate recombinant proteins (Storer and Menard 1994). Engineering of 
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P. pastoris strains in order to generate the correct glycosylation patterns (if known) may 
provide a solution to this problem without significantly affecting yeast viability or protein 
expression (Vervecken et al. 2004). The higher fluorescence achieved by PiTci-CF-1 
compared to nTci-CF-1 could also have been caused by the presence of two N-linked 
glycans on the PiTci-CF-1 as opposed to one on the mature native Tci-CF-1. As a tentative 
confirmation of this hypothesis, only the higher molecular size PiTci-CF-1 band showed 
the brightest glycan-dependent fluorescence, whereas the lower molecular weight band 
showed brightness comparable to nTci-CF-1 (Figure 4.15). CeTci-CF-1 was also expressed 
as a zymogen with two N-linked glycosylation sites, assuming that both sites carried a 
glycan structure. However, the glycan-specific fluorescence of CeTci-CF-1 was much 
lower than that of the high molecular mass PiTci-CF-1, possibly due to yeast-derived 
hyperglycosylation occurring at both predicted sites.  
Further characterisation of the glycosylation of Tci-CF-1 versions was performed using a 
panel of lectins to determine which types of carbohydrate residues were present in each 
Tci-CF-1. Lectins have been used to detect, purify and characterise glycoproteins for many 
years by virtue of their specificity for certain carbohydrate residues (Bunkenborg et al. 
2004, Glass et al. 1981). In studies of helminth parasites, lectins have been extensively 
used to isolate and purify H. contortus H11 and H-gal-GP antigens, subsequently used in 
immunisation studies (Smith et al. 1993, Smith et al. 1994). In another study, a 42 kDa 
antigen from D. viviparus adult ES bound to lentil lectin and ConA, and appeared to be 
synthesized in both a glycosylated and non-glycosylated form, both of which were 
recognised by serum antibodies from calves repeatedly infected with the parasite (Britton 
et al. 1993). Lectins have also been used to characterise antigens of the trematode F. 
hepatica, and highlighted the complexity of glycoconjugates of this parasite (McAllister et 
al. 2011). The results of the lectin binding experiments carried out in this chapter showed 
that each Tci-CF-1 version was glycosylated with a variety of carbohydrate residues; also 
that PiTci-CF-1 was hyper glycosylated, as shown by stronger binding of some lectins 
compared to either nTci-CF-1 or CeTci-CF-1. The three Tci-CF-1 versions did not show 
major differences in their glycan composition, with most of the lectins binding to a similar 
degree to each Tci-CF-1 version. However, one lectin (Peanut agglutinin, PNA) was able 
to bind to nTci-CF-1 but to a much lesser extent to PiTci-CF-1 and no binding was shown 
to CeTci-CF-1. This may indicate the presence of -gal(1-3)galNAc residues in the 
glycosylation of nTci-CF-1, but not in the recombinant versions and could provide a partial 
explanation for the differences in immune recognition showed in previous results.  
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Here it was also shown that ConA and to a lesser extent LCH bound to carbohydrate 
residues on both isoforms of PiTci-CF-1, whereas other lectins only bound to the higher 
molecular weight protein band. This suggests some differences in the carbohydrate 
composition of glycans on the two PiTci-CF-1 forms expressed by the yeast cells. As T. 
circumcincta Tci-CF-1 had two predicted N-linked glycosylation sites, one on the pro-
peptide and one on the mature enzyme (Redmond et al. 2006), differing structures in each 
of these glycans would change the reactivity of the molecule to lectins and antibodies after 
the pro-peptide was cleaved. If the lower molecular weight PiTci-CF-1 band was an 
inappropriately cleaved version (carried out by yeast cells but not enzymatically active), 
removal of all or part of the pro-peptide would also have removed the glycan structure 
linked to it. Therefore, if the two glycan structures of PiTci-CF-1 differed in composition, 
this was reflected in the slightly different pattern of lectin binding observed where only 
two of the lectins were able to bind both PiTci-CF-1 forms. 
PNGase F and O-glycosidase enzymes were used to further investigate the glycosylation of 
Tci-CF-1 versions. PNGase F is an amidase frequently used to investigate carbohydrate 
structures, and releases most protein-bound N-linked carbohydrates except those with 
fucose attached to the 3 position of the Asn-linked GlcNAc residue (Morelle et al. 2009). 
O-glycosidase catalyzes the removal of Core 1 and Core 3 O-linked disaccharides from 
glycoproteins and it may also be used to characterise proteoglycan structures (Koutsioulis 
et al. 2008). The results of this chapter showed that a portion of PiTci-CF-1 N-linked 
glycans were cleaved, as the molecular mass of the protein band after PNGase F treatment 
was reduced, but native Tci-CF-1 or CeTCi-CF-1 were not. Indeed nTci-CF-1 protein 
appeared to be refractory to either PNGase or O-glycosidase treatment, as the molecular 
mass was unchanged. However, N-glycans with core fucose linked α1,3 to the Asn-bound 
N-acetylglucosamine have been shown to be resistant to the action of PNGase F (Tretter et 
al. 1991). Since these particular residues have been identified in helminth glycan structures 
previously (Haslam et al. 2000, Haslam et al. 1998, Khoo et al. 1997, Poltl et al. 2007, van 
Die et al. 1999), their presence cannot, at this stage, be excluded from Tci-CF-1 versions. 
In this situation, glycan analysis using PNGase A might have been more successful and 
could be included in further experiments of Tci-CF-1 glycan characterisation.  
Further experiments would be required to repeat the glycosylation analysis with a larger 
amount of nTci-CF-1 and each recombinant version, testing various incubation times and 
conditions to investigate whether complete glycan removal is achievable. The results 
following O-glycosidase treatment were also unclear due to dilution of the proteins. 
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However neither protein showed predicted O-glycosylation sites in their amino acid 
sequences. These results agree with the study of Ov-CF-1 from O. viverrini, in which only 
a conserved N-linked glycosylation site was identified (Pinlaor et al. 2009). However, O-
glycans are a common occurrence in helminths, as shown by Khoo et al. (1991). In this 
study, it was shown that O-glycans were major carbohydrate constituents of the Toxocara 
canis and Toxocara cati ES mixture. It was also reported that N-linked glycans were more 
commonly found on small molecular weight proteins, whereas O-glycosylation was more 
common in high molecular weight antigens (Khoo et al. 1991). Another study involved a 
number of helminth parasites, among which were T. canis and Nippostrongylus 
brasiliensis, which showed that a type of truncated O-glycosylation (GalNAc-O-Ser/Thr, 
termed Tn antigen) was commonly expressed in the helminth species examined 
(Casaravilla et al. 2003). These reports suggest that other T. circumcincta antigens are 
likely to present types of O-glycosylation and that they might play an important role in the 
immune response to the parasite.  
Glycans have been shown to influence the immune response to antigens, either by masking 
epitopes or having higher immunogenicity than the protein backbone. These characteristics 
can mislead the antibody response and facilitate parasite escape from the immune system 
[reviewed by Harn et al. (2009) and Thomas and Harn (2004)]. For example, in a study 
carried out by Eberl et al. (2001) it was suggested that the antibody responses to 
Schistosoma mansoni larval glycans might be interpreted as a smoke screen to divert the 
host immune system [chimpanzees, Pan troglodytes (Eberl et al. 2001)]. The same 
mechanism may have played a role in the differences of antibody reactivity observed in 
this work to recombinant and nTci-CF-1. In the case of PiTci-CF-1, hyper-glycosylation 
may mask immunogenic protein epitopes and impair the antibody binding to amino acid 
structures. It was demonstrated here and Chapter 2 of this work that serum, ASC probes 
and gastric lymph antibodies were able to bind carbohydrate epitopes, as shown by the loss 
of antibody binding following periodate treatment of the T. circumcincta Tci-CF-1 
versions considered. In the case of PiTci-CF-1, glycan-specific antibodies found in the 
lymph of T. circumcincta previously infected sheep may not have shown optimal 
recognition of the glycan structures on PiTci-CF-1 if these had a higher mass or very 
complex shape that hindered binding to the immunogenic glycans present on nTci-CF-1. 
Detailed glycan analysis of all three Tci-CF-1 versions is currently being carried out by 
Prof. Cornelis Hokke at the University of Leiden and results are expected to shed more 
light on any differences in the glycan structures of Tci-CF-1 versions.  
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The results of this Chapter have shown that denaturing conditions (as occur in SDS-
PAGE/Western blot) allowed gastric lymph antibody to bind to each recombinant Tci-CF-
1 version. This was in contrast with previous results from ELISA experiments (both in this 
Chapter and Chapter 2), where no antibody binding was shown to take place against PiTci-
CF-1 or CeTci-CF-1. Further work showed that enzyme activity, as a measure of correct 
protein folding, was detected following activation with an exogenous enzyme for both 
recombinant Tci-CF-1 versions. The glycosylation of Tci-CF-1 versions was confirmed 
and investigated, showing a few differences between L4 ES-purified Tci-CF-1 and PiTci-
CF-1/CeTci-CF-1, and also between the two recombinant versions; this may partially 
explain the differences in ELISA reactivity. This work has shown that C. elegans is a 
viable method to express T. circumcincta enzyme vaccine candidates which retain correct 
conformation and enzyme activity. In terms of immunological performance of a vaccine 
candidate, the ELISA reactivity should be considered more biologically relevant than 
Western blotting, as it is the folded version of the protein that will be targeted by B cells 
for the production of antibodies and not the denatured form. A possible alternative 
approach in the case of Tci-CF-1 may be to generate a recombinant version of this protein 
and denature it using the same conditions applied to Western blotting, before using it as 
denatured immunising agent. This may allow greater access of epitopes on the denatured 
form that are shared with the native version, and may therefore generate a more 
appropriate antibody response. Taken together these results imply that the ideal Tci-CF-1 
protein to use as vaccine antigen has yet to be reached, and further work is required to 
identify the best version. 
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Chapter 5 – Characterisation of Enzyme Activity 
and Stimulatory Properties on Ovine Cells of 
Recombinant Tci-MIF-1 from Teladorsagia 
circumcincta  
  
5.1 Introduction 
A monocyte Migration Inhibitory Factor (MIF) was one of the first cytokines identified 
during studies on delayed hypersensitivity reactions in guinea pigs sensitised with 
Mycobacteria purified protein derivative [PPD; (Bloom and Bennett 1966, David 1966)]. 
In these studies, in vitro experiments showed that peritoneal exudate cells collected from 
guinea pigs (GP-PECs) that exhibited delayed hypersensitivity to specific Mycobacteria 
antigens were inhibited from migration through capillaries. A cell migration inhibitory 
factor which could not be dialysed and was hypothesised to be a protein, was present in the 
cell supernatant of lymphocytes isolated from GP-PECs and inhibited the migration of 
guinea pig peritoneal macrophages (Bloom and Bennett 1966, David 1966). The ability of 
MIF proteins to act as immune regulators was later confirmed; human MIF, secreted by 
peripheral lymphocytes, was demonstrated to possess the same migration inhibitory 
activity on guinea pig peritoneal exudate cells (Thor et al. 1968). Subsequently, cDNAs 
encoding human and mouse MIF were cloned and the expressed recombinant proteins 
characterised (Bernhagen et al. 1994, Weiser et al. 1989). Recombinant human MIF 
showed inhibition of the chemotactic migration of human peripheral blood monocytes 
stimulated by a gradient of monocyte chemotactic protein 1 (MCP-1), and was also able to 
inhibit the random migration of similarly isolated monocytes in vitro (Hermanowski-
Vosatka et al. 1999). Since then, a number of MIF homologues have been identified in 
numerous species, including cattle, sheep, fish, nematode parasites and arachnids (Galat et 
al. 1993, Jaworski et al. 2001, Lopes et al. 2011, Sato et al. 2003, Vermeire et al. 2008); 
such widespread conservation suggests important biological functions among living 
organisms [reviewed by Calandra and Roger (2003)].  
As well as the immunoregulatory functions described above, one striking characteristic of 
MIF that sets it apart from other cytokines is its enzymatic activity. The first report of the 
tautomerase  activity of MIF was provided by (Rosengren et al. 1996), in which MIF 
purified from bovine eye lenses was able to catalyze the tautomerization of D-dopachrome 
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into 5,6-dihydroxyindole-2 carboxylic acid (DHICA). Another native MIF enriched from 
T. circumcincta L3 somatic extract was shown to possess the same type of enzyme activity 
(Nisbet et al. 2010b). Further studies on bovine MIF isolated from the eye lens showed that 
this protein also possessed oxidoreductase activity and was able to catalyse the keto-enol 
isomerization of p-hydroxyphenylpyruvate (HPP) and of phenylpyruvate (Rosengren et al. 
1997). Moreover, studies on recombinant mutant versions of human MIF showed that a 
specific disulfide Cys57-Ala-Leu-Cys60 motif (CALC) of the MIF amino acid sequence was 
responsible for thiol-protein oxidoreductase activity. When either cysteine residue was 
exchanged for serine, this enzyme activity was significantly lower compared to the wild 
type recombinant MIF (Kleemann et al. 1998). In the same study, the CALC motif was 
also shown to influence immunological functions: in a Leishmania-killing assay, mouse 
peritoneal macrophages showed significantly lower ability to kill parasitized cells when 
co-incubated with the mutant MIFs, compared to wild type [Kleemann et al. (1998) and 
reviewed by Thiele and Bernhagen (2005)]. 
In the free-living nematode C. elegans, four MIF genes have been identified; of these, Ce-
MIF-2 and -3 transcripts were shown to be up-regulated in the dauer stage (Marson et al. 
2001). Other evidence supports the hypothesis that in nematodes as well as mammals, MIF 
could be a multifunctional protein, with possible roles in response to environmental 
stressors and embryonic development (Marson et al. 2001, Pastrana et al., 1998, Zang et 
al., 2001). Indeed a previous study on T. circumcincta MIF has shown that the strongest 
expression of this gene was found in cDNA from L3 larval stages, suggesting that its 
functions lie within the metabolism of this pre-parasitic stage (Nisbet et al. 2010b). 
In mammals, MIF is a pro-inflammatory cytokine expressed by a variety of cells of the 
immune and endocrine systems, and also by epithelial cells in direct contact with the 
“outside world”, suggesting a role as a regulator of host responses to infection and stress 
[reviewed by Calandra and Roger (2003)]. For example, MIF was produced by a mouse 
anterior pituitary cell line following stimulation with E. coli LPS; furthermore, MIF 
secreted by mouse hypophysis in vivo was found to contribute to circulating MIF levels in 
the post-acute phases of endotoxaemia (Bernhagen et al. 1993). In other experiments, 
injections of recombinant murine MIF increased markedly the lethality of LPS-induced 
endotoxic shock in BALB/c mice and anti-recombinant MIF serum protected them fully 
from LPS challenge; this suggests that MIF proteins can interfere with and enhance the 
pro-inflammatory response observed following LPS challenge (Bernhagen et al. 1993, 
Calandra et al. 1995, Roger et al. 2001). Another study in mice showed that MIF could be 
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produced not only by activated T cells, but also by macrophages treated with LPS, TNFα 
and IFNγ; furthermore, MIF-activated mouse macrophages secreted TNFα in what 
appeared to be a pro-inflammatory loop (Calandra et al. 1994). MIF was also shown to 
counteract the protective effect of glucocorticoids during LPS challenge; in a model of 
endotoxic shock, mice that received recombinant murine MIF in addition to LPS and 
dexamethasone showed significantly lower survival rates (35 %) than the control mice 
which received LPS and dexamethasone only [80 %; p < 0.005 (Calandra et al. 1995)]. 
The addition of dexamethasone and neutralising anti-MIF IgG to human monocytes that 
had been stimulated in vitro with LPS inhibited the production of TNFα by 32.7 %, 
compared to only 9.4 % of cells stimulated with LPS in the presence of dexamethasone and 
control IgG; this suggests that during an inflammatory response MIF is able to override the 
anti-inflammatory effect of glucocorticoids (Calandra et al. 1995). Finally, it was 
demonstrated using macrophages from MIF
-/-
 mice that MIF is required for the 
maintenance of activation-induced p53 induction and macrophage apoptosis and that, when 
MIF is lost, cell survival and function are compromised (Mitchell et al. 2002). 
In recent years a novel subset of macrophages belonging to the Th2 arm of the immune 
response has been identified. These cells were named “alternatively” activated 
macrophages (AAMΦ), to differentiate them from other macrophages widely known as 
classically activated macrophages [CAMΦ (Goerdt and Orfanos 1999)]. CAMΦs are 
generated in vivo in pro-inflammatory environments and in vitro following stimulation 
with LPS or IFN Upon activation, CAMΦs are able to express, amongst other cytokines 
and enzymes, TNF, inducible Nitric Oxide Synthase (iNOS) and IL-12 (Coico et al. 
2003, Goerdt and Orfanos 1999). Data gathered mostly from studies carried out in mice 
models showed that on the contrary, the novel macrophage phenotype, AAMΦ, occurs in 
strongly Th2-biased environments where IL-4 and IL-13 are present and are characterised 
by the production of IL-10, TGFβ, upregulated Mannose Receptor (CD206) and MHC II, 
markedly decreased TNFα and release of Nitric Oxide (NO) in favour of arginase-type 
enzymes [summarised in Figure 5.1; reviewed by Doyle et al. (1994), Kreider et al. (2007), 
Maizels and Yazdanbakhsh (2003), Noel et al. (2004), Stein et al. (1992)]. A defining 
characteristic of AAMΦ is the ability to inhibit T cell proliferation, in a contact-dependent 
manner (Loke et al. 2000). Most studies concur on the varied regulatory activity of 
AAMΦs on the immune response to infections, and on the inhibition of inflammatory 
reactions that can ultimately lead to tissue damage and pathology [reviewed by Jenkins and 
Allen (2010), Noel et al. (2004), Reyes and Terrazas (2007)].  
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Other genes have been found to be upregulated during alternative activation of mouse 
macrophages during parasitic infections (such as Trichinella spiralis and Brugia malayi), 
including Resistin-like molecules (RELM), members of the chitinase family (acidic 
mammalian chitinase, AMCase), a lectin (Ym1) and arginase 1 (Arg1) (Chang et al. 2001, 
Loke et al. 2002, Nair et al. 2005, Raes et al. 2002). Interestingly, increased Arginase 1 
activity inhibits the classical activation phenotype by competing with iNOS for the 
substrate L-arginine, and also helps inhibit T cell responses by depleting the environment 
of available arginine (Rutschman et al. 2001). In ruminants, it has been shown that adult 
Fasciola hepatica Excretory/Secretory (ES) products can elicit an alternatively activated 
phenotype in sheep and mouse macrophages in vitro (Donnelly et al. 2005, Flynn et al. 
2007), and there is evidence that a chitinase-like molecule is upregulated in sheep 
abomasal tissue with T. circumcincta infections, suggesting that the presence of T. 
circumcincta may also induce AAMΦ in vivo (Knight et al. 2007).  
Recently, a further role in the complex activity of MIF has been shown: B. malayi 
recombinant MIF was associated with the induction of AAMΦ in mouse models [(Falcone 
et al. 2001, Loke et al. 2002, Prieto-Lafuente et al. 2009); mechanism summarised in 
Figure 5.1]. It was also suggested that MIF produced by parasites and released during 
infection may be capable of activating an anti-inflammatory pathway through the 
recruitment of AAMΦ (Maizels and Yazdanbakhsh 2003). As numerous MIF orthologues 
have been identified in other nematodes (Vermeire et al. 2008), speculations were made 
about the anti-inflammatory role of parasite MIF when released in the host as a promoter 
of parasite survival in a hostile environment [reviewed by Kreider et al. (2007)]. 
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Figure 5.1 Diagram summarising the mechanisms of macrophage alternative activation and 
potential role of parasite-derived MIF in a mouse model. 
Adapted from Vermeire et al. (2008). The cytokines IL-4, IL-13 and IL-21 synergise to induce 
alternative activation in macrophages, which is here shown as up-regulation of surface 
markers such as MHC-II and CD206 (Mannose Receptor). Other genes such as Ym-1, Arg-1 
and FIZZ-1 are also up-regulated following exposure to IL-4 and IL-13. Alternatively 
activated macrophages initiate a Th2-biased immune response, by secreting TGF-β and IL-
10. This can result in inhibition of T cell proliferation and promotion of eosinophil 
recruitment. It has been shown that parasite MIF could potentiate the mechanisms 
described when present at the same time as IL-4.  
 
A MIF-like molecule (Tci-MIF-1) has been identified in T. circumcincta L3 extracts and it 
was shown that MIF mRNA was present in eggs, L3, L4 to a lower level and adult stages 
(Nisbet et al. 2010b). The protein content was highest in L3 extract and staining of the 
worms showed localization of the protein to the guts of L3, L4 and adult worms (Nisbet et 
al. 2010b). Although mammalian MIF acts as a pro-inflammatory cytokine, it has been 
demonstrated that MIFs derived from parasitic nematodes can induce alternative activation 
of macrophages, effectively acting as anti-inflammatory cytokines (Prieto-Lafuente et al. 
2009). As Tci-MIF-1 might have an anti-inflammatory, immunosuppressing role 
facilitating parasite survival during T. circumcincta infection in sheep, it was decided to 
generate a recombinant version of Tci-MIF-1 and test its validity as vaccine candidate. 
Inhibition of monocyte migration is a function common to other recombinant or native 
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parasite MIFs (Pastrana et al. 1998, Tan et al. 2001). A recombinant version was expressed 
in E. coli and was shown to possess the dopachrome tautomerase enzyme activity 
associated with native MIF; however the results from monocyte migration inhibition 
assays on sheep cells did not convincingly show an inhibitory effect on monocyte 
migration (Nisbet et al. 2010b). The E. coli-expressed Tci-MIF-1 version was also 
included in immunisation trials where sheep received three immunisations with a cocktail 
of 8 T. circumcincta recombinant antigens, then were subsequently challenged with T. 
circumcincta L3 (2000 L3, three times a week for 4 weeks). The vaccine cocktail proved to 
be successful in reducing the faecal egg output by 59-70 % and worm burdens by 56-75 % 
in the immunised animals compared to the controls. The results also showed that E. coli-
expressed Tci-MIF-1 was one of the least immunogenic antigens used in the vaccine 
(Nisbet et al. 2013). Although a component of a protective vaccine cocktail, it is currently 
unclear what role the Tci-MIF-1 generated in E. coli had on the overall levels of 
protection. In addition, although the enzymatic activity of recombinant Tci-MIF-1 was 
maintained, its inability to inhibit the migration of monocytes in vitro suggests that the 
recombinant version might have differed from the native T. circumcincta MIF. This may 
have occurred because of impaired post-translational modifications; therefore, in the work 
reported in Chapter 3 of this thesis, the nematode C. elegans was used to generate an 
alternative recombinant Tci-MIF-1 version in order to determine whether this expression 
system may be able to deliver a version of Tci-MIF-1 which maintains all its putative 
functions.  
The overall aims of this, current, chapter were: 
i) To express and purify recombinant Tci-MIF-1 using E. coli    
ii) To characterise the enzymatic dopachrome tautomerase activity of recombinant CeTci-
MIF-1 (generated in Chapter 3 of this thesis) and compare it with the enzyme activity of 
Tci-MIF-1 expressed in E. coli. 
iii) To investigate the monocyte migration inhibitory factor activity of CeTci-MIF-1 and 
compare it with activity of Tci-MIF-1 expressed in E. coli. 
iv) To use both recombinant Tci-MIF-1 versions to stimulate in vitro ovine macrophages 
and determine what type of activation, if any, this stimulation elicits.   
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5.2 Materials and Methods 
5.2.1 Purification of recombinant Tci-MIF-1 in E. coli (EcTci-MIF-1) 
A bacterial (E. coli BL21 codon (+) clone expressing Tci-MIF-1 was previously 
established and stored in 60 % glycerol at -80°C by Dr Alasdair Nisbet at MRI (Nisbet et 
al. 2010b). A scraping of the glycerol stock was incubated overnight in 10ml LB broth 
(Appendix D) at 37°C with shaking at 220 rpm. The process of induction of protein 
expression and purification of the bacterial recombinant Tci-MIF-1 had been previously 
described by (Nisbet et al. 2010b, 2013) and in Chapter 2, Section 2.2.4 of this thesis. The 
technique was reproduced for the experiments here described without modifications; the 
recipes for the buffers and solutions used are detailed in Appendix D.  
5.2.2 Generation of recombinant Tci-MIF-1 in C. elegans  
Recombinant Tci-MIF-1 was expressed using the free-living nematode C. elegans and 
purified as described in Chapter 3 of this thesis. 
5.2.3 Dopachrome tautomerase activity assays 
The procedure used in this assay was adapted from Nisbet et al. (2010b) and Pennock et al. 
(1998). Briefly, 720 μl of reaction buffer (Appendix D) were added to a 1 ml polystyrene 
disposable cuvette, followed by 4.8 μl of 0.1 M L-DOPA methyl ester and 3.2 μl of 0.2 M 
sodium m-periodate (both in Appendix D) to generate L-dopachrome methyl ester. The 
solution was mixed well by pipetting until the colour reached a uniform bright orange. Five 
microliters of each recombinant Tci-MIF-1 (diluted in PBS from stock solutions) or PBS 
as blank were added (approx. 250 ng protein/assay) and the loss of absorbance at 474 nm 
(A474) was monitored for 2 min, recording reads at 15 sec intervals. Recombinant MIFs 
from the filarial parasite Brugia malayi [‘Bm-MIF-1’ (enzymically active) and ‘Bm-MIF-
1G’ (enzymatically inactive; Zang et al. 2002)], provided by Prof. Rick Maizels 
(University of Edinburgh), were used as positive and negative controls. Once the 
absorbance data over 2 min were collected, a plot of time vs absorbance was generated and 
the slope of the linear phase was the rate of the reactions. Enzyme activity was expressed 
as loss of A474/min/µg of enzyme. All assays were repeated in triplicate and repeated three 
times. 
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5.2.4 Stripping of LPS from purified recombinant Tci-MIF-1  
LPS contamination was removed from recombinant proteins using the following protocol 
[adapted from Aida and Pabst (1990)]. Triton X-114 (Sigma-Aldrich, Gillingham, UK) 
was added to each sample to a final concentration of 1 %; this was left at 4°C rotating for 
at least 30 min or overnight to allow Triton X-114 to bind LPS. Samples mixed with Triton 
X-114 were incubated at 37°C for 10 min (samples became cloudy). These were 
centrifuged at 13 700 x g for 15 min at 30°C and the aqueous phase collected (temperatures 
above 23°C facilitated separation of the aqueous phase containing the LPS-free proteins). 
The aqueous phase was heated at 37°C for 5 min and centrifuged again at 13 700 x g for 15 
min. The aqueous phase was again collected and ~20 µl were left at the bottom of each 
tube to avoid Triton X-114 contamination of the protein samples. This whole process was 
repeated 3 times for each protein sample, to ensure maximum LPS removal. Recombinant 
protein integrity was checked by polyacrylamide gel electrophoresis (Appendix B) and 
concentration was estimated using a BCA assay (Appendix B). 
5.2.4.1 LPS quantification 
LPS was quantified in protein samples used for cell stimulations using the Limulus 
amebocyte lysate (LAL) assay (Endpoint Chromogenic LAL Assay, Lonza, Basel, 
Switzerland) following the manufacturer’s instructions. As the standard curve of the assay 
had a tight range (0.1-1 EU/ml), all samples were tested undiluted and diluted 1:10 in LPS-
free dH2O. All experiments were carried out using LPS-free reagents, glassware and 
polystyrene microplates. The wells were read using a microplate reader (Tecan, Sunrise) 
with filters set at 405 nm. 
5.2.5 Differentiation of ovine macrophages from CD14+ cells and 
bone marrow stem cells 
5.2.5.1 Isolation of ovine CD14+ cells from PBMC 
Blood circulating monocytes in sheep are believed to amount to between 0-6 % of PBMC 
(Aiello 1998). Blood was collected by jugular venepuncture in EDTA (Vacutainer, BD 
Biosciences, Oxford, UK) or Alsever’s solution (1:1 ratio, Appendix D) and PBMC 
isolated as previously described (Goddeeris and Morrison 1988). Briefly, blood was 
diluted 50 % with Alserver’s solution or sterile PBS and carefully layered over 20 ml of 
Ficoll-Paque Plus (GE Healthcare, 2:3 ratio of Ficoll:blood) in 50 ml Falcon tubes. PBMC 
were isolated as described by Goddeeris and Morrison (1988), including cell washes.  
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After the last wash, PBMC were re-suspended in SCM (Appendix D) and counted in a 
haemocytometer by Trypan Blue exclusion. In order to carry out a positive selection on 
CD14
+
 cells of PBMC, anti-human CD14 MicroBeads (Miltenyi Biotech, Bisley, Surrey, 
UK) were used following the manufacturer’s instructions. The volumes of microbeads and 
buffers used were scaled up or down depending on the PBMC numbers isolated.  The 
collected CD14
+
 cells (labelled fraction) were washed once in MACS Buffer and re-
suspended in SCM for counting as described above. The cells were then cultured in vitro as 
described below. Purity was assessed by morphology examination of cytospin slides of a 
100 µl aliquot of cells (Section 5.2.7.1). 
5.2.5.2 In vitro culture of ovine CD14+ cells 
CD14
+
 ovine cells obtained as described in Section 5.2.5.1 were cultured at a concentration 
of 1 x 10
6
 in flat bottomed 48-well or flat bottomed 96-well plates. The cells did not 
receive stimulation for 7 days and once the cells had adhered to the bottom of wells, half of 
the volume of the SCM was changed twice during this period, according to Flynn and 
Mulcahy (2008). This was to allow the differentiation of blood monocytes into mature 
macrophages (Mo-MΦ). Once cells appeared of the correct morphology, supernatant was 
harvested and stored at -20°C until use, and cell lysates obtained by re-suspending the 
adherent cells in 100 μl of 1 % Triton X-100 in PBS, shaken for 15 min at RT and stored at 
-20°C until use. 
5.2.5.3 Isolation of ovine bone marrow stem cells 
Bone marrow was collected from 7 sheep at post mortem. These animals were of a variety 
of ages (range 6 months to > 5 years old); the sheep were Scottish Blackface or crosses 
thereof. The animals had been part of control groups in experiments carried out by other 
research groups at MRI, with the exception of one animal (the oldest) which had been 
admitted from a commercial farm under suspicion of ovine pulmonary adenocarcinoma 
(OPA). Prior to use, all equipment was either autoclaved or sprayed with 70 % ethanol, or 
both, to sterilise it. The bone marrow-donor sheep were stunned and exsanguinated by a 
qualified person; during exsanguination, at least 500 ml of blood from each animal was 
collected into a sterile glass beaker for serum separation as previously described. Directly 
following exsanguination, the sterna were removed from each carcass and the excess 
adipose and muscular tissues removed with a sterile scalpel, until the periosteum was 
visible on the majority of the parts, which were also sprayed with 70 % ethanol. A clean, 
sterile handsaw was used to cut the sterna longitudinally along the median line and each 
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side was placed into the mouth of a cleaned vice lined with clean absorbent paper. Pressure 
was applied on the sternebrae until the bone marrow was squeezed out. The bone marrow 
was collected immediately using a sterile scalpel blade into a sterile universal containing 
ice cold Sheep Wash Medium (SWM, Appendix D), mixed gently and put on ice. The 
process was repeated with the other half of the sternum. 
Under a tissue culture hood, the bone marrow cells were harvested from below the layer of 
fat that floated above the SWM using a sterile syringe and a 19G needle. The bone marrow 
cells were filtered through a double layer of sterile lens tissue paper into a glass beaker. 
The filtrate was centrifuged 550 x g for 10 min. The supernatant was discarded and the cell 
pellets resuspended and pooled in 50 ml of SWM. Subsequently, 25-30 ml of cell 
suspension was gently laid over 20 ml of Ficoll-Paque Plus (GE Healthcare, ratio 
Ficoll:cell = 2:3). The Ficoll-cell suspension was then centrifuged at 900 x g for 30 min 
without braking. The cells at the interface between the Ficoll and the SWM were collected 
and washed with SWM, then centrifuged at 550 x g for 10 min. The cells were resuspended 
in 1 ml SWM, then 1 ml of pre-warmed red blood cell Lysis Buffer (Appendix D) was 
added and the suspension was incubated at 37°C for 45 sec-1 min, after which fresh SWM 
was added and the cells centrifuged at 550 x g for 10 min. One last wash in SWM was 
carried out after which the cell pellet was resuspended in Bone Marrow Culture Medium 
(BM-CM, Appendix D) and a viable cell count (Trypan Blue exclusion) was carried out. 
The cells were then cultured in vitro as described below. 
5.2.5.4 In vitro culture of ovine bone marrow stem cells 
Bone marrow cells were re-suspended in BM-CM (Appendix D) at a concentration of 2 x 
10
5
 – 1 x 106 cells/ml and placed in a sterile non adherent T75 tissue culture flask 
(Sarstedt, Leicester, UK), with no other stimulation. All cells were cultured in the presence 
of 20 % FBS and 20 % autologous sheep serum (both heat inactivated) to allow 
macrophage maturation in the presence of Macrophage colony-stimulating factor (M-
CSF)-like factors naturally present in serum (Francey et al. 1992, Francey et al. 1992). 
Bone marrow stem cells from one animal were cultured under different conditions to 
investigate the optimal incubation protocol to facilitate macrophage differentiation from 
the pool of monocyte and macrophage precursor cells. The bone marrow stem cells were 
cultured at the same concentration range (2 x 10
5
 – 1 x 106 cells/ml) in either a Teflon-
coated cell culture bag, a non-adherent polystyrene tissue culture flask, a polystyrene 6- 
well tissue culture plate or a polystyrene 24- well tissue culture plate, in order to 
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investigate the optimal differentiation rates and recovery of mature macrophages. In all 
cases, cells were left to differentiate for 15-18 days, by which point the majority of cells 
were adherent, with morphology consistent with macrophage type as assessed by staining 
of cytospin slides (described in Section 5.2.7). The adherent cells were detached using 
TrypLE™ Express 1X (Gibco, Life Technologies, Paisley, UK), collected in a 50 ml 
Falcon tube and centrifuged at 550 x g for 10 min, re-suspended in BM-CM, counted and 
characterised as described below prior to stimulation (BM-MΦ). 
5.2.6 Collection of ovine alveolar macrophages 
This procedure was carried out as described by McNeilly et al. (2008) without 
modifications. An average of 500 ml of SWM had been used for each set of lungs. The cell 
rich suspension was washed three times in SWM and the abundant, frothy surfactant 
removed by filtering the solution through lens tissue paper. Cells were finally re-suspended 
in SCM and counted. These cells (A-MΦ) were used in functional assays immediately. 
5.2.7 Morphological and functional characterisation of ovine 
monocytes/macrophages 
5.2.7.1 Fluorescence-Activated Cell Sorting (FACS) analysis 
Sheep PBMC were isolated from 9 animals and flow cytometry carried out in order to 
determine the percentage of CD14
+
 cells within the PBMC fraction. Aliquots of 1-2 x 10
5
 
cells in 100-150 μl were resuspended in 75 μl of FACS medium (Appendix D) in a 96-
wells U-bottomed culture plate. To the cells, 25 μl of a mouse anti-human CD14:Alexa 
647 antibody (dilution 1:1000; clone TUK4, IgG2a; MCA1568A647, Serotec) were added 
and incubated at 4°C for 30 min. Following incubation, the cells were washed 3 times in 
FACS medium (by centrifugation of the microplate at 1500 x g for 20 sec) and 
resuspended in 200 µl of 1X PBS. After one further wash, the cells were fixated in 200 µl 
of cell fixating medium (Appendix D) until analysis in a flow cytometer. The machine 
used was a Cyan™ ADP Flow Cytometer (Beckman Coulter Inc., Fullerton, CA, USA), 
using the manufacturer’s acquisition software (Summit v4.3). 
5.2.7.2 Cytospin of ovine cells 
Ovine monocytes or macrophages were re-suspended at 1-2 x 10
5
 in 100-150 μl standard 
culture medium or sheep wash medium (SCM and SWM, Appendix D) and smeared onto 
glass slides by centrifugation at 300 x g for 3 min using a Cytospin cytocentrifuge 
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(Shandon Thermo Scientific). The slides were left to dry at RT for 10 min before 
proceeding with staining procedures.   
5.2.7.3 Hematoxylin-eosin stain 
The air-dried slides were stained to visualize cell morphology using a hematoxylin-eosin 
based stain, Reastain Quick-Diff Kit (Reagena, Toivala, Finland) following the 
manufacturer’s instructions. The slides were mounted with a glass coverslip using Consul-
Mount mountant for glass cover slides (Shandon Thermo Scientific). Slides were prepared 
from at least 2 sheep and cells counted for the purposes of cell identification and 
descriptive statistics analysis. Cells from at least 5 fields in each slide were counted and 
differentiated on the basis of their morphology.  
5.2.7.4 Non-specific esterase stain 
Air-dried slides were subjected to the α-Naphthyl acetate esterase procedure (Kit 91A, 
Sigma-Aldrich, UK) as described by the manufacturer’s instructions for the staining of 
non-specific esterase enzymes in monocytes. After the staining procedure was completed, 
slides were mounted with an aqueous mounting medium (Crystal Mount™ Aqueous 
Mounting Medium, Sigma-Aldrich). Slides were prepared from at least 2 sheep and cells 
counted for the purposes of cell identification and descriptive statistics analysis. Cells from 
at least 5 fields in each slide were counted and differentiated on the basis of the 
positive/negative non-specific esterase staining. 
5.2.7.5 Immunocytochemistry (HCC) for CD68 receptor 
The immunocytochemistry staining for CD68 receptor was carried out using an 
EnVision™ Kit (Dako, Ely, UK), following the manufacturer’s instructions without 
modifications regarding dilutions and volumes of reagents used. Following an incubation 
in 3 % hydrogen peroxide (H2O2) in methanol for 20 min to remove endogenous 
peroxidase activity, the slides were washed with PBS. The reagents used subsequently 
were: for blocking, 100 μl of 25 % normal goat serum in PBS; primary antibody, a 
monoclonal mouse anti-human CD68 (clone EBM11 IgG1 κ, Dako); antibody isotype 
control, a mouse IgG1κ (clone MOPC-21, Sigma-Aldrich, Gillingham, UK). The 
secondary antibody used was a peroxidase-labelled anti-mouse EnVision™ with reagent 
(Dako; provided with the kit); the chromagen solution was DAB chromagen in substrate 
buffer (Dako; provided with the kit). At the end, slides were stained with haematoxylin in 
 163 
 
an automatic slide stainer (Varistain 24-4, Shandon Thermo Scientific, Runcorn, UK) and 
mounted with Crystal Mount™ Aqueous Mounting Medium (Sigma-Aldrich). Slides were 
prepared from at least 2 sheep and cells counted for the purposes of cell identification and 
descriptive statistics analysis. Cells from at least 5 fields in each slide were counted and 
differentiated on the basis of their staining of CD68. 
5.2.7.6 Phagocytosis assay 
A cell phagocytosis assay using fluorescent FITC-labelled E. coli as target was adapted 
from Werners et al. (2004). Briefly, 1 x 10
5
 ovine macrophages were placed in each well 
of a chamber slide and incubated at 37°C, 5 % CO2 for 2 h. FITC-labelled E. coli cells 
(stock ~2 x 10
7
/ml) were added at a range of macrophage:bacteria ratios (e.g. 10:1, 5:1, 
1:1, no bacteria) and incubated at 37°C, 5 % CO2 for 2 h. After 2 h the medium was 
removed and 1 ml of quencher solution (250 mg/ml trypan blue in citrate buffer, pH 4.4) 
added. The wells of the chamber slide were washed 1-2 times with PBS and fixed with 4 % 
paraformaldehyde (PFA) for 1 h at RT. After another 2 washes in PBS, the cell nuclei were 
stained with DAPI for 10-15 min, then the wells of the chamber slide were washed in PBS 
and the well partitions removed. The slide was mounted with Crystal Mount™ Aqueous 
Mounting Medium (Sigma-Aldrich) and clear nail varnish used to seal the edges. If not 
immediately visualized, the slides were stored at 4°C for a maximum of 24 h. Fluorescent 
cell nuclei and FITC-labelled E. coli were visualized using an Axiovert 200M inverted 
fluorescence microscope (Carl Zeiss Ltd., Welwyn Garden City, UK).  
5.2.8 Monocyte migration assays 
Ovine CD14
+
 cells isolated as described in Section 5.2.4 were used in in vitro fluorimetric 
cell migration tests. The kit used was QCM Chemotaxis Cell Migration Assay, 96-well (5 
μm; Millipore, Billerica, MA, USA), following the manufacturer’s instructions with 
adaptations. The adaptations were as follows: the cells were counted and resuspended in 
monocyte migration assay quencher (MoMQ, Appendix D) to 1 x 10
6
/ml. Two 
recombinant Tci-MIF-1 versions (EcTci-MIF-1 and CeTci-MIF-1) were added to a final 
concentration of 1 μg/ml. Two negative controls of C. elegans N2 extract and an extract of 
uninduced E. coli cells (BL21 (+) carrying the Tci-MIF-1 plasmid but where protein 
expression was not induced) were used throughout at the same final concentration as 
recombinant Tci-MIF-1. Cells (1 x 10
5
 in 100 μl with or without stimulating molecules) 
were always placed in the top assembly compartments (inside the 5 μm-filter wells; see 
Figure 5.2). Monocyte migration assay medium (150 μl MoMM, Appendix D), with or 
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without stimulating molecules, was placed in the bottom compartments (migration feeder 
tray). Once the tray/filter assembly was complete with cells and stimulating molecules, it 
was placed at 37°C, 5 % CO2 for 3 h to allow the cells to migrate through the 5 μm filter 
into the bottom compartment. After 3 h, the cells that migrated were harvested without 
modifications as described in the manufacturer’s instructions for the QCM Chemotaxis 
Cell Migration Assay kit. Fluorescence emitted by the cells that had migrated through the 
filter was measured with a Cytofluor 4000 microplate reader (PerSeptive Biosystems, now 
Applied Biosystems, Foster City, CA, USA) using a 480 nm excitation/520 nm emission 
filter set. The fluorescence data were used to calculate the percentage of migration in each 
well, using the fluorescence emitted by wells containing cells incubated with medium only 
as 100 %. Positive controls were 7.5 x 10
5
 cells lysed directly in the presence of CyQuant 
GR Dye in two wells of the black plate.  
 
Figure 5.2 Diagrams of the filter-tray assembly used in the monocyte migration assays. 
Panel A: adapted from the kit instructions manual (ECM512, Millipore). A: lid; B: 5 µm -filter 
wells; C: 96-well feeder tray (2 provided); D: base. Panel B: a cross-section showing the 
placement of cells and stimulating MIF molecules or controls on relation to each other and 
the 5 µm filter. 
 
5.2.9 Ovine macrophage in vitro stimulation protocols 
5.2.9.1 Stimulation protocol for Mo-MΦ 
Blood monocyte derived macrophages (Mo-MΦ) generated as previously described 
(Section 5.2.5.2) were used in stimulation assays as follows: 2 x 10
5
 cells/well were placed 
in each well of a flat bottomed 96-well plate. To the cells, the following molecules were 
added: LPS A (E. coli O55:B5 LPS, Sigma-Aldrich); LPS B (E. coli O111:B4 LPS, 
Sigma-Aldrich); LPS C (E. coli O111:B4 LPS, Invivogen, San Diego, CA, USA), all to a 
final concentration of 20, 10 and 5 µg/ml. Wells that received 20 µg/ml of each LPS were 
harvested at 24 and 48 h; wells that received 10 or 5 µg/ml were only harvested at 48 h. 
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LPS was titrated to be used as positive control for classical activation of macrophages, 
whereas ovine recombinant IL-4 was used as inducer of alternative activation phenotype. 
Ovine recombinant IL-4 (ov rIL-4, a gift from Dr Sean Wattegedera, MRI) was diluted in 
SCM from a stock solution of 15.4 µg/ml and was added to final concentrations of 1.54, 
0.308, 0.154 and 0.077 µg/ml; these wells were harvested at 48 h only. Treatments were 
administered to single wells only, due to constraints with cell numbers. 
5.2.9.2 Stimulation protocol for BM-MΦ 
Bone marrow-derived macrophages (BM-MΦ generated as previously described in Section 
5.2.5.4) were stimulated as follows: 10
5
 cells/well (for the first pilot experiment in which 
cells were tested with E. coli or Rhodobacter sphaeroides LPS (Invivogen), Figure 9.2, 
Appendix C) or 2 x 10
4
 cells/well (for every other subsequent experiment) were added to 
flat bottomed 96-well plates. Cells were stimulated with the following: LPS B (E. coli 
O111:B4 LPS, Sigma-Aldrich) and R. sphaeroides LPS (Invivogen) at a final 
concentration of 10 µg/ml each. Recombinant ovine IL-4 was used at a final concentration 
of 0.3 µg/ml. Escherichia coli-expressed Tci-MIF-1 (EcTci-MIF-1) and C. elegans-
expressed Tci-MIF-1 (CeTci-MIF-1) were both used at a final concentration of 10 µg/ml. 
All treatments were administered in duplicate wells and LPS contamination of recombinant 
proteins had not been evaluated at this stage. 
5.2.9.3 Stimulation protocol for A-MΦ 
Alveolar macrophages (A-MΦ) collected as described in Section 5.2.6 were stimulated as 
follows: 10
5
 cells/well were placed in flat bottomed 96-well plates. All treatments of E. 
coli LPS (O111:B4, Sigma-Aldrich), EcTci-MIF-1 and CeTci-MIF-1 were used at a final 
concentration of 5 µg/ml. Recombinant ovine IL-4 was used at a final concentration of 0.3 
µg/ml. All preparations had been de-contaminated from LPS as described in Section 
5.2.4.1. All treatments were administered in duplicate wells. 
5.2.10 Cytokine ELISA  
Cell supernatant from all ovine macrophage cultures were used in ELISA assays to 
measure the release of the cytokines IL-10 and TNFα. 
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5.2.10.1 Ovine IL-10 ELISA 
Secretion of IL-10 in the cell culture supernatant was investigated with a sandwich ELISA 
using the following adapted protocol (provided by Dr Tom McNeilly): high binding 
microplates were coated with 100 µl/well of a capture antibody (final concentration 4 
μg/ml of monoclonal mouse anti-bovine IL-10, MCA2110, AbD Serotec), diluted in 
carbonate coating buffer (Appendix D), then incubated at 4°C overnight. The following 
day the plates were washed 4 times in PBST (Appendix D), wells were blocked with 200 
µl/well of blocking buffer (3 % BSA in PBST) and after 1 h incubation at RT, plates were 
washed 4 times with PBST. A standard curve of recombinant ovine IL-10 was prepared by 
diluting a stock solution of recombinant ovine IL-10 (kindly provided by Sean 
Wattegedera, MRI) in Reagent Dilution Buffer (RDB, 1 % BSA in PBST) to obtain a 
concentration of 13.2 U/ml for the top standard. A 2-fold serial dilution in RDB was used 
to complete the standard curve (range 13.2-0.026 U/ml). Fifty microliters of either 
standards or cell culture supernatants was added to each well and incubated for 1 h at RT. 
Wells were washed 4 times in PBST and 50 µl of biotin-conjugated detection antibody 
(final concentration 1 μg/ml of monoclonal mouse anti-bovine IL-10, MCA2111B, 
AbDSerotec) were added to each well; the plate was then incubated for 1 h at RT. Plates 
were washed 4 times in PBST and 50 µl of Streptavidin polymer-HRP (Sigma-Aldrich, 
1:1000 dilution in RDB) were added to each well; plates were incubated at RT for 45 min, 
then washed 4 times in PBST. One hundred microliters of TMB substrate were added to 
each well (SureBlue™ TMB Microwell Peroxidase Substrate, KPL Inc., Gaithersburg, 
MA, USA) and incubated for 5-10 min. Reactions were stopped using 100 µl/well of TMB 
Stop Solution (KPL, Inc.) and plates were read using a Sunrise microplate reader (Tecan, 
Reading, UK) with a 450 nm filter. 
5.2.10.2 TNFα ELISA 
Investigation of the release of TNFα from ovine macrophage cultures was carried out using 
a commercially available kit (Bovine TNFα Vet Set, Kingfisher Biotech, St. Paul, MN, 
USA). The manufacturer’s instructions were followed to carry out the experiments. This 
kit uses the sandwich ELISA technique and provided microplates coated with an anti-
bovine TNFα antibody (cross-reactive with sheep TNFα), pre-blocked and ready to use. A 
bovine TNFα standard was provided to generate a standard curve, together with an anti-
bovine TNFα detection antibody (cross-reactive with sheep TNFα). Biotin-conjugated 
streptavidin (provided with the kit) and TMB substrate (SureBlue™ TMB Microwell 
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Peroxidase Substrate, KPL Inc.) were used to detect antibody binding. A Sunrise 
microplate reader (Tecan) was used with a 450 nm filter. 
5.2.11 Analysis of macrophage transcripts by quantitative RT-
PCR 
5.2.11.1 Extraction of total RNA from ovine macrophages 
The Qiagen RNeasy Plus Mini kit was used each time. Briefly, between 1-2 x 10
5
 cells 
were harvested from flat-bottomed 96-well plates following stimulation by adding 200μl of 
TrypLE™ Express (Invitrogen, Paisley, UK) in each well and incubating the cells at 37°C, 
5% CO2 for 10 min. The cells were detached by pipetting and transferred into sterile, 
RNAse-free Eppendorfs and pelleted by centrifuged at 300 x g for 5 min. The supernatant 
was discarded and the cell pellet either frozen at -80°C prior to processing, or processed 
immediately using an RNEasy Plus Mini kit (Qiagen) to extract total RNA according to the 
manufacturer’s instructions. As part of the kit protocol, samples were passed through a 
gDNA Eliminator column (Qiagen) to eliminate genomic DNA. The concentration of RNA 
was estimated using a NanoDrop 1000 spectrophotometer (Thermo Scientific) and stored 
at -80°C until use.  
5.2.11.2 Generation of cDNA from mRNA 
Complementary DNA (cDNA) was generated following two procedures, for logistical 
reasons of different kits available at the time of the cDNA generation. The first method 
used reagents supplied as Precision™ nanoScript Reverse Transcription kit by 
PrimerDesign Ltd. (Southampton, UK) and it was carried out following the manufacturer’s 
instructions (for details of each reaction refer to appendix A). The second method used to 
generate cDNA was carried out using reagents already present in the laboratory, following 
the method detailed by McNeilly et al. (2008); the reaction volumes and conditions are 
also detailed in Appendix A. Complementary DNA thus generated was stored at -20°C 
until use. 
5.2.11.3 Oligonucleotides 
Primers used in qRT-PCR reactions for ovine iNOS-2, Chit3-L1, Arg-1, YWHAZ were 
designed and optimized by PrimerDesign Ltd. (Gold Sponsorship Student Award). The 
primers were supplied as pre-mixed solutions of forward and reverse primers, at a working 
concentration of 6 pmol each. Primers for ovine TNF-α, IL-10, IL-8, IL-12p40 and GAPDH 
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were as described by McNeilly et al. (2008) and were supplied by Eurofins MWG Operon 
(Ebersberg, Germany) and diluted to a stock concentration of 100 pmol. The working 
concentration of all primers was 10 pmol. All primer sequences and the gene accession 
numbers are reported in Appendix A. 
5.2.11.4 Standard qPCR reactions 
For the iNOS-2, Chit3-L1, Arg-1, YWHAZ qRT-PCR assays, each standard reaction 
contained reagents provided by PrimerDesign Ltd. (see Appendix A for details of the 
reaction conditions). For all other assays (IL-10, IL-8, IL-12p40, TNFα, GAPDH), each 
standard reaction also contained PrimerDesign Ltd. reagents, however the cycling 
conditions were maintained as described by McNeilly et al. (2008) (see Appendix A for 
details). 
Normalisation of data (copy number/µl) was carried out using the following calculation: 
    
 eomean [     ]
 
 
And the following: 
    
 
 
 
Where: C was the normalisation coefficient; A was the geometric mean of the copy 
number/µl in each of the two housekeeping (HK) genes YWHAZ and GAPDH for each 
cDNA sample considered; B was the average value of the housekeeping genes geometric 
means across all cDNA samples; E was the normalised copy number/µl of each test gene 
and D was the copy number/µl in each cDNA sample for each of the test genes 
investigated. Values E were plotted and used for statistical analysis of differences in gene 
expression. 
5.2.11.5 GeNorm analysis 
Appropriate HK sheep genes were chosen from a panel of 12 provided in a geNorm kit by 
PrimerDesign Ltd. Reactions were prepared with cDNA derived from six BM-MΦ cell 
cultures stimulated with a series of molecules (E. coli O111:B4 LPS, R. sphaeroides LPS, 
EcTci-MIF-1, ov rIL-4, and unstimulated cells control; see section 5.2.10 for details) and 
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cDNA from 15 A-MΦ cultures that had been stimulated with the molecules detailed above 
for BM-MΦ, with the addition of CeTci-MIF-1. Ct values were collected for all cDNA 
samples across the candidate HK genes in the panel and analysed with the software qBase 
(Biogazelle, Belgium) to determine the most stable genes for this type of ovine cell culture.  
5.2.12 Statistical analysis 
Statistical analysis was carried out using GraphPad Prism version 5.01 and GenStat 12
th
 
Edition. Arithmetic means with standard errors and replicate number (n) are shown 
throughout this chapter. Data were checked for normal distribution by analysing the 
histogram of frequencies and residual plots. If data were not normally distributed, a Box-
Cox transformation (Box 1964, Peltier et al. 1998) was used to choose the appropriate 
transformation method; the details of each transformation are provided for the data sets in 
each figure throughout this chapter. For data normally distributed (with or without 
transformation), a one-way Analysis of Variance (ANOVA) test was used, followed by the 
Tukey post hoc test for pair wise comparison of means; when only one pair of means was 
compared, a two-tailed unpaired t-test was used. If data were not normally distributed and 
Box-Cox analysis failed to suggest an appropriate transformation method, the non-
parametric Mann-Whitney test and Kruskal-Wallis test were used (details are provided for 
the data sets in each figure). P values of < 0.05 were considered significant.   
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5.3 Results 
5.3.1 Purification of E. coli-expressed recombinant Tci-MIF-1 
Recombinant Tci-MIF-1 expression was induced in an E. coli BL21 (+) codon clone 
provided by Dr Alasdair Nisbet. The recombinant protein was purified from the cell pellets 
as a soluble fraction and the identity confirmed by MALDI-ToF. Figure 5.3 shows the 
pattern of elution of the protein from the bacterial cell lysate. The recombinant EcTci-MIF-
1 was purified using a Ni
2+
 IMAC system (as described in Section 5.2.1) and the protein 
was visualised in polyacrylamide gels using a Coomassie blue-based stain. 
 
Figure 5.3 SDS-PAGE analysis of the fractions eluted by Ni
2+
 IMAC from E. coli BL21 (+) cell 
pellet expressing Tci-MIF-1. 
Coomassie stained gel. Lane M: molecular weight marker (kDa); lane 1: Flow through; lane 
2: fraction eluted at 20 mM imidazole; lane 3: fraction eluted at 50 mM imidazole; lane 4: 
fraction eluted at 200 mM imidazole; lane 5: fraction eluted at 350 mM imidazole; lanes 6-7: 
proteins eluted at 500 mM imidazole. Tci-MIF-1 is the prominent band in both lane 5 and 6. 
 
5.3.2 Dopachrome tautomerase activity of recombinant Tci-MIF-1 
versions 
The ability of recombinant Tci-MIF-1 versions (EcTci-MIF-1 and CeTci-MIF-1) to 
tautomerise the substrate l-dopachrome methyl ester was assessed in a dopachrome 
tautomerase enzyme activity assay. The results of the experiment are shown in Figure 5.4. 
CeTci-MIF-1 was able to tautomerise the substrate l-dopachrome methyl ester indicating it 
possessed dopachrome tautomerase activity; however, CeTci-MIF-1 showed significantly 
lower dopachrome tautomerase activity compared to EcTci-MIF-1 (p < 0.01). The enzyme 
activity was significantly higher than the PBS negative controls for both EcTci-MIF-1 and 
CeTci-MIF-1 (p < 0.001). The enzyme activity of EcTci-MIF-1 was also significantly 
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higher than the extract of BL21 (+) cells (p < 0.001) and the enzyme activity of Ce Tci-
MIF-1 was significantly higher than the extract of N2 C. elegans worms (p < 0.001). The 
enzyme activity of both recombinant T. circumcincta Tci-MIF-1 proteins was compared 
with a positive and a negative control provided by Prof. Rick Maizels; these were a 
recombinant version of wild type Brugia malayi MIF-1 and a mutant of the same protein 
with a Gly residue instead of Pro at amino acid position 2, both expressed in E. coli (Zang 
et al. 2002). The results showed that EcTci-MIF-1 enzyme activity was not significantly 
different from Bm-MIF-1; while CeTci-MIF-1 showed dopachrome tautomerase activity, 
this was significantly lower than Bm-MIF-1 (p < 0.001) based on the same amount of total 
protein assayed.  
 
 
Figure 5.4 Dopachrome tautomerase activity of two recombinant Tci-MIF-1 versions and two 
recombinant Bm-MIF-1 versions, measured in the linear phase of the reaction. 
The enzyme activity was calculated as Δ mOD (A474) per minute per µg of protein. 
Spontaneous decay of L-dopachrome methyl ester as a result of decarboxylation of the 
substrate was measured by adding an equal volume of PBS instead of enzyme to the 
assays. Data were transformed with the formula y = x
0.25
 to carry out statistical analysis. 
One-way overall ANOVA p value relative to transformed data is shown below the graph; *** p 
< 0.001; ** 0.001 < p < 0.05; ns, not significant. Untransformed data are shown, representing 
mean±SEM of 3 experiments in which samples were analysed in triplicate (n=3). Negative 
controls were: PBS (used instead of enzyme), Bm-MIF-1G (a recombinant B. malayi MIF-1 
version in which the Pro-2 residue was mutated to a Gly), E. coli BL21 (+) cell extracts 
(eluted at the same imidazole conditions as EcTci-MIF-1 from cells carrying the Tci-MIF-1 
plasmid, but not induced for protein expression), and N2 C. elegans worms extracts (eluted 
from worms under the same conditions used to purify CeTci-MIF-1). Recombinant Bm-MIF-
1wt was a positive control. 
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5.3.3 Removal of LPS contamination from purified recombinant 
Tci-MIF-1 
In order to correctly interpret results from the in vitro stimulation of monocytes (in 
migration assays) and alveolar macrophages, LPS was removed from the recombinant Tci-
MIF-1 versions. Initial LPS contamination was quantified by LAL assay and shown to be 
0.12 EU/μg of EcTci-MIF-1 and 2.26 EU/μg of CeTci-MIF-1. Following 2-3 rounds of 
LPS removal using Triton X-114, the LPS contamination was quantified again by LAL 
assay and estimated between 1.6-9.7 mEU/μg protein (1 pg LPS = 10 EU). Levels of LPS 
< 0.05 pg/ml LPS per ng/MIF proteins were considered negligible in an in vitro experiment 
using human monocytes and recombinant human and murine MIF (Hermanowski-Vosatka 
et al. 1999). Therefore, although it was not certain whether cells from different species 
might show similar negligible reactivity to low levels of LPS, it was assumed that the 
remaining LPS contamination (≤ 9.7 fg of LPS per ml of MIF) would not have negatively 
affected or altered results in the sheep monocyte migration and macrophage stimulation 
experiments carried out in the study described here. As the recombinant Tci-MIF-1 
proteins had to be heated at 37°C for the process involving Triton X-114, an aliquot of the 
LPS-free Tci-MIF-1 proteins was tested for maintained dopachrome tautomerase activity 
after being heated (as measure of correct folding of the active site). Following 
decontamination, both Tci-MIF-1 versions maintained dopachrome tautomerase activity in 
the LPS-free protein aliquots (data not shown). This suggested that no major denaturation 
of these proteins occurred during LPS-decontamination treatment and that therefore they 
could be used in cell stimulation experiments. 
5.3.4 Monocyte migration inhibitory factor activity of recombinant 
Tci-MIF-1 versions 
Two versions of recombinant T. circumcincta MIF, EcTci-MIF-1 and CeTci-MIF-1, were 
used in a trans-filter migration assay to investigate the effect of each on the migration of 
blood-derived ovine CD14
+
 monocytes. To test the ability of Tci-MIF-1 to inhibit cell 
migration, cells were placed in the top compartment of the filter/tray assembly (above the 
5µm filter) in the presence of either recombinant Tci-MIF-1 version or their controls 
[BL21 (+) E. coli cells containing the Tci-MIF-1 plasmid where protein expression had not 
been induced, and C. elegans N2 extract fraction eluted from cleared lysate at the same 
imidazole concentration as CeTci-MIF-1 (N2)]. To test the ability of Tci-MIF-1 to induce 
enhanced migration of cells through the filter, in some experiments cells were placed in the 
top compartment and recombinant Tci-MIF-1 versions or their controls were placed in the 
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bottom compartment (across the filter from the cells). The results from three experiments 
showed a trend of CeTci-MIF-1 to inhibit the migration of ovine CD14
+
 monocytes 
through the filter compared to cells incubated in the absence of MIF (C. elegans N2 extract 
or uninduced E. coli BL21 (+) extract). However, no significant difference was observed in 
the inhibition of the migration of cells between treatments (Figure 5.5).  
 
Figure 5.5 Monocyte migration inhibitory activity of purified recombinant Tci-MIF-1 versions 
on sheep CD14
+
 cells. 
The inhibition of migration is represented as percentage of the medium control (set as 100 
%) Data were transformed before carrying out statistical analysis, using the formulae y = x
3
 
(panel A) and y = 1/x
2
 (panel B), where x = percentage of medium control migration. 
Untransformed data is represented as mean±SEM (n=3), with monocytes isolated from the 
same donor sheep. Overall one-way ANOVA p values are shown below each graph; p > 0.05, 
not significant. 1 x 10
5 
sheep CD14
+
 cells were treated with 1 µg/ml of each recombinant Tci-
MIF-1 or negative controls, which were: E. coli BL21 (+) cell extracts (eluted at the same 
imidazole conditions as EcTci-MIF-1 from cells carrying the Tci-MIF-1 plasmid, but not 
induced for protein expression), and N2 C. elegans worms extracts (eluted from worms 
under the same conditions used to purify CeTci-MIF-1). All treatments were stripped of LPS 
using Triton X-114. Panel (A): cells and recombinant Tci-MIF-1 versions or their controls 
were placed in the top compartment for 3 h. Panel (B): cells were placed in the top 
compartment and stimulating recombinant Tci-MIF-1 versions or their controls in the bottom 
compartment, incubated for 3 h. 
 
5.3.5 Pilot study on monocyte- and bone marrow-derived ovine 
macrophages 
In order to investigate the ability of recombinant Tci-MIF-1 versions to induce ovine cell 
activation, a reproducible and robust ovine macrophage culture system needed to be 
optimised. Three different approaches were taken in the search for the most reliable and 
practical technique (from a cell collection logistics point of view) to induce sheep 
 174 
 
macrophage maturation in vitro. The results are presented in chronological order and the 
reasons for changing the approach are provided in each section. Sheep CD14
+
 cells were 
isolated from the PBMC of two animals and cultured in vitro with the aim of harvesting 
differentiated macrophages to be subsequently stimulated with recombinant Tci-MIF-1. 
The sheep CD14
+
 cells differentiated into macrophage-like cells (Mo-MΦ) over a period of 
7-days in vitro culture. The identity of these newly differentiated macrophage-like cells 
was assessed by morphology and cytokine release upon stimulation (see Appendix C, 
Section 9.1). The preliminary results showed that after 48 h stimulation with E. coli LPS, 
the cells had responded with production of both IL-10 and TNFα, suggesting that the 
culture method was a viable technique in generating macrophages in vitro.  
However, data could only be collected from Mo-MΦ derived from one sheep, as a large 
proportion of monocytes isolated from other sheep died during the culture period prior to 
stimulation, as assessed by Trypan Blue exclusion stain. Less than 1 x 10
6
 viable cells 
could be recovered for subsequent stimulation assays and after a further unsuccessful 
attempt to generate sufficient ovine macrophages from CD14
+
 cells this culture method 
was deemed unsatisfactory and collection of bone marrow cells was initiated. 
Bone marrow stem cells were collected from the sternum of 7 sheep; cells from 4 of these 
animals were subsequently cultured in vitro for at least 15 days (up to 18 days) to allow 
macrophage maturation. The number of bone marrow cells isolated from each animal 
could not be consistently repeated (range between 2.8 x 10
6
 and 8.8 x 10
7
 cells/sternum of 
individual sheep). Cytospins slides were prepared at regular intervals during the in vitro 
culture of bone marrow cells to follow the maturation process of bone marrow-derived 
macrophages (BM-MΦ). Bone marrow cells were cultured from one animal using different 
tissue culture plates or flasks to investigate the optimal culture conditions. The purest (95 
%) and more reliably reproduced macrophage culture was obtained using non-adherent 
tissue culture flasks (see Appendix C and Table 9.1 for details). At day 15 of in vitro 
culture in the above mentioned flasks, monocyte- and macrophage-like appearance (large 
nucleus with chromatine granules and large cytoplasm rich in vacuoles, “foamy cell” 
appearance) was predominant in the cells (Figure 5.6). 
 175 
 
 
Figure 5.6 Staining with haematoxylin-eosin of ovine BM-MΦ cytospin slides at different 
stages of maturation. 
All cells were collected from the adherent fraction of the polystyrene flask at day 1 (A), 8 (B) 
and 15 (C) of in vitro culture. The bar shows the size of cells relative to 50 µm. Magnification 
400x in each panel. Panel A, day 1: red arrows indicate the presence of neutrophils, green 
arrows for eosinophils; block black arrow show a cell with monocyte-like appearance; 
panels B and C, day 8-15: red arrows show the presence of neutrophils; black arrow heads 
indicate mature macrophages with a large cytoplasm rich in vacuoles (“foamy cells”); red 
arrow heads indicate cells of the monocyte/macrophage lineage at a less differentiated 
stage. 
 
The cell populations thus generated showed morphological and phenotypical 
characteristics consistent with mature macrophages (BM-MΦ), as shown by the staining of 
CD68, positive staining of the monocyte/macrophage-specific non-specific esterase 
enzymes and the ability to phagocytise fluorescent labelled E. coli cells (see Appendix C 
for details). The BM-MΦ cultures were able to initiate an inflammatory immune response 
following stimulation with two different types of LPS (E. coli O111:B4 LPS or R. 
sphaeroides LPS), as shown by the production of TNFα (Figure 9.2, Appendix C). 
Furthermore, the BM-MΦ cells generated in vitro were able to secrete detectable levels of 
IL-10 in the culture supernatant following LPS stimulation. Although the amount of 
cytokine produced by BM-MΦ was not significantly higher than unstimulated cells, it 
presented encouraging preliminary data. The results described showed that the in vitro 
culture of sheep bone marrow stem cells is able to generate morphologically and 
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functionally mature macrophages. However, the number of cells thus generated was 
consistently too low (< 1 x 10
6
) to complete a thorough investigation of the cell responses 
to recombinant Tci-MIF-1 versions. Therefore this culture method was also abandoned in 
favour of the collection of alveolar macrophages, a cell population which is mature and 
fully differentiated. 
5.3.6 Collection and characterisation of macrophages from sheep 
lungs  
Alveolar macrophages (A-MΦ) were collected from each lung lobe of 7 sheep. Cytospins 
of cells were stained with a hematoxylin-eosin based stain (Diff-Quick). Cell counts on at 
least 5 fields/slide and differential morphology of the adherent cells harvested after 2 h 
incubation of the mixed population found in the lung lavages, showed that > 90 % of the 
cells were differentiated macrophages (black arrow heads, Figure 5.7). A small number of 
PMNs and lymphocytes could also be observed (Figure 5.7, red arrow head and arrow, 
respectively). Total cell counts of the adherent populations ranged from 2.5 x 10
5
 to 2.25 x 
10
7
 (average 7.23 x 10
6
).  
 
Figure 5.7 Staining with hematoxylin of ovine A-MΦ cytospin slides at the time of collection. 
These cells were the adherent fraction of the cells collected by lung lavage from one sheep. 
The bar shows the size of cells relative to 100 µm. Magnification 200x. Red arrow head 
indicates the presence of PMNs (neutrophil cell); red arrow indicates two lymphocytes; 
black arrow heads indicate examples of mature macrophages with a large cytoplasm. The 
figure is representative of cells from one of seven sheep used in subsequent experiments. 
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5.3.6.1 Non-specific esterase staining of A-MΦ 
Non-specific esterase enzymes can be detected primarily in monocytes, macrophages and 
histiocytes; this type of enzyme is considered virtually absent in granulocytes, thus they are 
considered specific markers of the monocyte/macrophage cell lineage (Miller 1981). 
Cytospin slides of sheep A-MΦ carried out shortly after isolation from lung lavage showed 
a macrophage population with heterogeneous non-specific esterase staining. Some A-MΦ 
cells showed a more diffuse staining of the cytoplasm (slim arrow, Figure 5.8), other cells 
appeared with diffuse grey cytoplasm and darker granules (thick arrow, Figure 5.8) and 
cells with a diffuse black staining and undistinguishable black granules were also observed 
(arrow head, Figure 5.8). 
 
Figure 5.8 Staining for non-specific esterase in ovine A-MΦ cells on the day of isolation 
from sheep lungs. 
The bar shows the size of cells relative to 100 µm. Magnification of 200x was used to 
visualise stained cells. Slim arrow: cell with more diffuse cytoplasmic staining; thick arrow: 
cell with diffuse cytoplasmic staining and darker granules; arrow head: cell with dark 
coloured cytoplasm where granules of non-specific esterase are not distinguishable. The 
figure shows representative alveolar cells harvested from one of three sheep used in this 
experiment. 
 
5.3.6.2 CD68 staining of A-MΦ 
The cell surface marker CD68 (also known as macrosialin) is a glycoprotein of 
intracellular membranes, and was first identified in mouse macrophages as a specific 
surface marker for this type of cell (Rabinowitz and Gordon 1991, Smith and Koch 1987). 
CD68 has been shown to bind low density lipoproteins (LDL), suggesting a potential role 
as a lipoprotein uptake receptor (Van Velzen et al. 1997). Cytospins of A-MΦ showed that 
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although ~100 % cells were characterised by macrophage morphology, on average only 21 
% of cells (cells from two sheep, over 5 fields each, range 0-46 %) stained for CD68. A-
MΦ that were positive for CD68 showed a uniform pattern of labelling, occurring mostly 
in defined cytoplasmic areas (Figure 5.9). Negative control slides of A-MΦ incubated with 
an isotype control antibody and without primary antibody did not show CD68 stain. 
 
Figure 5.9 Immunocytochemical (ICC) labelling of CD68 in ovine A-MΦ. 
The bar shows the size of cells relative to 50 µm. Magnification of 400x was used to 
visualise positively labelled cells. Black arrows: A-MΦ showing various degrees of CD68 
staining.  
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5.3.6.3 In vitro phagocytosis activity of A-MΦ 
The phagocytic activity of A-MΦ was investigated by using fluorescent (FITC-labelled) E. 
coli cells in macrophage feeding assays. The results showed A-MΦ were able to 
phagocytise the FITC-labelled E. coli cells. Dual fluorescent microscopy showed that co-
localisation of green fluorescent particles (E. coli) occurred within the area of macrophage 
cytoplasm and next to the blue DAPI-stained nucleus (Figure 5.10). A-MΦ incubated 
without FITC-labelled E. coli cells did not show any fluorescent labelling (data not 
shown). 
 
Figure 5.10 Fluorescent labelling of ovine A-MΦ following phagocytosis of FITC-labelled E. 
coli cells. 
Green fluorescent labelling within cells represents the phagocytosed FITC-labelled E. coli 
cells (both panels). Dual fluorescence staining demonstrating FITC-labelled E. coli cells 
(green) adjacent to the DAPI-labelled cell nuclei (blue). Ratio of A-MΦ to E. coli cells was 
1:5. Magnification used was 400x; the bar shows the size of cells relative to 20 µm.  
 
5.3.6.4 Cytokine production of A-MΦ upon stimulation  
The production of IL-10 and TNFα was investigated in in vitro cultures of ovine alveolar 
macrophages (A-MΦ). Alveolar macrophages were collected from sheep by bronchial 
lavages and immediately stimulated for 6, 24 or 48 h to investigate the cytokine responses 
to stimulation. IL-10 release was measured in the cell supernatant of sheep A-MΦ 
harvested at 6, 24 and 48 h following stimulation with LPS B (from E. coli O111:B4), both 
recombinant Tci-MIF-1 versions and ov rIL-4. Although an increase in IL-10 was shown 
to occur in cell supernatants 24 h post stimulation with LPS B, the IL-10 release measured 
both at 6 h and 24 h post-LPS stimulation did not show significant differences between 
unstimulated and stimulated cells (Figure 5.11, panels A and B). At 48 h post-stimulation, 
the IL-10 release in the supernatant of cells stimulated with LPS B was significantly higher 
than supernatant from cells stimulated with either CeTci-MIF-1 (0.01 < p <0.05) or ov rIL-
4 (p < 0.001). However, neither LPS, CeTci-MIF-1 or ov rIL-4 stimulation induced an IL-
10 release significantly different from unstimulated cells (Figure 5.11, panel C). 
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Figure 5.11 IL-10 detection in the cell supernatant of ovine AM-MΦ cultures stimulated with 
a range of molecules. 
Cells were plated at 10
5
/well and supernatants harvested after 6-24-48h co-incubation with 
the molecules indicated below each graph (final concentrations), or with medium alone 
(unstimulated control). Data was transformed prior to carrying out statistical analysis to 
reduce skew using the formulae y = 1/x, where x = IL-10 U/ml (panels A, B) and y = 1/sqrt x, 
where x = IL-10 U/ml (panel C). Mean±SEM of untransformed data is shown [panel A, n=4; 
panel B, n=7; panel C, n=6). Overall one-way ANOVA p value of transformed data is shown 
below each graph; p > 0.05, not significant; *** indicates p < 0.001; * indicates 0.01 < p <0.05. 
Panel A: IL-10 release in A-MΦ supernatant after 6 h incubation in the presence of the 
molecules indicated below the graph; panel B: IL-10 release in A-MΦ supernatant after 24 h 
incubation in the presence of the molecules indicated below the graph; panel C: IL-10 
release in A-MΦ supernatant after 48 h incubation in the presence of the molecules 
indicated below the graph. 
 
The TNFα release of A-MΦ cultures was also investigated at 6, 24 and 48 h following 
stimulation with the molecules previously indicated. At 6 h post-stimulation, cells that 
received LPS B (from E. coli O111:B4) stimulation secreted a significantly higher level of 
TNFα than cells stimulated with ov rIL-4 (0.01 < p < 0.05, Figure 5.12, panel A). 
However, neither stimulation protocol induced a significant change in TNFα secretion 
compared to unstimulated cells. Although LPS B (from O111:B4 E. coli) appeared to 
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induce the highest TNFα release after 24 and 48 h stimulation, the change was again not 
significant compared to unstimulated cells. Neither recombinant Tci-MIF-1 version was 
able to induce a significant change in TNFα secretion compared to supernatant from 
unstimulated cells, at any of the time points investigated (Figure 5.12). 
 
Figure 5.12 TNFα detection in the cell supernatant of ovine AM-MΦ cultures stimulated with 
a range of molecules. 
Cells were plated at 10
5
/well and supernatants harvested after 6-24-48 h co-incubation with 
the molecules indicated below the graph (final concentrations), or with medium alone 
(unstimulated control). Data was transformed to reduce skew prior to statistical analysis 
using the formulae y = 1/x (panel A) and y = log10 x (panel B), where x = TNFα ng/ml. Overall 
one-way ANOVA p value of transformed data is shown below each graph; p > 0.05, not 
significant; * indicates 0.01 < p < 0.05. Untransformed data is represented as mean±SEM 
[panel A, n=4, panel B, n=7 and panel C, n=6). Panel A: TNFα release in A-MΦ supernatant 
after 6 h incubation in the presence of the molecules indicated below the graph; panel B: 
TNFα release in A-MΦ supernatant after 24 h incubation in the presence of the molecules 
indicated below the graph; panel C: TNFα release in A-MΦ supernatant after 48 h incubation 
in the presence of the molecules indicated below the graph.  
 
Although the cytokine production of A-MΦ cultures stimulated with LPS, ov rIL-4 or 
indeed recombinant Tci-MIF-1 was not significantly higher than unstimulated cells, the 
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significant differences observed between stimulation protocols suggest that these cells may 
be able to initiate an immune response. In addition, A-MΦ are fully differentiated cells 
which are logistically easier to collect and handle than Mo-MΦ and BM-MΦ. A-MΦ also 
show the macrophage-specific expression of non-specific esterase enzymes, CD68 surface 
marker and the ability to phagocytise E. coli cells. For these combined reasons, the 
experiments on gene expression described below were carried out using only cDNA from 
A-MΦ, with the exception of the initial GeNorm algorithm analysis. 
 
5.3.7 Gene expression analysis of stimulated ovine macrophages 
by qRT-PCR 
5.3.7.1 Selection of candidate reference genes by GeNorm analysis 
The geNorm algorithm (Vandesompele et al. 2002) was used to analyse the stability of 
candidate reference genes (i.e. genes of which the mRNA expression did not change 
significantly when different cell stimulations were used). This analysis was carried out on 
Ct values from cDNA of both BM-MΦ and A-MΦ; cDNA was generated from stimulated 
(with LPS, ov rIL-4 or recombinant Tci-MIF-1 versions) and unstimulated cells of both 
culture systems, to compare which may have been the cell type most suited to this analysis. 
The results showed that the candidate house-keeping (HK) genes YWHAZ and GAPDH 
were the two most stable in the experiment carried out using cDNA generated from BM-
MΦ (Figure 5.13). When cDNA from A-MΦ was analysed, GAPDH was the most stable 
gene for this type of cell, with YWHAZ being the fifth (out of 6) most stable (Figure 5.14). 
In this instance, it was expected to use cDNA from both BM-MΦ and A-MΦ for all 
subsequent RT-qPCR experiments, therefore the choice of HK genes fell on the most 
stable for each cell type considered (YWHAZ and GAPDH). However, due to cell numbers, 
reagents and time constraints it was later decided to only use cDNA from A-MΦ in the 
qPCR experiments and the choice of HK genes was maintained. 
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Figure 5.13 GeNorm analysis results from ovine cDNA of 6 BM-MΦ cultures. 
The x axis shows the 12 candidate HK genes considered in this assay, with the most stable 
at the right end and the less stable at the left. The y axis shows the M coefficient, calculated 
with the geNorm algorithm on the basis of the variation of a gene compared to all other 
candidates. The box shows the two genes considered most stable (YWHAZ and GAPDH) on 
the basis of the Ct values achieved from 6 BM-MΦ cDNA samples from cells which were 
stimulated as described in Section 5.2.10. The box shows the position of the relative 
stability ranking of both genes in cDNA from the BM-MΦ cultures considered. 
 
 
Figure 5.14 GeNorm analysis results from ovine cDNA of 15 A-MΦ cultures. 
The x axis shows the 12 candidate HK genes considered in this assay, with the most stable 
at the right end and the less stable at the left. The y axis shows the M coefficient, calculated 
with the geNorm algorithm on the basis of the variation of a gene compared to all other 
candidates. The boxes shows the position of the genes considered (GAPDH, right box and 
YWHAZ, left box) on the basis of the Ct values achieved by 15 A-MΦ cDNA samples from 
cells which were stimulated as described in Section 5.2.10. The boxes show the position of 
the relative stability ranking of both genes in cDNA from the A-MΦ cultures considered. 
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5.3.7.2 Essential information on qPCR reactions 
A list of essential information that must be included in studies carried out using qPCR 
experiments has been published by Bustin et al. (2009). For the purposes of this thesis, all 
available information on validation and analysis of data is reported below. Section 5.2 
(Materials and Methods) and Appendix A can be consulted for details of the protocols and 
sequences of primers used. 
Reaction efficiencies were calculated by the ABI 7500 v2.0.6 software for each plate and 
each gene investigated in this study. The results are summarised in Table 5.3 below. 
Reaction efficiency of 100 % indicates that for each of the 40 cycles used there was 
doubling of the amplified product. Reaction efficiency below 80 % suggested that data 
interpretation should be carefully carried out, as reaction artefacts were likely to have 
affected the estimated copy number of the genes examined. 
Table 5.1 The RT-qPCR reaction efficiency calculated as mean (±SEM) of 4 PCR plates, for 
each of the genes included in this study. 
 
Genes 
Mean % of reaction 
efficiency (±SEM; 
n=4) 
YWHAZ 90.68 (1.61) 
GAPDH 76.07 (3.22) 
iNOS 92.33 (1.54) 
Chit3-L1 91.47 (2.20) 
Arg-1 89.97 (9.41) 
TNFα 88.90 (2.52) 
IL-10 78.61 (2.88) 
IL-8 83.62 (2.86) 
IL-12p40 86.21 (1.70) 
 
5.3.7.3 Identification of qRT-PCR target genes 
A panel of 7 ovine genes was selected for investigation of expression in sheep A-MΦ 
cultures. Genes that were chosen as representatives of a classical inflammatory 
macrophage response were TNFα, IL-8, iNOS (or NO as the product of iNOS enzymatic 
activity) and IL-12p40 [as inducer of the Th1 cytokine IFNγ (Finkelman et al. 2004, Flynn 
et al. 2007, Harada et al. 1994, Raes et al. 2002)]. Representative genes tested as markers 
of alternative activation status were IL-10, Chitinase 3-like molecule (Chit3-L1) and 
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Arginase-1 (Arg-1) (Flynn et al. 2007, Gordon 2003, Knight et al. 2007). Assays for a 
number of these genes (TNFα, IL-8, IL-12p40, IL-10) had been previously validated 
(McNeilly et al. 2008). The remaining three qRT-PCR assays (iNOS, Chit3-L1 and Arg-1) 
had been developed de novo in collaboration with PrimerDesign Ltd. In order to produce 
and validate the assays, this company requested sequences of the genes of interest (GOIs) 
which had been sourced during the course of this study. Briefly, ovine iNOS nucleotide 
sequence was identified in NCBI as a partial coding sequence of inducible nitric oxide 
synthase mRNA [accession number AF223942.1 (Mershon et al. 2002)]. Ovine chitinase 
3-like molecule Chi3-L1 had been previously described as a signal processing protein; 
mRNA partial coding sequence was available in NCBI [accession number AY392761.1 
(Knight et al. 2007)]. Both iNOS and Chi3-L1 sequences had been submitted to 
PrimerDesign Ltd in order to design and validate appropriate primers to be used in qPCR 
assays.  
An EST sequence for ovine Arg-1 was identified in autumn 2012 in NCBI (accession 
number EE768328.1) by BLAST search using the nucleotide sequence encoding Bos 
taurus liver Arginase-1 (accession number NM_001046154), mouse Arginase-1 (Mus 
musculus, accession number EDL04794.1) and goat Arginase-1 (Capra hircus, accession 
number ACS34711.1). Nucleotide sequence identity between the ovine EST sequence thus 
identified and the above bovine, mouse and goat arginase-1 sequences is shown in Table 
5.4. As the nucleotide sequence identity between bovine, mouse, goat and putative ovine 
Arginase-1 was shown to be at least 82 % (Table 5.4), the identified ovine EST 
(EE768328.1) was considered an adequate representative of ovine Arginase-1 gene and 
was therefore also submitted to PrimerDesign Ltd in order to design and validate 
appropriate qPCR primers. At the time of writing, a BLAST search of the ovine EST 
sequence EE768328.1 within the NCBI nucleotide collection identified two predicted Ovis 
aries liver Arginase-1 sequences, named variant 1 and 2 (accession numbers 
XM_004011323.1 and XM_004011324.1 respectively). These had been predicted from the 
Ovis aries (Texel) chromosome 8 genomic scaffold (NCBI accession number 
NW_004080171.1) and both showed > 99 % nucleotide sequence identity with the 
previously identified EST sequence EE768328.1.  
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Table 5.2 The nucleotide sequence identity of 4 mammalian Arg-1 genes. 
 
Species 
NCBI 
Accession 
number 
% identity 
Bos taurus Ovis aries Capra hircus 
Mus 
musculus 
Bos taurus NM_001046154 100 97.32 96.90 82.25 
Ovis aries EE768328.1 97.32 100 99.26 82.25 
Capra hircus ACS34711.1 96.90 99.26 100 82.87 
Mus musculus NM_007482.3 82.25 82.25 82.87 100 
 
5.3.7.4 Gene expression analysis in ovine A-MΦ cultures 
Sheep A-MΦ cultures were stimulated with a range of molecules to induce activation (E. 
coli O111:B4 LPS as inducer of classical activation, ov rIL-4 as inducer of alternative 
activation and EcTci-MIF-1 or CeTci-MIF-1). RNA was purified at 6 and 24 h post-
stimulation and qRT-PCR carried out to determine the expression levels of genes 
indicative of classical activation (TNFα, IL-8, IL-12p40 and iNOS) or alternative activation 
(Arg-1, Chit3-L1 and IL-10). Levels of Arg-1 and IL-12p40 mRNA were below the 
detection threshold of the assay for all samples and these genes were therefore not 
represented in the analysis shown. Ovine A-MΦ which were stimulated for 6 h did not 
show significant differences in gene expression compared to the unstimulated cells, with 
the exception of cultures stimulated with ov rIL-4 which resulted in significantly lower 
iNOS expression compared to unstimulated cultures (Figure 5.15). 
The gene expression levels in A-MΦ at 24 h were also investigated, to detect later changes 
in cell responses to activating stimuli. Similar to the results shown at 6 h post stimulation, 
no major changes in gene expression were observed after 24 h except for iNOS and Chit3-
L1. Ovine rIL-4 stimulation of cells induced significantly lower levels of iNOS expression 
compared to stimulation with LPS and CeTci-MIF-1 and unstimulated controls. 
Surprisingly, ov rIL-4 was able to significantly down-regulate Chit3-L1 expression levels 
compared to unstimulated cells or cells after 24 h of LPS stimulation (Figure 5.16). 
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Figure 5.15 The gene expression analysis of ovine A-MΦ cultures after 6 h in incubation 
with a range of molecules. 
Complementary cDNA samples of A-MΦ cultures stimulated with E. coli O111:B4 LPS (LPS 
B), EcTci-MIF-1, CeTci-MIF-1 and ov rIL-4 were analysed for expression of the genes iNOS, 
TNFα, IL-8, Chit3-L1 and IL-10. Cells stimulated with medium alone were unstimulated 
controls. Data was normalised against the two housekeeping genes GAPDH and YWHAZ; 
normalised copies/µl values were transformed to reduce skew using the formulae y = log10 x 
(panels A, B), y = x
0.5
 (panels C, E), and y = 1/x (panel D); in each formula x = normalised 
copies/µl. Overall one-way ANOVA p value of transformed data is shown below each graph; 
*** p < 0.001. Untransformed data is shown as mean±SEM of normalised copies/µl (n=4). 
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Figure 5.16 The gene expression analysis of ovine A-MΦ cultures after 24 h in incubation 
with a range of molecules.  
Complementary cDNA samples of A-MΦ cultures stimulated with E. coli O111:B4 LPS (LPS 
B), EcTci-MIF-1, CeTci-MIF-1 and ov rIL-4  were analysed for expression of the genes iNOS, 
TNFα, IL-8, Chit3-L1 and IL-10. Cells stimulated with medium alone were unstimulated 
controls. Data were normalised against the two housekeeping genes GAPDH and YWHAZ; 
normalised copies/µl values were transformed to reduce skew using the formulae y = x
0.5
 
(panels A-C) and y = log10 x (panels D, E); in each formula x = normalised copies/µl. Overall 
one-way ANOVA p value of transformed data is shown below each graph; ** 0.001 < p < 0.01; 
* 0.01 < p < 0.05. Untransformed data is shown as mean±SEM of normalised copies/µl (n=7). 
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5.3.8 MIF proteins alignment 
Previous results in this chapter have shown that Tci-MIF-1 did not convincingly inhibit the 
migration of sheep monocytes, nor activate sheep alveolar macrophages. As a preliminary 
investigation of these results, a comparison of the amino acid sequences of Tci-MIF-1, 
Bm-MIF-1 (Zang et al. 2002), ovine MIF (Lopes et al. 2011) and human MIF (Bernhagen 
et al. 1994) was carried out. 
The results showed that mammalian MIF protein sequences showed higher sequence 
similarity to each other compared to parasite MIF sequences (92.17 % amino acid 
sequence identity between human and sheep MIF, compared to 49.57 % ID between T. 
circumcincta Tci-MIF-1 and B. malayi MIFs). In addition, both mammalian MIFs showed 
between 40 and 42 % amino acid sequence identity with each of the parasite MIFs. Only 
the human and sheep MIF sequences possess the CALC motif (solid line box, Figure 5.17), 
which had been implicated in the ability of human MIF to show oxidoreductase enzyme 
activity (Kleemann et al. 1998). Residues involved in the formation of the dopachrome 
tautomerase function active site are highlighted in each version (yellow boxes, Figure 
5.17), as described by Nisbet et al. (2010b). All the MIF proteins investigated here showed 
the presence of a conserved Pro residue in position 2 of the amino acid chain (Pro2), which 
had been previously indicated as pivotal for the tautomerase activity of this protein 
(Hermanowski-Vosatka et al. 1999, Swope et al. 1998, Zang et al. 2002). 
 
Figure 5.17 Alignment of deduced amino acid sequence of different MIF versions. 
Human MIF (Hs-MIF-1, NCBI accession number P14174), ovine MIF (Oa-MIF-1, accession 
number NP_001072123), T. circumcincta MIF (Tci-MIF-1, accession number FN599526) and 
Brugia malayi MIF (Bm-MIF-1, accession number AAB60943) were compared. Green letters 
indicate the conserved residues; bold letters indicate the CALC motif; yellow highlights 
indicate the active site residues. The Pro2 residue is shown in bold red letters. 
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5.4 Discussion 
This chapter reports the characterisation of recombinant Tci-MIF-1 with respect to its 
enzymatic activity as a dopachrome tautomerase and its biological activities on ovine cells 
both as an inhibitor of monocyte migration and as an activator of sheep macrophages. The 
experiments were carried out using two versions of Tci-MIF-1, one generated using a 
traditional E. coli expression system and the other purified from transgenic Tci-mif-1-
expressing C. elegans worms. The comparisons between the two recombinant Tci-MIF-1 
versions showed that both maintained dopachrome tautomerase activity and that C. 
elegans-expressed Tci-MIF-1, similarly to E. coli-expressed Tci-MIF-1, was not able to 
inhibit the migration of ovine monocytes. To investigate the ability of either recombinant 
Tci-MIF-1 version to activate ovine macrophages, in vitro cultures were established. Three 
different methods were tested: macrophages derived from blood CD14
+
 monocytes (Mo-
MΦ), those derived in vitro from bone marrow (BM-MΦ) and macrophages isolated from 
lungs (alveolar macrophages, A-MΦ). Each of these culture methods proved successful in 
generating macrophages and characterisation of these cells showed that they maintained 
features typical of this cell type such as cytokine production (TNFα and IL-10), 
phagocytosis, CD68 expression and non-specific esterase enzymes contained in 
cytoplasmic granules. Stimulation of BM-MΦ and A-MΦ with different types of LPS, both 
recombinant Tci-MIF-1 versions and recombinant ovine IL-4 (ov rIL-4) showed that these 
cells were able to secrete TNFα and IL-10 into the culture supernatant in response to in 
vitro culture. It is possible that collection and in vitro handling of these cells may initiate a 
low background level of cell activation, which was detected by cytokine ELISA 
experiments here carried out. However investigation of gene expression in A-MΦ cultures 
did not show major changes in expression between the LPS and ov rIL-4 stimulated cells 
(used as controls of classical and alternative activation, respectively) and the recombinant 
Tci-MIF-1 stimulated cultures. 
MIF cytokines have been shown to possess different types of enzyme activity, such as 
dopachrome tautomerase, keto-enol isomerase and oxidoreductase (Kleemann et al. 1998, 
Nisbet et al. 2010b, Rosengren et al. 1997, Rosengren et al. 1996). Experiments using 
mutated recombinant MIF versions have shown that the dopachrome tautomerase activity 
of mammalian MIF is dependent on a Proline residue in position 2 of the amino acid chain, 
which becomes the N-terminal residue once the initiating Met residue is cleaved post-
translationally (Bernhagen et al. 1993, Swope et al. 1998). Furthermore, it was shown that 
the P1G mutant MIF (i.e. a recombinant human MIF version in which the residue Pro2 was 
 191 
 
mutated to Gly) had a significantly lower ability to induce superoxide in a human 
neutrophil priming assay, compared to wild type recombinant MIF (Swope et al. 1998). 
However, in the study carried out by Swope et al. (1998) the cell migration inhibitory 
activity was not investigated, therefore a complete assessment of the cytokine activity 
could not be established. In the parasitic filarioid Brugia malayi, mutant recombinant 
versions of MIF-1 and MIF-2 in which Pro was substituted with Gly showed significantly 
reduced dopachrome tautomerase activity across a range of substrates compared to wild 
type Bm-MIF-1 and -2; therefore, as in mammalian MIF, a Pro residue in position 2 is 
required for the enzyme activity of Bm-MIF-1 and -2 (Zang et al. 2002). Furthermore, 
although significantly reduced compared to wild type Bm-MIF-1 and -2, the two Gly 
mutants were still able to partially inhibit the migration of human monocytes (Zang et al. 
2002). In another study, on mouse recombinant MIF, two mutant versions in which a Phe 
or Ser residue substituted Pro1 (P1F and P1S) showed no phenylpyruvate tautomerase 
activity but retained full ability to inhibit both the chemotactic and random migration of 
human monocytes (Hermanowski-Vosatka et al. 1999). These results showed that Pro in 
position 2 of the amino acid chain has a pivotal role in conferring MIF tautomerase 
activity; however the cytokine functions appear to be only partially dependent on the 
presence of this residue. Results from this chapter confirmed that both recombinant T. 
circumcincta Tci-MIF-1 versions possess dopachrome tautomerase activity, as previously 
shown for E. coli-expressed Tci-MIF-1 (Nisbet et al. 2010b). Both these proteins have a 
Pro residue in position 2 of their amino acid chain; however, it was not investigated 
whether the N-terminal Met had been post-translationally cleaved, as is the case in 
mammalian MIF.  
Neither of the T. circumcincta recombinant Tci-MIF-1 versions used in this chapter was 
able to inhibit migration of sheep CD14
+
 monocytes; the results from three experiments 
showed a trend of the CeTci-MIF-1 preparations used to inhibit the migration of cells 
through the filter compared to the relevant unstimulated control cells. However, the 
differences observed were not statistically significant. Although previous studies have 
shown the ability of two recombinant MIF from the parasite Brugia malayi to inhibit the 
migration of human monocytes (Pastrana et al. 1998, Zang et al. 2002), the results of this 
chapter agree with the findings reported by (Nisbet et al. 2010b), which showed that T. 
circumcincta recombinant MIF was unable to inhibit the migration of sheep monocytes. 
Lipopolysaccharide (LPS) is capable of inhibiting monocyte chemotaxis at concentrations 
> 0.5 ng/ml (Hermanowski-Vosatka et al. 1999). For this reason, all Tci-MIF-1 
preparations used in the monocyte migration experiments were treated with Triton X-114 
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to reduce the LPS contamination below the level mentioned above, (which equates in the 
experiments here described to < 9.7 fg LPS/μg protein). For the experiments described in 
this thesis it was not possible to purify adequate amounts of Tci-MIF-1 from T. 
circumcincta L3 stages to study the effect of the native protein on these cells. A possible 
explanation for the lack of function of recombinant Tci-MIF-1 on sheep monocytes could 
be that Tci-MIF-1 might not be involved in the immune interplay between T. circumcincta 
and sheep host, and that the real functions of this enzyme lie in the survival of L3 larvae on 
pasture, as suggested previously (Nisbet et al. 2010b). Future work could further 
investigate the ability of Tci-MIF-1 to inhibit sheep monocyte migration, with the addition 
of i) an inhibitor of monocyte migration [such as LPS (Hermanowski-Vosatka et al. 
1999)]; or ii) an enhancer of monocyte migration [such as vascular endothelial growth 
factor, VEGF (Barleon et al. 1996), plateled-derived growth factor, PDGF (Deuel et al. 
1982), or macrophage colony stimulating factor M-CSF (Wang et al. 1988)]; iii) native L3-
purified Tci-MIF-1 (Nisbet et al. 2010b); iv) recombinant and v) native ovine MIF as 
controls [described by Lopes et al. (2011)]. Moreover, it should be possible to generate 
mutants of both sheep and T. circumcincta MIF in order to investigate whether the N-
terminal Pro residue is as important for MIF functions as shown previously in other 
species. 
In this chapter, three different methods of obtaining ovine macrophages have been 
demonstrated. Preliminary data has shown that each method proved successful in 
delivering differentiated macrophage cultures; however, the efficiency and repeatability 
were very variable for each method considered and the final decision was taken to only use 
alveolar macrophages in order to be able to carry out complete experiments. Blood-derived 
monocytes from cattle had been previously used to generate macrophage cultures in vitro 
(Flynn et al. 2007). In the veterinary literature, cattle circulating monocytes are estimated 
at between 0 and 8 % of PBMC (averaging around 5-6 %, personal observation from 
previous MSc studies), whereas in sheep values of between 0-6 % are reported (Aiello 
1998). In these conditions, finding individual animals that could be used as monocyte 
donors would involve screening of the wider population, with considerable use of time and 
resources. Moreover, the culture method previously described by Flynn et al. (2007) to 
generate macrophages from blood monocytes appeared to be less effective in the ovine 
species, as cells showed scarce viability after 7 days of in vitro culture. For these reasons 
and the low number of cells available following 7 days in culture (<1 x 10
6
), it was decided 
to attempt culture from a different source of cells. 
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Bone marrow has been previously used as a source of stem cells from which to generate 
fully differentiated macrophages. In mice, this process involves the use of macrophage 
colony stimulating factor (M-CSF), often available as supernatant of L929 fibroblast cell 
cultures (Cho et al. 2012, Corraliza et al. 1994, Flesch and Kaufmann 1987). In cattle, 
bone marrow-derived macrophages had been previously generated in vitro from foetal 
bone marrow without additional cytokines and the addition only of FBS (Adler et al. 
1994); presumably FBS contains M-CSF. In sheep, dendritic cells (DCs), a cell population 
that may share features with macrophages (Coico et al. 2003), have been previously 
generated from blood-derived monocytes and bone marrow, using recombinant ovine GM-
CSF and IL-4 (Chan et al. 2002, Foulon and Foucras 2008). Ovine macrophage generation 
from bone marrow had been previously achieved with the use of a high concentration of 
FBS and autologous serum (Francey et al. 1992, Francey et al. 1992). In one of these 
studies, a number of recombinant cytokines (including recombinant mouse, human and 
bovine GM-CSF, pure mouse M-CSF and recombinant human M-CSF) had been tested for 
their ability to induce macrophage proliferation. Although all cytokines tested induced 
macrophage proliferation, the cells had been cultured in Teflon-coated bags and this did 
not allow for separation of BM-MΦ from cells of other lineage or undifferentiated myeloid 
cells present in culture (Francey et al. 1992).  
Ovine recombinant IL-4 is not widely available as a single reagent and titrations of its 
biological activity were not available at the time it was used for the experiments described 
here. Similarly, a purified native or recombinant ovine M-CSF has not yet been developed, 
and therefore the approaches described above could not be used. In order to achieve 
macrophage differentiation, separation from other cell types and a certain degree of 
proliferation, high concentrations of serum were used in the culture medium in the current 
study. In addition to M-CSF, the amount of which will naturally vary, it is hypothesised 
that serum may contain other molecules (as yet unknown) contributing to macrophage 
differentiation and proliferation (Francey et al. 1992, Yen and Stewart 1982). Relying on 
unknown growth factor(s) in serum to induce cell proliferation/differentiation for lack of 
biologically active recombinant ovine M-CSF may present some problems; notably that 
these factors are not only of unknown identity but also not titrated, and therefore their 
amount and effect would be variable with each culture. This was empirically shown by the 
results of this chapter, as the number of cells available for stimulation was not only 
affected by the amount of bone marrow cells that could be isolated (ranging between 2.8 x 
10
6
 and 8.8 x 10
7
 total bone marrow cells from individual animals), but also by the 
incubation method (flask, Teflon bag or tissue culture plates). As all other factors were 
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identical across cultures, the only variable introduced (except from the sheep itself) was the 
composition of the FBS and autologous serum used.  
All results considered, in vitro sheep macrophage culture from bone marrow stem cells 
proved to be a successful method in delivering completely differentiated macrophages, as 
shown by positive CD68 and non-specific esterase staining of these cells, and also by their 
ability to phagocytose E. coli cells. Although CD68 could not be considered a definitive, 
specific macrophage marker (Kunisch et al. 2004), in combination with other markers such 
as staining of non-specific esterase enzymes, the use of CD68 can be considered a good 
compromise (Edwards et al. 1993). The BM-MΦ cultures characterised here were able to 
respond to stimulation with E. coli LPS by producing detectable levels of TNFα and IL-10, 
although it was not possible to demonstrate significant changes compared to the 
unstimulated cells. Further work may include more numerous repeats of stimulation wells 
and higher cell numbers/well. In order to be able to correctly assess cell responses to 
recombinant Tci-MIF-1, a reliable positive control of macrophage stimulation using LPS 
or other molecule [such as poly(I:C), a TLR3 agonist that imitates viral infections 
(Alexopoulou et al. 2001), or thioglycollate, used to elicit peritoneal macrophages in mice 
(Iqbal et al. 2013)], must first be established. A further possibility in designing a positive 
control could be found in the use of combinations of Pathogen-Associated Molecular 
Patterns (PAMPs) to stimulate cells into in vitro activation, as described in a murine model 
of DCs and cytotoxic T cells by (Warger et al. 2006). Indeed, recent unpublished work 
suggests that ruminant immune cells’ hyporesponsiveness could be overcome by using a 
combination of PAMPs in order to elicit activation (Tom McNeilly, unpublished data). It is 
also possible that bone marrow-derived ovine macrophages do not fully activate in 
response to certain types of LPS, and that they might use different activation pathways in 
their response to it. As convincing classical activation of BM-MΦ was not achieved for 
this thesis, it would be favourable for future experiments to optimise this aspect of ovine 
macrophage culture before proceeding to further stimulate cells with other molecules. In 
this chapter, although BM-MΦ were successfully generated and reliably characterised, the 
cell numbers available for stimulation experiments were unpredictably low (< 1 x 
10
6
/culture). Furthermore, results from stimulation of BM-MΦ described here must be 
carefully interpreted as the stimulation protocol had not involved LPS decontamination of 
proteins. For these reasons, it was decided to use alveolar macrophages (A-MΦ) instead, 
which are already differentiated and can be readily isolated from lung lavage.  
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A-MΦ cells do not need any specific isolation technique and can be used as soon as 
separated from the other cell populations present in the lung lavage. Ovine A-MΦ were 
shown here to stain for CD68 and the enzyme non-specific esterase, and were able to 
phagocytose FITC-labelled E. coli cells. Their morphology and functionality confirmed, 
these cells were stimulated following a protocol similar to that used for BM-MΦ. The 
results showed that A-MΦ were also able to produce the cytokines TNFα and IL-10 
following stimulation with LPS; however, again the difference between stimulated cells 
and unstimulated controls was not significant.  One of the main receptors involved in LPS 
recognition, TLR4, has been shown to possess various degrees of polymorphism in 
vertebrates (Matsushima et al. 2007), with varied responses to LPS challenges between 
species [reviewed by Miller et al. (2005) and Werling et al. (2009)]. In humans, it has been 
shown that activation of TLR4 by E. coli lipid A was found to be host species-independent, 
whereas recognition of Salmonella enterica lipid A depended on the TLR4 molecule of the 
host (Muroi and Tanamoto 2002). In this respect, it has been shown that sheep TLRs 
present more similarity to cattle and humans, than mice (Nalubamba et al. 2007). TLR4 
mRNA, together with TLR1, -2, -3 and -10, has been shown to be relatively highly 
expressed in sheep alveolar macrophages, compared to other TLRs (Chang et al. 2009). 
Although it was not investigated for this thesis, it is unlikely that the A-MΦ used in this 
study did not express TLR4, and therefore they should have been able to bind LPS. 
However, based on observations on sheep keratinocytes, it appeared that ovine TLR4 may 
preferentially recognise under-acetylated forms of LPS such as that derived from 
Rhodobacter sphaeroides, being only poorly responsive to E. coli LPS (Tom McNeilly, 
personal communication). In cattle, it has been shown that LPS-dependent activation of 
cells could not be fully achieved unless both the co-receptors CD14 (in cell-bound or 
soluble form) and MD-2 were present (Lizundia et al. 2008). Moreover, it has been 
previously shown that R. sphaeroides LPS acted as an agonist for cells expressing equine 
TLR4/CD14/MD-2 complex, but not for cells expressing the human homologues 
(Lohmann et al. 2007). Interestingly, when ovine BM-MΦ generated in this chapter were 
stimulated with both E. coli and R. sphaeroides LPS versions, it was possible to elicit 
similar results in terms of TNFα secretion in the cell supernatant. This could be explained 
by the use of autologous sheep serum for the BM-MΦ in vitro culture, which may have 
contained soluble sheep CD14. As sheep serum had not been added to the A-MΦ cultures, 
a lack of co-receptor such as CD14 might have induced sub-optimal TLR4 activation. It 
would have been interesting to investigate the activation of sheep A-MΦ following 
stimulation with R. sphaeroides LPS, had the cell numbers available for pilot experiments 
been higher. Another explanation for the sub-optimal activation observed may be that 
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sheep A-MΦ were hyporesponsive to the particular E. coli O111:B4 LPS used in this 
study, possibly due to cell signalling independent from the TLR4/CD14 complex.  
For both IL-10 and TNFα production, the addition of ov rIL-4 showed a significant 
decrease in the levels of cytokines produced compared to LPS-stimulated cells, suggesting 
that IL-4 may have generated an alternatively activated macrophage phenotype, inhibiting 
release of these cytokines. However, as the cytokine release in response to IL-4 stimulation 
was not significantly reduced compared to unstimulated cells, these results should also be 
carefully interpreted. MIF alone has been reported to have an inflammatory effect 
[reviewed by Calandra and Roger (2003)], and therefore a phenotype closer to classical 
activation might have been observed when either recombinant Tci-MIF-1 was used. 
However, the results from this chapter did not show a significant effect due to either 
recombinant Tci-MIF-1 version. A more pronounced alternative activation phenotype 
might have been observed if combined stimulation protocols were used, such as MIF in 
association with IL-4 as previously described in mice (Prieto-Lafuente et al. 2009). 
However, inconsistencies in the numbers of cells viable for stimulation meant that the 
stimulation protocols used in this work had to be curtailed and only single molecules could 
be used at any one time.  
The gene expression in A-MΦ cultures was investigated with the aim of identifying 
markers of classical (CAMΦ) or alternative activation (AAMΦ) in ovine cells following 
stimulation with either recombinant version of Tci-MIF-1 generated in this thesis. 
Alternative activation of macrophages following stimulation with MIF proteins has not 
been shown before in sheep, although previous work showed that a predominant Th2 
environment was indicative of AAMΦ and characteristic of parasitic infections in general 
[reviewed by Jenkins and Allen (2010)], and T. circumcincta infection in sheep in 
particular (Craig et al. 2007). Following the example of macrophage stimulation in cattle 
systems (Flynn et al. 2007), a number of sheep genes had been selected for this purpose 
[iNOS, IL-8, IL-12p40 and TNFα for classical activation; Arg-1, Chit3-L1 and IL-10 as 
measure of alternative activation (Knight et al. 2007, McNeilly et al. 2008, Mershon et al. 
2002)]. Although the qPCR data failed to highlight significant differences in the gene 
expression of the macrophage cultures examined, a few observations could be made from 
the results gained. In sheep, Arg-1 and iNOS genes had not been previously linked to 
macrophage alternative activation. The work shown here aimed to provide some 
preliminary data on these aspects of macrophage biology and it was achieved with respect 
to iNOS: this gene showed significant down-regulation following stimulation with ov rIL-
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4. IL-4 is a Th2 cytokine that drives alternative activation by switching the use of L-
Arginine by iNOS to Arg-1, therefore inhibiting nitric oxide (NO) release (Modolell et al. 
1995). Theoretically, expression of iNOS would exclude Arg-1, and vice-versa. In the work 
described here, expression of Arg-1 was below detection levels in all cell cultures 
examined and it was not possible to determine whether this gene was an appropriate choice 
for alternative activation status, or whether the assay needed further optimisation. For this 
reason, the results involving iNOS gene expression should also be carefully interpreted. IL-
8, IL-12p40 and TNFα are classical pro-inflammatory cytokines that are secreted by 
macrophages upon classical activation [generally by LPS or viral activation, although 
methamphetamine has also been shown to increase release of pro-inflammatory cytokines 
(Liu et al. 2012, McNeilly et al. 2008)]. Following T. circumcincta infection, the cytokines 
IL-10, IL-12p40 and TNFα have been shown to be up-regulated in abomasal lymph nodes 
(Craig et al. 2007). Mammalian acidic chitinase (AMCase) molecules have been 
previously described in mouse models of alternative activation (Prieto-Lafuente et al. 
2009). In mice the gene Ym1 (also known as Chit3-L3), was significantly up-regulated in 
the lung, small intestine and peritoneal macrophages of mice infected with the nematode 
Nippostrongylus brasiliensis or the protozoan Trypanosoma brucei, and was found to be 
predominantly produced by alternatively activated macrophages in an IL-4-dependent 
manner (Nair et al. 2005, Raes et al. 2002). In sheep, primers to murine Ym1 and Ym2 
failed to amplify any product; however Chit3-L1 (belonging to the same family of 
mammalian chitinases of Chit3-L3 or Ym1) had been shown to be up-regulated in the 
abomasal mucosa of sheep infected with T. circumcincta and therefore appeared a likely 
candidate to study the alternative activation of sheep macrophages (Knight et al. 2007). 
However, it was shown in this chapter that Chit3-L1 was significantly down-regulated in 
A-MΦ stimulated with ov rIL-4 compared to unstimulated cells. This result contrasts with 
the previous observations of this gene’s IL-4 dependent expression in murine 
macrophages. Indeed the gene choice was broadly based on mouse models, and therefore it 
is possible that sheep macrophages may respond differently to IL-4 and/or predominantly 
Th2 environments. Another possibility may be that the observed up-regulation of Chit3-L1 
in the abomasal mucosa during T. circumcincta infection [as described by Knight et al. 
(2007)] involved cell-types other than macrophages; it is also possible that macrophages 
might up-regulate different chitinase genes in response to IL-4 stimulation, and that Chit3-
L1 is not the major gene involved in this activity. 
The qPCR data were acquired using mRNA samples extracted from the A-MΦ cells 
stimulated with E. coli LPS, ov rIL-4 and two Tci-MIF-1 recombinant versions (EcTci-
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MIF-1 and CeTci-MIF-1). In this occasion, RNA quantification and quality control was 
carried out using the Nanodrop method. Acquisition of a RIN (RNA integrity number) had 
not been possible at this time, as the amounts of mRNA extracted from the cells were too 
small to allow further characterisation of the samples. However, in further experiments a 
better approach should include higher cell number/well, in order to allow higher quality 
and quantity of mRNA available for qPCR assays. Housekeeping genes are used as internal 
reference in qPCR assays, as it is assumed that their expression levels would remain stable 
throughout the tissue culture experiment. Traditionally, it was believed that once a 
housekeeping gene was chosen for a particular species or cell type, it was not necessary to 
review the choice (Thellin et al. 1999). However, experiments have shown that candidate 
housekeeping genes transcription levels can vary (Thellin et al. 1999). To avoid errors 
caused by the use of inappropriate housekeeping genes, a new algorithm was developed 
(geNorm); this enables analysis of a number of reference genes and allows choice of the 
most stable for any specific experiment, cell type or organism (Vandesompele et al. 2002). 
This software has been used previously to identify the best housekeeping gene candidates 
in various species, such as dog, sheep, cattle and horse (Bogaert et al. 2006, Etschmann et 
al. 2006, Nalubamba et al. 2007, Robinson et al. 2007). In this chapter, insufficient cell 
viability and low quantities of mRNA available from each sample meant that the geNorm 
analysis could not be carried out on every single cDNA sample derived from A-MΦ 
cultures. Therefore, the candidate housekeeping genes YWHAZ and GAPDH had been 
chosen on the basis of a partial analysis carried out on both A-MΦ and BM-MΦ cultures. 
In future experiments, it would be advisable to test every cDNA sample for expression of 
each candidate housekeeping gene, in order to obtain a more accurate estimate of the most 
stable genes to use as reference. 
Further work should also be carried out on the reliability of efficient qPCR reactions; the 
results of this chapter have shown that acceptable reaction efficiency between 90-100 % 
(Bustin et al. 2009) could only be achieved for 4 of the target or house-keeping genes 
considered (see Table 5.1). As A-MΦ cell numbers used in the stimulation experiments 
and the qPCR reaction set-up had both been consistent, the variable reaction efficiency 
may have been a reflection of the two different methods used to generate cDNA from 
mRNA extracted from the cell cultures. A PCR reaction with lower efficiency will have 
lower sensitivity (Bustin et al. 2009). For example, compared to a reaction in which 
efficiency is 100 %, the copies of PCR product/μl will be underestimated in a sample 
where transcript is relatively abundant, and conversely, will be overestimated in a sample 
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where the transcript has low abundancy (Bustin et al. 2009). Therefore, the results here 
shown should be carefully interpreted and further validation is required. 
In conclusion, ovine macrophages showed the ability to be partially stimulated by LPS, 
recombinant ovine IL-4 and recombinant T. circumcincta MIF versions; however, the 
preliminary data presented here showed that further work is required to reach full protocol 
optimisation. The inconsistencies shown in this chapter regarding the activation of sheep 
macrophages indicate that data obtained from stimulation protocols (especially from either 
recombinant Tci-MIF-1 version) should be carefully interpreted. Further stimulation 
experiments of ovine macrophages should involve a molecule able to reliably and 
consistently activate the cell response in the classical way [such as poly(I:C) or 
thioglycollate (Alexopoulou et al. 2001, Calandra et al. 1994, Iqbal et al. 2013)], to be able 
to distinguish the classical and alternative phenotype. Titration of stimulating molecules 
should also be investigated, as in this chapter only one set concentration of each was 
tested. Production of endogenous ovine MIF from the in vitro macrophage cultures was not 
investigated in this occasion; it has been previously shown in a mouse model that only low 
concentrations (10-100 pg/ml) of MIF may induce a positive loop of further MIF release 
from macrophages (Calandra et al. 1994). Indeed in their experiment, it was shown that 
concentrations of 1-10 µg MIF had significantly decreased macrophage MIF production 
compared to the lower MIF concentrations (Calandra et al. 1994). In this chapter, 
stimulation assays used 5 µg/ml of both recombinant Tci-MIF-1, therefore the likelihood 
of detecting an increase in sheep MIF produced by the A-MΦ was greatly reduced. 
However, ovine MIF, if produced by activated macrophages, would be an interesting 
product to investigate in further experiments as this could provide another measure of the 
activation status of these cells. The results reported in this chapter have shown that careful 
interpretation of data is essential when analysing sheep macrophage responses to stimuli. 
Moreover, ruminants (and sheep in particular) may show distinct immunological responses 
from other mammalian species, and therefore species-specific work is required to better 
understand the immune response of these animals. Indeed mouse models cannot always be 
proficiently used in comparative studies to infer data upon other species, and careful 
planning must always be considered when testing hypotheses previously confirmed in 
other host species. 
The inability of either recombinant Tci-MIF-1 versions used in this chapter to inhibit cell 
migration is consistent with (Nisbet et al. 2010b) and suggested that Tci-MIF-1 might not 
be involved in the immunomodulation of the sheep immune response against T. 
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circumcincta. This hypothesis was further corroborated by the subsequent findings that 
neither recombinant Tci-MIF-1 version was able to induce consistent in vitro activation of 
sheep macrophages, either by cytokine production or gene expression. It would however be 
important to test activity of native Tci-MIF-1 from the parasite, before concluding that this 
molecule has no effect on sheep cells. T. circumcincta MIF may have evolved to mediate 
parasite development and may be used during the process of melanisation, as suggested by 
(Nisbet et al. 2010b). In support of this hypothesis, the amino acid sequence alignment 
shown in this Chapter revealed that sheep MIF did not share the same similarities with Tci-
MIF-1, as it did with human MIF. This suggests that the sheep host version of this cytokine 
may have retained different functions from Tci-MIF-1, and that T. circumcincta had not 
evolved an immunomodulatory function for this cytokine, as opposed to the 
immunomodulatory activity achieved by B. malayi MIFs (Pastrana et al. 1998, Zang et al. 
2002). Indeed in the free-living nematode C. elegans, Ce-MIF-2 and -3 transcripts were 
shown to be up-regulated in the dauer stage (Marson et al. 2001). The dauer stage is 
characterised by arrested metabolism and growth until more favourable conditions become 
available (Hu 2007), and suggestions have been made that L3 stages of parasitic nematodes 
may represent a dauer-like stage (Brand et al. 2005). This aspect of the T. circumcincta life 
cycle is currently still unclear, and therefore further work is required to shed light on the 
biological functions of Tci-MIF-1. 
Taken together, the results shown in this chapter have provided an insight into the 
biological activity of Tci-MIF-1 as an enzyme and as a cytokine. The aims of this chapter 
were achieved and two recombinant versions of Tci-MIF-1 were compared in respect to 
their enzymatic activity and biological effect on sheep cells. It was shown that both 
recombinant Tci-MIF-1 proteins maintained the putative dopachrome tautomerase activity, 
each being capable of degrading the substrate L-dopachrome methyl ester. This confirmed 
once again that C. elegans is a viable means of expressing active recombinant enzymes, as 
previously shown by Murray et al. (2007) and Roberts et al. (2013). As neither 
recombinant Tci-MIF-1 version had a significant effect in the monocyte migration assays 
or the macrophage stimulation experiments, it is possible that this molecule is not involved 
in the immunomodulation of the sheep immune response as other parasite MIFs have been 
shown to be (Loke et al. 2000). Furthermore, C. elegans was used as an alternative 
expression system in an attempt to generate a recombinant version of Tci-MIF-1 that might 
show improved enzymatic activity or biological effects on sheep cells, compared to the E. 
coli-expressed version. However, the two enzymes showed similar activity in all fields 
examined. It is therefore concluded that C. elegans-expressed Tci-MIF-1 did not 
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substantially differ from its E. coli-expressed counterpart and that both proteins were 
equally valid in in vitro experiments. Moreover, it is suggested that the lack of convincing 
monocyte/macrophage activation may not be due to experimental artefacts or PTM defects 
of the recombinant Tci-MIF-1 versions, but perhaps to a different biological function that 
Tci-MIF-1 carries out within its natural host, T. circumcincta.  
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Chapter 6 – General Discussion 
Teladorsagia circumcincta is a parasitic pathogen of sheep in temperate areas and is the 
principal causative agent of parasitic gastroenteritis (PGE) in growing lambs (Bartley et al. 
2003, Taylor M. A. et al. 2007). T. circumcincta causes major production losses due to 
clinical PGE, with a huge economic impact on the sheep industry calculated as > 80 
millions of pounds sterling (Nieuwhof and Bishop 2005). The associated clinical signs of 
PGE range from suppressed appetite to diarrhoea, quickly followed by dehydration and 
sometimes death in heavy infections (i.e. a mixed species parasite burden of ~10 000 
worms in sheep; Radostits O.M.  et al. 2007). The sum of the clinical signs of PGE results 
in weight gain reduction in the first few months of life in store lambs, often causing delays 
in reaching target slaughter weights (Gibson and Everett 1976, Miller et al. 2012). Studies 
in which corticosteroid drugs (with a potent immunosuppressive effect) were administered 
to sheep infected with T. circumcincta have shown that the resulting growth check may not 
only be due to the parasite infection per se, but can also arise from immune responses of 
the sheep. This may happen through redirection of nutrients from the processes required 
for meat and wool production towards the immune response (Greer et al. 2008). 
Control of teladorsagiosis relies heavily on the use of anthelminthic drugs. Three major 
classes of chemicals are used in this respect: benzimidazoles (BZs or white drenches), 
levamisole (yellow drenches) and macrocyclic lactones (MLs or clear drenches). Recently, 
two new classes of anthelmintics have been introduced:  the amino-acetonitrile derivatives 
(AADs or orange drenches) and the spiroindoles (purple drenches). However, despite the 
number of drugs available to treat sheep against GI nematodes, heavy or inappropriate uses 
of all classes have resulted in widespread anthelmintic resistance. Anthelmintic resistant 
parasites have been known since the late 1950s (Drudge et al. 1957) although, until more 
recent years, isolates that showed resistance to more than one type of drug had been 
relatively rare. However, T. circumcincta isolates showing multiple resistance to the three 
most commonly used drug classes have been identified (Bartley et al. 2003, Bartley et al. 
2005, Sargison et al. 2005, Sargison et al. 2010, Sutherland et al. 2008). In some cases, 
these parasites represented a threat so great to the local sheep industry that farms were 
forced to stop all sheep operations until clear of the offending parasites (Blake and Coles 
2007, Sargison et al. 2005). 
For these reasons, alternative means of controlling these parasites are urgently needed. 
Research has focused not only on developing new anthelmintic drugs (against which 
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resistance is inevitable in the long term), but also on alternative measures such as pasture 
management, breeding resistant or resilient breeds of sheep, targeted treatments of only 
certain individuals in a flock, establishing a refugia worm population, and more 
importantly, studying the sheep immune response against the parasite (Bahirathan et al. 
1996, Behnke et al. 2008, Besier 2012, Bisset et al. 2001, Golding and Small 2009, Good 
et al. 2006, Kenyon and Jackson 2012, McNeilly et al. 2009, Miller and Horohov 2006, 
Nisbet et al. 2013, Sargison et al. 2005, Stepek et al. 2005, Stepek et al. 2010b, Stepek et 
al. 2010a). 
It has been established that immunity to T. circumcincta can be induced by natural 
infection on infected pasture or experimental trickle infection (Seaton et al. 1989, Taylor 
M. A. et al. 2007). Immunity against this parasite occurs through different mechanisms 
such as exclusion/expulsion of L3 stages, production of IgA in the gastric environment and 
local lymph nodes and circulating IgE resulting in impaired larval development at the L4 
stage and reduced fecundity in adults (Halliday et al. 2007, Huntley et al. 2001, Pettit et al. 
2005, Smith et al. 2009, Smith et al. 1985, Stear et al. 1995, Stear et al. 1999, Strain et al. 
2002). However, antibody responses alone may not be sufficient to clear the infection and 
recruitment of specialised cells such as DCs has been documented [reviewed by McNeilly 
et al. (2009)]. 
As protective immunity against T. circumcincta can be elicited in sheep over a period of 
time, it may be possible to quicken this natural process by administering vaccinations 
against the parasite, in order to protect the most susceptible animals (Knox 2000). 
Vaccinations could reduce the widespread use of anthelmintic drugs, therefore reducing 
costs and handling procedures for the farmers, increasing the number of lambs reaching 
slaughter weights within time targets expected, with a further beneficial effect due to 
reduced or nil withdrawal times on the meat products and slowing down the establishment 
of anthelmintic resistance in the parasite populations (Knox 2000, Smith and Zarlenga 
2006). Vaccinating animals against gastrointestinal parasites is therefore a desirable 
alternative control strategy to treating animals with anthelmintic drugs; firstly because of 
the ever-rising drug-resistant parasite population, and secondly due to consumer concerns 
about chemical residues in the food and environment (Science for Environment Policy, 
2008). However, there have been limited successes in developing vaccines against 
helminth parasites, especially when recombinant proteins were used (See Tables 1.1 and 
1.2 of this thesis). For example, immunisation of dogs with a P. pastoris-expressed Ac-CP-
2 antigen (a cysteine protease) from the hookworm Ancylostoma caninum achieved 
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significant reductions in the faecal egg output [approximately 13 000 eggs/g faeces (epg) 
and ~ 5000 epg  in controls and immunised dogs, respectively] following intradermal 
challenge with A. caninum L3 (Loukas et al. 2004). However, in other cases when native 
proteins such as Ostertagia ostertagi ASP (activation-associated secreted proteins) 
afforded protection against homologous challenge (Meyvis et al. 2007), trials carried out 
using recombinant versions (baculovirus-expressed Oo-ASP-1) showed that this version 
did not confer protection against O. ostertagi challenge when used to immunise calves 
(Geldhof et al. 2008). Several studies have shown that certain Haemonchus contortus 
proteins such as H11 and H-Gal-GP are highly protective against homologous challenge in 
their native form (Roberts et al. 2013, Smith et al. 1994, Smith et al. 2000). However, 
when the same proteins have been expressed in recombinant form, using different 
expression systems, they have not been able to achieve protection against H. contortus 
challenge (Cachat et al. 2010, Roberts et al. 2013), suggesting that the process of 
recombinant expression reduces potential to induce a protective immune response. 
Recently, a study published by Nisbet et al. (2013) has shown that a vaccine against T. 
circumcincta which contained 8 recombinant antigens protected sheep from trickle 
challenge. The reductions in faecal egg counts and worm burdens were significantly lower 
in the immunised sheep compared to the controls in both trials that were carried out 
(Nisbet et al. 2013). These are promising results and show that recombinant antigen 
immunisation can achieve protection in vaccine trials in an experimental setting. However, 
the road to a commercial T. circumcincta vaccine is still long and further refinement is 
required, initially to determine which components of the vaccine were crucial in the 
protection elicited. No less importantly, it should be determined whether a vaccine of this 
type could still be effective in field conditions where sheep are subjected to different 
challenges (i.e. mixed worm populations, the pressure of intensive farming, etc.) than in an 
experimental setting. For these purposes, a better understanding of the interactions between 
the sheep host, the parasite and the vaccine antigens is required. This can be achieved by 
investigating the sheep immune response to both T. circumcincta and the recombinant 
vaccine, and by characterising the relative biological properties of native and recombinant 
antigens. These requirements set the origins of the study here presented, with the 
assumption that a more intimate knowledge of the vaccine candidates used and their 
interactions would lead to an improved prototype of the vaccine. 
The main aim of this thesis was to establish a nematode expression system that would 
allow the generation of T. circumcincta recombinant antigens which could be compared to 
the exisiting vaccine candidates. For this purpose, two T. circumcincta antigens which had 
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already been expressed in recombinant form and used in the successful vaccine (Nisbet et 
al. 2013) were chosen for further characterisation; these were an immunogenic cysteine 
protease, Tci-CF-1 (Redmond et al. 2006), and a putative immunoregulatory monocyte 
migration inhibitory factor, Tci-MIF-1 (Nisbet et al. 2010b). The sheep antibody response 
to the existing recombinant (expressed in P. pastoris) and native antigens was first studied, 
in order to have data with which to compare the antibody response to the C. elegans-
generated recombinant version. The results of this work (Chapter 2 of this thesis) showed 
that a different antibody response is generated in sheep following the immunisation with 
the existing, yeast- and bacteria-generated recombinant antigens (Tci-CF-1 and Tci-MIF-1) 
than that observed during trickle challenge. In these studies [and those described by Nisbet 
et al. (2013)] it was evident that although the antigens present in the vaccine cocktail 
induced an antibody response in the serum and abomasal mucus of immunised sheep 
which was able to bind native antigens, the antibodies generated by trickle infection in 
control sheep (non–immunised) did not bind the recombinant Tci-CF-1 and Tci-MIF-1 
used in the vaccine, suggesting that the recombinant antigens differed somewhat from the 
native versions produced by the parasite to which the sheep host is exposed to. This was in 
contrast to the antibody binding demonstrated to occur to native T. circumcincta ES 
antigens (Halliday et al. 2007, Redmond et al. 2006) and more particularly, to Tci-CF-1 
purified from ES (Chapter 2 of this thesis). 
In an attempt to generate recombinant antigens that would be recognised by sheep 
antibodies in a manner more similar to native antigens, the free-living nematode C. elegans 
was used. The work reported here showed that C. elegans is a viable expression system for 
the generation of T. circumcincta vaccine candidates, although it may require some 
optimisation regarding expression yields. Two different methods have been used in order 
to generate a C. elegans-expressed T. circumcincta protein: firstly, transformation of wild 
type C. elegans worms with an engineered plasmid encoding T. circumcincta Tci-CF-1 
and, subsequently, phenotype rescue of a mutant C. elegans-strain (DR96) with a plasmid 
encoding T. circumcincta Tci-MIF-1. Both methods involved the use of marker genes to 
enable identification of the transformed C. elegans worms. Both methods were successful 
in delivering C. elegans-expressed T. circumcincta antigens and these could be purified in 
stable, soluble forms in order to carry out further characterisation.  
Characterisation of the biological functions of both Pichia pastoris- and C. elegans-
expressed Tci-CF-1 and comparison with the native ES-purified version showed that 
indeed some differences do exist. The enzymatic activity of either recombinant version 
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could be analysed only following trans-activation with another enzyme (exogenously 
added human, liver cathepsin L). Together with the observation that native Tci-CF-1 is 
present in T. circumcincta L4 ES as a mature enzyme, these results suggest that in order to 
be correctly recognised by T. circumcincta infection-induced antibodies the recombinant 
antigens should be cleaved in a similar manner to the native Tci-CF-1. Furthermore, the 
results showed that glycosylation of this antigen appears to have a role in the induction of 
an appropriate antibody response in sheep, as shown by the sodium-periodate ELISA 
experiments of Chapters 2 and 4 of this thesis. Moreover, the recombinant version 
expressed in the yeast P. pastoris is likely to be hyperglycosylated with carbohydrate 
residues that differ in size and conformation to those of the native protein. The results from 
the initial lectin binding experiments also showed that the glycan composition C. elegans-
expressed version appeared similar to the P. pastoris recombinant Tci-CF-1; however, 
detailed comparative analysis of the defined glycan structures on each will provide more 
information (glycan analysis of native and recombinant Tci-CF-1 versions is currently in 
progress in collaboration with Prof. Cornelis Hokke, University of Leiden). Further work 
could be carried out to investigate the hypothesis of the presence of disulphide bonds 
within the cysteine residues of the Tci-CF-1 amino acid chain; if differences in folding 
were identified (i.e. bonds were present in certain positions within nTci-CF-1 but not 
present or scrambled within either recombinant version), it could provide an explanation as 
to why in this study antibody binding differed between Tci-CF-1 versions. 
The putative immunoregulatory functions of T. circumcincta Tci-MIF-1 had been 
previously listed (Nisbet et al. 2010b). This protein in its native state was thought to have a 
role both in the maturation of T. circumcincta larval stages and also to affect the immune 
response of sheep mononuclear cells, more specifically to inhibit their ability to migrate. 
These functions had been hypothesised on the basis Tci-MIF-1 enzyme activity [as 
dopachrome tautomerase (Nisbet et al. 2010b)] and studies carried out in other nematode 
species, such as Brugia malayi and Trichinella spiralis, which showed the ability of 
parasite MIFs to inhibit the random migration of host monocytes (Pastrana et al. 1998, Tan 
et al. 2001, Zang et al. 2002). The characterisation of recombinant Tci-MIF-1 versions 
carried out for this thesis has shown that although both of these proteins maintain the 
dopachrome tautomerase enzymatic activity previously shown, neither was able to 
significantly influence the migration of sheep monocytes in in vitro assays. This confirmed 
the results reported by (Nisbet et al. 2010b), and suggests that perhaps the main biological 
functions of Tci-MIF-1 do not involve interaction with sheep immune cells but instead are 
involved in larval development of the parasite. Nonetheless, the hypothesis that Tci-MIF-1 
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might modulate the sheep immune response was supported by studies of other parasite 
MIFs (Pastrana et al. 1998, Prieto-Lafuente et al. 2009, Tan et al. 2001, Vermeire et al. 
2008), and it was thought that although it did not have an effect on cell migration, it may 
have been involved in the induction of activated macrophages. MIF has been known as 
pro-inflammatory cytokine expressed by a variety of cells of the immune and endocrine 
systems (Calandra and Roger 2003). For example, a previous study showed that mouse 
macrophages stimulated with MIF molecules secreted TNFα in a pro-inflammatory loop 
(Calandra et al. 1994). In contrast to the pro-inflammatory function of MIF, other 
experiments showed that this molecule can also act in an anti-inflammatory fashion, and it 
is able to induce alternatively activated macrophages, which have been reported to occur 
during parasite infections (Allen and Loke 2001, Loke et al. 2000, Vermeire et al. 2008). 
To investigate this hypothesis, Tci-MIF-1 was further tested by stimulating in vitro-
generated sheep macrophages. The results of these experiments have been largely 
consistent with the lack of migration inhibitory capacities of recombinant Tci-MIF-1, as 
although sheep macrophages were able to produce detectable levels of cytokines (TNF 
and IL-10) in response to Tci-MIF-1, these were not significantly different from the 
unstimulated cells. Furthermore, when gene expression following exposure to LPS and 
both recombinant Tci-MIF-1 versions was investigated, few significant changes were 
noted at 6 and 24 hours post-stimulation in the expression of pro-inflammatory and 
alternatively activation-associated gene expression (Chapter 5 of this thesis). It is not clear 
whether sheep macrophages might respond differently than human and mouse cells to 
various types of infectious insult through their TLRs, although it is possible. Werling et al. 
(2009) and Zhou et al. (2007) showed with phylogenetic trees the differences in structure 
of the extracellular TLRs domains between livestock species, rodents and primates. 
Differences in structure might suggest differences in binding ligands, or the affinity with 
which a ligand is bound (Werling et al. 2009). Differences in macrophage activation were 
shown by experiments in which bovine and murine macrophages were stimulated in vitro 
with Salmonella dublin and/or homologous recombinant IFNγ, TNFα and IL-1 (Adler et 
al. 1995). Although both mouse and bovine macrophages showed expression of iNOS 
following S. dublin stimulation, neither of the recombinant cytokines was able to induce 
iNOS in the bovine macrophages, nor priming of these cells, compared to mouse 
macrophages (Adler et al. 1995). Furthermore, there are profound differences in the 
physiology of these species (i.e. monogastrics vs ruminants, omnivores vs strict 
herbivores). The environment in which sheep live constantly exposes them to a large 
variety of immunological challenges. Moreover, ruminants survive thanks to the presence 
of the rumen, which is, put simply, a very large incubator of microrganisms. It is possible 
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that ruminants might have evolved mechanisms of tolerance or hypo-responsiveness to 
certain bacterial stimuli, and this would be reflected in the results of the experiments here 
described. Another possibility could be that ruminants, and sheep in particular, may adopt 
different immunological strategies to combat infection compared to monogastric mammals 
such as mice. Innate immune responses, for example, may show a degree of antigen 
specificity, due to the interactions between Pattern Recognition Receptors [PRRs, such as 
Toll-like Receptors (TLRs)] and generic Pathogen-Associated Molecular Patterns 
(PAMPs); thus, different exposure to PAMPs and different host usage of TLRs may 
ultimately achieve the same cell response (McNeilly 2008). In this respect, it has been 
shown that sheep TLRs present more similarity to bovine and human receptors than those 
present in mice (Nalubamba et al. 2007). Moreover, a perceived hyporesponsiveness (or 
higher activation threshold) of ruminant cells may be overcome by using a combination of 
two or more PAMPs to achieve activation and allow investigations (Dr Tom McNeilly, 
personal communication). 
Taken together, the results from Chapter 5 of this thesis confirm the hypothesis that Tci-
MIF-1 might be mostly involved in processes related with T. circumcincta larval 
development, rather than influencing the sheep immune response. This does not mean that 
Tci-MIF-1 may be a less valid candidate for the investigation of the biology of T. 
circumcincta. (Nisbet et al. 2010b) have shown that although the highest expression of 
Tci-MIF-1 (both mRNA and protein) was in the L3 stages, protein was also detectable in 
somatic extracts of L4 and adult stages. This suggests that, although to a lesser extent, Tci-
MIF-1 is present in host-dependent stages. If the functions of this protein were primarily 
involved in larval development, this could make Tci-MIF-1 a candidate for drug targeting 
still worth investigating. Furthermore, the role of Tci-MIF-1 in the vaccine cocktail 
developed by Nisbet et al. (2013) is still to be defined and, not being a particularly 
abundant or immunogenic protein in its native state, it is harder to characterise its putative 
protective effect during T. circumcincta infection compared to Tci-CF-1. 
Overall, the results of this thesis have answered the main aim: the generation of alternative 
T. circumcincta recombinant vaccine candidates has been achieved using a novel nematode 
expression system, C. elegans. The proteins were purified and characterised alongside the 
existing recombinant versions of Tci-CF-1 (expressed in the yeast P. pastoris) and Tci-
MIF-1 (expressed in E. coli), and showed similar characteristics. In the greater picture of 
vaccine development, considering that the existing Tci-CF-1 and Tci-MIF-1 versions had 
already been used in a successful vaccine cocktail against T. circumcincta (Nisbet et al. 
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2013), it appears that the C. elegans-expressed versions here generated might be equally 
successfully used in vaccination studies, given their high degree of similarity in in vitro 
studies. However, minute differences between the exisiting recombinant versions and those 
expressed in C. elegans may nonetheless exist and influence the host immune response; 
these questions could only be answered by further immunisation trials. 
To date, there have been no immunisation studies that used C. elegans-expressed T. 
circumcincta antigens in sheep, and this would be an interesting avenue to explore. An 
initial pilot study may involve immunisation of a small number of sheep with a 
traditionally expressed antigen (generated using E. coli or P. pastoris), and including both 
sheep immunised with a C. elegans-expressed antigens, and unvaccinated animals. Serum 
samples collected from each group could then be tested for their efficacy in reducing 
protein functions (e.g. loss of enzyme activity if exposed to immune serum) and 
recombinant systems thus compared. However, given the relatively small amounts of 
recombinant protein obtained in this study from C. elegans compared to yeast and bacterial 
cultures, this option would require further optimisation, especially with views of producing 
the vaccine on a large scale for commercialisation. A recent study has shown that C. 
elegans can be successfully and productively employed to generate amounts of nematode 
(H. contortus) recombinant proteins sufficient to immunise sheep for a vaccine trial 
(Roberts et al. 2013). This further confirms that C. elegans is a viable alternative to other 
expression systems and that it may be used to generate recombinant vaccine antigens, 
particularly where expression of soluble and/or active proteins is challenging. However, 
further validation work is required to establish whether the recombinant proteins expressed 
using C. elegans are sufficiently antigenically similar to the native versions than those 
expressed using traditional methods (such as E. coli and yeast cultures), in order to afford 
the ultimate protective nematode vaccine. 
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Appendix A – Primers, cDNA and PCR reactions 
  
7.1 Semi-quantitative RT-PCR primers 
Unless otherwise stated, oligonucleotide primers used throughout this project were 
designed using Eurofins MWG Biotech and Primer3 tools (www.eurofinsdna.com and 
http://frodo.wi.mit.edu/, respectively) to design the primers and calculate melting 
temperatures (Tm). Primers were ordered from Eurofins MWG Operon (Ebersberg, 
Germany) and diluted to a stock concentration of 100 pmol. The working concentration of 
all primers for PCR was 10 pmol. Primers used to generate PCR products in Chapter 2 are 
listed in Table 7.1; the primers used for reactions in Chapter 3 are listed in Table 7.2. 
Details of the reaction conditions used are available in each individual results chapter. 
Table 7.1 Primers used for cloning Tci-CF-1 into Pichia pastoris. 
 
Set 
number 
Name Forward (F) 5’ → 3’ Reverse (R) 5’ → 3’ 
Product 
Size (bp) 
Average 
pair Tm 
(°C) 
1* FLCF-1 
ATGTCTCTTTTGTTCCTGCT
TCTC 
TAGGACAACAGCTGAAGTGG 1095 60 
2* 
CathFPIC
z 
AATTCACGTGGCGCTACTG
TAAAGCAGCAATACTC 
TTTGTTCTAGAAGGACAACAG
CTGACGTGG 
1052 60 
3 
tci-cf-1-
specific 
ForIN 
AGGAAAACGATAAGGGAAC
AG 
RevIN 
CGCCTTTATAGAACTGTATGT
C 
594 56 
4^ 
pPICZαC-
specific 
5’  OX  
GACTGGTTCCAATTGACAA
GC 
α-factor 
TACTATTGCCAGCATTGCTG
C 
3’  OX  
GCAAATGGCATTCTGACATCC 
(empty 
vector) 
5’AOX1 
593 
αfactor 
304 
Annealed 
at 
52 
The underlined nucleotides represent the recognition sites of restriction enzymes: dashed 
line: PmlI, solid line: XbaI. Primer sets noted with * were provided by Dr Alasdair Nisbet 
(MRI). Primers noted by ^ were included in the EasySelect™ Pichia Expression kit 
(Invitrogen). 
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Table 7.2 Primers used for cloning Tci-CF-1 and Tci-MIF-1 into Caenorhabditis elegans. 
  
Set 
number 
Name Forward (F) 5’ → 3’ Reverse (R) 5’ → 3’ 
Product 
Size (bp) 
Average 
pair Tm 
(°C) 
1 Tci-[CF1] 
GCGGCCGCATGTCTCTTTTGT
TCCTGCTTCTC 
GTCGACCTAAGCGCTTAGGA
CAACAGCTGACGTGG 
1115 60 
2 [CF1]-His GCGGCCGCATGTCTCTTTTG 
Rev1: 
GTGGTGGTGGTGGTGGTGTA
GGACAACAGCTGAGCTGG 
1118 57 
Rev2: 
GTCGACCTAGTGGTGGTGGT
GGTGGTGGTGGTGGTGGTGT
AGGACAAC 
1139 60 
3 
Sequencing  
ABR-09-
specific 
ForOut: 
ATCGCTCTCTGTTTCTCTCC 
RevOut: 
TACGAGCTAATTATATGCTCT
TAC 
1586 56.5 
4* Ce-cpl-1 
TTGGTCGACATTTGAACTTAA
TAATTAA 
CCAGAGCTCCCACCGAGATT
TGAAC 
512 55 
5 [MIF]+His 
AATTGCGGCCGCATGCCGGT
TTTCTCATTCCAC 
Rev1: 
GTGGTGGTGGTGGTGGGCAA
AAGTTCTGCTGTTGAAG 
375 57.9 
Rev2: 
AATTCTCGAGCTAGTGGTGGT
GGTGGTGGTGGTGGTGGTGG
TGGGCAAAAGTTC 
403 62 
6 
Sequencing 
TciMIF 
ForIN: 
ATGCCGGTTTTCTCATTCCAC 
RevIN: 
CAAAAGTTCTGCTGTTGAAGG 
343 57 
The underlined nucleotides represent the recognition sites of restriction enzymes: dashed 
line: NotI, solid line: SalI; double line: XhoI; nucleotides in italics represent the poly-
histidine tag. An aliquot of the primer set noted with * was provided by Dr Brett Roberts at 
the University of Glasgow (Britton and Murray 2002).  
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7.2 Generation of cDNA from ovine macrophages 
For the generation of cDNA from ovine macrophages, one method used the kit Precision™ 
nanoScript Reverse Transcription kit by PrimerDesign Ltd. (Southampton, UK) was used 
in the following reactions: 1 μl of Oligo-dT Primers was added to ~120 ng of RNA 
previously diluted to the desired concentration in dH2O in sterile, RNAse free 0.2 ml thin-
walled PCR tubes. The samples were then heated at 65°C for 5 min and immediately 
cooled on ice. A master mix was prepared, containing 2 μl of nanoScript 10X Buffer, 1 μl 
of dNTP mix (10 mM of each), 2 μl of DTT (100 mM), 4 μl of RNAse/DNAse free dH2O 
and 1 μl of nanoScript enzyme for each reaction. Ten microliters of the master mix were 
aliquoted into each RNA samples on ice, which were then incubated at 55°C for 20 min, 
then heat inactivated at 75°C for 15 min. 
The second method used for the generation of cDNA was as follows: a master mix 
containing 1 μl of Oligo(dT)23 Primers (anchored) (Sigma-Aldrich) was added to 1 μl of 
dNTP mix (10 mM) and 2 μl of this solution was aliquoted into each 10 μl RNA sample 
(diluted in RNAse-free dH2O as previously described). The samples were incubated at 
65°C for 5 min, then immediately transferred on ice. Another master mix was prepared 
containing 4 μl of 5X First strand buffer (Invitrogen, Paisley, UK), 2 μl of 0.1 M DTT 
(Invitrogen) and 1 μl of RNaseOUT (Invitrogen) for each reaction. Seven microliters of 
this master mix was added to each RNA sample and incubated at 42°C for 2 min; 1 μl of 
Superscript™ II Reverse Transcriptase (Invitrogen) was added to each sample, mixed by 
pipetting and incubated at 42°C for 50 min, then heat inactivated at 70°C for 15 min. 
7.3 Quantitative RT-qPCR primers 
Primers used in qRT-PCR reactions for ovine iNOS-2, Chit3-L1, Arg-1, YWHAZ were 
designed and optimized by PrimerDesign Ltd, courtesy of a Gold Sponsorship Student 
Award. The primers were supplied as pre-mixed solutions of forward and reverse primers, 
at a working concentration of 6 pmol/μl each.  
Primers sequences for ovine TNF-α, IL-10, IL-8, IL-12p40 and GAPDH were previously 
detailed by McNeilly et al. (2008) and supplied by Eurofins MWG Operon (Ebersberg, 
Germany); upon arrival, the primers were diluted to a stock concentration of 100 pmol. 
The working concentration of all primers was 10 pmol. Details of all primers are 
summarised in Table 7.3.  
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Table 7.3 Primers used in this study in RT-qPCR experiments. 
 
Gene 
product 
Accession 
number 
Sequences 
Product 
size 
Annealing 
temperature 
(°C) 
iNOS AF223942 
F, GCC TCT GGA CCT CAA CAA AG 
R, GTG GTG CGG CTG GAT TTC 
108 60 
Chit3-L1 AY392761 
F, CCA ACA TAA GCA ACA ATG AGA TC 
R, CCA AAG TTC CAT CCT CCA ACA 
130 60 
Arg-1 EE768328 
F, CAT ATC TGC CAA AGA CAT TGT G 
R, ACC TTG CCA ATT CCC AGT T 
129 60 
YWHAZ N/A N/A N/A 60 
TNFα^ X55152 
F, GAA TAC CTG GAC TAT GCC GA 
R, CCT CAC TTC CCT ACA TCC CT 
238 57 
GAPDH^ AF030943 
F, GGT GAT GCT GGT GCT GAG TA 
R, TCA TAA GTC CCT CCA CGA TG 
265 57 
IL-10^ NM_001009327 
F, TGA AGG ACC AAC TGA ACA GC 
R, TTC ACG TGC TCC TTG ATG TC 
160 55 
IL-8^ NM_001009401 
F, ATG AGT ACA GAA CTT CGA 
R, TCA TGG ATC TTG CTT CTC 
222 55 
IL-12p40^ AF209435 
F, TCA GAC CAG AGC AGT GAG GT 
R, GCA GGT GAA GTG TCC AGA AT 
243 57 
N/A: data not available for commercial reasons (property of PrimerDesign Ltd., 
Southampton, UK), as included in sheep Genorm kit. ^ = primer sequences provided by Dr 
Tom McNeilly (MRI), as detailed by McNeilly et al (2008). 
 
7.4 Standard qPCR reactions 
Assays for the detection of iNOS-2, Chit3-L1, Arg-1, YWHAZ gene products were carried 
out as follows: 4 μl of dH2O, 10 μl of Precision 2x SYBR green MasterMix 
(PrimerDesign) were added to 1 μl of primers mix (a solution prepared adding 10 μl of 
forward primer to 10 μl of reverse primer; Table 7.3) and 5 μl of cDNA template diluted 
1:10 in dH2O. Cycling conditions were: 95°C for 10 min, then 40 cycles of (95°C for 30 
sec, 60°C for 1 min); fluorescent data was collected during the 60°C for 1 min step. The 
cycling was completed with the addition of dissociation steps for melting temperature data 
collection. Negative control reactions (NTC) contained 5 μl of dH2O instead of template. A 
standard curve was prepared using serial dilutions of positive control plasmids 
(PrimerDesign Ltd); the undiluted plasmid was 2 x 10
5
 copies/μl (5 μl/reaction = 106 
copies/reaction), diluted ten-fold serially (range of the standard curve: 10
6
-10
1
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copies/reaction). The above reaction volumes and cycling conditions were also used for 
generation of qPCR data used in the GeNorm analysis described in Chapter 5. 
Other assays (IL-10, IL-8, IL-12p40, TNFα, GAPDH) used the following conditions: 4 μl 
of dH2O, 10 μl of Precision 2x SYBR green MasterMix (PrimerDesign) were added to 0.5 
μl of forward and 0.5 μl of reverse primers (see Table 7.3), 5 μl of cDNA diluted 1:10 in 
dH2O. Cycling conditions for all assays were: 50°C for 2 min, 95°C for 10 min, then 40 
cycles of (95°C for 30 sec, X°C for 30 sec and 72°C for 32 sec, where X was the annealing 
temperature specific of each primer set); fluorescent data was collected during the 72°C for 
32 sec step. The cycling was completed with the addition of dissociation steps for melting 
temperature data collection. Negative control reactions (NTC) contained 5 μl of dH2O 
instead of template. A standard curve was prepared using serial dilutions of positive 
control plasmids (provided by Dr Tom McNeilly, MRI); the undiluted plasmid was 10
9
 
copies/μl, diluted ten-fold serially (range of the standard curve: 107-102 copies/reaction).  
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Appendix B – Other Laboratory Techniques 
  
8.1 Electrophoresis 
8.1.1 DNA electrophoresis 
PCR products were visualized in 1 % agarose gels  prepared with 1 X TAE Buffer; 2 g 
agarose (Bioline, London, UK) were dissolved in 200 ml of 1 X TAE Buffer (Appendix 
B), heated on full power in a microwave for approximately 3 min (until boiling 
temperature was reached and the solution turned clear) and then cooled before use. Twenty 
microliters of 10 000 X Gel Red (Biotium, Hayward, CA, USA) were added and mixed. 
The gel was poured into a gel electrophoresis tank with a comb to leave wells during the 
setting of the gel. Once the gel had set, the comb was removed and 1 X TAE poured in the 
tank to submerge the gel. Six microliters of samples were mixed with 2 μl of DNA loading 
buffer (Appendix B); one or two wells at either end of the gel was loaded with Ready-
Load™ 1 kb DNA Ladder (Invitrogen, Life Technologies Ltd, Paisley, UK) and the tank 
attached to a power supply. One hundred Volts (V) were applied for approximately 35 min 
and gels were visualized using an UV transilluminator. 
8.1.2 Protein electrophoresis 
Unless otherwise stated, a standard amount of 130 ng (13 μl of a 10 μg/ml solution) of 
protein sample was added to 5 μl of NuPAGE® LDS Sample Buffer (4X) with the addition 
of 2 μl of NuPAGE® Reducing agent (all from Invitrogen), for a total volume of 20 μl, 
heated at 70°C for 10 min and loaded into each well of NuPAGE® Bis-Tris 4–12 % 
polyacrylamide gels, with the addition of running buffer into the chambers of the 
electrophoresis assembly. This was prepared by mixing 50 ml of 20 X NuPAGE® running 
buffer (Invitrogen) with 950 ml distilled water; 200 ml were removed, poured in the inner 
chamber of the gel/clamp assembly, and 500 μl of NuPAGE® Antioxidant (Invitrogen) 
were added. Further 500-600 ml of diluted running buffer were poured into the outer 
chamber. Eight microliters of SeeBlue® Plus2 Pre-Stained standard (Invitrogen) were 
added in the first and last well of each gel for protein size estimation. Gel electrophoresis 
conditions were 200 Volts for 35 min. Gels were routinely stained with Coomassie-based 
dye (SimplyBlue™ SafeStain, Invitrogen) and when more detection sensitivity was 
required, silver staining was also used (SilverQuest™ Silver Staining Kit, Invitrogen). 
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8.2 Western blotting 
Following SDS-PAGE, protein samples were transferred onto a nitrocellulose membrane 
using iBlot System (Invitrogen), stained with Ponceau S (Sigma-Aldrich, Gillingham, UK) 
for protein band identification and membranes cut into strips with a scalpel blade. All steps 
from hereon were conducted on a rotary shaker. The strips were blocked overnight in 20 
ml TNTT (10 mM Tris, 0.5 M NaCl, 0.05 % Tween 20); the same were used for washes 
between incubations. TNTT/5 % dried skimmed milk was also used for blocking and 
washes when probing blots with an anti-His antibody (Invitrogen). The strips were then 
incubated with serum, gastric lymph or commercial antibodies detailed in each chapter of 
this work. Strips were washed three times for 20 min, and subsequently incubated with the 
appropriate secondary antibody (detailed in each individual chapter). After three 20 min 
washes, the strips were incubated with a tertiary antibody, where appropriate, or left 
rocking in TNTT for two hours/overnight for a final wash to reduce the background 
binding. The strips were developed with Amersham ECL Prime Western Blotting 
Detection Reagent (GE Healthcare, Little Chalfont, UK) following the manufacturer’s 
instructions. Occasionally strips were also developed with 3,3′-Diaminobenzidine (DAB, 
SIGMAFAST™ DAB with Metal Enhancer, Sigma-Aldrich). 
8.3 Protein concentration estimations 
8.3.1 BCA assays 
These assays based on the use of  bicinchoninic acid were carried out following the 
manufacturer’s instructions (Pierce™ BCA Protein Assay Kit, Thermo Scientific, 
Loughborough, UK). Twenty-five microliters of BSA standards or protein preparations 
were placed in duplicate or triplicate wells of a flat bottomed, clear 96-well microplate. 
Blanks were prepared using 25 μl of PBS instead of protein preparations. The working 
reagent (WR), prepared with the ratio 50:1 or reagent A:B, was added to each well (200 
μl). The plate was incubated at 37°C for 30 min and when cooled at RT; the absorbance 
was read using a microplate reader with a 562 nm filter. The average blank reading was 
subtracted from every other well reading and standard curve calculated by plotting the 
blank-corrected BSA well readings vs. the respective concentrations. The protein 
concentration of unknown protein samples was derived from the equation of the standard 
curve.  
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8.3.2 ImageQuant method 
Another method used in this study for the estimation of protein concentration used 
polyacrylamide gels and the ImageQuant LAS 4000 digital imaging system (GE 
Healthcare). A SDS-PAGE of the protein of interest and a serial dilution of a BSA standard 
curve was carried out as previously described (Section 8.1.2) and stained used coomassie 
blue- or silver-based stains. A digital image of the gel was acquired and analysed using the 
software ImageQuant TL (GE Healthcare), using the default settings for image acquisition 
and background stain removal. The software calculated the pixel density of each band of 
BSA standard curve, and after the operator specified each individual concentration of the 
BSA bands, the software provided an estimate of the concentration of the unknown protein 
band of interest. 
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Appendix C – Additional data 
  
9.1 Generation and characterisation of ovine 
macrophages from blood monocytes 
On average, CD14
+
 cells represented 3.54 % of the total PBMC isolated, with a wide inter-
donor range between 0.46-5.8 % [normal range of ovine monocytes was reported by The 
Merck Veterinary Manual , ed. Aiello (1998) as 0-6 % of total PBMC]. PBMC were 
subsequently collected from 2 animals with the highest number of PBMC/ml blood and 
circulating CD14
+
 cells above 3 % to attempt in vitro culture once the CD14
+
 fraction had 
been isolated. Cultures of the CD14
+
 cell fraction from these two animals proved partly 
successful. Sufficient macrophages were recovered from the 7-day culture of CD14
+
 cells 
from one sheep to investigate the effect of three types of LPS [LPS preparations A (E. coli 
O55:B5, Sigma-Aldrich), B (E. coli O111:B4, Sigma-Aldrich) and C (E. coli O111:B4 
LPS, Invivogen), as detailed in Section 5.2.9.1] and ovine recombinant IL-4 (ov rIL-4), for 
induction of classically activated (LPS) and alternatively activated (ov rIL-4) 
macrophages. The results are summarised in Figure 9.1. 
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Figure 9.1 IL-10 and TNFα detection in the cell supernatant of sheep monocyte-derived 
macrophages stimulated with a range of molecules. 
Data represent one experiment in which supernatant from 3 wells in each cell culture was 
pooled and analysed. Cells were stimulated with a range of concentrations of the molecules 
shown below each graph: SCM, unstimulated cells; LPS (A), O55:B5 E. coli LPS; LPS (B), 
O111:B4 E. coli LPS (Sigma-Aldrich); LPS (C), O111:B4 E. coli LPS (Invivogen); ov rIL-4, 
recombinant ovine IL-4 provided by Dr Sean Wattegedera at MRI. Panel (A): IL-10 
represented as Biological Units/ml, as calculated from a standard curve of recombinant 
ovine IL-10; data represent one ELISA well analysed. Panel (B): TNFα concentrations shown 
in pg/ml, as calculated from a standard curve of bovine TNFα; data represent mean of two 
ELISA wells from each pooled supernatant.  
 
9.2 Generation and characterisation of ovine 
macrophages from bone marrow stem cells 
One hundred microliter aliquots representative of adherent and non-adherent cells were 
collected from each culture vessel at specific time points (day 0, 8 and 15) and cytospin 
slides prepared. Between the day of collection and day 15, the composition of cell 
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population changed at a variable rate depending on which culture system and which 
fraction (adherent or non-adherent cells) was considered. At the beginning of the period of 
culture in vitro, polymorphonuclear cells (PMNs; neutrophil and eosinophil-like cells, each 
with multi-lobed nuclei and eosin-stained cytoplasm for eosinophils) were predominant in 
each culture vessel used. Only a few lymphocyte-like cells were identified (1-2 %, small, 
medium sized cells with a round nucleus and small haematoxylin-stained cytoplasm); 10-
12 % cells showed morphology consistent with monocyte/macrophage precursors and/or 
monocytes (large, round or kidney-shaped nucleus with surrounding medium to large 
hematoxylin stained cytoplasm). Progressing from day 8 towards day 15, the number of 
PMNs gradually decreased as the differentiated cells died and myeloid precursors of the 
PMN lineage did not further proliferate. At the same time, lymphocyte numbers remained 
unchanged or decreased and cells with monocyte- and macrophage-like appearance (large 
nucleus with chromatine granules and large cytoplasm rich in vacuoles, “foamy cell” 
appearance) became predominant around day 10 of culture. At this time, both the adherent 
and non-adherent fraction in each vessel showed predominant macrophage morphology (> 
50 % cells), with the exception of non-adherent cells in the 6-well plate format. Adherent 
cells in the flask and 6-well plate reached the highest macrophage purity, with 95 % cells 
showing typical macrophage morphology (Table 9.1). At day 15 of culture, both adherent 
and non-adherent cells from all the culture vessels were harvested and counted. Viability 
was assessed by Trypan blue staining. Counts of viable macrophages are summarised in 
Table 9.2. 
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Table 9.1 The percentages of cell types in different sheep bone marrow cell in vitro cultures. 
 
Culture vessel 
Day 0 Day 8 Day 15 
M/
MΦ 
L N Eo 
M/
MΦ 
L N Eo 
M/
MΦ 
L N Eo 
Bone marrow 
cells  
11 3 38 48 n/a n/a 
Teflon bag 
n/a 
40 2 39 19 77 0 17 6 
Flask (adherent 
cells) 
n/d n/d n/d n/d 95 0 5 0 
Flask (non-
adherent cells) 
32 2 51 16 62 1 7 30 
6-well plate 
(adherent cells) 
n/d n/d n/d n/d 95 1 2 2 
6-well plate (non- 
adherent cells) 
31 0 41 28 45 0 26 29 
24-well plate 
(adherent cells) 
n/d n/d n/d n/d 90 0 8 2 
24-well plate 
(non-adherent 
cells) 
27 2 42 29 33 0 22 45 
Legend: M/MΦ, monocyte and/or macrophage-like cells; L, lymphocytes; N, mature 
neutrophils; Eo, eosinophils; n/a, not available; n/d, not determined. 
 
Table 9.2 Ovine BM-MΦ cell counts after 15 days of in vitro culture in different vessels.  
 
Culture vessel 
Viable cell count at day 15 
(x 10
6
) 
% of dead cells 
Teflon bag 1.7 5 
75 cm
2
 Flask (adherent 
cells) 
1.4 5 
75 cm
2
 Flask (non-
adherent cells) 
2.8 9 
6-well plate (adherent 
cells) 
0.95 10 
6-well plate (non- 
adherent cells) 
0.66 11 
24-well plate (adherent 
cells) 
0.62 9 
24-well plate (non-
adherent cells) 
0.88 9 
 
Taken together, these preliminary results indicate that in vitro culture of sheep BM-MΦ 
can be achieved by incubating cells for 15 days in the presence of 20 % FBS and 20 % 
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autologous serum. The optimal culture conditions which achieved the highest cell purity 
(95 %) combined with low cell mortality (5 %) were obtained by harvesting adherent cells 
from the 75 cm
2
 polystyrene flask. The cells harvested from the polystyrene flask were 
used to gather preliminary data on the ability of these cells to produce cytokines following 
stimulation. The cells were stimulated with two types of LPS (O111:B4 E. coli LPS and 
Rhodobacter sphaeroides LPS). Although statistical analysis could not be carried out, the 
results in Figure 9.2 showed that these cells were able to produce detectable levels of 
TNFα above the unstimulated controls. 
 
Figure 9.2 TNFα response in culture supernatant of ovine BM-MΦ generated in different 
vessels and stimulated with LPS. 
Cells were stimulated with 10 µg/ml of either O111:B4 E. coli LPS or R. sphaeroides LPS. 
Supernatants were collected after 48 h of culture and levels of TNFα quantified by ELISA. 
BM-MΦ were generated in the culture vessels indicated under each set of bars [Bag (all): 
cells could not adhere therefore all cell types represented; Flask Adh or NON Adh: cells that 
adhered or did not adhere to the polystyrene flask; 6w Adh or NON Adh: cells that adhered 
or did not adhere to the 6-well culture plate; 24w Adh or NON Adh: cells that adhered or did 
not adhere to the 24-well culture plate]. All cells were harvested and stimulated in flat-
bottomed 96-well plates. Data represent one experiment carried out in duplicate. Data 
shown are means of the two ELISA wells. 
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9.2.1 Intracellular non-specific esterase activity of BM-MΦ 
Cytospin slides of bone marrow cells prepared immediately after collection showed a 
heterogeneous population of cells with highly variable non-specific esterase staining; all 
cells that showed monocyte, macrophage-like and monocyte precursor morphology stained 
with non-specific esterase, though the intensity of the stain was variable. Some cells 
showed an uniform black/grey cytoplasm of diffuse stain and others with only a few 
stained granules within a clear cytoplasm (black arrows in Figure 9.3, panel A).  Cells with 
morphology consistent with PMNs did not stain. Bone marrow cells cultured in vitro for 15 
days in polystyrene flasks had differentiated into BM-MΦ (population purity > 90 %) and 
also showed heterogeneous staining; all cells with macrophage-like morphology showed 
some degree of staining; some macrophage-like cells only stained well defined granules in 
their unstained cytoplasm (black arrow heads in Figure 9.3, panel B), whereas other 
macrophage-like cells showed a diffuse punctuate  staining pattern and cells with 
morphology consistent with PMNs did not stain (red arrow heads, Figure 9.3, panel B). 
 
Figure 9.3 Staining for non-specific esterase in ovine bone marrow cells at day 0 of in vitro 
culture and BM-MΦ at day 15. 
The bar shows the size of cells relative to 100 µm. Magnification of 200x was used to 
visualise stained cells. Panel (A): bone marrow cells were isolated from a sheep and stained 
for non- specific esterase. Black arrows: monocyte-like cells that stained more intensely; 
red arrows: PMN cells which did not stain. Panel (B): ovine BM-MΦ were harvested after 15 
days in culture and stained for non-specific esterase. Black arrow heads: BM-MΦ with 
individual granule staining; red arrow heads: BM-MΦ with black granules filling the 
cytoplasm full. Note the increase in cell size from the monocyte-like cells indicated by black 
arrows in (A) compared to mature the macrophages in (B). The figures show representative 
cells derived from one of two sheep used in this experiment. 
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9.2.2 Expression of CD68 
The expression of CD68 was investigated here in BM-MΦ cultures by 
immunocytochemistry (ICC). Bone marrow cells cultured in vitro for 15 day had 
differentiated into BM-MΦ (population purity > 90 %) and showed heterogeneous CD68 
labelling; > 90 % cells with macrophage-like morphology showed some degree of labelling 
for CD68, though some possessed macrophage morphology without CD68 staining (Figure 
9.4). 
 
Figure 9.4 Immunocytochemical (ICC) labelling of CD68 in ovine BM-MΦ. 
The bar shows the size of cells relative to 50 µm. Magnification of 400x was used to 
visualise positively labelled cells. BM-MΦ were cultured for 15 days and CD68 expression 
determined by ICC. Black arrow heads indicate the BM-MΦ cells that stained more intensely. 
  
9.2.3 In vitro phagocytosis activity of ovine macrophages 
The phagocytic activity of BM-MΦ was investigated by using fluorescent (FITC-labelled) 
E. coli cells in macrophage feeding assays. The results showed BM-MΦ were able to 
phagocytise the FITC-labelled E. coli cells. Dual fluorescent microscopy showed that co-
localisation of green fluorescent particles (E. coli) occurred within the area of macrophage 
cytoplasm (BM-MΦ, Figure 9.5). BM-MΦ incubated without FITC-labelled E. coli cells 
did not show any fluorescent labelling (not shown). 
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Figure 9.5 Fluorescent labelling of ovine BM-MΦ following phagocytosis of FITC-labelled E. 
coli cells. 
Green fluorescent labelling within cells represent the phagocytosed FITC-labelled E. coli 
cells. Combined phase contrast microscopy and fluorescence microscopy demonstrating 
fluorescent labelling within BM-MΦ cells. Ratio of BM-MΦ to E. coli cells was 1:5. 
Magnification used was 200x; the bar shows the size of cells relative to 100µm. The figure is 
representative of two experiments. 
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9.2.4 Cytokine production of BM-MΦ upon stimulation  
The production of IL-10 and TNFα was investigated, by ELISA, in in vitro BM-MΦ 
cultures. Cells were collected from the adherent cell fraction of the 15-18 day old in vitro 
cultures and stimulated for 48 h with LPS B (from E. coli O111:B4, Sigma), recombinant 
Tci-MIF-1 and recombinant ovine IL-4 (ov rIL-4). BM-MΦ were able to produce 
detectable levels of IL-10, however these were not found to be statistically significant 
between cells incubated without stimulation and cells that received LPS B, either 
recombinant Tci-MIF-1 version, or ov rIL-4. IL-10 production in cells stimulated with 
recombinant EcTci-MIF-1 was lower than in LPS-stimulated cells but this was not 
significantly different. The increase in IL-10 production observed in cells stimulated with 
LPS B compared to CeTci-MIF-1 was statistically significant (p < 0.05, Figure 9.6). 
 
Figure 9.6 IL-10 detection in the cell supernatant of ovine BM-MΦ cultures stimulated with a 
range of molecules. 
Cells were plated at 2 x 10
4
/well and supernatants harvested after 48 h incubation with the 
molecules indicated below the graph (final concentrations), or with medium alone 
(unstimulated control). Data were transformed prior to carrying out statistical analysis to 
reduce skew using the formula y = 1/x, where x = IL-10 Biological Units/ml. Mean±SEM of 
untransformed data are shown [n=2 (CeTci-MIF-1 and IL-4 stimulation), n=4 (remaining BM-
MΦ stimulation protocols). Overall one-way ANOVA p value is shown below the graph; * 
indicates 0.01 < p < 0.05. 
 
The TNFα release of BM-MΦ cultures was also investigated. As previously shown for IL-
10, LPS elicited the highest TNFα release in BM-MΦ supernatant, however this increase 
was not significant compared to unstimulated cells. Ovine recombinant IL-4 and both 
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recombinant Tci-MIF-1versions appeared to inhibit TNFα release in the BM-MΦ 
supernatant, but again these changes was not significantly different from unstimulated cell 
supernatant (Figure 9.7). Careful interpretation of ELISA data was required in both the IL-
10 and TNFα experiments, as the results shown were based on small replicate numbers. 
This is likely to have resulted in highly variable standard errors. 
 
Figure 9.7 TNFα detection in the cell supernatant of ovine BM-MΦ cultures stimulated with a 
range of molecules. 
Cells were plated at 2 x 10
4
/well and supernatants harvested after 48 h co-incubation with 
the molecules indicated below the graph (final concentrations), or with medium alone 
(unstimulated control). Data represent mean±SEM [n=5 (medium and LPS (B)-stimulated 
cells), n=4 (EcTci-MIF-1), n=2 (CeTci-MIF-1 and IL-4 stimulation). Overall one-way ANOVA p 
value is shown below the graph; p > 0.05, not significant.  
 
Overall, the results shown here confirm that functional sheep BM-MΦ can be generated in 
vitro and that these cells could provide a valuable insight in sheep basic immunology. 
However, further work is required to optimise the culture system and the stimulation 
protocols.  
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Appendix D - Reagents and Solutions 
   
10.1 Tissue culture 
10.1.1 Cell culture solutions 
10.1.1.1 Sheep Wash Medium (SWM) 
Hanks Balanced Salt Solution (HBSS) w/o Ca or Mg  
2 % FBS  
100 U/ml penicillin 
0.1 mg/ml streptomycin 
0.2 % gentamycin 
10.1.1.2 ASC Culture Medium (ASC-CM) 
Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, Paisley, UK) 
10 % FBS 
2 mM glutamine 
100 U/ml penicillin 
0.1 mg/ml streptomycin 
2.5 x 10
-5 
M -Mercaptoethanol 
10.1.1.3 Bone Marrow Culture Medium (BM-CM) 
RPMI 1640 (Gibco)  
2 mM L-glutamine 
100 U/ml penicillin  
100 µg/ml streptomycin  
20 % FBS 
20 % sheep autologous serum       
Sodium Pyruvate (100 X, Sigma) 
2.5 x 10
-5 
M -Mercaptoethanol 
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2.5 % 1M HEPES (Sigma)  
MEM non-essential amino acids (100 X, Sigma) 
10.1.1.4 Bone marrow transport medium 
Hanks Balanced Salt Solution (HBSS) w/o Ca or Mg  
2 % FBS 
100 U/ml penicillin 
100 μg/ml streptomycin 
7000 U/ml Heparin 
 0.2 % Gentamycin 
70 U/ml nystatin 
10.1.1.5 Standard Culture Medium (SCM) 
RPMI 1640  
10 % FBS 
100 U/ml penicillin 
0.1 mg/ml streptomycin 
MEM non-essential amino acids (100 X, Sigma) 
2 mM L-glutamine 
2.5 x 10
-5 
M -Mercaptoethanol 
10.1.1.6 FACS medium 
5 % FBS in 1X PBS with the addition of 0.2 % of sodium azide. 
10.1.1.7 Cell fixating medium for FACS 
20 % paraformaldehyde (PFA) was diluted to a final concentration of 1 % in 1X PBS. 
10.1.1.8 MACS wash 
0.5 % filter-sterilised bovine serum albumin (BSA) and 2 mM filter-sterilised EDTA in 1X 
PBS pH 7.2. 
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10.1.1.9 10X Red Blood Cells (RBC) Lysis Solution 
1.5 M NH4Cl   40.1 g 
100 mM NaHCO3  4.20 g 
10 mM EDTA   1.85 g 
Adjusted pH to 7.4 with 1 N HCl or 1 N NaOH,  then adjusted volume to 500 ml. Stored 
less than 6 months at 4˚C. For use, dilute 10X solution 1:10 in dH2O. The working solution 
was prepared fresh on the day of use. Kept working solution cold and discarded any 
unused portion. Pre warmed working solution at 37˚C before use. 
10.1.1.10 Monocyte migration assay medium (MoMM) 
RPMI 1640 
100 U/ml penicillin 
0.1 mg/ml streptomycin  
Sodium Pyruvate (100 X, Sigma) 
2.5 % 1 M HEPES  
MEM non-essential amino acids (100 X, Sigma) 
2 mM L-glutamine 
2.5 x 10
-5 
M -Mercaptoethanol 
10.1.1.11 Quencher for monocyte migration assay (MoMQ) 
As above (monocyte migration assay medium, 10.1.1.10), with addition of 5 % BSA. 
10.1.1.12 Alveolar macrophages transport medium 
Sterile PBS 
70 U/ml nystatin 
100 U/ml penicillin 
0.1 mg/ml streptomycin 
10.1.1.13 Alveolar macrophages culture medium  
RPMI 1640 
10 % FBS 
2 mM L-glutamine 
100 U/ml penicillin 
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0.1 mg/ml streptomycin 
2.5 x 10
-5 
M -Mercaptoethanol 
10.2 Solutions for ELISA assays 
10.2.1 Buffers and blocking solutions 
10.2.1.1 Carbonate coating buffer  
Na2CO3    0.795 g 
NaHCO3    1.465 g 
Made up with the above in 400 ml dH2O, adjusting the pH to 9.6 and making up to a final 
volume of 500 ml. 
10.2.1.2 PBST 
Phosphate Buffered Saline (PBS)  
0.05 % Tween 20® (Sigma-Aldrich, Gillingham, UK). 
10.2.1.3 PBST/Milk 
PBST as above with the addition of 5 % non fat, dry milk (Marvel Dried Skimmed milk). 
10.2.1.4 TBST 
Tris      1.211 g 
NaCl     29.22 g 
Tween 20®    500 μl  
Made up to 1L with dH2O.  
10.2.1.5 TBST/5% soya  
As above with the addition of 5 % (w/v) of dried soya milk (Infasoy, Cow and Gate). 
10.2.1.6 50mM Sodium Acetate Buffer 
Dissolved 2.05 g sodium acetate (CH3COONa; Sigma-Aldrich) in approximately 400 ml of 
dH2O, adjusting the pH to 4.5 and making up to a final volume of 500 ml. 
10.2.1.7 20mM Sodium periodate solution 
Dissolved 42.8 mg of NaIO4 (Sigma-Aldrich) in 10 ml 50 mM Sodium Acetate Buffer; 
adjusted pH to 4.5. 
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10.2.1.8 50mM Sodium Borohydride solution 
Dissolved 18.9 mg of NaBH4 (Sigma-Aldrich) in 10 ml TNTT. A 250 ml glass vessel must 
be used to prepare this solution, as it produces gas when NaBH4 is mixed with the TNTT. 
10.3 Reagents for cloning and protein expression  
10.3.1 Buffers for bacterial and yeast growth 
10.3.1.1 Luria-Bertani (LB) broth and agar 
For 1 L solution: 
1 % Bacto®-tryptone   10 g 
0.5 % Bacto®-yeast extract  5 g 
1 % NaCl    10 g 
[15 % agar    15 g] 
The volume was made up to 1 litre with distilled water and the pH was adjusted to 
7.5 with NaOH. This solution was autoclaved to sterilise. 
10.3.1.2 SOC medium 
In 100 ml of distilled water: 
Bacto®-tryptone   2 g 
Bacto®-yeast extract   0.5 g 
NaCl     0.05 g 
250 mM KCl    1 ml 
This solution was autoclaved for 15min. Once the liquid had cooled to below 60°C, the 
final two components were added: 
0.5 ml filter-sterilised MgCl2 (1.9 g MgCl2 in 10 ml water) 
2 ml filter-sterilised glucose (1.8 g glucose in 10 ml water) 
Aliquots were taken and stored at -20 °C. 
10.3.1.3 Low Salt LB broth and agar 
For 1 L solution: 
1 % Bacto®-tryptone   10 g 
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0.5 % Bacto®-yeast extract  5 g 
0.5 % NaCl     5 g 
[1.5 % agar    15 g]  
Dissolved in 900 ml of dH2O and pH was adjusted to 7.5 with 1 N NaOH, then made up to 
1 L with dH2O. The solution was autoclaved at 121°C for 15 min and stored at 4°C until 
used. When Zeocin® (25 μg/ml, Invitrogen, Paisley, UK) was added, the solution was 
stored at 4°C in the dark. 
10.3.1.4 Yeast Peptone Dextrose medium (YPD), liquid and agar 
For 1 L solution: 
1 % Yeast extract    10 g 
2 % peptone     20 g 
[2 % agar    20 g]  
Dissolved in 900 ml of dH2O. The solution was autoclaved at 121°C for 15 min and stored 
at 4°C until use. Before use, 100 ml of a 20 % dextrose solution were added.  
10.3.1.5 Yeast Peptone Dextrose Sorbitol medium (YPDS) 
For 1 L solution: 
1 % Yeast extract    10 g 
2 % peptone     20 g 
1 M Sorbitol     182.2 g 
2 % agar    20 g 
Dissolved in 900 ml of dH2O. The solution was autoclaved at 121°C for 15 min and stored 
at 4°C until use. Before use, 100 ml of a 20 % dextrose solution were added. When 
Zeocin® (100 μg/ml, Invitrogen) was added, the solution was stored at 4°C in the dark. 
10.3.1.6 Buffered Glycerol-complex Medium (BMGY) 
For 1 L solution: 
1 % yeast extract    10 g 
2 % peptone     20 g 
Dissolved in 700 ml of dH2O. The solution was autoclaved at 121°C for 15 min and stored 
at 4°C until use. Before use, the following additions were made: 
20 % dextrose solution       100 ml  
1 M K Phosphate buffer, pH 6      100 ml 
 xxv 
 
13.4 % Yeast Nitrogen Base (with NH4, no amino acids)  100 ml 
0.02 % biotin solution       2 ml 
10 % Glycerol        100 ml 
The complete medium was stored at 4°C until use. 
10.3.1.7 Buffered Methanol-complex Medium (BMMY) 
For 1 L solution: 
1 % yeast extract    10 g 
2 % peptone     20 g 
1 M Sorbitol     182.2 g 
2 % agar    20 g 
Dissolved in 700 ml of dH2O. The solution was autoclaved at 121°C for 15 min and stored 
at 4°C until use. Before use, the following additions were made: 
20 % dextrose solution   100 ml  
1 M K Phosphate buffer, pH 6  100 ml 
13.4 % Yeast Nitrogen Base  100 ml 
0.02 % biotin solution   2 ml 
5 % Methanol    100 ml 
The complete medium was stored at 4°C until use. 
10.4 Solutions for handling of recombinant proteins 
10.4.1 Protein purification  
10.4.1.1 0.1M Sodium Phosphate Buffer (pH 7.4) 
NaH2PO4•H2O   3.1 g 
NaH2PO4    10.9 g 
Adjusted to pH 7.4, made up to 1 L with dH2O and autoclaved. Stored at RT. 
10.4.1.2 Binding Buffer A (Ni2+ column) 
0.1 M Sodium Phosphate Buffer 20 ml 
dH2O     80 ml 
NaCl (0.5 M)    2.92 g 
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Imidazole (20 mM)   0.136 g 
Adjusted to pH 7.4 and stored at 4°C. 
10.4.1.3 Elution buffers (1-4; Ni2+ column) 
All elution buffers are based on:  
0.1 M Na Phosphate buffer  20 ml 
dH2O     80 ml    
NaCl (0.5 M)    2.92 g 
Then for each elution buffer the following amounts of imidazole were added: 
Elution buffer 1 (50 mM)  0.34 g  
Elution buffer 2 (200 mM)  1.36 g 
Elution buffer 3 (350 mm)  2.38 g 
Elution buffer 4 (500 mM)  3.4 g 
All buffers were adjusted to pH 7.4 and stored at 4°C. 
10.4.1.4 Binding Buffer B (Co2+ column) 
0.1 M Sodium Phosphate Buffer 20 ml 
dH2O     80 ml 
NaCl (0.3 M)    1.94 g 
Imidazole (20 mM)   0.136 g 
Adjusted to pH 7.4 and stored at 4°C. 
10.4.1.5 Wash buffer 
0.1 M Sodium Phosphate Buffer 20 ml 
dH2O     80 ml 
NaCl (0.3 M)    1.94 g 
Imidazole (40 mM)   0.272 g 
Adjusted to pH 7.4 and stored at 4°C. 
10.4.1.6 Elution buffer (5; Co2+ column) 
0.1 M Sodium Phosphate Buffer 20 ml 
dH2O     80 ml 
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NaCl (0.3 M)    1.94 g 
Imidazole (165 mM)   1.122 g 
Adjusted to pH 7.4 and stored at 4°C. 
10.4.1.7 Dialysis Buffers 
10.4.1.7.1 Dialysis Buffer 1 
0.1 M Sodium Phosphate Buffer, 0.5 M NaCl pH 7.4. 
10.4.1.7.2 Dialysis Buffer 2 
0.1 M Sodium Phosphate Buffer, 0.3 M NaCl pH 7.4. 
10.4.2 Solutions for use with D-galactose agarose gel 
10.4.2.1 Binding buffer 
0.1 M Sodium Phosphate Buffer 
NaCl (0.15 M)   8.766 g  
Adjusted to pH 7.2 and stored at 4°C. 
10.4.2.2 Elution buffer 
Binding Buffer (100 ml) with the addition of  
D-galactose (0.1 M)   1.8 g 
Stored at 4°C. 
10.5 Solutions for use with C. elegans  
10.5.1 Buffers and growth media 
10.5.1.1 1M Potassium Phosphate Buffer 
KH2PO4    108.3 g 
K2HPO4    35.6 g 
Salts were weighed and dH2O added to 900 ml, stirred, pH adjusted to 6.0 with 85 % 
orthophosphoric acid or KOH and made up to 1 litre with dH2O. 
10.5.1.2 Nematode Growth medium (NGM) 
For 500 ml of NGM: 
NaCl     1.5 g 
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Agar     8.5 g 
Peptone    1.25 g 
The components were mixed in 486 ml of dH2O, stirred and autoclaved at 121°C for 15 
min. The solid agar was stored at RT and when needed, melted in a microwave oven (full 
power until boiling) and left the settle for 15-30 min in water bath at 55°C. The following 
were added: 
5 mg/ml cholesterol dissolved in ethanol (stored at -20°C)  0.5 ml 
1 M KPO4 Buffer pH 6.0      12.5 ml 
1 M MgSO4        0.5 ml 
1 M CaCl2        0.5 ml 
The solution was stirred thoroughly and 20 ml aliquoted into new Petri dishes.  
10.5.1.3 Peptone Rich Agar  
For 500 ml of medium: 
NaCl     1.2 g  
Agar      25 g  
Peptone     20 g  
The components were mixed in 486 ml of dH2O, stirred and autoclaved at 121°C for 15 
min. The solid agar was stored at RT and when needed, melted in a microwave oven (full 
power until boiling) and left the settle for 15-30 min in water bath at 55°C. The following 
were added: 
5 mg/ml cholesterol dissolved in ethanol (stored at -20°C)  0.5 ml 
1 M KPO4 Buffer pH 6.0      12.5 ml 
1 M MgSO4        0.5 ml 
1 M CaCl2        0.5 ml 
The solution was stirred thoroughly and 20 ml aliquoted into new Petri dishes. 
 
10.5.1.4 M9 Buffer 
Na2HPO4     6 g   
KH2PO4     3 g 
NaCl      5 g 
MgSO4•7H2O     0.25 g 
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Salts were weighed and dH2O added to 900 ml, stirred, then topped up to 1 L and 
autoclaved at 121°C for 15 min. 
10.5.1.5 S Buffer  
50 mM K2HPO4   12.9 ml 
50 mM KH2PO4   87.1 ml 
NaCl     0.585 g 
The solution was autoclaved at 121°C for 15 min and stored at RT. 
10.5.1.6 S Buffer for freezing worms 
Solution prepared as above, with the addition of 30 % glycerin (v/v), then autoclaved.  
10.5.1.7 Soft Agar Freezing Solution  
NaCl     0.58 g 
KH2PO4    0.68 g 
Glycerol    30 g 
1 M NaOH    0.56 ml 
Agar     0.4 g 
The solution was made up to 100 ml with dH2O, autoclaved for 15 min and stored at RT. 
10.6 Other solutions 
10.6.1.1 50 X Tris-acetate/EDTA (TAE) Buffer 
Trizma base   242 g 
Glacial acetic acid  57.1 ml 
50 mM EDTA   100 ml of 0.5 M solution 
pH was adjusted to 7.7-8 using glacial acetic acid if required, made up to a volume of 1 L 
with dH2O. The 1 X solutions were prepared adding 20 ml of the 50 X stock to 980 ml 
dH2O. 
10.6.1.2 6 X DNA loading Buffer 
0.25 % Bromophenol blue 
0.2 % Xylene cyanol FF 
40 % (w/v) Sucrose in water 
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Stored at 4°C. 
10.6.1.3 5 X TNTT 
1 M Tris   50 ml 
NaCl    146.1 g 
Tween 20®   2.5 ml 
The pH was adjusted to 7.4 using HCl and stored at 4°C. The 1 X solutions were made by 
mixing 200 ml of 5 X TNTT in 800 ml dH2O. 
10.6.1.4 0.1 M Citrate buffer (for use in fluorescence quencher solution) 
0.1 M Citric acid   25.5 ml 
0.1 M Na citrate dihydrate  24.5 ml 
The solution was adjusted to pH 4.4 and made up to 100 ml with dH2O. 
10.6.1.5 Cysteine protease assay buffers 
1) Cysteine was prepared as 0.5 M stock solution (100 X), aliquoted and stored at -20°C; 
DTT was prepared as 0.8 M stock solution (100 X), aliquoted and stored at -20°C. 
2) Four reaction buffers stock at different pH were prepared as follows:  
pH 3.5, 4.5 and 5.5 were 50 mM Sodium acetate buffer, 1 mM EDTA; 100 X cysteine and 
100 X DTT were added fresh before use, to a final concentration of 5 mM cysteine and 8 
mM DTT. The pH 7 buffer was 50 mM Tris-HCl buffer, 1 mM EDTA; 100 X cysteine and 
100 X DTT were added fresh before use, to a final concentration of 5 mM cysteine and 8 
mM DTT. 
2) 7-Amino-4-methylcoumarin (AMC, Sigma-Aldrich) was dissolved in DMSO to a stock 
concentration of 10 mM and serial dilutions were prepared from that in DMSO. 
3) The substrate Z-Phe-Arg-AMC (Enzo Life Sciences, Exeter, UK) was dissolved in 
DMSO to a stock concentration of 10 mM and serial dilutions were prepared from that in 
DMSO. 
4) The cysteine protease inhibitor E-64 (Sigma-Aldrich) was dissolved in dH2O to a stock 
concentration of 1 mM. 
10.6.1.6 Dopachrome tautomerase assay buffers 
1) Two hundred millilitres of reaction buffer 10 mM Na Phosphate Buffer, 1 mM EDTA 
was prepared by diluting 1:10 0.1M Na Phosphate buffer (this appendix, 8.1.4.1) and 
adding 200 μl of 1 M EDTA; pH 6.2. 
2) 0.1 M 3,4-Dihydroxy-L-phenylalanine (L-DOPA methyl ester, Sigma-Aldrich) was 
prepared by dissolving 24.7 mg/ml in dH2O. 
 xxxi 
 
3) 0.2 M sodium m-periodate (Sigma-Aldrich) was prepared by dissolving 42.8 mg/ml in 
dH2O
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